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Summary 
 
The translationally controlled tumour protein (TCTP) family are highly conserved 
eukaryotic proteins that have been assigned a variety of functions.  Most studies of TCTP 
have focused on the intracellular functions of the protein, including its roles in 
microtubule binding (Gachet et al., 1999), in the inhibition of apoptosis (Li et al., 2001b; 
Zhang et al., 2002), and calcium binding (Arcuri et al., 2004; Sanchez et al., 1997).  The 
human TCTP has also been reported to have a second extracellular function, in the 
induction of histamine and interleukin (IL)-8 release from immune cells of allergic donors 
in vitro (e.g. Bheekha-Escura et al., 2000; MacDonald et al., 1995).  The TCTP of the 
malarial species Plasmodium falciparum has been demonstrated to induce histamine 
release from basophils and IL-8 release from eosinophils, and is present in the sera of 
malaria-infected individuals (MacDonald et al., 2001).  The TCTP from the parasites 
Schistosoma mansoni and Brugia malayi can induce histamine release in vitro and can 
induce eosinophil recruitment in mice in vivo (Gnanasekar et al., 2002; Rao et al., 2002).  
Little other research has been conducted into the functions of malarial TCTP, however it 
is known to bind to the antimalarial drug artemisinin (Bhisutthibhan and Meshnick, 2001; 
Bhisutthibhan et al., 1998).  
 
Malaria is a widespread parasitic disease, causing 300-500 million infections per 
year and resulting in over 1 million deaths.  There is widespread resistance of the 
parasite to most of the antimalarial treatments available, indicating the need for a vaccine 
(http://www.rbm.who.int/wmr2005/).  Several candidate malarial vaccines are currently in 
clinical trials, however due to the ability of the parasite to rapidly mutate to evade host 
immune responses the most effective malarial vaccine may consist of several subunits.  
Various malarial species exist that infect non-human hosts, allowing for candidate 
vaccine studies using animal models.   
 
Previously, we studied the vaccine potential of P. falciparum TCTP in a malarial 
challenge model in mice infected with the lethal malaria P. yoelii YM.  In that study, a 
significant delay in the establishment of infection was observed in immunised mice, as 
judged by reduced parasitemia and prolonged survival (Taylor, 2002).  It was thought 
that the protective effect conferred by immunisation might have been due to the inhibition 
of the extracellular actions of malarial TCTP by the acquired host immune response. 
 
  2 
This study was undertaken to confirm the modest protective effect conferred by P. 
falciparum TCTP immunisation, and to investigate if immunisation using homologous 
proteins would induce greater protection.  P. falciparum and P. yoelii TCTP were initially 
expressed in S. cerevisiae, as in the previous study.  The recombinant proteins were 
used to immunise mice, which were then challenged with two strains of P. yoelii.  No 
protective effect was observed for either vaccine, and so the previous results using 
PfTCTP could not be confirmed.   
 
Due to low yields and significant proteolysis being encountered using the yeast 
expression system, the TCTP of P. yoelii and P. berghei was expressed in E. coli.  
Proteins of greater than 95% purity were obtained from a single purification step using 
Profinity™ resin, and no significant proteolysis was observed.  These recombinant 
proteins were used as vaccines in mice challenged with P. yoelii YM, P. c. chabaudi AS, 
or P. berghei ANKA.  A significant delay in disease progression was observed in 
PyTCTP-immunised mice challenged with the non-lethal P.c. chabaudi, as determined by 
a significantly reduced parasitemia at each day post-infection leading up to a delayed 
peak parasitemia. A significant reduction in parasitemia was also observed in the early 
stages of P. yoelii YM infection in PyTCTP-immunised mice. 
 
  P. berghei ANKA was used to challenge C57BL/6 mice to evaluate the potential 
of PbTCTP immunisation to protect mice from cerebral malaria development.  No 
significant differences were observed between immunised mice and controls.  P. berghei 
ANKA was also used as a second lethal malaria challenge model in BALB/c mice, again 
no significant differences in disease progression were observed in immunised mice.  
 
To further assess the functions of malarial TCTP, several attempts were made to 
create a TCTP-knockout strain of P. berghei ANKA.  A TCTP-knockout malaria strain 
could be assessed for alterations in morphology, infectivity and artemisinin sensitivity 
compared with wild-type parasites.  Initial genotype analysis of parasites resulting from 
several transfection experiments indicated that TCTP disruption had been successful, 
however TCTP-disrupted parasites were strongly selected against, and stable knockout 
strains could not be obtained.  This indicates that TCTP performs an important role within 
the malaria parasite. 
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Chapter 1: Literature review 
 
1.1 Introduction 
Malaria is a parasitic disease caused by members of the Plasmodium genus, 
infecting 300-500 million people per year and resulting in 1-3 million deaths.  Malarial 
species have high host specificity, and rodent malarial species are commonly used as 
models of human infection. As yet, there is no commercially available malaria vaccine, 
although several promising candidates are in clinical trials.  In a small-scale vaccine trial 
in mice, immunisation with P. falciparum TCTP induced a significant delay in the 
progression of a P. yoelii YM infection (Taylor, 2002). 
  
A member of the translationally controlled tumour protein (TCTP) family was first 
identified in mouse tumour cell lines (Chitpatima et al., 1988), with expression under 
translational control (Gross et al., 1989).  Since then, TCTP expression has been found 
in normal tissues, as well as in tumours, in all eukaryotes examined.  Members of the 
TCTP family are highly conserved and abundantly expressed (Thaw et al., 2001).  
 
Several functions, mostly intracellular, have been ascribed to members of the 
TCTP family.  Some of the intracellular functions attributed to TCTP include calcium 
binding (e.g. Arcuri et al., 2005; Feng et al., 2007; Gnanasekar et al., 2002; Kim et al., 
2000; Sanchez et al., 1997) and microtubule stabilisation (Gachet et al., 1999).  Several 
research groups have also identified secretion and extracellular functions of TCTP from 
several species, including humans, ticks, malaria and filarial worms.  These extracellular 
functions include the induction of histamine release from basophils and IL-8 release from 
eosinophils (Gnanasekar et al., 2002; MacDonald et al., 2001; Rao et al., 2002). 
 
The TCTP vaccine trial represented a different approach to the generation of 
protective responses to malaria, as other vaccines so far trialled have consisted of 
attenuated whole parasites (e.g. Renia et al., 2006a) or of proteins exposed on the 
surface of the parasite (e.g. Anders et al., 1998; Daly and Long, 1996).  In contrast, an 
induced immune response to TCTP would recognise and inhibit the actions of an 
extracellular protein. This project was designed to further evaluate the potential of 
malarial TCTP as a vaccine, and to further investigate the functions of the protein. 
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1.2 Malaria 
1.2.1 Causative agents of malarial infection 
The name malaria is derived from the Italian mal’aria, meaning bad air.  The 
disease is caused by unicellular eukaryotic parasites belonging to the genus 
Plasmodium.  More than one hundred species of Plasmodium exist, with a broad range 
of hosts including reptiles, birds and mammals.  Four Plasmodium species can infect 
humans under natural conditions, these being P. falciparum, P. vivax, P. ovale and P. 
malariae.  The most widespread human malaria species is P. vivax, but this rarely 
causes fatal disease.  P. falciparum is the major cause of human malaria deaths, mostly 
in children under five in sub-Saharan Africa (Tuteja, 2007).   
 
1.2.2 Global incidence of malaria 
According to the most recent figures (2005), 3.2 billion people live in areas at risk 
of malaria transmission.  It is estimated that 350-500 million cases of clinical malaria 
occur annually.  Malaria caused by P. falciparum results in more than one million deaths 
per year, and contributes indirectly to many more deaths.  Around 60% of total malaria 
cases, 75% of falciparum malaria cases and 80% of malaria deaths occur in areas of 
Africa south of the Saharan desert.  In these areas, P. falciparum infections are 
responsible for approximately 18% of total deaths in children under 5 years of age.  In 
African countries in which malaria is endemic, malaria infections account for 20-45% of 
hospital admissions (http://www.rbm.who.int/wmr2005/). 
 
Malaria has highest incidence in children; studies in areas of Liberia with 
continual malarial transmission show that blood density of P. falciparum peaks between 
six months and two years of age.  Malaria morbidity also decreases with age, peak 
incidence of cerebral malaria and other malaria-related deaths in Gambia occurs at four 
years old (Ramasamy, 1998).  
 
The global distribution of malaria transmission areas has decreased between 
1946 and 1994 (Figure 1.1).  Malarial transmission has been successfully halted in 
temperate climates, with the result that the disease is now confined to tropical and sub-
tropical climates.  This is due to a combination of factors.  The reproduction rate of 
malaria is lower in colder areas (below 18°C), meaning that malarial prevention schemes 
such as insecticide treatment and the use of antimalarial drugs are much more likely to 
successfully eradicate the parasite. Also, the main species of vector mosquitoes 
(Anopheles gambiae) in sub-Saharan Africa has a strong tendency to feed on humans.  
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There is also a strong correlation between poverty and malarial incidence (Sachs and 
Malaney, 2002).  
 
 
 
Figure 1.1: The global incidence of malaria  
(Sachs and Malaney, 2002) 
 
1.2.3 Mechanisms of malaria infection 
Malarial parasites are transmitted between hosts by Anopheles mosquito vectors.  
Mosquitoes inject the sporozoite stage of malaria into subcutaneous tissue, or directly 
into the bloodstream.  The sporozoites then travel to the liver, where they invade 
hepatocytes.  Each sporozoite develops into thousands of merozoites, which invade 
erythrocytes following hepatocyte rupture.  Disease symptoms occur following the 
multiplication of the asexual parasite stages within erythrocytes (Miller et al., 2002).   
 
The time required for parasites to complete an asexual life cycle varies between 
malaria species.  The following times relate to the P. falciparum cycle, which is 
completed in 48 hours.  Parasites grow from merozoites to ring stages and then 
trophozoites within the host erythrocyte, finally forming schizonts that produce daughter 
merozoites capable of infecting new erythrocytes.  The merozoites form rings, which 
develop to trophozoite stage in 15-18 hours.  The mature trophozoite undergoes 
schizogony to produce around 16 merozoites, which are released by rupture of the 
erythrocyte membrane.  These merozoites then invade new erythrocytes, leading to rapid 
expansion of the parasite population within the host.  A small proportion of the 
merozoites develop into male or female gametocytes within the erythrocytes.  These 
gametocytes are essential for transmission to new hosts via the Anopheles vector.  
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Gametocytogenesis occurs 10-12 days after the start of the erythrocytic cycle.  The 
gametocytes are ingested by feeding mosquitoes, where they are fertilised in the midgut.  
The diploid zygote undergoes meiosis and differentiates into the motile ookinete.  
Ookinetes develop into oocysts and then into sporozoites, which migrate to the mosquito 
salivary glands where they are injected into new mammalian hosts (Figure 1.2) (Tuteja, 
2007). 
 
 
Figure 1.2: The life cycle of malaria within the human host and mosquito vector   
(Tuteja, 2007) 
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1.2.4 Malaria pathogenesis 
Much research has been conducted into the mechanisms of malaria 
pathogenesis.  In terms of symptoms observed in human patients, the principal malarial 
complication that is the most important determinant of survival is metabolic acidosis, 
which is observed in both cerebral malaria and severe malarial anaemia.  Metabolic 
acidosis leads to a syndrome of respiratory distress, most likely caused by decreased 
oxygenation of tissues.  The pathogenic processes that lead to severe disease include 
rapid expansion of infected erythrocytes, destruction of both infected and uninfected 
erythrocytes, obstruction of small blood vessels, and inflammatory processes (Miller et 
al., 2002).  Other common clinical complications include liver failure, circulatory collapse, 
hypoglycaemia, anaemia, hyperpyrexia, pulmonary oedema, and renal failure, as well as 
maternal death, premature delivery, and low birth weight (Ramasamy, 1998).   
 
A major factor in the pathogenesis of P. falciparum infections is the ability of the 
parasite-infected erythrocytes to sequester in various organs such as the brain, lung and 
placenta.  Sequestration is the result of parasite proteins on the surface of infected 
erythrocytes binding to host adhesion molecules on the surface of uninfected 
erythrocytes and endothelial cells (Tuteja, 2007).  After invasion, the major parasite 
protein expressed on the surface of the infected erythrocyte is known as P. falciparum 
erythrocyte membrane protein 1 (PfEMP1).  This is encoded by a multigene family of 
between 50 and 150 var genes (Newbold 1999, Ramasamy, 1998).  PfEMP1 proteins on 
the surface of red blood cells mediate binding to host adhesion molecules, including 
glycoprotein, thrombospondin, intercellular adhesion molecule-1 (ICAM-1), E-selectin, 
vascular cell adhesion molecule-1 (VCAM-1) and chondroitin sulphate A (CSA), on 
endothelial cells.  Cytoadherence by the parasite is believed to be a mechanism to avoid 
circulation through the spleen, where infected erythrocytes can be destroyed by T cell-
derived cytokines, phagocytosis and physical trapping (Ramasamy, 1998).  
 
Sequestration causes obstruction in small blood vessels, which contributes to 
cerebral malaria (CM), the most dangerous complication of malarial infection 
(Ramasamy, 1998).  In humans, CM mostly occurs in people living in malaria-endemic 
areas with a ‘naïve’ immune system, i.e. children under 5 and recent immigrants.  
Immunity to CM develops slowly.  Recently, the proposed mechanisms of human 
cerebral malaria pathogenesis were reviewed (van der Heyde et al., 2006).  It was 
hypothesised that cerebral malaria development is due the binding of parasitised 
erythrocytes to small blood vessels in the brain, partly via the upregulation of host 
endothelial adhesion molecules, and partly via mechanical plugging of vessels due to the 
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increased rigidity of parasitised erythrocytes.  Host systemic inflammatory responses are 
also involved in cerebral malaria development, via the actions of malarial toxins such as 
glycophosphoinositol (GPI) inducing the release of proinflammatory cytokines such as IL-
1 and -6, macrophage colony-stimulating factor (M-CSF) and tumour necrosis factor 
(TNF).  These proinflammatory cytokines upregulate the expression of host adhesion 
molecules.  In the mouse model of experimental cerebral malaria (ECM) (discussed in 
the next section) the involvement of the inflammatory response has been proven, 
however the model fitness of ECM to human cerebral malaria is debatable, and not all 
cerebral malaria pathology can be accounted for by inflammatory responses.  It is 
hypothesised that platelets are also involved in cerebral malaria development via 
hemostasis, and via adhesion to microvasculature (van der Heyde et al., 2006).  
 
1.2.5 Mouse models of malaria 
Animal models of malaria are mostly used for studying immune mechanisms.  
Malaria has narrow host specificity, and species exist that infect rodents, primates, and 
birds.  Four species of rodent malaria exist: P. berghei, P. yoelii, P. chabaudi and P. 
vinkei.  No single mouse model completely mimics human infection (Taylor-Robinson, 
1998).  P. yoelii is commonly used in mouse immunisation and challenge models.  Lethal 
strains (e.g. YM, 17XL) exist, as well as non-lethal strains (e.g. 17 XNL) (Kim et al., 1980; 
Li et al., 2001a; Ma et al., 2007; Taylor et al., 1986). 
  
P. chabaudi species are used in both lethal and non-lethal malaria models, 
depending on the parasite and mouse species used.  Using both susceptible and 
resistant mouse models, it was found that levels of pro-inflammatory cytokines such as 
interferon (IFN) -γ and TNF-α correlate with disease severity (Cross and Langhorne, 
1998). 
  
Several strains of P. berghei, most commonly P. berghei ANKA, are used as 
models of cerebral malaria.  The susceptibility of mice to CM is strain-specific.  In 
susceptible mouse strains, including CBA/Ca and C57BL/6, around 80-90% of mice 
develop CM following P. berghei ANKA infection.  These mice develop neurological 
symptoms including ataxia, paralysis and convulsions at low parasitemia.  In the mouse 
model of CM, sequestration of parasitised red blood cells (pRBC) is not seen, instead 
vessel haemorrhages are due to obstruction with leukocytes.  Similar malarial antigens 
and similar immune responses exist in both diseases.  Disease symptoms shared 
between human and murine CM include hypoglycaemia, hyper immunoglobulin (Ig), high 
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serum TNF levels and perivascular haemorrhages.  Neutralising anti-TNFα antibodies 
prevented CM in mice, and CM-resistant strains of mice (BALB/c) that were treated daily 
with TNFα during P. berghei ANKA infection developed CM (Chen et al., 2000).  Non-
CM-susceptible strains of mice, such as BALB/c, succumb to P. berghei ANKA 3-4 
weeks after infection due to hyperparasitemia and anaemia.  The remaining 10% of 
C57BL/6 mice that do not develop CM also follow this disease progression (Lou et al., 
2001).   
 
1.2.6 Malaria prevention and treatment 
The major methods used to prevent and treat malaria are control of the mosquito 
vector, through the use of insecticides and bed nets, and treatment using antimalarial 
drugs.  Drugs commonly used to treat malaria include chloroquine, which inhibits 
haemoglobin digestion, and drugs such as sulfadoxine and pyrimethamine that inhibit 
enzymes in the parasite folate synthesis pathway.  Alkylating agents, such as 
artemisinin, are a newer class of drug that are becoming more widely used as the 
parasite develops increasing resistance to chloroquine and the antifolate drugs 
(Winstanley et al., 2004).  The actions of artemisinin are discussed further in section 1.7. 
 
The Roll Back Malaria (RBM) partnership was implemented in 2000 with the goal 
of halving the global malaria burden by 2010.  Initiatives implemented by this partnership 
included distribution of insecticide-treated bed nets and the replacement of chloroquine 
treatment for malaria infections with artemisinin-based combination therapy (ACT).  
Other treatment and prevention programs recommended by the partnership included 
intermittent preventative treatment for pregnant women and indoor residual spraying 
(IRS) with insecticides.  Early results indicate that usage rates of insecticide-treated bed 
nets and IRS have increased in many countries since 2000, and that 23 African countries 
had changed their national drug policy to ACT.  In many Asian countries, rates of 
reported malaria cases and deaths have decreased since the introduction of these 
control measures (http://www.rbm.who.int/wmr2005/).   
 
It is estimated that the minimum cost of effective malarial control measures is 
around US $3.2 billion per year.  This is partly due to the fact that ACT is 10 to 20 times 
more expensive than chloroquine.  Financial commitment to malaria control has 
increased, with governments in malaria-affected countries providing most of the funds 
(between 71 and 96%).  As poor countries tend to have the highest malaria burden, in 
many cases the required level of funding is not available.  Several international funding 
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organizations exist, including the Global Fund to Fight AIDS, Tuberculosis and Malaria, 
and the Bill and Melinda Gates Foundation.  These organizations have helped to fill the 
gap between the funds required and those available (http://www.rbm.who.int/wmr2005/).    
 
1.2.7 Malaria vaccines 
As yet, no vaccine to protect against malaria development is commercially 
available.  Malaria sporozoites rendered uninfective by methods such as irradiation have 
previously been shown to confer immunity in humans, however a widespread vaccine 
using whole sporozoites is not economically viable in the developing countries in which 
malaria is concentrated.  Recently, sporozoites with attenuated infectivity through newer 
methods such as gene disruption have shown some promise as vaccine candidates 
(Renia et al., 2006a). 
  
Extensive research has been conducted into the subunit vaccine potential of 
several malarial proteins, generally using mice as the challenge model.  Merozoite 
surface proteins (MSPs) are integral membrane proteins on the surface of free 
merozoites.  They are involved in recognition and invasion of host erythrocytes.  The 
carboxyl terminal region of MSP-1 is a promising malarial vaccine candidate and is 
currently in clinical trials (Shi et al., 2007). The processed 42-kDa form of this protein can 
induce protective immunity in mice and monkeys (e.g. Daly and Long, 1996; 
Hirunpetcharat et al., 1997).  However, this vaccine candidate has narrow specificity, as 
immunisation with the P. yoelii MSP-1 could induce protection in mice challenged with P. 
yoelii but not P. chabaudi or P. berghei (Rotman et al., 1999).  In natural human 
infections, MSP-1-specific antibody responses can be low, despite repeated infection 
(Hensmann et al., 2004).  
 
Another promising vaccine candidate is apical membrane antigen 1 (AMA-1), 
present on the surface of merozoites during erythrocyte invasion.  Production of the 
recombinant protein in yeast can produce an economically viable vaccine for use in 
clinical studies (Kennedy et al., 2002).  Antibodies against AMA-1 prevent merozoite 
invasion of erythrocytes in mice and monkeys (Anders et al., 1998; Collins et al., 1994).  
Adoptive transfer of AMA-1 antibodies induced protection against P. yoelii infection in 
mice (Crewther et al., 1996).  AMA-1 has been evaluated in clinical trials by several 
groups (Ballou et al., 2004).    
 
Research into many other malarial vaccine candidates is continuing. The 
circumsporozoite (CS) protein present on the surface of sporozoites can confer 
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protection in mouse malaria models (Bergmann-Leitner et al., 2007).  Another candidate 
vaccine is MSP-8, which could confer immunity in mice particularly when combined with 
MSP-1 (Shi et al., 2007).  Used alone, MSP-8 immunisation could prevent malaria 
mortality but could not prevent patent infection, with mice infected with P. yoelii 17XL 
displaying a delayed parasitemia that was eventually resolved (Petritus and Burns, 
2008).  The MSP 4/5 proteins of P. yoelii have also shown promise in vaccine trials in 
mice, with complete prevention of patent infection (Alonso et al., 2004; Goschnick et al., 
2004; Kedzierski et al., 2000).  
 
The most clinically advanced malaria vaccine candidate currently available is the 
RTS,S/AS recombinant protein, which is a comprised of part of the P. falciparum CS 
protein fused with the hepatitis B surface antigen combined with a proprietary adjuvant 
system.  This vaccine candidate was developed by GlaxoSmithKline (GSK) in 
collaboration with the Walter Reed Army Institute of Research, and in 2001 GSK and the 
PATH Malaria Vaccine Initiative partnered to develop RTS,S/AS as a vaccine for children 
in sub-Saharan Africa 
(http://www.malariavaccine.org/files/12052008__RTSSfactsheet.pdf).  An RTS,S/AS02A 
vaccine trial in Mozambique in 2003 resulted in a 37% reduction in incidence of clinical P. 
falciparum malaria  (Alonso et al., 2004) and a 49% reduction in the incidence of severe 
malaria for at least 18 months following vaccination (Alonso et al., 2005).  A large-scale 
Phase III multi-center efficacy trial in both infants and young children is planned for 2009           
(http://www.malariavaccine.org/files/12052008__RTSSfactsheet.pdf).  
 
1.2.8 Malarial immunity and parasite immune evasion 
Maintenance of malarial semi-immunity is dependent on persistent sub-clinical 
infection and is lost when people leave malaria-endemic areas (Taylor-Robinson, 1998).  
The malaria parasite is able to evade the host immune system via several mechanisms.  
One mechanism is antigen switching.  In P. falciparum, only one PfEMP1 variant is 
expressed on the surface of the infected erythrocyte at a given time, but the parasite is 
able to alter expression of the multigene var family to evade host immune responses by 
expressing a different PfEMP1 variant (Newbold, 1999).  There is some evidence that the 
tandem repeats in the circumsporozoite (CS) protein can participate in immune evasion.  
Antibodies are usually generated to these repeats, and it has been hypothesis that cross-
reactions between the repeats can interfere with affinity maturation of the antibody 
response.  The repeats may also act to mop up antibodies, preventing them from binding 
to functionally important parasite proteins (Ramasamy, 1998). 
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1.3 Functions of TCTP 
Many intracellular and extracellular functions have been ascribed to TCTP, a 
comprehensive review of which was published in 2004 (Bommer and Thiele, 2004).  
Many of the functions that have been determined for TCTP are unrelated, and some 
seem to be contradictory.  An overall function of TCTP has yet to be determined, and 
much is left to be learned.  
 
1.3.1 Discovery of TCTP 
The nucleotide sequence of the mouse gene later identified as TCTP was first 
published in 1988.  The cDNA was derived from an abundant mRNA species in mouse 
tumour cell lines.  This mRNA was found to exist mainly as messenger ribonucleoprotein 
(mRNP) particles that were unable to interact with translational apparatus within the cells 
(Chitpatima et al., 1988).  
 
TCTP was originally named p21/p23 by several research groups.  One group 
identified the mouse TCTP, which they named p23, as a growth-dependent protein in 
Ehrlich ascites tumour (EAT) cells.  The synthesis of TCTP varied depending on the 
growth phase of the tumour, and was increased in the presence of serum (Benndorf et 
al., 1988).  Further work by this research group provided evidence that the synthesis of 
TCTP was regulated at the post-transcriptional level. Several transcription inhibitors were 
added to EAT cell culture, no inhibition of TCTP synthesis was seen.  Using a cell-free 
translation system, a similar amount of TCTP mRNA was found in early and late phase 
EAT cells, indicating that the increased protein seen in early phase cells was due to 
translational control (Bohm et al., 1989).  
 
The name TCTP was first used to describe the human homolog of the mouse p23 
gene.  The human TCTP homolog was isolated from a mammary carcinoma cDNA 
library using probes derived from the mouse sequence, the two genes shared 86% 
nucleotide and 96% amino acid similarity.  Three putative translation inhibitory elements 
were identified in the 3’ non-coding region (Gross et al., 1989). 
 
1.3.2 Translational regulation of TCTP 
The untranslated regions (UTRs) of TCTP have several features typical of 
translationally controlled proteins including a 5’-terminal polypyrimidine tract found mainly 
in mRNAs of ribosomal proteins, a high GC content in the 5’-UTR indicating a high 
degree of secondary structure, and two AUUUA motifs in the 3’-UTR, which are typical 
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recognition sequences for regulated degradation of mRNA (Bommer et al., 1994).  
Previous studies had reported that the 5’-UTR was important in the translation of TCTP 
mRNA (Bohm et al., 1989).   
 
There is evidence that the translational control of TCTP involves the action of the 
cap-binding initiation factor complex eIF-4F, particularly its smallest subunit (EIF-4E/eIF-
4Fα).  The initiation factor mediates unwinding of mRNA secondary structure prior to 
translation.  TCTP synthesis and eIF-4E phosphorylation were induced by the same 
mitogenic stimuli.  Over-expression of eIF-4E resulted in a higher basal rate of TCTP 
synthesis and knockdown of eIF4E using anti-sense RNA reduced TCTP levels (Bommer 
et al., 1994).   
 
The ability of TCTP mRNA to bind to the protein kinase PKR has been reported.  
PKR is activated by double-stranded RNA (dsRNA), and is hypothesised to be involved 
in signal transduction pathways that mediate cell growth and differentiation, stress 
responses and apoptosis.  Full-length double-stranded TCTP mRNA, but not the coding 
region alone, could bind to PKR in vitro by both co-precipitation and retention 
experiments, and could activate PKR in vivo (Bommer et al., 2002).  
 
Investigations of the TPT1 promoter of the TCTP gene revealed that expression 
was regulated by CREB transcription factors (Andree et al., 2006).  In recent work by the 
same group, the transcriptional and translational regulation of TCTP by several different 
compounds was examined.  Copper induced the greatest levels of TCTP expression, and 
a metal-responsive element was found in the TPT1 promoter (Schmidt et al., 2007).  
 
1.3.3 Identification of TCTP isoforms 
In one study, analysis of several tissue lysates by two-dimensional 
polyacrylamide gel electrophoresis (2D-PAGE) found three isoforms of human TCTP 
present in erythrocytes, liver cells, non-differentiated keratinocytes, melanoma, 
hepatoblastoma, and glioma cells.  The TCTP isoforms had an isoelectric point (pI) of 
4.8-4.9.  TCTP was also expressed in platelets, lymphoma, erythroleukemia, astrocytes 
and macrophages. The proportion of each isoform differed between normal and tumour 
cells, however the relative abundance of TCTP was similar in all of the tissues analysed.  
TCTP was not found in normal kidney cells or in renal cell carcinoma (Sanchez et al., 
1997).  In another study, high levels of TCTP mRNA were detected in human and rabbit 
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kidney (Thiele et al., 2000).  It could be that translation of TCTP is repressed in kidney 
tissue.   
 
1.3.4 TCTP involvement in cell growth and differentiation 
TCTP is generally accepted to have a role in cell growth and differentiation.  
TCTP is involved in the induction of flowering in violets (Sage-Ono et al., 1998), and high 
levels of TCTP mRNA and protein were found in regions of active cell proliferation, but 
not in regions that had undergone terminal differentiation, in the aquatic Hydrozoa Hydra 
vulgaris (Yan et al., 2000). 
 
Differential mRNA analysis was performed on exponentially growing and 
ammonium-starved Schizosaccharomyces pombe cells. Most of the mRNA species 
down-regulated during nitrogen starvation encoded ribosomal proteins, so the authors 
conclude that the major transcriptional control induced by nitrogen starvation is the 
inhibition of ribosomal protein expression.  The expression of TCTP was down-regulated 
in a similar manner to ribosomal proteins during nitrogen starvation, indicating shared 
expression control mechanisms (Bonnet et al., 2000).  
 
1.3.5 Induction of TCTP in response to stress 
Xu et al., (1999) studied altered protein synthesis in response to loss of calcium 
homeostasis in Cos7 cells.  The endoplasmic reticulum (ER) is the major dynamic 
calcium storage site in non-muscle cells.  Rapid calcium exchange is essential for correct 
protein folding and post-translational modifications, as well as for translation of mRNA 
and in maintaining the structural integrity of the ER.  Sustained elevation of cytosolic 
calcium levels can induce apoptosis and necrotic cell death.  TCTP was up-regulated in 
response to loss of calcium homeostasis, and the steady-state mRNA abundance 
increased.  Depletion of ER levels of calcium up-regulated TCTP transcription, while an 
increase in cytosolic calcium up-regulated TCTP translation (Xu et al., 1999).  A study on 
skeletal muscle proteins altered during prolonged potassium depletion revealed that 
TCTP was up-regulated (Thongboonkerd et al., 2006).  
 
TCTP was found to be up-regulated in response to heavy metal stress in 
earthworms.  In this study, TCTP expression was found to also be regulated at the 
transcriptional level (Sturzenbaum et al., 1998).  
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In S. cerevisiase yeast, induction of apoptosis by stress leads to translocation of 
TCTP from the cytoplasm to the outer surface of mitochondria.  Deletion of the TCTP 
gene in yeast confers sensitivity to benomyl, a fungicide that destabilises microtubules 
(Rinnerthaler et al., 2006).  In other studies, TCTP has been shown to bind to and 
stabilise microtubules, as discussed in section 1.3.10.   
 
The TCTP from the nematode species Trichinella psuedospiralis was reported to 
have a role in heat-stress adaptation.  The TCTP expressed in response to heat stress 
was shown to be due to regulation at the translational level. It was suggested that TCTP 
might be up-regulated when T. psuedospiralis is transferred from a mammalian to an 
avian host, as an adaptive response (Mak et al., 2007).  The up-regulation of expression 
of the parasitic filarial worm TCTP was also observed upon transfer from a cold-blooded 
vector to a warm-blooded host (Gnanasekar et al., 2002).       
 
1.3.6 Self-interaction of TCTP 
Rat TCTP was found to self-interact using a yeast two-hybrid screen.  TCTP was 
found to form stable dimers and oligomers under non-denaturing conditions, whereas a 
single band at around 22 kDa was seen on SDS gels.  The use of several truncated 
TCTP mutants determined that the C-terminal domain of TCTP, involving residues 126-
172, was important in self-interaction (Yoon et al., 2000).  In another study, native mouse 
and human TCTPs were found to form at least one complex of 100-150 kDa, whereas 
recombinant mouse TCTP eluted at 40-60 kDa (Gachet et al., 1999). 
 
1.3.7 Identification of TCTP pseudogenes 
In dot-blot experiments of a rabbit genomic DNA (gDNA) library 30 TCTP-positive 
plaques were found.  A Southern blot on rabbit liver gDNA using a TCTP exon probe 
resulted in multiple bands whereas a re-screening of the blot with a TCTP intron probe 
found only one band, suggesting that several processed pseudogenes exist in the rabbit 
genome.  It was suggested that these pseudogenes arose from retrotransposition of 
mRNA.  All pseudogenes had complete 5’UTRs and a short 3’ polyadenylation 
structures.  There was some evidence that the TCTP pseudogenes were transcribed 
(Thiele et al., 2000). 
 
The mouse Tpt1 gene encoding TCTP was examined.  Seven putative Tpt1 
genes were identified in the mouse genome.  Six of these had traits typical of 
pseudogenes that had arisen from retrotransposition of mRNA back into the genome.  
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These traits include flanking direct repeats in the 5’ and 3’ UTRs and residual poly(A) 
tails.  Only one transcript was found to be expressed in all tissues.  The mouse Tpt1 
gene was found to be located on chromosome 14, and to contain six exons (Fiucci et al., 
2003).        
 
1.3.8 Calcium binding by TCTP 
Several reports have identified calcium-binding activity of TCTP.  TCTP was 
identified to migrate abnormally on SDS-PAGE, which is common for calcium-binding 
proteins.  While TCTP has a hypothetical Mr of ~19.5 kDa, several reports have identified 
the protein as migrating above 25 kDa (e.g. Bhisutthibhan et al., 1998; Gnanasekar et al., 
2002; Rao et al., 2002).  The addition of 1 mM calcium caused TCTP to migrate faster on 
1D-PAGE (Sanchez et al., 1997). 
 
 TCTP was found to be up-regulated in response to a loss of calcium 
homeostasis.   While this could be part of a general stress response, this finding also 
lends support to the action of TCTP as a calcium-binding protein.  TCTP could act as a 
calcium chelator in the cytoplasm (Xu et al., 1999).   
 
Human prostate TCTP was shown to bind calcium in vitro, and had the highest 
expression levels of the calcium-binding proteins examined (Arcuri et al., 2004). Further 
work by this group examined the calcium-binding activity of human placental TCTP using 
small interfering RNA (siRNA) to knock-down protein expression.  The concentration of 
calcium in foetal blood is much higher than the maternal circulation, indicating that an 
active transport mechanism exists within the placenta.  Down-regulation of TCTP using 
siRNA resulted in a decreased calcium-uptake activity and an altered intracellular 
calcium profile in HTR-8/SV neo trophoblastic cells, suggesting that TCTP may have a 
direct role in placental calcium transport (Arcuri et al., 2005).   
 
Deletion constructs of rat TCTP determined that that the calcium-binding region of 
TCTP is confined to residues 81-112 using a 45Ca2+-overlay assay (Kim et al., 2000).  
However, in a recent report the calcium-binding site of human TCTP was determined by 
NMR, and was found to involve the residues N131, Q133, L149 and D150, with very low 
affinity (Feng et al., 2007). 
 
TCTP was reported to repress activity of a Na+,K+-ATPase pump and induce 
systemic hypertension in mice. Increased calcium mobilisation from the ER to the 
cytoplasm was also observed (Kim et al., 2008).  
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1.3.9 Tubulin binding activity of TCTP 
TCTP has been found to bind to microtubules.  Around 10% of total TCTP could 
be immuno-precipitated from HeLa cell extracts using α-tubulin antibodies, indicating that 
either the interaction between TCTP and tubulin is weak, or that only a fraction of TCTP 
binds.  TCTP and tubulin were localised in similar areas of Cos7 cells at different stages 
of the replication cycle.  TCTP co-localised with microtubules during the G1, S, and G2 
phases of the cell cycle.  TCTP could also bind to Taxol-stabilised rat brain microtubules 
in vitro.  Over-expression of mouse TCTP in bovine mammary epithelial cells (MACs) 
resulted in a much slower cell growth rate; cell morphology was also altered.  A general 
increase in cell size was seen, and there were a higher percentage of cells in the G2/M 
phase of the cell cycle.  Cells over-expressing TCTP had a 30-40% higher density of 
microtubules.  It was thought that the reduced growth rate could be due to the over-
expression of TCTP inhibiting mitosis (Gachet et al., 1999).  In a recent study, TCTP the 
only protein found to be up-regulated in the metaphase II-arrested oocytes compared to 
the germinal vesicle stage (Vitale et al., 2007).   
 
1.3.10 Chaperone activity of TCTP  
Several reports have given evidence for the involvement of TCTP in guanine 
nucleotide exchange for several proteins.  In an early report, the structure of the S. 
pombe TCTP was solved by NMR (Thaw et al., 2001).  Structural similarity to 
mammalian suppressor of Sec4 (Mss4) was observed.  Mss4 is a small GTPase 
accessory protein, binding to the GDP/GTP free form of Rab proteins and acting as a 
guanine nucleotide-free chaperone (GFC) or as a guanine nucleotide exchange factor 
(GEF).  Rabs are part of the Ras superfamily of small G proteins involved in the 
secretory pathway (Takai et al., 2001).  The Rab binding site of Mss4 coincided with the 
region of highest sequence conservation in TCTP, however, the H2 and H3 helices of 
TCTP were missing in Mss4, and the zinc-binding motif of Mss4 was not present in TCTP 
(Thaw et al., 2001).  It has previously been stated that the Zn-motif of Mss4 is essential 
for Rab binding (Yu and Schreiber, 1995).   
 
Therefore, the activity of TCTP as a chaperone is debatable.  It was reported that 
in Drosophila TCTP associated with Rheb, a Ras superfamily GTPase.  TCTP was 
immunoprecipitated together with Rheb in cell extracts, and bound preferentially to the 
nucleotide-free form.  In vitro, TCTP stimulated GDP/GTP exchange, indicating that it 
acts as a GEF for Rheb.  In vivo, cells with TCTP expression inhibited using RNAi had a 
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lower percentage of GTP-bound Rheb (Hsu et al., 2007).  However, another study 
refuted the claim that TCTP acts as a GEF for Rheb.   In this study, knockdown of TCTP 
expression by RNAi did not affect the ratio of GDP/GTP-bound Rheb, no interaction or 
exchange activity of TCTP with Rheb was detected, and TCTP depletion did not affect 
the direct downstream targets of Rheb in vivo.  It was hypothesised that the additional 
structures present in TCTP compared with Mss4 would inhibit the binding of TCTP to 
Rheb (Rehmann et al., 2008).  
 
In another study, TCTP was reported to interact with the translation elongation 
factor eEF1A, which is a GTPase.  TCTP acted as a guanine nucleotide dissociation 
inhibitor (GDI), stabilising the GDP form of eEF1A and inhibiting the GDP exchange 
reaction performed by eEF1Bβ (Cans et al., 2003).   
 
1.3.11 Anti-apoptotic functions of TCTP  
Using a yeast two-hybrid screen, TCTP was found to interact with the Bcl-2 
homolog myeloid leukaemia protein-1 (Mcl-1).  Bcl-2 is a major negative regulator of 
apoptosis and binds to Bax, a pro-apoptotic protein, preventing the formation of cytotoxic 
pores in the mitochondrial membrane (Li et al., 2001b).  A recent report stated that TCTP 
acts as an anti-apoptotic protein due to its function in inhibiting Bax dimerisation (Susini 
et al., 2008).  Western blot showed greater TCTP abundance in cancer cell lines than in 
normal cell lines, especially in cancers of epithelial origin.  Over-expression of TCTP in 
HeLa cells and in U2OS osteosarcoma cells prevented them from undergoing drug-
induced apoptosis, and anti-sense depletion of TCTP from the breast cancer cell line 
MCF-7 led to increased cell death.  Unlike the majority of reports that have found TCTP 
located in the cytoplasm or secreted, the authors reported that TCTP was localised in the 
nucleus, as determined by immunocytohistochemistry (Li et al., 2001b).  
 
The interaction of TCTP with Mcl-1 was investigated further.  Whereas other 
members of the Bcl-2 family are constitutively expressed, Mcl-1 is inducible in cells 
exposed to growth and differentiation stimuli.  TCTP was found not to interact with other 
Bcl-2 proteins.  Depletion of Mcl-1 by siRNA significantly reduced TCTP protein levels, 
and was associated with rapid degradation of TCTP.  It was concluded that Mcl-1 binds 
to and stabilises TCTP in vivo (Zhang et al., 2002).  Another report stated that over-
expression of TCTP increased Mcl-1 stability, and inhibition of TCTP expression by 
siRNA destabilised Mcl-1 (Liu et al., 2005).  
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1.3.12 TCTP and cancer 
Sinha et al. (2000) investigated proteins involved in the development of 
chemotherapeutic drug resistance in melanoma cells, which have a high level of intrinsic 
drug resistance.  In chemoresistant cells a general down-regulation of protein expression 
was observed, however TCTP was over-expressed, along with 15 other proteins in the 
same pI range (2.8-5) (Sinha et al., 2000).  
 
One model of tumour reversion uses human leukaemia and breast cancer cell 
lines transfected with SIAH-1, a gene involved in cell death and tumour suppression.  In 
malignant cells that had reverted to a non-malignant phenotype, TCTP was the most 
strongly down-regulated protein following reversion.  Additionally, inhibition of TCTP 
expression using siRNA resulted in a suppressed malignant phenotype and resulted in 
cellular reorganisation.  Decreased TCTP expression led to a 15% increase in the rate of 
apoptosis (Tuynder et al., 2002).  A more recent report by this group studied tumour 
revertants from colon, lung and melanoma cell lines.  In most of the tumour revertant cell 
lines tested, TCTP expression was reduced compared to the parental tumour lines.  
Using antisense TCTP to inhibit protein expression, anchorage-dependent cell growth 
was re-established (Tuynder et al., 2004).  Down-regulation of TCTP expression was 
also observed in a colorectal cell line that had lost the tumorigenic phenotype (Stierum et 
al., 2003).   
 
Chemicals that could inhibit TCTP expression in cancer cells were evaluated for 
their potential cytopathic effects.  As described in section 1.5, evidence exists for TCTP 
involvement in the induction of histamine release from basophils.  Chemicals that could 
inhibit the histaminic pathway of the human leukaemia U937 cell line were examined.  
Two of the four drugs (hydroxyzine and promethazine) had a significant cytopathic effect.  
However, structurally related chemicals with no antihistaminic properties had a more 
pronounced effect.  In drugs with a cytopathic effect, the expression of TCTP mRNA was 
increased, but the protein levels were decreased (Tuynder et al., 2004).  
 
1.3.13 Studies of the conserved domains of TCTP 
Thorough bioinformatics analysis was performed to investigate the sequence and 
predicted structure of the TCTPs from many species (Hinojosa-Moya et al., 2008).   
Extensive sequence analysis revealed that most species, including malaria parasites, 
have only a single TCTP gene.  Mammals possess several copies of TCTP 
pseudogenes.  Three residues are highly conserved in the region that likely corresponds 
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to the binding surface for G proteins, including Glu12 (Hinojosa-Moya et al., 2008).  It 
was previously reported that glutamic acid at residue 12 was essential for interaction with 
the Rheb GTPase (Hsu et al., 2007).  
 
TCTP is generally reported to have two conserved domains, named TCTP1 and 
TCTP2.  The TCTP1 domain is predominantly hydrophilic, comprising of a mobile loop at 
around residues 45-55.  The TCTP2 domain is also an irregular loop, together with the 
two flanking beta-sheets, at around residues 130 to 150 (Thaw et al., 2001).  An 
additional conserved domain was suggested to be present in the first 16 amino acids 
following the N-terminus.  The amino acid at position 15 is nearly always a serine, which 
may be a phosphorylation site (Venugopal, 2005).  In a model of P. yoelii TCTP using the 
solved 3D structure of P. knowelsi as a template, an extra helical segment is present at 
the end of the TCTP1 loop, at residues 53-58 (Figure 1.3). 
 
Figure 1.3: Structure of P. yoelii TCTP, modelled using the Swiss-model server 
(http://swissmodel.expasy.org/SWISS-MODEL.html)   
 
1.3.14 Summary of intracellular functions of TCTP 
Several proposed activities of TCTP support a role for the protein in cell growth, 
including interaction with anti-apoptotic proteins, decreased expression in tumour cells 
that reverted to a non-malignant phenotype, and tubulin binding.  However, how these 
discrete functions integrate is unknown.  The upregulation of TCTP in response to stress 
could be related to its calcium binding activity, but this again is a separate function, as is 
the proposed role of TCTP as a chaperone in the secretory pathway.  Therefore, much is 
yet to be determined regarding the true role of TCTP within the cell.  
TCTP2 
TCTP1 
extra helix 
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1.4 Secretion of TCTP 
The majority of published reports on TCTP focus on the intracellular actions of the 
protein.  However, an increasing number of reports have observed secretion and 
extracellular actions of TCTP.  Most secretory and membrane proteins contain a 
hydrophobic N-terminal sequence which mediates translocation across the ER 
membrane, the sequence is then cleaved (Palade, 1975).  However, more than 15 
proteins with a defined extracellular function have been found to lack a secretory signal 
sequence.  The proteins include the human IL-1β, thioredoxin, Annexin 1, the 
coagulation factor XIII a-chain, the platelet-derived endothelial cell growth factor and the 
fibroblast growth factor.  These proteins share several biochemical features, including a 
lack of N-linked glycosylation at potential sites and a lack of disulphide bonds between 
cysteines, indicating that their route of secretion bypasses the ER.  Many of the proteins 
secreted without a signal sequence have functions related to inflammation or tissue 
damage, and TCTP has been shown to have inflammatory functions (as discussed in 
section 1.5).  It was hypothesised that these proteins are secreted via an alternative 
pathway as secretion via the classical pathway may destroy the biological function of the 
protein.  Many of these proteins have free SH groups, and secretion via the ER might 
cause misfolding (Rubartelli and Sitia, 1991).  
 
Research into the mechanisms of TCTP secretion concluded that the tumour 
suppressor activated pathway-6 (TSAP6) gene product can facilitate the secretion of 
TCTP (Amzallag et al., 2004).  TSAP6 is a transmembrane protein, and was shown to 
interact with TCTP in a yeast two-hybrid screen.  TCTP partially co-localised with TSAP6 
in vesicular-like structures at the plasma and nuclear membranes.  The TSAP6 gene 
product increases cell susceptibility to apoptosis, and is inducible by the p53 tumour 
suppressor protein.  TSAP6 associates with the Bcl-2-related protein Nix, and the two 
proteins work together to promote apoptosis (Passer et al., 2003).  The interaction of 
TCTP with the Bcl-1 homolog Mcl-1 has previously been reported (as described in 
section 1.3.11).  
 
Only ~0.3% of the total intracellular TCTP was secreted after three hours 
incubation in cultured 293T cells.  The active secretion of TCTP was confirmed by the 
absence of cytosolic proteins, such as tubulin and actin, in the culture supernatants.  
TCTP secretion was found to be insensitive to either brefeldin A or monesin, suggesting 
that it is not processed through the ER/Golgi complex, but instead is secreted through a 
non-classical pathway.  TCTP was found in small secreted vesicles (exosomes), which 
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have been implicated in non-classical secretion.  The implication of the interaction of the 
pro-apoptotic protein TSAP6 and TCTP, which has been widely reported to inhibit 
apoptosis, was not discussed (Amzallag et al., 2004).  Although only a small amount of 
the total intracellular TCTP was observed to be secreted, it is probable that over longer 
time periods or under specific conditions a greater proportion of the intracellular TCTP 
would be exported out of the cell.  The removal of the anti-apoptotic TCTP from the cell 
could result in favourable conditions for apoptosis.  
 
In other studies, dioxin exposure increased secretion of TCTP from in vitro 
cultures of human B and T cells (Oikawa et al., 2002).  In a review of TCTP structure, it 
was suggested that two pools of TCTP may exist, and that one isoform may be secreted 
while the other has intracellular activities (Hinojosa-Moya et al., 2008).  
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1.5 Extracellular functions of TCTP 
1.5.1 Actions of TCTP in promoting histamine release from basophils 
Although the majority of research has focused on the intracellular functions of 
TCTP, several groups have reported extracellular activities for the protein. As yet, no 
attempt has been made to integrate the extracellular functions of TCTP with the variety of 
intracellular functions ascribed to the protein family.  
 
A protein later identified as TCTP was partially purified from nasal lavage fluids of 
allergic donors.  The protein was initially named histamine-releasing factor (HRF), due to 
its ability to induce histamine release in allergic donor basophils in an IgE-dependent 
manner.  The IgE dependency of this HRF was shown by removal of surface IgE from 
basophils using lactic acid.  Additionally, HRF was dependent on a particular form of IgE, 
as only certain basophil donors would respond, and passive sensitisation of lactic acid-
stripped donor basophils could be achieved using sera from donors responsive to HRF.  
The sensitising property of these donor sera was shown to be IgE, as heating of sera at 
56°C, passage of sera over anti-IgE sepharose, or competitive inhibition using non-
responsive donor IgE all reduced the subsequent response of basophils to HRF 
(MacDonald et al., 1987).  IgE that could sensitise basophils to respond to HRF was 
designated as IgE+, IgE that did not induce this sensitivity was designated IgE- 
(MacDonald et al., 1991).  
 
The protein first named HRF was found as one of four major bands present in 
macrophage culture (U937) supernatants, and was identified as human TCTP by N-
terminal amino acid sequencing.  The genes for mouse and human TCTP were 
expressed in E. coli as GST fusion proteins; the GST was cleaved before activity trials.  
The recombinant proteins were tested in basophil histamine release assays alongside 
native HRF purified from nasal lavages and PMBC culture.  Antibodies raised to mouse 
TCTP recognised recombinant mouse and human TCTP, and the HRF present in nasal 
lavages.  Both of the recombinant proteins had identical histamine releasing activity, and 
were less active than the native HRF.  The proteins were tested on donated basophils 
from IgE+ and IgE- donors; only IgE+ basophils were responsive.  The kinetics of 
histamine release from basophils induced with HRF were slow, with around 50% of 
maximum release between 5 and 10 minutes.  The release kinetics were identical 
between the recombinant TCTPs and the native HRF (MacDonald et al., 1995).  These 
results supported the hypothesis that the HRF purified from nasal lavages was TCTP.  
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TCTP has also been reported to prime IgE- basophils.  In stripped basophils 
passively sensitised with IgE-, treatment with TCTP for 15 minutes enhanced the 
secretion of histamine, IL-13 and IL-4 after activation with anti-IgE, in a dose-dependent 
manner (Schroeder et al., 1997). 
 
TCTP expression and secretion in basophils was identified.  TCTP synthesis was 
increased after stimulation with rIL-3, and to a lesser extent with α-IgE.  There was a 
dose-dependent increase in intracellular and secreted TCTP levels in response to rIL-3 
up to 100 ng/ml.  Only a small amount of the TCTP was found in the supernatants 
compared with the intracellular amounts, however there was evidence of active secretion 
of TCTP, including the fact that basophil viability counts were >95% and that other 
cellular proteins were not seen on culture supernatant gels.  Basophil culture 
supernatants could induce histamine release from other basophils, and histamine release 
was decreased by an average of 28% when TCTP was partially precipitated out of the 
supernatants (Nielsen et al., 1998).  
 
1.5.2 Studies of the interaction of TCTP and IgE 
It was suggested that action of IgE as IgE+ and IgE- could be due to differential 
glycosylation.  This hypothesis was investigated by testing the responsiveness of IgE+ 
and IgE--sensitised basophils to eight different oligosaccharide-specific lectins.  A large 
variation in histamine release was observed from basophils of different donors to all of 
the lectins tested, and it was concluded that lectins could not distinguish between IgE+ 
and IgE- (Kleine-Tebbe et al., 1996).  It has also been suggested that the IgE+/IgE- 
heterogeneity could be due to alternative mRNA splicing (Schroeder et al., 1996).  
 
In several experiments, attempts to show TCTP interacting with IgE were 
unsuccessful.  By analysis using ELISA or affinity chromatography, TCTP did not bind to 
soluble IgE (Schroeder et al., 1997).  In a rat basophilic leukaemia cell line was 
transfected with a functional human FcεRI, cells were incubated with IgE+ or IgE- along 
with α-IgE, human rTCTP or mouse rTCTP.  Neither human nor mouse TCTP induced 
any histamine release in cells sensitised with IgE+.  It was concluded that TCTP doesn’t 
cause histamine release through IgE, and that its receptor is not functional on rat RBL-
2H3 cells (Wantke et al., 1999).   
 
The effect of different chemicals thought to inhibit protein kinase C was studied 
on the release of histamine by human basophils in response to rTCTP, α-IgE, or specific 
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antigen.  The chemical rottlerin enhanced histamine release mediated by TCTP and had 
no effect on the histamine release induced by α-IgE or antigen. Rottlerin is a non-
staurosporine-derived inhibitor isolated from Mallotus philippinensis; it targets calcium-
dependent PKC isozymes.  Therefore, it was suggested that TCTP works through a 
separate signalling pathway to IgE (Bheekha-Escura et al., 1999). 
 
1.5.3 Actions of TCTP in promoting IL-8 release  
TCTP was shown to act on eosinophils, promoting chemotaxis, calcium flux and 
IL-8 production (MacDonald, 1996).  Eosinophils contribute to pathology in allergic 
diseases by secreting proinflammatory granule proteins, including major basic protein 
(MBP) and eosinophil cationic protein (ECP), which induce damage of bronchial epithelial 
cells.  TCTP could induce IL-8 secretion from a proportion of eosinophil preparations 
primed with granulocyte-macrophage colony stimulating factor (GM-CSF), however a 
large variability in the amount of IL-8 secreted in response to TCTP was observed in 
different donors.  Constant stimulation with TCTP was needed for IL-8 release, whereas 
this was not needed for TCTP-primed histamine release (Bheekha-Escura et al., 2000).  
TCTP signalling may be different between basophils and eosinophils, as pertussis toxin 
treatment is known to have no effect on TCTP-induced histamine release (Bheekha-
Escura et al., 1999) but was found to decrease IL-8 secretion in response to TCTP by 
50%.  TCTP also induced elevated calcium levels in 25% of eosinophil samples, and 
induced eosinophil chemotaxis in vitro (Bheekha-Escura et al., 2000). 
 
TCTP induced secretion of both IL-8 and GM-CSF from primary cultures of 
human bronchial epithelial cells (BECs) and from the transformed BEC line BEAS-2B.  
TCTP also enhanced secretion of IL-8 from BEAS-2B cells in response to IL-1β, TNFα or 
LPS.  Hydrogen peroxide induced secretion of a 30 kDa TCTP isoform from BEAS-2B 
cells without increasing the intracellular 26 kDa TCTP isoform concentration; the authors 
suggested that oxidative stress may induce TCTP release.  The researchers also found 
that bronchoalveolar lavage (BAL) samples from asthmatic patients had significantly 
higher levels of TCTP compared with healthy controls, TCTP levels were higher again in 
patients with idiopathic eosinophilic pneumonia.  It was previously known that IL-8 levels 
in BAL samples of asthma patients were several-fold higher than healthy controls 
(Yoneda et al., 2004).       
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1.5.4 Actions of TCTP in stimulation of IL-4 release from basophils 
Further investigations of the actions of TCTP on the immune response found that 
TCTP also induced IL-4 release from human IgE+ basophils passively sensitised with 
IgE+.  A four-hour treatment with mouse or human TCTP or anti-IgE induced IL-4 
synthesis (Schroeder et al., 1996). 
 
1.5.5 TCTP secretion from macrophages 
In the initial studies of the histamine-releasing activities of human TCTP, the 
protein was purified from macrophage culture (U937) supernatants (MacDonald et al., 
1995).  In further work, TCTP was found to be secreted from cultured macrophages and 
isolated peritoneal macrophages from ovalbumin (OVA)-sensitised mice following 
stimulation with macrophage colony stimulating factor (M-CSF).  TCTP was secreted 
from cultured macrophages at a rate of 5-15 ng per hour.  In vivo, repeated injections of 
M-CSF increased macrophage TCTP expression.  An i.p. injection of M-CSF or TCTP 
resulted in eosinophil recruitment in OVA-sensitised mice but not in controls.  M-CSF 
treatment also stimulated the secretion of an N-glycosylated TCTP with a MW of 30 kDa.  
Treatment with N-glycosidase F decreased the amount of the 30 kDa band present on 
Western blot, whereas the amount of the 25 kDa band present increased.  Mouse TCTP 
has a potential N-linked glycosylation site (Asp-X-Ser) at amino acid residues 51-53 
(Teshima et al., 1998). 
 
TCTP may be also be involved in macrophage activation.  A 2D SDS-PAGE study 
of the human monocytic U937 cell line examined proteins associated with macrophage 
activation.  LPS, IFN-γ, and phorbol myristate acetate (PMA) are all known to activate 
macrophages but have different specific activities.  TCTP was identified as one of the 
proteins upregulated by LPS and PMA, and was found at 28.5 kDa and a pI of 4.7 
(Walsh et al., 1995).  
 
1.5.6 TCTP involvement in B cell proliferation 
Culture supernatants of mouse erythroleukemia cells have activities in B cell-
stimulation.  An investigation into proteins present in these supernatants identified TCTP.  
Recombinant TCTP expressed in both E. coli and kidney cells stimulated B cell 
proliferation in a dose-dependent manner.  Recombinant TCTP enhanced B cell-
activation induced by IL-2, IL-4, IL-5 and anti-CD40-antibodies, and up-regulated the 
expression of IL-1 and IL-6.  This response was not due to an indirect effect caused by 
histamine secreted in response to TCTP, as the B-cell cytokine expression profile 
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induced by histamine is different to that induced by TCTP.  Additionally, TCTP was 
shown to bind to B cells by FACS analysis (Kang et al., 2001).    
 
1.5.7 Inhibition of T-cell activation by TCTP 
Inhibition of IL-2 and IL-13 production was observed in purified primary T cells 
and the Jurkat T cell line incubated with TCTP then stimulated with PMA and the calcium 
ionophore A23187 compared with cells stimulated without TCTP incubation.  The activity 
of the IL-2, IL-4 and IL-13 promoters was shown to be inhibited by up to 70% by TCTP 
incubation.  Incubation of T cells with TCTP did not affect rates of apoptosis or cell 
proliferation (Vonakis et al., 2003).         
 
1.5.8 Interaction of TCTP and SHIP 
The group that has performed much of the research into the induction of 
histamine release by TCTP have now altered their hypothesis of the function of TCTP.  
Recent work has focused on characterisation of basophils with a hyper-releasable 
phenotype, by investigation of alterations in intracellular signalling molecules in IgE+ 
basophils.  The signalling molecules studied were the Lyn and Syk tyrosine kinases, 
which are positive basophil activity regulators, and the SH2 domain-containing inositol 5’-
phosphatase (SHIP), which is a negative activity regulator.  SHIP is implicated in limiting 
basophil degranulation to incomplete stimuli; and TCTP was hypothesised to be an 
incomplete stimulus for basophils, along with IL-3 and D2O.  A negative correlation was 
observed between the amount of SHIP protein present and the maximum histamine 
release to TCTP.  The basophil mRNA levels of SHIP were not significantly different 
between the IgE+ and IgE- donors, implying post-transcriptional regulation of SHIP 
levels.  SHIP regulates phosphatidylinositol (3,4,5) triphosphate (PIP3) levels, and a 
PIP3 kinase inhibitor prevented TCTP-induced histamine release in IgE+ basophils 
(Vonakis et al., 2001).  In another study, knock-down of SHIP-1 expression in cultured 
basophils was performed using siRNA.  Histamine release induced by TCTP was 
enhanced in the SHIP-1 knock-down basophils, with the amount of enhancement 
correlating to the percentage of expression inhibition (Langdon et al., 2008).  No 
explanation was given as to how these new findings fit with the earlier stripped basophil 
assay experiments, where basophils could be made IgE+ with the addition of sera 
(MacDonald et al., 1991).  
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1.6 Parasite TCTP functions 
1.6.1 Malarial TCTP induces histamine and IL-8 release 
Malaria pathogenesis is complex, and the host immune system may contribute to 
pathology.  Histamine, IL-8 and eosinophils are all reported to be elevated during malaria 
infection. Increased histamine has been associated with disease severity in both P. 
falciparum infections and in several animal models.  Elevated IgE levels have also been 
associated with malaria severity (MacDonald et al., 2001).   
 
At the amino acid level, P. falciparum TCTP shares 33% identity and 54% 
similarity with human TCTP.  In IgE+ allergic donor basophils, recombinant Pf TCTP 
stimulated histamine release, and also induced IL-8 release from allergic donor 
eosinophils in vitro.  Pf TCTP was a log less active than human TCTP (MacDonald et al., 
2001).   
 
Evidence of Pf TCTP secretion was observed in in vitro cultures and in malaria-
infected individuals.  Cultured trophozoite stages of P. falciparum contained 87±21 µg of 
TCTP per 109 infected red blood cell (irbc).  When cultured P. falciparum was harvested 
after schizogony, the culture supernatants contained 44±6 µg TCTP per 109 irbc, 
therefore around half of the total parasite TCTP was released during schizogony.  Pf 
TCTP was found at concentrations of around 0.6 µg/ml in the plasma of human 
volunteers with subpatent (<4 irbc/µl) infections, and at concentrations of 1.41 µg/ml in 
severely infected Malawian children.  No PfTCTP was detected in the plasma of 
uninfected controls.  There was no correlation between plasma PfTCTP levels and 
parasitemia. It was suggested that as P. falciparum parasites are sequestered, secreted 
Pf TCTP might have local rather than systemic effects.  The induction of histamine 
release by malarial TCTP could assist the parasite by inducing vasodilation and 
increased expression of endothelial adhesion factors such as thrombomodulin, to which 
P. falciparum-infected erythrocytes adhere (MacDonald et al., 2001). 
 
1.6.2 Malaria TCTP may competitively inhibit activation of B-cells by 
host TCTP 
The 3D structure of P. knowelsi, a primate malaria, has been solved, and 
structural analysis revealed the presence of an extra helical segment that is a β-sheet in 
other TCTPs.  This helix is present at amino acid residues 22-30, close to the GTPase 
binding pocket, and the researchers propose that this would hinder G protein binding.  
The researchers propose that Plasmodium TCTP may act as a dominant negative 
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mutant in the host, as it could potentially block the action of B cells due to its proposed 
inability to bind G proteins (Hinojosa-Moya et al., 2008).  Therefore it would compete with 
the host endogenous TCTP, which has been shown to activate B cells in mice (Kang et 
al., 2001).  This extra helical segment is also present in P. yoelii TCTP at residues 22-31.    
 
1.6.3 Malarial TCTP may self-interact, and binds calcium 
Analysis of P. falciparum TCTP using the Multicoil server showed that amino 
acids 75 to 106 had a possibility of forming a coiled coil, and thus being a potential site 
for self-interaction to form multimers (Chae et al., 2006).  Like several other TCTPs, 
malarial TCTP was shown to bind calcium (Bhisutthibhan et al., 1999). 
 
1.6.4 Other parasite TCTPs induce histamine release from basophils 
and induce host immune responses 
The TCTP from the human filarial parasites Wuchereria bancrofti and Brugia 
malayi can induce histamine release in a basophil cell line in vitro.  W. bancrofti and B. 
malayi cause human lymphatic filariasis, with symptoms including lymphoedema and 
elephantitis.  These parasites can also induce a rare allergic condition known as tropical 
pulmonary eosinophilia, which involves elevations in levels of circulating eosinophils, IgE 
and IgG4.  
 
Both B. malayi and W. bancrofti TCTP induced release of histamine in vitro. 
TCTP induced histamine release in an IgE-independent manner in peritoneal mast cell 
preparations from C57Bl/6 mice, and also induced histamine release from RBL-2H3 
cells.  When injected into the peritoneal cavity of ovalbumin-sensitised C57BL/6 mice, B. 
malayi TCTP induced an inflammatory infiltration of eosinophils. Additionally, both Bm 
and Wb TCTP bound calcium as tested with a 45Ca overlay assay (Gnanasekar et al., 
2002). 
 
Anti-BmTCTP antibodies recognised a 25 kDa protein in adult females, in 
microfilaria and in the ES of microfilaria, and recognised proteins around 48 and 96 kDa 
in adult males, adult females and in microfilaria, indicating the presence of TCTP 
multimers in these life stages.  Recombinant filarial TCTP also formed multimers under 
non-reducing conditions.  Evidence for the secretion of TCTP from some parasite life 
stages was observed, as B. malayi TCTP was found in abundance in 
excretory/secretions of microfilariae, despite lacking a signal sequence.  TCTP found in 
excretory/secretion products was mostly monomeric. Differential expression of TCTP 
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mRNA and protein was observed in different B. malayi life stages.  Only low transcript 
and protein expression of TCTP was detected in L3 stages, which are the infective 
stages transmitted by the cold-blooded mosquito vector.  In the subsequent L4, adult and 
microfilariae stages found in the warm-blooded human host, abundant TCTP mRNA and 
protein expression was observed.  As discussed in section 1.3.5, the upregulation of 
TCTP expression in response to a host body temperature increase was also observed in 
Trichinella nematodes, and may be part of a parasite adaptive response (Mak et al., 
2007). 
 
Work by the same group revealed similar activities for the TCTP of Schistosoma 
mansoni, a human flatworm parasite.  SmTCTP could induce the release of histamine 
from RBL-2H3 cells, and bound calcium.  SmTCTP injected into OVA-sensitised C57Bl/6 
mice induced eosinophil infiltration within 24 hours. SmTCTP formed monomers and 
dimers in different life stages, and differential expression was observed, in that high 
levels of TCTP mRNA and protein were only detected in the vertebrate host life stages 
(Rao et al., 2002). 
 
A recent report by this group stated that B. malayi TCTP functions as an 
antioxidant protein.  TCTP chemically reduced by a number of agents was able to protect 
DNA from oxidative damage, and this activity was shown to involve the three cysteine 
residues.  No further histamine-releasing activities of filarial TCTP were reported, and 
attempts were not made to relate this new finding to the earlier work (Gnanasekar and 
Ramaswamy, 2007). 
 
A TCTP homolog from the dog tick species Dermacentor variabilis was identified 
as a secreted tick saliva protein.  The tick TCTP was expressed in E. coli as a 
thioredoxin-fusion protein, and was able to induce histamine release from RBL-2H3 cells 
in a dose-dependent manner (Mulenga et al., 2003).  A more recent report by this group 
identified that TCTPs present in several tick species were immunologically cross-
reactive, and did not bind calcium as demonstrated by an overlay assay (Mulenga and 
Azad, 2005).    
 
Cladosporium herbarum is an allergenic fungal species, and between 5 and 30% 
of allergy patients have IgE reactive to the fungus.  Specific IgE antibodies to fungal 
TCTP were found in nine individuals allergic to C. herbarum out of a total of 306 patients, 
and so TCTP was classed as a minor allergen.  In five of the nine patients, IgE that could 
recognise fungal TCTP also recognised human TCTP.  It was found that patients reactive 
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to TCTP had a higher occurrence of asthma.  The fungal TCTP was able to induce 
histamine release from human basophils with around half the potency of the human 
TCTP (Rid et al., 2008).  
 
Eumycetoma patients have cancerous swellings caused by the fungus Madurella 
mycetomatis.  TCTP was identified as an immunogenic antigen from this fungus, and 
was secreted in in vitro cultures.  A significant number of eumycetoma patients and some 
healthy controls had elevated levels of anti-TCTP antibodies.  TCTP was expressed in 
newly forming fungal grain cells, which are in direct contact with host neutrophils, but was 
not expressed in fully formed grain, which forms a cement material in which neutrophils 
are not present.  Eumycetoma patients with the largest lesions and the greatest disease 
duration had the highest anti-TCTP IgG antibody levels (van de Sande et al., 2006).    
 
1.6.5 The role of histamine and eosinophils in malaria 
Elevations in histamine in humans infected with P. falciparum have been 
observed, with greater elevations in patients with systemic complications (Srichaikul et 
al., 1976).  One report observed a significant increase (p<0.025) in plasma histidine and 
a five-fold elevation (p<0.001) in plasma histamine in children infected with P. falciparum 
compared with uninfected controls (Enwonwu et al., 2000).   
 
In one experiment, tricyclic antihistamine treatment prior to and during infection 
with sporozoites could completely prevent patent infection in mice inoculated with P. 
yoelii nigeriensis.  At the doses used, the antihistamines did not have direct 
schizontocidal activity, meaning that the prevention of infection by these drugs was most 
likely due to their indirect activity in preventing histamine release in the mice (Singh and 
Puri, 1998).  The antihistamines tested could also induce a reversal of chloroquine 
resistance in P. falciparum and P. yoelii (Peters et al., 1990; Singh and Puri, 1998).    
 
In another study, C57BL/6 mice deficient in histamine due to disruption of the 
histidine decarboxylase gene were resistant to cerebral malaria development, instead 
succumbing to hyperparasitemia at around 20 days post-infection.  Mice deficient in the 
H1 histamine receptor also had delayed mortality when infected with P. berghei 
sporozoites or irbc, and treatment with drugs that inhibit the H1 receptor could also delay 
mortality.  In the histidine decarboxylase-deficient mice, the BBB integrity was preserved, 
and infected erythrocytes did not sequester in the brain blood vessels.  The expression of 
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vascular adhesion molecules in the brain was also decreased in the mutant mice 
(Beghdadi et al., 2008).   
 
Elevations in eosinophils have been observed in P. falciparum infections.  
Eosinophils may be protective in malaria infection by inducing parasite killing or they may 
contribute to pathology by the release of their granule proteins, including eosinophil 
cationic protein (ECP) and eosinophil protein X (EPX), as these are potent neurotoxins 
and may contribute to CM.  Increased eosinophil counts were observed in Ghanian 
children with asymptomatic infections, whereas children who acquired symptomatic 
infections had a decrease in eosinophil counts.  In a separate hospital-based study, 
children with cerebral malaria, severe anaemia, or uncomplicated malaria all had 
significantly low eosinophil counts during acute illness followed by eosinophilia 30 days 
after cure.  Plasma levels of ECP and EPX are used as markers of eosinophil activation.  
Despite low eosinophil counts, plasma ECP levels were significantly higher in all patient 
groups prior to treatment than on day 30.  EPX levels were significantly higher in patients 
with CM prior to treatment.  In infected children at time of low eosinophil counts the bone 
marrow is rich in eosinophil precursors. Therefore, low eosinophil counts may be due to 
tissue sequestration and destruction (Kurtzhals et al., 1998).   
 
In a small study of P. falciparum-infected Malawian children, IL-8 levels 
decreased in eight of ten patients following antimalarial treatment (MacDonald et al., 
2001).
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1.7 Artemisinin and TCTP: 
1.7.1 Antimalarial action of artemisinin 
Artemisinin (qinghaosu) is extracted from the sweet wormwood plant Artemisia 
annua.  The brewed leaves of the plant have been used in traditional Chinese medicine 
for thousands of years to treat chills and fever.  Due to the low solubility of artemisinin in 
oil and water, several semi-synthetic derivatives have been developed.  These include 
artemether, arteether, and artesunate (Efferth, 2005).  By the early 1990’s artemisinin 
derivatives were widely used in Thailand, Burma and Vietnam (Meshnick, 2002), and are 
now a major part of the recommended antimalarial therapy in many countries 
(http://www.rbm.who.int/wmr2005/).  Artemisinin has a short half-life, which has helped to 
prevent the development of drug resistance by parasites but also led to recrudescence of 
parasitemia in early clinical trials.  Artemisinin acts on the most parasite life stages of any 
antimalarial, from young rings to schizonts as well as gametocytes, this may also 
contribute to the slow development of drug resistance (Krishna et al., 2004).  
 
The precise antimalarial action of artemisinin is disputed, with most but not all 
researchers agreeing that artemisinin interacts with intraparasitic haem as well as other 
parasite proteins (e.g. Meshnick, 2002; Olliaro et al., 2001; Robert et al., 2002).  The 
malaria parasite is rich in haem as a by-product of haemoglobin digestion.  Artemisinin 
derivatives are inactive against the RC strain of P. berghei, which doesn’t produce 
hemozoin (Meshnick, 2002).   
 
In the argument against the haem-activation of artemisinin, it is stated that haem 
must be in the ferrous state for the interaction to occur.  As the food vacuole is not a 
reducing environment, haem would not be present in this state for extended lengths of 
time.  Also, artemisinin derivatives unable to react with haem but with potent antimalarial 
activity exist, and artemisinin is active against young ring stages, which do not contain 
haemozoin.  Instead, it is argued that artemisinin binds to an active site of a parasite 
protein, specifically the PfATP6 Ca2+-transporting ATPase (as reviewed in section 1.7.4), 
(Krishna et al., 2004).  
 
The precise mechanism of the antimalarial action of artemisinin is not yet fully 
determined, however one hypothesis is that haem-mediated decomposition of the 
artemisinin endoperoxide bridge produces carbon-centred free radicals that then act as 
alkylating agents for specific parasite proteins (Meshnick, 2002).   
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1.7.2 Artemisinin and TCTP 
Some evidence exists that TCTP is a target of artemisinin, although whether this 
interaction contributes to parasite killing is unknown.  In a study of potential drug targets, 
P. falciparum-infected erythrocyte cultures were incubated with radio labelled 
dihydroartemisinin.  Several malarial proteins became labelled, including TCTP.  
Labelled proteins were identified by isoelectric focusing followed by SDS-PAGE and 
autoradiography.  TCTP was present as a strong band on the coomassie-stained gel and 
was the brightest band seen on autoradiography.   Dihydroartemisinin reacted covalently 
with TCTP in vitro in the presence of hemin, and the association increased up to a 
concentration of 1 drug/TCTP molecule.  More labelled dihydroartemisinin was retained 
in vitro when added to TCTP and hemin compared with artemisinin added to TCTP or 
hemin alone.  Scatchard analysis showed that two hemin-binding sites of modest affinity 
existed on TCTP.  The absorption spectra of TCTP+hemin were different to hemin alone, 
suggesting that binding occurs. Artemisinin was shown to bind to TCTP and not hemin by 
the fact that the TCTP was radio labelled (Bhisutthibhan et al., 1998). 
 
The same group then investigated the localisation of TCTP within malarial cells.  
By immunofluorescence and immuno-electron microscopy, TCTP was found to be mainly 
present in the cytoplasm and the parasitophorous vacuolar and/or parasite limiting 
membranes.  Some TCTP was also present in the food vacuolar membrane 
(Bhisutthibhan et al., 1999). 
 
TCTP expression at the protein level was found to be up-regulated in an 
artemisinin-resistant strain of P. yoelii.  The art-resistant strain was approximately four 
times less sensitive to artemisinin than the sensitive strain, and accumulated 43% less 
radio-labelled drug in vitro.  Artemisinin appeared to react with the same parasite 
proteins in both strains, with artemisinin-associated bands at 14, 22.5, 36.5, 42 and >150 
kDa.  The TCTP DNA sequence was identical in both P. yoelii strains, but the art-
resistant parasite strain expressed 2.5-fold more TCTP protein, as quantified by western 
blot (Walker et al., 2000).  
 
In further research, it was demonstrated that [3H] dihydroartemisinin adducts 
could be immunoprecipitated using anti-TCTP antibodies.  Cultured P. falciparum at the 
late ring and trophozoite stages were incubated with [3H] dihydroartemisinin or [35S] 
methionine.  Isolated parasites were lysed, incubated with anti-TCTP or control 
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antibodies, and proteins were precipitated with protein A-sepharose.  The proteins 
obtained were separated by SDS-PAGE, and visualised both by coomassie stain and by 
autoradiography.  Radio labelled bands were seen at 22 and 45 kDa in artemisinin-
incubated parasite lysates following anti-TCTP immunoprecipitation.  It was suggested 
that the 45 kDa band might be a TCTP oligomer not reduced by SDS (Bhisutthibhan and 
Meshnick, 2001).   
 
A molecular docking study using the computer program FlexiDock was used to 
study the interaction of heme, artemisinin and TCTP.  A 3D model of P. falciparum TCTP 
was created using the solved NMR structure of S. pombe TCTP as a template.  The 
peroxide bond of artemisinin was docked within a short distance (2.6Å) of the iron of 
heme.  The C4-radical of the heme-activated artemisinin docked within a short distance 
(2.8Å) of the single cysteine residue (amino acid position 14) of the P. falciparum TCTP 
(Chae et al., 2006).  Earlier research had found that blocking the single cysteine of 
PfTCTP reduced artemisinin binding by 67% (Bhisutthibhan et al., 1998). 
 
A recent study of potential drug targets was performed on artemisinin-resistant 
P.c. chabaudi parasites.  The drug resistance was genetically stable and mosquito-
transmissible.  Artemisinin resistance could only be generated in parasite clones already 
resistant to chloroquine, suggesting a potentiation mechanism in the development of 
drug resistance.  The nucleotide sequences of potential drug targets, including the P. 
chabaudi homologs of PfATP6, TCTP, pfmdr1 and pfcrt, were analysed in the drug-
resistant mutants. The nucleotide sequences of the mutant resistant parasites and the 
parental sensitive parasites were identical in both the coding sequences and the 
untranslated regions for all of the genes analysed.  These genes were also not present in 
increased copy number in the resistant parasites (Afonso et al., 2006).  However, as 
increased protein levels of TCTP were previously found in artemisinin-resistant P. yoelii 
parasites (Walker et al., 2000), and TCTP expression is controlled at the translational 
level and is not proportionate to mRNA levels, this finding does not disprove the theory 
that TCTP is involved in the antimalarial action of artemisinin.    
 
1.7.3 Other malarial targets of artemisinin 
In P. falciparum, artemisinin, but not quinine or chloroquine, was shown to inhibit 
PfATP6, a sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) othologue.  SERCAs are 
involved in transport of cytosolic calcium into the ER, and assist in the maintenance of 
high ER calcium levels (Xu et al., 1999).  In this study, a fluorescent artemisinin 
derivative localised to membranes in the parasite cytoplasm and to tubovesicular 
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membranes in the cytoplasm of the host erythrocyte, and did not localise to the parasite 
food vacuole.  Thapsigargin, another SERCA inhibitor, antagonised the antimalarial 
activity of artemisinin.  Chelation of iron inhibited the antimalarial activity of artemisinin 
but did not affect the activity of thapsigargin (Eckstein-Ludwig et al., 2003).  
 
The effects of chloroquine and artemisinin treatment on the mechanisms involved 
in the parasite regulation of H+ and Ca2+ homeostasis were studied.  Pools of calcium 
have been found in the acidic compartment of several malaria species.  Both artemisinin 
and chloroquine were shown to act of the acidic compartment of the parasite, promoting 
alkalisation.  The drugs also had a possible effect on the release of calcium from the 
acidic compartment, although this was not confirmed directly (Gazarini et al., 2007).  This 
finding lends support to the theory of interaction of artemisinin with both PfATP6 and 
TCTP, as both are involved in calcium homeostasis (e.g. Arcuri et al., 2005; 
Bhisutthibhan et al., 1999; Eckstein-Ludwig et al., 2003; Feng et al., 2007; Sanchez et 
al., 1997). 
 
1.7.4 Artemisinin acts as an anti-cancer agent 
Artemisinin and its derivatives are cytotoxic to cancer cells at low concentrations 
in vitro, however higher concentrations are required for efficacy in vivo.  It was found that 
yeast strains deficient in certain mitosis-regulating or proliferation-regulating genes were 
more sensitive to artesunate (Efferth et al., 2001), and artemisinin was found to 
potentiate proliferation of leukaemia cells (Kim et al., 2003).   
 
A study to identify candidate genes that may contribute to the action of 
artemisinin on tumour cells was performed using mRNA expression analysis.  Candidate 
genes identified included those involved in regulation of proliferation, angiogenesis, and 
apoptosis (including the anti-apoptotic protein Bcl-2 and the pro-apoptotic protein Bax).  
Artesunate treatment caused a decrease in the number of Bcl-2 positive hepatic 
carcinoma cells, and an increase in the number of Bax-positive cells (Wang et al., 2002).  
TCTP has been reported to interact with Bcl-2 to synergistically inhibit the action of Bax 
in promoting apoptosis (Li et al., 2001b), (reviewed in section 1.3.11).   
 
The mRNA expression of TCTP correlated with sensitivity to artesunate in tumour 
cells.  Cells expressing high levels of TCTP were more sensitive to artesunate, while 
cells with a low expression level of TCTP were resistant (Efferth, 2005).  Direct 
comparisons between this work and the work of Walker et al. (2000) are difficult, as one 
study was based on mRNA levels and the other on protein, and it has been repeatedly 
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shown that TCTP protein and mRNA levels are not proportionate.  However, this finding 
appears to be in contrast with the earlier finding of increased TCTP present in 
artemisinin-resistant parasites.  
 
The work on the interaction of PfATP6 with artemisinin stated that artemisinin has 
specificity to malarial calcium pumps and does not work on mammalian protein homologs 
(Krishna et al., 2004).  This suggests that artemisinin has a different mode of action on 
human cancer cells, possibly through interaction with TCTP.  However, in a recent 
review, it was suggested that artemisinin has anti-cancer activity via its interaction with 
iron, which is present at higher concentrations in cancer cells than in normal cells 
(Nakase et al., 2008).   
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1.8 TCTP gene knockout or expression inhibition 
experiments 
Expression of TCTP has been inhibited in several species, using several methods 
including gene disruption and siRNA.  In an early experiment, a TCTP null mutant made 
in yeast had no mutant phenotype (Sanchez et al., 1997).  In a recent experiment in 
Drosophila flies, TCTP expression was disrupted using RNAi and gene disruption.  
Targeted inhibition of TCTP expression by RNAi reduced the size of various tissues, 
caused by a decrease in both cell size and cell number.  Ubiquitous inhibition of TCTP 
expression was incompletely lethal in the larval stage.  Co-expression of complementary 
TCTP DNA rescued the mutant phenotypes.  In Drosophila TCTP knockouts (made by 
targeted gene disruption), 100% lethality was observed at the larval stage (Hsu et al., 
2007).    
 
TCTP knockouts have been created in mice by gene disruption.  Mice 
heterozygous for the TCTP deleted allele were fertile and morphologically normal, and 
heterozygous embryos developed normally.  No homozygous mutant progeny were 
obtained from heterozygote crosses, indicating that the TCTP -/- mutation was 
embryonically lethal.  Embryos at various life stages were examined to determine the 
gestation stage at which the TCTP deletion became lethal.  Homozygote mutant embryos 
were present up to 10.5 days after fertilisation, however the phenotype appeared 
abnormal from 6.5 days onwards.  The major abnormalities seen were severe growth 
retardation and cellular disorganisation.  Increased cell death was observed in the TCTP 
mutant embryos from day 6.5 onwards.  Conditional TCTP deletion experiments were 
also performed to investigate if TCTP was essential in mouse embryonic fibroblast (MEF) 
cells.  MEFs were isolated from homozygous TCTP mutant mice and infected with Cre 
recombinase to generate knockouts.  These knockout fibroblasts developed normally, 
and were not more sensitive to apoptotic stimuli than wild-type MEFs.  This indicates that 
TCTP is essential only in some stages of mouse development, or in some cell types 
(Chen et al., 2007). 
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1.9 Malarial gene knockout experiments 
Methods for the disruption of gene expression have been developed for several 
malarial species.  Disruption of gene expression by homologous recombination of 
exogenous DNA is a commonly used technique in P. falciparum and P. berghei.  In P. 
falciparum, the target DNA used for recombination is a circular plasmid, in P. berghei 
linearised target DNA is used (Waters et al., 1997a).  These methods exploit the haploid 
nature of the parasite over much of its life cycle, meaning that the phenotype conferred 
by particular proteins can be studied by the disruption of a single gene copy.  
 
The transfection of P. berghei with exogenous DNA was first reported in 1995.  
Initially, circular plasmids were used to transfect exoerythrocytic P. berghei merozoites 
by electroporation, with a drug-resistant mutant (Ser110→Asn) of the P. berghei 
bifunctional dihydrofolate reductase-thymidylate synthase (DHFR/TS) enzyme used as a 
selectable marker.  Parasites were injected into rats following electroporation, and 
transfected parasites were selected for by treatment of rats with an i.p. injection of the 
antifolate antimalarial pyrimethamine.  Cloning by limiting dilution in mice was then used 
to separate drug-resistant parasites for genotype analysis.  In this initial experiment, the 
plasmid DNA was found to not integrate at the designed sites of homologous 
recombination, but instead was maintained as an extrachromosomal plasmid (van Dijk et 
al., 1995).  Later, it was reported that although P. berghei parasites can maintain 
episomal plasmids over several generations, the plasmids are randomly segregated 
during schizogony and are lost during cell division in the absence of drug pressure 
(Waters et al., 1997a). 
 
The method for P. berghei transfection has since undergone several 
modifications.  The successful disruption of target genes using linearised plasmids was 
first reported in 1997 for genes encoding both the circumsporozoite (CS) protein (Menard 
et al., 1997) and the thrombospondin-related anonymous protein (TRAP) (Sultan et al., 
1997).  Linearised plasmids were introduced into mature schizonts rather than free 
merozoites.  In these experiments, the targeting plasmid was linearised with a single 
restriction endonuclease, and in the TRAP knockout experiment revertant parasites were 
obtained in which the linearised plasmid had been excised from the genome.  A 
replacement construct was then designed to allow recombination by double crossover 
recombination, preventing reversion.  The TRAP knockout parasites were 10,000 times 
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less infective than wild-type parasites, and sporozoite gliding motility and mosquito 
salivary gland invasion were not observed (Sultan et al., 1997).     
 
To reduce the likelihood of unwanted homologous recombination, a drug-resistant 
form of the Toxoplasma gondii DHFR/TS was developed for use as the selectable 
marker, with the 5’ and 3’ untranslated regions (UTRs) of the P. berghei DHFR 
incorporated (Waters et al., 1997a).    
 
Depending on the desired outcome, P. berghei transfection is performed using 
either insertion constructs, with one continuous sequence of target gene, or with 
replacement constructs that contain two regions of the target gene separated by the 
selectable marker.  Linearised insertion constructs integrate via a single crossover, with 
integration of the entire plasmid.  Linearised replacement constructs are designed to 
integrate by double crossover, leading to disruption of the target gene by allelic 
exchange.  These constructs are also often designed to delete the majority or all of the 
coding sequence of the target DNA.  Thus the wild-type gene cannot be spontaneously 
re-created by excision of the replacement construct or gene rearrangements.  However, 
the integration of replacement constructs by single crossover has been observed, in 
which the wild-type genotype can recur by excision of the target DNA.  It is hypothesised 
that the replacement vectors are present as re-circularised plasmids prior to single 
crossover recombination (Menard and Janse, 1997).  
 
Using electroporation techniques, regions of target DNA as small as 500 bp have 
been shown to be sufficient for recombination, with an upper size limit of around 1 kb 
recommended due to the instability of plasmids containing large regions of A/T-rich 
Plasmodium DNA (Waters et al., 1997a). 
 
Repeated erythrocytic cycles of Plasmodium can lead to the accumulation of 
spontaneous genomic rearrangements, including large deletions of protein-coding 
sequences.  Therefore the recommendation is to analyse the phenotype of several 
clones generated from independent experiments, and to complement the disrupted gene 
using a second selectable marker to see if the wild-type phenotype is restored (Menard 
and Janse, 1997).   
 
The P. berghei transfection techniques have been used to introduce gene 
expression in parasite life stages.  Using circular plasmids, the Pbs21 gene, encoding a 
stage-specific surface protein, was expressed in trophozoites, schizonts and 
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gametocytes.  This expression of this protein is usually restricted to mosquito life stages 
(Margos et al., 1998).  The P. falciparum AMA-1 gene has also been expressed in P. 
berghei by transfection with circular plasmids (Kocken et al., 1998).  Green fluorescent 
protein (GFP) and luciferase have been expressed in P. berghei parasites, using stage-
specific promoters, which could allow the selection of specific life stages by FACS 
analysis (de Koning-Ward et al., 1999; de Koning-Ward et al., 1998). 
 
In P. berghei transfections, the human DHFR gene has also been used as a 
selectable marker, with a separate antifolate drug (WR99210) used for selection.  This 
combination can be used for selection in both pyrimethamine resistant and sensitive 
parasites.  This second selectable marker allows for complementation of disrupted genes 
to confirm that the wild-type phenotype can be reinstated, as it is possible that alterations 
in phenotype seen after transfection could be due to genetic disruptions to areas other 
than the target gene (de Koning-Ward et al., 2000).  Using this second selectable marker 
system, the TRAP gene was re-introduced into TRAP-knockout parasites, and the wild-
type phenotype was restored (Sultan et al., 2001). 
 
These transfection techniques have also been used to disrupt genes in P. yoelii.  
The drug-resistant form of the P. berghei DHFR/TS gene was used as a selectable 
marker.  The TRAP gene was disrupted, with the phenotype obtained identical to the P. 
berghei TRAP knockout.  In this experiment, circular and linearised plasmids were used.  
Transfected circular DNA could be maintained under drug pressure as autonomously 
replicating plasmids.  Linearised plasmids integrated at the TRAP locus by a single 
crossover, but the transfected DNA was found to be excised from the genome in blood-
stage parasites, resulting in the restoration of the wild-type phenotype (Mota et al., 2001).    
 
  One application of the P. berghei transfection system is in the use of knockout 
parasites as a vaccine.  In one experiment, the sporozoite-specific P36p protein was 
disrupted using a replacement vector.  In mice, immunisation with the P36p-knockout 
sporozoites conferred protective immunity against subsequent challenge with wild-type 
sporozoites.  Within hepatocytes, the P36p-knockout sporozoites failed to develop fully 
and were unable to form a mature parasitophorous vacuole (van Dijk et al., 2005). 
 
The use of a more advanced transfection method for P. berghei was first reported 
in 2006 (Janse et al., 2006b).  In this method, a nucleofector machine (Amaxa) was used 
in place of an electroporator.  The nucleofector device is designed with specific electrical 
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parameters for the transfection of various cell types, allowing for efficient transport of 
DNA directly into the nucleus (http://www.amaxa.com/products/technology/).  The 
transfection efficiency, as determined by the number of parasites surviving following 
pyrimethamine selection, was between 10-2 and 10-3 using the nucleofector, compared 
with transfection efficiencies of between 10-7 and 10-9 using electroporation.  The 
nucleofector machine was used to generate parasites with a GFP or luciferase genes 
integrated by double crossover homologous recombination into the ssu-rna or p230p 
genes of P. berghei.  Disruption of these genes has a negligible phenotypic effect.  A 
drug-selectable marker was not introduced, instead transfected parasites were selected 
for by FACS sorting.  Flow cytometry sorting can be performed immediately after 
transfection, without the need for drug selection.  Transfection using the nucleofector 
allows homologous recombination of linear DNA with target fragments of around 300 bp 
(Janse et al., 2006a). 
 
The Amaxa nucleofector has also been used for P. yoelii transfection.  Circular 
plasmids containing human DHFR and TgDHFR/TS selectable markers were introduced, 
however the disruption of genes by the integration of linear DNA was not assessed 
(Jongco et al., 2006). 
 
Stage-specific gene disruption techniques have been used in P. berghei for the 
examination of genes essential in blood-stage parasites.  The Flp/FRT system of yeast 
was used for site-specific recombination after cross-fertilisation in the mosquito vector 
(Carvalho et al., 2004).  However, further development of this system has not been 
reported, and requires the use of specific mosquito species. 
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1.10 Research Aims 
The research aims of this thesis were: 
 
1) To confirm the protective effect of P. falciparum TCTP immunisation previously 
observed in the P. yoelii YM challenge system 
 
2) To produce recombinant P. yoelii and P. berghei TCTP of high yield and purity 
 
3) To evaluate the protective effect of P. yoelii and P. berghei TCTP immunisation 
in several rodent malarial challenge models  
 
4) To produce P. berghei parasites with the TCTP gene disrupted, to further 
assess the functions of malarial TCTP 
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Chapter 2: Materials and Methods 
 
2.1 Materials and equipment suppliers 
 
Material Supplier 
10X AmpliTaq buffer Applied Biosystems, USA 
10X AmpliTaq Gold buffer “ 
10X Pfu PCR buffer Roche Diagnostics, Germany 
10X Ligase buffer Promega, USA 
96 well plate Grenier Bio-one, Germany 
Acetic acid, glacial BDH Chemicals, Australia 
Adenine sulfate Sigma-Aldrich, USA 
Agarose (DNA grade) Amresco, USA 
Amaxa Nucleofector Amaxa, Germany 
Amicon centrifugal filters (3 kDa cut-off) Millipore, USA 
Amino acids: 
L-Arginine HCl, L-Aspartic acid, L-Glutamic 
acid, L-Histidine HCl, L-Isoleucine, L-
Leucine, L-Lysine HCl, L-Methionine, L-
Phenylalanine, L-Serine, L-Threonine, L-
Tryptophan, L-Tyrosine, L-Valine  
 
Sigma-Aldrich, USA 
Ammonium bicarbonate (NH4HCO3) “ 
Ammonium persulfate (APS) “ 
Ampicillin CSL, Australia 
AmpliTaq DNA polymerase Applied Biosystems, USA 
Bacteriological agar Oxoid, Australia 
Balance: 
(i) Analytical balance 
(ii) 0.1 - 500 g balance 
 
Sartorius GMBH, Germany 
U-Lab, Australia 
Benzamidine Sigma-Aldrich, USA 
Bis-acrylamide (40%) Amresco, USA 
Blocking reagent (for southern blot) Roche Diagnostics, Germany 
Bovine serum albumin (BSA) Promega, USA 
Bromophenol blue BDH Chemicals, Australia 
Calcium chloride “ 
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Capillary tubes (for blood collection) Becton-Dickinson, USA 
Carousel shaker Ratek, Australia 
Casein Sigma-Aldrich, USA 
Cell Homogeniser Braun, Germany 
Centrifuges: 
(i) microcentrifuge 
(ii) Benchtop 1 (Sorvall 6000D) 
     Benchtop 2 (Allegra 21R) 
(iii) High-speed (Avanti J-25) 
 
Eppendorf, USA 
Thermo Scientific, USA 
Beckman, USA 
“ 
Centrifuge bottles (250 ml) “ 
Centrifuge tubes: 
(i) 1.5 ml 
(ii) 10 ml 
(iii) 15 ml 
(iv) 50 ml 
 
Eppendorf, USA 
Sarstedt, Germany 
“ 
Grenier Bio-one, Germany 
CF11 powder Whatman, England 
4-Chloro-1-Napthanol Sigma-Aldrich, USA 
Chromatography systems: 
Biologic LP system 
Biologic HP system 
Biologic Controller & HR software (v. 2.0) 
Fraction collector (model 2128) 
Mono-Q anion-exchange column 
 
Bio-Rad, USA 
“ 
“ 
“ 
Pharmacia Biotech, Sweden 
Chloroform LabScan 
Columns for chromatography (1 and 5 ml) Qiagen, USA 
Coomassie Brilliant Blue G-250 Sigma-Aldrich, USA 
Coomassie Brilliant Blue R-250 “ 
Copper sulphate BDH chemicals, Australia 
Cryovial (1.8 ml) Nunc (Thermo Scientific, USA) 
CSPD substrate Roche Diagnostics, Germany 
Detoxi-gel resin Qiagen, USA 
Dextran sulphate Pharmacia Biotech, Sweden 
D-Glucose BDH Chemicals, Australia 
DIG DNA Labelling and Detection kit Roche Diagnostics, Germany 
Dimethyl formamide (DMF) BDH Chemicals, Australia 
Dimethyl sulfoxide (DMSO) “ 
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Dithiothreitol (DTT) Diagnostic Chemicals, Canada 
DNase I Sigma-Aldrich, USA 
dNTPs Roche Diagnostics, Germany 
Dye-terminator Ready Reaction sequencing 
mix v3.1 and BigDye Sequencing buffer 
Micromon DNA sequencing facility, 
Monash University, Australia 
E-64 Roche Diagnostics, Germany 
Electrophoresis units: 
(i) DNA - minigel and midigel 
(ii) Protein - Mini-Protean II gel system 
(iii) Western - Mini-Protean II Transblot 
unit 
 
Plaztech, Australia 
Bio-Rad, USA 
“ 
Electroporation machine (Gene Pulser) “ 
Electroporation cuvette “ 
Ethanol Sigma-Aldrich, USA 
Ethidium bromide “ 
Ethylenediamine tetra-acetic acid (EDTA) BDH Chemicals, Australia 
Expand polymerase Roche Diagnostics, USA 
Euthal Obtained from RMIT Animal Facility 
Ficoll BDH Chemicals, Australia 
Freunds adjuvant (complete/incomplete) Sigma-Aldrich, USA 
Giemsa powder ProSciTech, Australia 
Glass beads (0.45 mm) Sigma-Aldrich, USA 
Glycerol BDH Chemicals, Australia 
Glycine “ 
Goat-anti-mouse IgG Sigma-Aldrich, USA 
Goat-anti-rabbit IgG “ 
Gradipure stain Gradipore Inc, USA 
Haemocytometer Superior Marienfeld, Germany 
Haemocytometer coverslips Menzel-Glaser, Germany 
Hydrochloric acid (32%) Sigma-Aldrich, USA 
Hydrogen peroxide (30%) BDH Chemicals, Australia 
Imidazole Sigma-Aldrich, USA 
IPTG “ 
Isoamyl alcohol BDH Chemicals, Australia 
Isopropanol “ 
Klenow polymerase Roche Diagnostics, Germany 
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Lambda DNA Promega 
Lethobarb Obtained from RMIT Animal Facility 
Leupeptin Roche Diagnostics, Germany 
Lithium acetate Sigma-Aldrich, USA 
Lysozyme Roche Diagnostics, Germany 
Magnesium chloride Applied Biosystems, and BDH, Aust. 
Magnesium sulphate BDH Chemicals, Australia 
Maleic acid “ 
β-mercaptoethanol Bio-Rad, USA 
Methanol BDH Chemicals, Australia 
Microscope Olympus, 
Microscope slides LOMB Scientific, Australia 
Molecular-grade water Invitrogen, USA 
NBT/BCIP Roche Diagnostics, Germany 
Needles (19-, 21-, 25-guage) Terumo, Australia 
Nitrocellulose membrane (Hybond-C) Amersham, USA 
N-lauryl-sarcosine Sigma-Aldrich, USA 
Nylon membrane (Hybond-N) Amersham, USA 
Omniscript RT kit Qiagen, USA 
OneShot™ competent cells Invitrogen, USA 
Orange G BDH Chemicals, Australia 
Orthophosphoric acid (85%) BDH Chemicals,Australia 
Parafilm Perchiney Plastic Packaging, USA 
Phosphate-buffered saline (PBS) tablets Oxoid, Australia 
pCR2.1 vector Invitrogen, USA 
Pefabloc Roche Diagnostics, Germany 
Pepstatin A Sigma-Aldrich, USA 
Peptone Oxoid, Australia 
Petri dishes Techno-plas, Australia 
Pfu polymerase Roche Diagnostics, Germany 
Phenol Amresco 
pH meter Radiometer, Denmark 
Pipettes: 
(i) Finnpipette Digital 
(ii) Nichipets 
 
Thermo Scientific, USA 
Nichiryo, Japan 
Platform shaker Ratek, Australia 
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Polyethylene glycol (PEG) 3350 Sigma-Aldrich, USA 
Potassium acetate BDH Chemicals, Australia 
Potassium chloride “ 
Potassium phosphate monobasic (KH2PO4) “ 
Pre-cast PAGE gels Gradipore Inc, USA 
Profinity™ resin Bio-Rad, USA 
Proteinase K “ 
Protein standards: 
BenchMark Pre-Stained  
Benchmark unstained 
Mark12 unstained 
SeeBlue Plus2 
 
Invitrogen, USA 
“ 
“ 
“ 
pRSETA vector Invitrogen, USA 
Pyrimethamine Obtained from WEHI, Australia 
Pyroneg detergent * 
Qiagen DNA Mini kit Qiagen,USA 
Qiaprep Spin Miniprep kit “ 
Qiaquick Gel Extraction kit “ 
Restriction endonucleases and buffers Promega, USA 
RNase A Sigma-Aldrich, USA 
RNase inhibitor Applied Biosyst 
Saponin Sigma-Aldrich, USA 
Single-stranded DNA Roche Diagnostics, Germany 
Shaking incubator (Multitron) Bottmingen, Switzerland 
Skim milk powder Bonlac Foods, Australia 
Sodium acetate (NaOAc) BDH Chemicals, Australia 
Sodium bicarbonate (NaHCO3) “ 
Sodium carbonate (Na2CO3) “ 
Sodium chloride (NaCl) “ 
Sodium dodecyl sulphate (SDS) “ 
Sodium hydroxide (NaOH) “ 
Sodium phosphate dibasic (Na2HPO4) “ 
Sodium phosphate monobasic (NaH2PO4) " 
Sorbitol “ 
Spectra/Por dialysis tubing Spectrum Laboratories, USA 
Spectrophotometer (UV-visible) Eppendorf, USA 
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Spectrophotometry cuvettes: 
(i) quartz 
(ii) plastic 
 
ATS, Australia 
Eppendorf 
Sucrose BDH Chemicals, Australia 
Sulphuric acid (H2SO4) “ 
Syringes (1, 3, 5, 10, 20, 60 ml) Terumo 
Syringe filters (0.2, 0.45 µm) Sartorius GMBH, Germany 
TA Cloning kit 
T4 DNA ligase 
Invitrogen, USA 
Promega, USA 
TALON™ resin Clontech, USA 
Tetramethylbenidine (TMB) substrate Becton-Dickinson, USA 
Tetramethylethylenediamine (TEMED) Bio-Rad, USA 
Tris base Amresco 
Tri-sodium citrate BDH Chemicals, USA 
Triton-X 100 Sigma-Aldrich, USA 
Tryptone Oxoid, USA 
Tween® 20 Sigma-Aldrich, USA 
UV transilluminator, Quantity One software Bio-Rad, USA 
Whatman paper Whatman, England 
X-Gal (5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside) 
Progen 
Yeast extract Oxoid, Australia 
Yeast nutrient base without amino acids BIO 101 Anachem, England 
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2.2 Preparation of materials 
Unless otherwise specified, the following conditions were used: All materials were 
prepared using deionised water filtered through a Milli-Q® system (Milli-Pore). All pH 
adjustments were made using 12 M (concentrated) HCl or 10 M NaOH.  Materials to be 
sterilised were autoclaved at 121°C for 20 min.  All reactions were performed at room 
temperature (rt).  Glassware was washed using Pyroneg detergent followed by rinsing in 
tap water with a final rinse in Milli-Q water.     
 
2.3 General DNA Materials and Methods 
2.3.1 DNA Materials 
2.3.1.1 TE Buffer 
10 mM Tris.HCl pH 8 
1 mM EDTA 
 
2.3.1.2 TEG/lysozyme 
25 mM Tris.HCl pH 8 
10 mM EDTA pH 8 
50 mM glucose 
Sterilised, 4 mg/ml lysozyme added.  Stored at 4°C.  
 
2.3.1.3 NaOH/SDS 
0.2 M NaOH 
1% w/v SDS 
 
2.3.1.4 KOAc 
2 M acetic acid 
3 M KAc 
 
2.3.1.5 Phenol/chloroform/isoamylalcohol (PCI) 
50% v/v phenol (distilled, neutralised, saturated with TE) 
46% v/v chloroform 
4% v/v isoamylalcohol 
 
2.3.1.6 Chloroform/isoamylalcohol (CI) 
96% v/v chloroform 
4% v/v isoamylalcohol 
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2.3.1.7 H2O/RNase A 
20 µg/ml pancreatic ribonuclease A in molecular grade water 
 
2.3.1.8 TE/RNase A 
20 µg/ml pancreatic ribonuclease A in TE buffer 
 
2.3.1.9 10X Loading dye 
40% w/v sucrose 
0.2% w/v Orange G 
 
2.3.1.10 TAE Buffer 
40 mM Tris 
20 mM acetic acid 
2 mM EDTA 
 
2.3.1.11 λ/HindIII marker 
1x Buffer E   
0.1 mg/ml BSA  
20 µg λ DNA  
40 U HindIII  
Incubated at 37°C for 16 h, stored at -20°C. 
 
2.3.1.12 λ/PstI marker 
1x buffer H  
0.1 mg/ml BSA  
20 µg λ DNA 
40 U PstI  
Incubated at 37°C for 16 h, mixed with a final conc. of 1X loading dye, stored  
at 4°C. 
 
2.3.1.13 λ/NdeI marker 
1x buffer D  
0.1 mg/ml BSA  
5 µg λ DNA  
10 U NdeI  
Chapter 2: Materials and Methods 
 52 
Incubated at 37°C for 16 h, stored at -20°C. 
 
2.3.1.14 Ethidium bromide staining bath 
2 mg/L ethidium bromide in 2L water 
 
2.3.2 DNA Methods 
2.3.2.1 DNA extraction and purification methods 
2.3.2.1.1 Plasmid DNA minipreparation – alkaline lysis method 
Single E. coli DH5α colonies were taken from LB+Amp agar plates and grown for 
16 h at 37°C in 5 ml LB+Amp broth, shaking at 200 rpm.  1.5 ml aliquots of culture were 
added to sterile 1.5 ml tubes and centrifuged at 10,000 x g for 2 min.  Supernatants were 
discarded and cell pellets were resuspended in 100 µl TEG/lysozyme by repeated 
pipetting.  200 µl of NaOH/SDS was added; the tube contents were mixed by inversion 
(4-6 times) and were incubated on ice for 5 min.  150 µl of ice-cold KOAc was added and 
tube contents were mixed by inversion (4-6 times).  Tubes were incubated on ice for 5 
min before centrifugation at 16,000 x g for 10 min.  Supernatants were transferred to 
fresh 1.5 ml tubes and 300 µl of PCI was added.  Tube contents were mixed by vortexing 
for 10 s and supernatants were recovered by centrifugation at 16,000 x g for 2 min.  
Supernatants were transferred to new 1.5 ml tubes and 300 µl of CI was added.  Tube 
contents were mixed by vortexing for 10 s, and supernatants were recovered as 
previously described. 
 
Supernatants were transferred to new 1.5 ml tubes and 900 µl of 100% EtOH was 
added.  Tube contents were mixed by vortexing for 10 s before incubation at rt for 5 min.  
DNA pellets were recovered by centrifugation at 16,000 x g for 5 min and washed with 1 
ml of 70% EtOH before recovery by centrifugation as before.  The DNA pellets dried by 
incubation at rt with the lids of the tubes open.  DNA was resuspended in 50 µl of 
H2O/RNase, except when long-term storage of plasmid DNA was required, in which case 
pellets were resuspended in TE/RNase.  Resuspended DNA was stored at -20°C. 
 
2.3.2.1.2 Plasmid midipreparation – Alkaline lysis method 
Plasmid purification by midipreparation was performed as per the minipreparation 
method, with larger volumes of bacterial culture and extraction reagents.  Plasmid DNA 
was extracted from 10 ml of o/night bacterial culture using 200 µl of TEG/lysozyme, 400 
µl of NaOH/SDS and 300 µl of KOAc.  Plasmid DNA from 600 µl of the supernatant was 
purified using 600 µl of PCI and CI.  DNA was precipitated using 600 µl of isopropanol, 
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and washed with 1 ml of 70% EtOH.  Purified plasmid DNA was resuspended in 100 µl of 
H2O/RNase or TE/RNase. 
 
2.3.2.2 PCR Methods 
2.3.2.2.1 Primer reconstitution for 100 µM stock solutions 
Lyophilised primers were reconstituted in TE to 100 µM.  Primer solutions were 
incubated at rt for 5 mins and then mixed by vortexing for 10 s.  Primers were pulse 
centrifuged and stored at -20°C. 
 
2.3.2.2.2 Creation of primer working stocks 
The 100 mM primer stock solutions were diluted in sterile TE or molecular grade 
water to create working stocks of 3 or 5 µM.  These were stored at -20°C. 
 
2.3.2.2.3 PCR using Taq polymerase 
PCR using Taq polymerase was performed in 25 µl reaction volumes unless 
otherwise stated.  Either AmpliTaq or AmpliTaq Gold was used, along with the 
appropriate 1X PCR buffer.  A standard reaction contained 0.3 µM of each primer, 2.5 
mM MgCl2, 0.2 mM of dNTP mix and 1.25 U of Taq polymerase.  PCR reactions were 
made to a final volume using Milli-Q or molecular-grade water.  DNA template 
concentrations of between 10 and 500 ng were used.  Aliquots were dispensed into 
sterile 0.2 ml PCR tubes.  All experiments included a negative control reaction (master 
mix with no DNA template).  Standard reaction parameters are described in Table 2.1. 
Table 2.1: Standard Taq PCR reaction parameters 
Step Temperature (°C) Time No. of cycles 
1. Initial denaturation 95 2-5 min 1 
2. Amplification: 
a) Denaturation 
b) Annealing 
c) Extension 
 
95 
variable 
72 
 
30 s 
30 s 
1 min per kb 
 
30-35 
3. Final extension 72 7 min 1 
4. Cooling 4 ∞ 1 
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2.3.2.2.4 PCR using Pfu polymerase 
Pfu polymerase was used when proofreading ability was required or to amplify 
large products (>3 kb).  Standard reactions were prepared in 50 µl volumes using 0.3 µM 
of each primer, 0.2 mM dNTP mix, 1 U of Pfu polymerase, 1X Pfu PCR buffer, and 0.5 µg 
of DNA template. PCR reactions were made to a final volume using Milli-Q or molecular-
grade water.  Aliquots of 50 µl were dispensed into sterile 0.2 ml PCR tubes.  All 
experiments included a negative control reaction.  Standard reaction parameters are 
described in Table 2.2. 
Table 2.2: Standard Pfu PCR parameters 
Step Temperature (°C) Time No. of cycles 
1. Initial denaturation 94 2 min 1 
2. Amplification: 
a) Denaturation 
b) Annealing 
c) Extension 
 
94 
variable 
68 
 
30 s 
30s 
2 min per kb 
 
30-35 
3. Final extension 68 5 min 1 
4. Cooling 4 ∞ 1 
 
2.3.2.2.5 PCR using Expand polymerase 
Expand polymerase was used to amplify large PCR products (>5 kb).  Buffer 3 
was used, which was supplied with the polymerase and contained 27.5 mM MgCl2 and 
detergents. Each reaction also contained 0.5 mM dNTP mix, 0.3 µM of each primer and 
3.75 U Expand polymerase.  Typically, 0.5 µg of template DNA was used per reaction.  
PCR reactions were made to a final volume using Milli-Q or molecular-grade water, and 
50 µl aliquots were dispensed into 0.2 ml PCR tubes. All experiments included a negative 
control reaction.  Standard reaction parameters are described in Table 2.3. 
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Table 2.3: Standard Expand PCR parameters 
Step Temp. (°C): Time: No. of cycles: 
1. Initial denaturation 94 2 min 1 
2. Initial amplification: 
a) Denaturation 
b) Annealing 
c) Extension 
 
94 
50 
68 
 
10 s 
30 s 
4 min 
 
10 
3. Second amplification: 
a) Denaturation 
b) Annealing 
c) Extension 
 
94 
50 
68 
 
15 s 
30 s 
4 min + 20 s each cycle 
 
 
25 
Final extension 68 7 min 1 
Cooling 4 ∞ 1 
 
 
2.3.2.2.6 DNA sequence analysis 
Reactions to incorporate dye terminators by PCR were set up in 20 µl reaction 
volumes with 4 µl Terminator Ready Reaction mix, 2 µl BigDye Sequencing buffer, 0.3-
0.5 µg of plasmid DNA and 3.2 pmol of a single primer.  The reactions were made up to a 
final volume of 20 µl in molecular-grade water.  The dye terminators were incorporated 
by PCR using the parameters described in Table 2.4. 
 
Table 2.4: PCR to incorporate dye terminators for DNA sequencing 
Step Temp. (°C) Time No. of cycles 
1. Initial denaturation 96 1 min 1 
2. Amplification: 
a) Denaturation 
b) Annealing 
c) Extension 
 
96 
50 
60 
 
10 s 
5 s 
4 min 
 
 
25 
3. Cooling 4 ∞ 1 
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To remove unincorporated dye terminators, 2 µl of 3 M NaOAc and 50 µl of EtOH 
were added to completed sequencing reactions.  Tubes were vortexed for ~10 s and left 
on ice for 12 min.  DNA was pelleted by centrifugation at 16,000 x g for 20 min and 
washed twice with 250 µl of 70% EtOH by vortexing for 10 s followed by centrifugation at 
16,000 x g for 5 min.  The DNA pellet was dried by leaving the tube lids open for ~15 
min.  The dried DNA was sent for sequence analysis to the Micromon DNA sequencing 
facility, Department of Microbiology, Monash University, Melbourne, Australia.  
 
2.3.2.3 Creation of cDNA 
Purified P. yoelii mRNA was obtained from the laboratory of Prof. Ross Coppel, 
Department of Microbiology, Monash University, Melbourne, Australia.  The Omniscript 
RT kit was used to produce cDNA from the P. yoelii mRNA, as per the manufacturer’s 
instructions.  To each reaction was added 1 U of RNase inhibitor, 1 µM of 3’PyTCTP 
primer, and 2.5 µl of P. yoelii mRNA. 
 
2.3.2.4 Restriction endonuclease digestion of DNA 
Purified genomic or plasmid DNA was digested using concentrations of restriction 
endonuclease enzymes between 3 U/µg (for 16 h digestions) to 10 U/µg (for 2-4 h 
digestions).  Digestion reactions were performed at 37°C in the presence of 0.1 µg/µl 
BSA and the appropriate buffer, as determined by the manufacturer.  When multiple 
enzymes were used in a single reaction, a buffer was chosen that would give at least 50-
75% activity for both enzymes, as determined by the manufacturer.  At the completion of 
the digestion reaction, enzyme activity was stopped either by heating at 65°C for 15 min, 
or by separation of the reaction either by agarose gel electrophoresis or Qiaquick column 
purification.   
 
2.3.2.5 Agarose gel electrophoresis 
Gels containing 0.8 - 2% w/v agarose were used to separate DNA based on size.  
Gels were prepared using DNA grade agarose solubilised in TAE by microwave heating.  
DNA samples were mixed with a final concentration of 1X DNA loading dye prior to 
loading on the gel.  One µg total of DNA marker was also loaded (λ/HindIII, λ/PstI, or 
λ/NdeI).  Electrophoresis was performed in TAE buffer at voltages ranging from 50 to 110 
V.  Gels were stained in an ethidium bromide (EtBr) bath for 5 - 10 minutes and 
destained under running tap water for 30 - 60 minutes.  DNA was visualised on a 
transilluminator using Quantity One software. 
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2.3.2.6 Quantification of DNA samples 
2.3.2.6.1 Spectrophotometric quantification of DNA 
DNA absorbance was measured using quartz cuvettes.  For quantification, an 
optical density (OD) reading of 1 at 260 nm was taken to equal a concentration of 50 
µg/ml DNA, while a 260/280 nm ratio of between 1.8 and 2 was indicative of acceptable 
DNA purity.  The standard procedure to measure DNA absorbance was to dilute DNA 
1:1000 using nuclease-free water, then convert the OD reading at 260 nm to a µg/ml 
concentration using the following equation: DNA concentration (µg/ml) = OD260 x 50 x 
1000.  Water was used as a blank. 
 
2.3.2.6.2 Quantification of DNA by gel electrophoresis 
DNA samples were separated by agarose gel electrophoresis alongside a DNA 
marker (λ/PstI) in which the quantity of DNA in each band was known.  The fluorescence 
between the band of interest and the nearest sized (in bp) marker band was compared. 
 
2.3.2.7 Cloning methods 
2.3.2.7.1 TA cloning into pCR 2.1 vectors 
Fresh products (<24 hours old) produced by Taq PCR were ligated into pCR 2.1 
vectors following the manufacturer’s specifications.  Briefly, the ligation reaction was set 
up in the supplied buffer using 1-2 µl of PCR product, 50 ng of pCR 2.1 vector and 4 U of 
T4 ligase.  The reaction was incubated at 14°C for 16 hours and was transformed into 
OneShot™ competent cells by the addition of 1 µl of ligation reaction to one vial of cells.  
The cell and DNA mixture was incubated on ice for 30 min then at 42°C for 30 s.  The 
cells were immediately placed on ice for 1-2 min, then  250 µl of SOC medium was 
added and the cells were incubated at 37°C for 1 hour, shaking at 225 rpm.  Aliquots of 
100 µl were plated onto LB+Amp+X-gal agar and incubated at 37°C for 16 h.  Plates 
were then incubated at 4°C to allow full colour development.  Plasmid DNA from white E. 
coli colonies was purified by minipreparation. 
  
2.3.2.7.2 Standard ligation method 
The following formula was used to calculate the relative amounts of insert and 
vector DNA for a ligation reaction: 
Insert (ng)  =  Vector (ng) x Insert size (kb)    x ratio insert:vector 
                               Vector size (kb) 
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Where 100 ng of vector was standard and the insert:vector ratio was 3:1.  The 
ligation reaction was set up using the calculated volumes of insert and vector DNA in T4 
ligase buffer with 1U of T4 ligase per 10 µl reaction.  The reactions were incubated 
overnight.  The standard incubation temperature was 14°C. 
 
2.3.2.7.3 Dextran purification of ligation reactions 
Completed ligation reactions were made up to 20 µl in water.  The following 
reagents were added: 1 µl of 10 mg/ml dextran sulphate, 2 µl of 3 M NaOAc (pH 5.2) and 
50 µl of cold EtOH.  The tube contents were mixed by vortexing and incubated on ice for 
10 min.  The DNA pellets were recovered by centrifugation at 16,000 x g for 15 min, the 
pellet was washed with 200 µl of 70% EtOH and recovered by centrifugation at 16,000 x 
g for 5 min.  The pellet was dried with the tube lid open for ~15 min and resuspended in 
10 µl of molecular grade water. 
 
2.3.2.8 Ethanol/sodium acetate precipitation of DNA from solutions 
A 1/10 volume of 3 M NaOAc (pH 5.2) was added to the DNA solution, together 
with 2.5 volumes of 100% EtOH.  Tubes were inverted several times to mix.  Precipitation 
reactions were incubated at -80°C for at least 20 minutes.  DNA was pelleted at 16,000 x 
g for 20 minutes at 4°C.  The DNA pellet was washed with 1 ml of 70% EtOH and 
recovered by centrifugation at 16,000 x g for 5 minutes.  The DNA pellet was dried with 
the tube lid open for ~15 min.  DNA was resuspended in 10 mM Tris.HCl pH 8.0, TE 
buffer, or molecular-grade water.  
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2.4 Bacteriological Materials and Methods 
2.4.1 Bacteriological Materials 
2.4.1.1 Luria-Bertani (LB) medium 
1% w/v tryptone 
0.5% w/v yeast extract 
1% w/v NaCl 
Made up in distilled water, sterilised 
 
2.4.1.2 LB + Amp medium 
Sterile LB medium 
100 µg/ml ampicillin (filter-sterilised, 0.2 µm)  
 
2.4.1.3 LB agar 
LB medium 
1.2% w/v bacteriological agar 
Made up in distilled water, sterilised 
 
2.4.1.4 LB + Amp agar 
LB agar, sterilised, cooled to 55°C 
100 µg/ml ampicillin (filter-sterilised, 0.2 µm) 
 
2.4.1.5 LB + Amp + X-gal agar 
LB + Amp agar  
When agar set, 40 µl of a 40 mg/ml X-gal solution in DMSO added and  
spread evenly over the plate.  
 
2.4.1.6 Super Optimal Catabolite (SOC) medium 
2% w/v tryptone 
0.5% w/v yeast extract 
10 mM NaCl 
10 mM KCl 
Sterilised, then the following filter-sterilised materials added: 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose  
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2.4.2 Bacterial strains used 
Top10F’, DH5α, and BL21 strains of E. coli were used as hosts for pCR2.1, 
pYEULCBX, b3D and pRSETA plasmids.  
 
2.4.3 Bacteriological methods 
2.4.3.1 Spectrophotometric quantification of bacterial cultures 
Plastic disposable cuvettes were used.  Sterile LB media was used as a blank.  
The OD was measured at 600 nm.      
 
2.4.3.2 Electro-transformation of E. coli 
2.4.3.2.1 Preparation of electro-competent cells 
The DH5α strain of E. coli was resuscitated from glycerol stocks by streak dilution 
onto a LB agar plate and incubated for 16 h at 37°C.  A single colony was subcultured 
into 5 ml of LB and incubated overnight (o/n) at 37°C, shaking at 160 rpm.  A 1/100 
volume of o/n culture was added to fresh LB (200-500 ml) and incubated at 37°C, 
shaking, until the bacterial culture reached an OD600 reading of ~0.4.  The culture was 
incubated on ice for 1 h, then divided into sterile 50 ml tubes and centrifuged at 4,500 x g 
for 15 min at 4°C.  The cell pellet was resuspended in 25 ml cold sterile water by gentle 
mixing.  The cells were recovered by centrifugation and were washed with 12.5 ml of cold 
sterile water.  The cell pellets were resuspended in 1 ml of cold sterile 10% v/v glycerol 
by gentle repeated pipetting.  The cell suspensions were transferred to sterile 1.5 ml 
tubes and centrifuged at 16,000 x g for 5 min at 4°C.  The cell pellets were resuspended 
in 200 µl of cold sterile 10% v/v glycerol and stored at -80°C in 40 µl aliquots in sterile 1.5 
ml tubes.     
 
2.4.3.2.2 Transformation of electro-competent cells 
Electro-competent DH5α E. coli cells were transformed by electroporation.  Cell 
aliquots were thawed on ice before the addition of 0.5 – 1 µl (~5 to 50 ng) of dextran-
purified DNA.  Cell suspensions were gently mixed and incubated on ice for 1 - 2 min.  A 
single cell suspension was transferred to a chilled 0.2 cm electroporation cuvette and 
placed in the chilled safety chamber slide of the Gene Pulser before electroporation at 25 
µF, 2.5 kV, 200 Ohms.  One millilitre of SOC medium was added to the electroporation 
cuvette and resuspended cells were transferred to a sterile 1.5 ml tube.  The cells were 
incubated at 37°C for 1 h, shaking at 200 rpm.  100 µl cell aliquots were spread-plated 
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onto LB+Amp agar.  The remaining suspension was centrifuged at 4,000 x g for 2 min, 
the supernatant was discarded, and 100 µl of the cell pellet was spread-plated onto a 
second LB+Amp agar plate.  Plates were incubated at 37°C for 16 h.  Plasmid DNA from 
the resulting colonies was purified by minipreparation. 
 
2.4.3.3 Preparation of glycerol stocks of E. coli 
Single colonies of E. coli were grown for 16 h in 5 ml LB+Amp broth.  Equal 
volumes of culture and sterile glycerol were combined in sterile cryovials and stored at -
70°C. 
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2.5 Yeast Materials and Methods 
2.5.1 Yeast Materials 
2.5.1.1 Yeast extract peptone dextrose (YEPD) medium  
2% w/v yeast extract 
1% w/v peptone 
2% w/v D-glucose 
Made up in distilled water, sterilised 
 
2.5.1.2 Yeast nutrient broth (YNB) + glucose 
0.67% w/v yeast nitrogen base without amino acids 
2% w/v D-glucose 
Made up in distilled water, sterilised 
 
2.5.1.3 Complete-Ura agar 
YNB + Glucose 
2% w/v agar 
0.2% w/v adenine sulfate, L-Tyrosine 
1% w/v L-Tryptophan, L-Histidine HCl, L-Arginine HCl, L-Methionine,  
L-Leucine, L-Isoleucine, L-Lysine HCl, L-Phenylalanine, L-Glutamic acid 
0.4% w/v L-Aspartic acid 
3% w/v L-Valine 
4% w/v L-Threonine 
8% w/v L-Serine 
 
2.5.2 Yeast methods 
2.5.2.1 Transformation of S. cerevisiae with pYEULCBX vectors 
The w303.1a strain of S. cerevisiae was used for recombinant protein expression.  
This yeast strain requires exogenous adenine, leucine, uracil, tryptophan and histidine for 
growth, and transformation with pYEULCBX eliminates the growth requirement for uracil 
and leucine.  The transformation protocol was performed essentially as described 
previously (Gietz et al., 1995).  Briefly, a single colony of S. cerevisiae was used to 
inoculate 5 ml of YEPD and grown overnight at 30°C, shaking at 200 rpm.  The cell 
density of the overnight culture was measured using a haemocytometer at 400X 
magnification. 50 ml of YEPD was inoculated to a density of 5 x 106 cells/ml.  The 50 ml 
culture was incubated at 30°C, shaking at 200 rpm, until the cell density reached 2 x 107 
cells/ml (typically 3-5 h).  The culture was centrifuged at 2,500 x g for 5 min, and the cell 
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pellet was washed in 25 ml sterile distilled water.  The cell pellet was resuspended in 1 
ml 0.1 M Lithium Acetate (LiAc) and transferred to a sterile 1.5 ml tube.  Cells were 
pelleted by centrifugation at 16,000 x g for 5 s.  The cell pellet was resuspended to a final 
volume of 0.5 ml in 0.1 M LiAc, corresponding to a cell density of 2 x 109 cells/ml.   
 
A sample of 10 mg/ml single-stranded (ss) carrier DNA was boiled for 5 min and 
quickly chilled in an ice-water bath.  Meanwhile, the cell suspension was vortexed for 10 
s then dispensed into 50 µl aliquots in sterile 1.5 ml tubes.  The cells were pelleted at 
16,000 x g for 5 s.  To the pellet was added: 240 µl of 50% w/v PEG 3350, 36 µl of 1 M 
LiAc, 5 µl of 10 mg/ml ss carrier DNA and 1 µg of pYEULCBX plasmid DNA.  The volume 
was made up to 350 µl in water, and tubes were vortexed for 1 min.  Tubes were 
incubated for 30 min at 30°C, then heat-shocked at 42°C for 22 min.  Tubes were spun at 
16,000 x g for 15 s and the cell pellet was resuspended in 200 µl of water.  The entire 
transformation mix was plated on Complete-Ura agar and incubated at 30°C for 2-3 days. 
 
2.5.2.2 Preparation of glycerol stocks of S. cerevisiae 
Overnight cultures of single colonies of S. cerevisiae were grown overnight in 
YEPD.  Glycerol stocks were made up of 85% v/v culture, 15% v/v sterile glycerol in 
sterile cryovials and stored at -70°C. 
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2.6 Protein Purification Materials and Methods 
2.6.1 Protein Purification Materials 
2.6.1.1 PBS 
1 PBS tablet per 100 ml water 
 
2.6.1.2 E. coli lysis buffer 
5 mM imidazole in PBS 
4 mg/ml lysozyme 
 
2.6.1.3 Phosphate buffer 
80 mM Na2HPO4  
20 mM KH2PO4 
0.3 M NaCl 
Made up in distilled water, pH adjusted to 7.3 
 
2.6.1.4 5 mM imidazole wash buffer 
5 mM imidazole in phosphate buffer or PBS 
 
2.6.1.5 0.2 M/0.25 M imidazole elution buffer 
0.2 M/0.25 imidazole in phosphate buffer or PBS 
 
2.6.1.6 Mono-Q dialysis buffer 1 
50 mM Tris.HCl pH 8.8 
1 mM DTT 
Made up in distilled water 
 
2.6.1.7 Mono-Q dialysis buffer 2 
1 mM CaCl2 in Mono-Q dialysis buffer 1 
 
2.6.1.8 Mono-Q buffer A 
50 mM Tris.HCl pH 8.8 
1 mM DTT 
1 mM CaCl2 
Made up in distilled water, filtered (0.2 µM cut-off) before use  
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2.6.1.9 Mono-Q buffer B 
0.5 M NaCl added to Mono-Q buffer A  
Filtered (0.2 µM cut-off) before use 
Made up in distilled water 
 
2.6.1.10 Bradford Assay reagent 
0.01% w/v Coomassie Blue G-250 
5% v/v EtOH 
10% w/v 85% Phosphoric acid 
Coomassie powder was added to ethanol and mixed on magnetic stirrer,  
phosphoric acid was added once dissolved.  Made up to final volume in  
water, filtered (0.45 µM cutoff) and stored at 4°C.  
 
2.6.2 Yeast protein expression and purification methods 
2.6.2.1 Confirming expression of TCTP in S. cerevisiae by Western blot 
Single colonies of yeast from pYEULCBX.PfTCTP or pYEULCBX.PyTCTP 
transformations were picked from Complete-Ura plates and used to inoculate 10 ml 
YEPD in a sterile 50 ml tube.  Cultures were grown at 30°C for 8 h, shaking at 200 rpm.  
A 1/10 volume of the pre-culture was used to inoculate 10 ml of YNB+Glucose 
supplemented with 0.002% w/v histidine and tryptophan and 0.004% w/v adenine for 
yeast growth, and with 0.5 mM CuSO4 for induction of protein expression.  Cultures were 
incubated at 30°C for 16 h, before centrifugation at 2,500 x g for 5 min at 4°C.  A 30 µl 
sample of the culture supernatant was retained for Western blot, the cell pellet was 
washed once in 10 ml PBS.  Samples of the washed cell pellet (~10 µl) were retained for 
Western blot analysis of TCTP expression.   
 
2.6.2.2 TCTP expression in S. cerevisiae 
Single colonies of PfTCTP- or PyTCTP-transformed yeast from Complete-Ura 
plates were used to inoculate 10 ml volumes of YEPD and grown at 30°C for 16 h, 
shaking at 200 rpm.  A 1/100 volume of the pre-cultures was used to inoculate 0.5-1L of 
YNB+Glucose supplemented with 0.002% w/v histidine and tryptophan and 0.004% w/v 
adenine, and TCTP expression was induced with 0.5 mM CuSO4 for 40 hours. 
 
2.6.2.3 Protease-minimising protein expression method in S. cerevisiae 
This protein expression method was adapted from the yeast expression method 
described in http://www.clontech.com/images/pt/dis_manuals/PT3081-1.pdf.  Single 
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colonies of pYEULCBX.PyTCTP transformed yeast were grown in 10 ml of YEPD for 16 
h at 30°C, shaking at 200 rpm.  A 1/100 volume of the overnight cultures was used to 
inoculate 0.5 L of YNB+Glucose supplemented with 0.002% w/v histidine and tryptophan 
and 0.004% w/v adenine.  The cultures were incubated at 30°C for 18 h, shaking. 
 
Cultures was transferred to sterile centrifuge bottles and centrifuged at 600 x g for 
5 min at RT.  The supernatant was discarded and the cell pellets were resuspended in 
fresh supplemented YNB+Glucose medium as before to the original culture volume.  The 
culture was incubated at 30°C, shaking, until the OD600nm was between 0.8 and 1.2.  
Protein expression was induced by the addition of 0.5 mM CuSO4 and the culture was 
incubated at 30°C for 1 h, shaking. 
 
2.6.2.4 Lysis of yeast cultures 
2.6.2.4.1 Lysis of yeast by homogenisation 
Yeast cultures were centrifuged at 2,500 x g for 5 min at 4°C.  The supernatant 
was discarded and the cell pellet washed twice in PBS.  The cell pellet was resuspended 
in one volume of PBS and the following protease inhibitors were added before cell lysis: 
1 mM Pefabloc, 5 mM Benzamidine, 1 µg/ml E-64, 1 µg/ml Pepstatin, and 1 µg/ml 
leupeptin. 
 
Yeast cells were lysed in 13 ml plastic homogenisation tubes using a Braun cell 
homogeniser.  The tubes were filled with ~4 ml cell pellet + PBS and ~2 ml 0.45 mm 
glass beads.  The cells were homogenised using 7 cycles of 25 s, using 5 s bursts of 
liquid CO2 between and during the homogenisation cycles.  The homogenate was 
decanted into a 50 ml tube and centrifuged at 2,500 x g for 5 min at 4°C.  The 
supernatant was decanted into a centrifuge bottle and centrifuged at 21,000 x g for 25 
min at 4°C. Protease inhibitors were added to the supernatant as before.  
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2.6.2.4.2 Yeast lysis by vortexing with glass beads 
This method was used with yeast cultures grown via the protease-minimising 
expression method (2.6.2.3).  Cells were pelleted by centrifugation at 3,000 x g for 5 min 
at 4°C.  The pellet was washed twice with PBS.  Cells were lysed in a mixture made up 
of equal volumes cell pellet, PBS and 0.45 mm glass beads in a 50 ml tube.  Protease 
inhibitors were added before cell lysis: 1 mM Pefabloc, 5 mM Benzamidine, 1 µg/ml E-64, 
1 µg/ml Pepstatin, and 1 µg/ml leupeptin.  Cells were lysed by repeated cycles of 
vortexing and cooling; 20 s of vortexing followed by 20 s incubation on ice.  This was 
repeated for 20 min in total.  The percentage of cell lysis was analysed by analysing the 
percentage of intact yeast cells in 1 µl samples before and lysis, using a haemocytometer 
under 400X magnification.  The vortexing cycles were continued until at least 50% cell 
lysis was achieved (up to 40 min total).  The lysis mixture was centrifuged at 3,000 x g for 
10 min at 4°C.  
 
2.6.2.5 Purification of His-tagged proteins expressed in S. cerevisiae using 
TALON™ resin 
2.6.2.5.1 Talon resin preparation for use and storage 
Before use, TALONTM metal affinity resin was washed to remove storage EtOH.  
A portion of resin slurry (usually ~ 2.5 – 5 ml) was decanted into a 50 ml tube and 
centrifuged at 2,500 x g for 10 min at 4°C.  The supernatant was decanted and the resin 
was washed three times with a full tube of PBS.   
 
After use in protein purifications, the Talon resin was centrifuged at 2,500 x g for 
10 min at 4°C, the supernatant was decanted, and the resin was washed twice with 50 ml 
of 30% EtOH.  The resin was resuspended in an equal volume of 30% EtOH and stored 
at 4°C.   
 
2.6.2.5.2 Incubation of proteins with Talon resin 
Yeast lysates were added to the prepared Talon slurry and incubated at 4°C for 
16 h on a carousel shaker at low speed. 
 
2.6.2.5.3 Elution of proteins from Talon resin 
 A Biologic Low Pressure system was used to measure absorbance of the eluate 
from the TALON™ resin.  The system was washed with deionised water and equilibrated 
with phosphate buffer.  The absorbance reader was set to zero and the incubated talon 
slurry was added to the column.  The column flowthrough was collected, then the resin 
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was washed with phosphate buffer until the absorbance reading had stabilised at around 
zero.  Approximately 20 column volumes (CV) of 5 mM imidazole wash buffer were 
added to elute weakly-binding proteins from the resin, the eluate was retained.  
Approximately 10 CV of 0.2 M imidazole elution buffer was added to elute polyhistidine-
tagged proteins.  Small samples (~30 µl) of the collected eluates were retained for SDS-
PAGE analysis; the remaining eluates were stored at 4°C for up to 24 h or at -20°C for 
longer periods.  The resin was washed in phosphate buffer until the UV absorbance 
reading had dropped to around zero, then was washed in at least 20 CV of deionised 
water.  The resin was decanted into a 50 ml tube and prepared for storage as described.  
The Biologic system was washed with ~20 ml water followed by ~20 ml of 30% EtOH.     
 
2.6.2.6 Further purification of yeast-derived proteins using an anion-
exchange column 
2.6.2.6.1 Dialysis of protein samples prior to anion-exchange 
chromatography 
TCTP samples from the 0.2 M imidazole eluate samples were combined and 
dialysed in at least 100 volumes of Mono-Q dialysis buffer 1 for between 4 - 16 h at 4°C, 
stirring.  Samples were then dialysed in Mono-Q dialysis buffer 2 as before.  Dialysis was 
performed using Spectra/Por tubing with a 3,500 MW cut-off.  
 
2.6.2.6.2 Preparation of Mono-Q anion exchange column 
Lines A and B were cleaned with RO water for 5 min.  100% Mono-Q Buffer B 
was run through the Mono-Q column for 3 min to elute any residual proteins, then 100 % 
Mono-Q Buffer A was run through the column for 5 min to remove the salt.    
 
2.6.2.6.3 Mono-Q column chromatography 
The protein samples were filtered with a 0.22 µm syringe filter.  The Biologic HP 
system was set to run at 1 ml/min.  The system was set to load and 5 ml of protein 
sample was injected into a 5 ml loop.  The samples were loaded onto a separate column 
attached to an Auto-Injection Valve.  The system was set to inject.  When multiple 5 ml 
samples were to be loaded, the sample was injected for 5 min then the system was set to 
load and another 5 ml of sample was injected into the loop.  The system was set to run a 
0-0.5 M NaCl gradient over 60 minutes.  When the UV reading was <0.025, 2 ml fractions 
were collected. Fractions corresponding to UV peaks were subjected to SDS-PAGE. 
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2.6.2.7 N-terminal sequencing of PyTCTP 
PyTCTP eluates from Mono-Q chromatography were subjected to N-terminal 
sequencing at CSIRO Health Sciences and Nutrition, Parkville, Australia (performed by 
Phil Strike).  
 
2.6.2.8 Protein lyophilisation and reconstitution 
Prior to lyophilization, TCTP samples previously dialysed in two changes of PBS 
were dialysed in two changes of at least 100 volumes of 50 mM ammonium bicarbonate 
pH 8, as previously described (2.6.2.6.1).  Lyophilisation of proteins was performed by Dr 
Ross Fernley, CSIRO Health Science and Nutrition, Parkville, Australia.  Lyophilised 
samples were reconstituted to a concentration of 0.5 mg/ml in PBS by vortexing for 10 s.  
 
2.6.3 E. coli protein expression and purification methods 
2.6.3.1 PbTCTP and PyTCTP expression in E. coli 
A single colony of E. coli BL21 transformed with either pRSETA.PbTCTP or 
pRSETA.PyTCTP was used to inoculate 10 ml of LB+Amp media, and grown for 16 h at 
37°C, shaking at 200 rpm.  Larger volumes of LB+Amp (typically 0.5 L) were inoculated 
with a 1/100 volume of the 16 h pre-culture, and incubated at 37°C, shaking at 200 rpm, 
until the OD600nm was approximately 0.5.  Expression of TCTP was then induced by the 
addition of 1 mM IPTG, and cultures were grown a further 3 hours.   
 
2.6.3.2 Lysis of E. coli 
Cells were pelleted by centrifugation at 5,500 x g for 10 minutes. E. coli lysis 
buffer at a 1/25 volume of the original culture media volume was used to resuspend the 
pellet, cells were then incubated at 4°C for 20 min, shaking at 70 rpm.  Four cycles of 
freeze/thaw were performed: pellets were frozen at -70°C for >20 min, followed by 
thawing in a 37°C water bath for >5 min.  After the second freeze/thaw cycle, DNase was 
added to a final concentration of 10 U per 100 ml original culture volume.  The pellets 
were incubated at 37°C for 15 min, shaking at 70 rpm.  Two further freeze/thaw cycles 
were then performed.  After completion of the freeze/thaw cycles, cell debris was 
removed by centrifugation at 5,500 x g for 20 minutes.  Supernatants were passed 
through 0.2 µm syringe filters.   
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2.6.3.3 Py and PbTCTP purification using Profinity™ metal affinity 
chromatography 
2.6.3.3.1 Preparation and storage of Profinity resin 
Small volumes of Profinity™ resin slurry, typically 5 ml, were washed with 10 CV 
of water followed by 20 CV of 5 mM imidazole wash buffer prior to use, to remove 
storage EtOH and to equilibrate the column.  After protein purification, Profinity™ resin 
was washed with 10 CV of 5 mM imidazole wash buffer, 10 CV of water, and 10 CV 30% 
EtOH, and stored at 4°C in two CV of 30% EtOH. 
 
2.6.3.3.2 Profinity™ chromatography 
Filtered PyTCTP and PbTCTP lysate supernatants (2.6.3.2) were added to 
prepared Profinity™ resin and incubated at rt for 15 min, shaking at 70 rpm.  The resin 
was washed with 20 CV 5 mM imidazole buffer and a 1.5 ml eluate sample was retained 
for analysis. His-tagged proteins were eluted with 10 CV of 0.25 M imidazole elution 
buffer and 1.5 ml fractions were collected, 20 µl samples of which were analysed for the 
presence of TCTP by SDS-PAGE.  The remaining volume of each fraction was stored at 
-70°C. 
 
2.6.3.4 Endotoxin removal 
One millilitre of resin was used in a 1 ml column per protein preparation.  The 
resin was washed with 5 CV of 1% w/v sodium deoxycholate, then with 15 CV of PBS.  
The protein samples were added, and the column flow was stopped when the samples 
had entered the resin.  The column was incubated at RT for 1 h, and the column flow 
was re-started.  Protein samples were eluted in PBS. 
 
2.6.4 Quantification of protein concentration 
2.6.4.1 Quantification of protein concentration by spectrophotometry 
Protein concentration was estimated by measuring absorbance at 280 nm, where 
a reading of 1 was taken to be equal to 1 mg/ml protein.  The blank was the buffer used 
in the protein sample of interest. 
 
2.6.4.2 Analysis of protein concentration by Bradford assay 
All samples were diluted using 0.15 M NaCl.  BSA was diluted to 1 mg/ml and the 
following protein concentration standards were prepared: 3, 6, 9, 12, 15, 18, and 21 
µg/ml.  Each standard was made up to a final volume of 200 µl in 1.5 ml tubes.  Around 
10 µg (as determined by spectrophotometry) of the protein samples of interest were 
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diluted to 200 µl in 0.15 M NaCl.  1 ml of Bradford Assay reagent was added to each 
tube. Tubes were vortexed and allowed to stand for 1 minute, and 200 µl duplicates of 
the samples were added to wells of a 96-well plate.  Abs595 nm was measured using an 
ELISA plate reader, and protein concentrations of samples of interest were calculated by 
plotting against the standard curve. 
 
2.6.5 Preparation of proteins for vaccine use 
2.6.5.1 Buffer exchange to PBS by dialysis 
Purified TCTP samples were dialysed using Spectra/Por dialysis tubing (3,500 
MW cut-off), in two changes of >100 volumes of PBS for between 4 and 16 h at 4°C, 
stirring. 
 
2.6.5.2 Buffer exchange to PBS using concentration columns 
Centricon columns were washed prior to use by adding 3.5 ml of 0.1 M NaOH 
and centrifuging at 3,000 x g for 15 min.  The columns were washed 3 times with water.  
Purified TCTP samples were added to prepared concentration columns and centrifuged 
at 3,000 x g until the volume was reduced to 0.1X the initial volume (400 µl in a 4 ml 
column).  The protein samples were resuspended to the original volume in PBS, and 
centrifuged as before.  The cycles of PBS resuspension and centrifugation were 
repeated until the original buffer concentration had been diluted approximately 100X.  
 
2.6.5.3 Storage of proteins prior to vaccine trial 
Proteins in PBS were generally stored at -70°C prior to use in vaccine trials, some 
yeast-derived proteins were stored in 50% glycerol at -70°C.  Lyophilised proteins were 
stored at -20°C. 
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2.6.6 SDS-PAGE and Western blot materials  
2.6.6.1 15-4% acrylamide gel for SDS-PAGE, for 2 mini-gels 
2.6.6.1.1 15% resolving gel 
Reagents (final concentrations) were added in the following order: 
water to 5 ml 
0.375 M Tris.HCl pH 8.8 
0.1% w/v SDS 
12% v/v acrylamide 
0.1% w/v APS 
0.1% v/v TEMED 
2.6.6.1.2 4% stacking gel 
Reagents (final concentrations) were added in the following order: 
water to 2.5 ml 
0.125 M Tris.HCl pH 6.8 
0.1% w/v SDS 
4% v/v acrylamide 
0.1% w/v APS 
0.1% v/v TEMED 
 
2.6.6.2 5X reducing sample buffer 
0.2 M Tris.HCl pH 6.8 
25% v/v glycerol 
17.5% w/v β-mercaptoethanol 
0.125% w/v bromophenol blue 
5% w/v SDS 
Made up in distilled water, stored at 4°C 
 
2.6.6.3 10X SDS-PAGE buffer 
14.4% w/v glycine 
3% w/v Tris 
2% w/v SDS 
Diluted 1:10 in distilled water before use 
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2.6.6.4 Coomassie staining solution 
0.05% w/v Coomassie blue R-250 
40% v/v methanol 
10% v/v glacial acetic acid 
 
2.6.6.5 Destaining solution 
10% v/v acetic acid 
10% v/v EtOH 
 
2.6.6.6 10X Transfer buffer 
3.025% w/v Tris 
14.49% w/v glycine 
Diluted 1:10 before use with water + 20% v/v methanol 
 
2.6.6.7 Tris-buffered saline (TBS) 
10 mM Tris 
0.5 M NaCl 
pH adjusted to 7.4 
 
2.6.6.8 Blocking solution 
5% w/v skim milk powder in TBS 
 
2.6.6.9 Diluent solution 
1% w/v skim milk powder in TBS 
 
2.6.6.10 10X Citrate-EDTA buffer 
10 mM tri-sodium citrate 
10 mM EDTA 
pH adjusted to 5.5, diluted 1:10 with distilled water before use 
 
2.6.6.11 Western substrate 1 
50 µl of 50 mg/ml TMB in DMSO 
2 µl H2O2 (30%) 
1% w/v dextran sulphate 
Made up in 10 ml 1X Citrate-EDTA buffer  
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2.6.6.12 Western substrate 2 
10% v/v of 3 mg/ml Chloro-1-naphthol in methanol 
6% v/v of 30% H2O2  
Made up in TBS 
 
2.6.6.13 Detection buffer 
0.1 M Tris.HCl pH 9.5 
0.1 M NaCl  
 
2.6.6.14 Western substrate 3 
600 µl NBT/BCIP in 10 ml Detection buffer 
 
2.6.7 SDS-PAGE method 
2.6.7.1 Preparing protein samples 
5 µl of 5X sample buffer was added to 20 µl of protein sample in PBS and 
samples were heated at 95°C for 5 min. 
 
2.6.7.2 SDS-PAGE 
Gels were prepared just before use.  The 15% resolving gel solution was 
prepared, mixed by inverting the tube several times and ~4 ml of solution was pipetted 
into a prepared glass plate mini-gel system.  The gel solution was overlaid with water 
using a pipette, and the gel was allowed to set for ~20 min.  The water overlay was 
removed and the 4% stacking gel solution was then added with the well comb in place.  
The gel was allowed to set for ~20 min.  Alternatively, 4-20% gradient pre-cast gels were 
used.   
 
Gels were placed in the Protean II mini-gel system, with a buffer dam if only one 
gel was used.  One litre of SDS-PAGE buffer was added to the gel tank and wells were 
washed with 30 µl of SDS running buffer twice before prepared protein samples were 
added.  Eight microlitres of SeeBluePlus2 Pre-Stained marker, BenchMark marker or 
Mark12 Unstained Marker was added to one well.  The samples underwent 
electrophoresis at 60 V for 30 min followed by 180 V for 45 min.  If pre-cast gels were 
used, samples underwent electrophoresis at 175 V, 100 mA (150 mA if two gels were 
used) for 1 hour.  Gels were washed briefly in distilled water before staining by shaking at 
50 rpm in Coomassie stain for 1 h or in Gradipure stain for 2 h.  Gels were destained by 
shaking incubation for 4-16 h in destaining solution. 
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2.6.8 Western Blot  
At the completion of SDS-PAGE, gels were washed 2X in transfer buffer for 15 
min, shaking at 50 rpm.  Meanwhile, Whatman paper, Scotchbrite sponge and 
nitrocellulose membrane were soaked separately in transfer buffer for 30 min. 
 
The blot was assembled as follows: The cassette was placed in a container filled 
with transfer buffer with the grey panel (anode) at the bottom.  One piece of scotchbrite 
was placed on top of the grey panel, followed by Whatman paper, then the gel, then the 
nitrocellulose membrane.  Air bubbles were removed by rolling a thin glass tube over the 
membrane, then Whatman paper was placed on top, followed by a piece of scotchbrite.  
The white panel of the Western cassette was placed on top and the sandwich was 
clipped together.  The Western cassette was placed in a Protean II tank.  A plastic mould 
filled with ice was placed in the tank.  Proteins were transferred onto the nitrocellulose 
membrane by electrophoresis either at 200 V for 50 min using a flea and a magnetic 
stirrer; or at 70 V for 1 hour. 
 
At the completion of the Western transfer, the membrane was removed from the 
sandwich and washed in TBS for 10 min, shaking at 50 rpm.  The membrane was 
incubated in blocking solution for 1 h, shaking, then incubated with the primary antibody 
in diluent solution for between 1 and 20 h, shaking.  The primary antibody was retained 
after incubation and stored at -20°C, for re-use up to 5 times.  The membrane was 
washed twice in TBS for 10 min, shaking, and then incubated in secondary antibody in 
diluent solution for 1 h, shaking.  The membrane was washed twice in TBS for 10 min, 
shaking, and then was incubated with 10-30 ml of substrate solution in the dark for 5-10 
minutes.  The blot was recorded either by scanning the image or by photography.   
 
2.6.9 β-hexosaminidase assays 
For further detail of the methods used and results obtained in the RBL-2H3 
degranulation assays, please refer to the Honours thesis of Aya Taki, Department of 
Biotechnology and Environmental Biology, RMIT University, Melbourne, Australia (Taki, 
2007).  
 
β-hexosaminidase release assays using RBL-2H3 cells generally have an 
incubation with IgE specific to a particular antigen as the initial step.  As a positive 
control, the specific antigen is added to stimulate IgE crosslinking on the surface of the 
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cells, prompting degranulation.  In the assays performed using TCTP, filter-sterilised (0.2 
µm) IgE specific to trinitrophenol (TNP) was used at a 100-fold dilution.  RBL-2H3 cells 
were grown to confluence in 96-well plates and washed twice with 200 µl of freshly-
prepared releasing buffer (1X HANKS, 0.14% w/v NaHCO3, 10 mM HEPES pH 7.2, 5.5 
mM glucose, 0.05% w/v BSA, 0.73 mM MgSO4, 1.8 mM CaCl2, pH adjusted to 7.3).  
Cells were incubated with α-TNP IgE for 16 h, washed twice in releasing buffer, and then 
resuspended in 150 µl releasing buffer.   
 
Cells were stimulated with either ionomycin, PfTCTP, PbTCTP, PyTCTP or SmpB 
(negative control) at protein concentrations of 10, 5, 2.5, 1.25, 0.6 and 0.3 µg/ml.  As a 
positive control, concentrations of 30, 10 3, 1, 0.3 and 0.1 ng/ml of TNP were used to 
stimulate IgE-crosslinking on the RBL-2H3 cells.  Each potential stimulant was used at a 
final volume of 50 µl per well, together with 50 µl of releasing buffer.  In a separate well, 
50 µl of lysis solution (0.1% Triton-X 100) was added to measure maximum 
degranulation.  The cell mixtures were incubated for 30 min at 37°C, and then 25 µl of 
supernatant from each well was transferred to a new 96-well plate.  To assess the 
amount of β-hexosaminiadase present, the supernatants were mixed with 25 µl of p-
nitrophenyl N-acetyl-D-glucosaminide (pNAG) substrate.  Plates were wrapped in foil and 
incubated at 37°C for 90-120 min.  The reaction was stopped with 50 µl of 0.4 M glycine 
and absorbance at 405 nm was measured. 
 
Degranulation was measured as a percentage of total release.  Cells incubated 
with releasing buffer alone served as a measure of spontaneous release.  Three 
separate experiments were used for each data point.  Both ionomycin and TNP were 
used as positive controls.   
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2.7 Malarial infection Materials and Methods 
2.7.1 Materials for malarial infection 
2.7.1.1 Citrate phosphate dextrose (CPD) 
3% w/v tri-sodium citrate 
0.015% w/v NaH2PO4.H2O 
0.2% w/v D-glucose 
Filter-sterilised (0.2 µm) before use 
 
2.7.1.2 Mouse-tonicity phosphate-buffered saline (MT-PBS) 
20 mM Na2HPO4.H2O 
4 mM NaH2PO4.H2O 
150 mM NaCl 
Filter-sterilised (0.2 µm) before use 
 
2.7.1.3 Malaria freezing solution (MFS) 
0.17 M sorbitol 
0.11 M NaCl 
28% v/v glycerol 
Filter-sterilised (0.2 µm) before use, stored at 4°C. 
 
2.7.1.4 Giemsa stain 
2.7.1.4.1 Giemsa stock 
50% v/v glycerol 
50% v/v methanol 
0.736% w/v Giemsa powder 
Giemsa powder added to glycerol and incubated at 50°C for 30 min, stirring. 
Cooled when powder completely dissolved, methanol added. Filtered (0.45  
µm)  
2.7.1.4.2 Sorenson’s modified phosphate buffer 
66.7 mM NaH2PO4 
66.7 mM Na2HPO4 
pH adjusted to 6.4 
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2.7.1.4.3 Giemsa stain 
10% v/v methanol 
10% v/v Giemsa stock 
8% v/v Sorenson’s modified phosphate buffer 
Made up just before use and filtered (0.45 µm) 
 
2.7.2 Malaria infection methods 
2.7.2.1 Marking of mice for identification 
Mice were marked with between 0 and 4 stripes on the tail using black permanent 
(non-toxic) marker, allowing for differentiation of 5 mice.  The markings were re-applied 
every 3-4 days for the duration of the experiment.  When larger numbers of mice were to 
be identified, i.e. when mice were challenged with malaria parasites in the vaccine trials, 
box numbers were assigned randomly by one experimenter and the number was written 
on the stomach of each mouse using permanent marker.  The malaria parasites were 
then injected into each mouse by a second experimenter, who was not aware of which 
box numbers corresponded with controls or immunised mice. 
 
2.7.2.2 Preparation of malaria stabilates 
Blood was taken from mice using retro-orbital puncture using capillary tubes into 
2 volumes of CPD in 1.5 ml tubes.  Blood was centrifuged at 100 x g for 10 min, and the 
erythrocyte pellet was washed once in 1 ml MT-PBS.  The supernatant was discarded 
and 10 pellet volumes of MFS were added.  The malaria stabilates were dispensed in 
250-500 µl aliquots in sterile cryovials and snap frozen in dry ice or liquid nitrogen.  
Stabilates were stored at -70°C or in liquid nitrogen. 
 
2.7.2.3 Injection of mice with malaria stabilates 
Only a fraction of the malaria parasites in a stabilate are viable, and so accurate 
numbers of parasitised erythrocytes cannot be calculated.  For this reason, passaging 
mice were required when exact numbers of parasites were needed for infection.  Two 
mice received between 50 and 200 µl of parasite stabilates by an i.p. injection using a 
25-guage needle.  Parasitemia was monitored daily.  Blood was taken either by retro-
orbital puncture, or by cardiac puncture following CO2 asphyxiation, when parasitemia 
was between 2 and 10%. Parasitised blood was used for stabilate creation or to infect 
mice with a specific number of parasites.      
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2.7.2.4 Infection of mice with specific doses of malaria parasites 
When infection with a specific number of parasites was required, the parasitemia 
of blood taken from passage mice was calculated and blood was diluted in MT-PBS to 
the appropriate parasite dose as follows: Mouse blood contains 5x109 rbc/ml (5x106 
rbc/µl), therefore a mouse with a 10% parasitemia has a total of 5 x 105 parasitised 
erythrocytes/µl.  Blood of known parasitemia was taken from passage mice by retro-
orbital puncture, and was diluted in two volumes of CPD.  The blood was further diluted 
in MT-PBS to give the correct concentration of parasitised erythrocytes/µl.  Mice in the 
vaccine trials were injected with a dose of 1x105 parasitised erythrocytes in a total 
volume of 200 µl by an i.p. injection using a 25-guage needle. 
 
2.7.2.5 Quantification of parasites in mouse blood 
Parasite numbers were quantified in the morning (prior to 10 am) daily, starting at 
two days post-infection (dpi).  One drop of blood was taken from the end of the tail of 
each mouse as follows:  The very end of the tail (~1-2 mm) was removed using EtOH-
sterilised scissors.  The tail was squeezed gently and a single drop of blood was 
collected on a glass microscope slide.  The blood was smeared across the slide using a 
second glass slide held at a 45° angle.  The blood was allowed to air-dry, then was fixed 
to the slide by incubation in 100% methanol for 5 min.  Excess methanol was removed 
and slides were incubated in Giemsa stain for 30 - 40 min.  Slides were washed in tap 
water, allowed to dry fully and red blood cells were visualised on a light microscope 
under oil-immersion at a 1,000 X magnification.  To ensure impartial counting, all 
identifying numbers on the slides were covered with opaque labels; slides were 
randomised and then numbered sequentially.  Parasite numbers were quantified for all 
slides prior to the uncovering of slide identifications.  Parasite numbers were quantified 
by the counting of 500 to 1,000 erythrocytes for each mouse at each time point. The 
numbers were expressed as percentage parasitemia.  At least 1,000 erythrocytes were 
counted before mice were declared to have 0% parasitemia.  
 
2.7.3 Blood collection methods 
2.7.3.1 Blood collection by retro-orbital puncture 
Blood was collected by retro-orbital puncture using heparinised capillary tubes 
into 1.5 ml tubes.   
 
2.7.3.2 Blood collection by cardiac puncture 
2.7.3.2.1 Anaesthesia of mice prior to blood collection 
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Prior to blood collection for parasite harvest, mice were anaesthetised using 100 
mg/kg ketamine and 10 mg/kg xylazine.  Unconsciousness was verified by the absence 
of pedal and eye responses, and blood was taken by cardiac puncture.  Mice were killed 
by cervical dislocation following blood collection. 
 
2.7.3.2.2 Exsanguination of mice by CO2 prior to blood collection 
Mice were placed in a container pre-filled with CO2.  Mice remained in the 
container for an additional minute after breathing had ceased.  Death was confirmed by 
the absence of pedal and eye responses, and blood was taken by cardiac puncture. 
 
2.7.3.2.3 Blood collection 
Once mice were anaesthetised or killed, an incision was made in the abdomen 
and diaphragm to visualise the heart, and blood was collected from the left ventricle 
using a 19-guage needle pre-washed with CPD.  The blood was collected in two volumes 
of CPD.  After blood collection, mice were killed by cervical dislocation.       
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2.8 Vaccine trial Materials and Methods 
2.8.1 ELISA Materials 
2.8.1.1 ELISA coating buffer 
A: 0.2 M Na2CO3 
B: 0.2 M NaHCO3 
Buffer made up of 8% A and 17% B in water, pH adjusted to 9.6  
 
2.8.1.2 PBS Tween 
0.05% v/v Tween 20 in PBS   
 
2.8.1.3 ELISA Blocking solution 
5% w/v skim milk powder in PBS Tween  
 
2.8.1.4 ELISA Diluent buffer 
1% w/v skim milk powder in PBS Tween  
 
2.8.1.5 TMB Substrate 
Equal parts TMB Solutions A and B combined just before use 
 
2.8.1.6 2N H2SO4 
5.5 ml concentrated H2SO4 added to 44.5 ml water in a dropwise fashion on  
ice 
 
2.8.2 Vaccine trial methods 
2.8.2.1 Preparation of vaccines 
Mice were immunised either with sterile PBS (negative control) or with filtered 
(0.2 µm) TCTP in PBS.  PBS or 0.5 mg/ml TCTP were combined with an equal volume of 
Freunds adjuvant.  The vaccines were made up as double the number of doses required, 
eg if 6 x 100 µl doses were needed, 1.2 ml of vaccine was prepared.  Vaccines were 
prepared in a Biosafety cabinet using sterile materials.  An emulsion was created using 
one of two methods:  
 
(1) The PBS/protein and Freunds adjuvant were added to 1.5 ml tubes and were 
emulsified using a 3 ml syringe and a 19-guage needle by syringing up and down 
repeatedly.  An emulsion was obtained when a single drop of vaccine formed a stable 
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ball when dropped into a beaker of tap water.  The vaccines were used within 2 h of 
preparation.  
 
(2) An emulsion was made by mixing the adjuvant and protein/PBS using two 
glass syringes connected with a stopcock, using around 300 mixing repetitions.  The 
emulsion was tested by injecting a single drop into a beaker of tap water as before.   
 
Mice were immunised three times, the first immunisation was emulsified in 
Freunds complete adjuvant; subsequent immunisations were emulsified in Freunds 
incomplete adjuvant. 
 
2.8.2.2 Mouse immunisations 
Mice were given an intraperitoneal injection of a total vaccine volume of 100 µl 
using a 25-guage needle. 
 
2.8.2.3 Serum collection  
Blood was collected from mice for antibody titre determination prior to the first 
immunisation and 1-2 days prior to challenge.  Approximately 150 µl of blood was 
collected by retro-orbital puncture into a 1.5 ml tube. Blood was centrifuged at 2,500 x g 
for 5 min and the sera supernatants were transferred to new 1.5 ml tubes.  Serum was 
stored at -70°C. 
 
2.8.2.4 Monitoring and scoring of mice during the immunisation period and 
following malaria challenge 
All animal experiments were approved by the RMIT Animal Ethics Committee 
(AEC).  After the commencement of all experiments, mice were monitored at least twice 
daily.   
 
In the vaccine trial described in Chapter 3, mice infected with P. yoelii YM were 
monitored twice daily until 3 dpi, after which time they were monitored at 4-hourly 
intervals between 7 am and 7 pm, then at a maximum of 7-hour intervals between 7 pm 
and 7 am.  Mice challenged with P. yoelii XNL were monitored twice daily unless malarial 
symptoms were observed, at which time the monitoring schedule was increased to that 
of a lethal infection.  
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In the vaccine trial described in chapter 4, mice infected with P. yoelii YM were 
monitored twice daily until parasitemia was >10%, after which time they were monitored 
at 4-hourly intervals between 8 am and 6 pm, then observed once between 12 and 1 am.  
Mice infected with P. berghei ANKA or P.c. chabaudi were monitored twice daily until 
malarial symptoms were observed, at which time the monitoring schedule was increased 
to 4-hourly intervals between 8 am and 6 pm, and one observation between 12 and 1 
am.  Mice able to clear parasites were monitored twice daily once parasite levels were 
decreasing.  
 
Mouse symptoms were scored following the table provided by the RMIT AEC.  A 
copy of this table is provided in Appendix 2, with the predicted scores for a lethal 
malarial infection provided.  Mice were euthanised when they reached a score of 8, or 
when definite cerebral malaria symptoms were observed.  
 
2.8.2.5  Euthanasia of mice 
When mice reached a symptom score of 8 they were euthanised with an i.p. 
injection of an overdose of the barbiturate Euthal or Lethobarb.  
 
2.8.2.6 Statistics 
 Comparison of parasitemia between TCTP-immunised and PBS-control groups 
was performed using the Student’s T-test (two-tailed). 
 
2.8.2.7 Analysis of antibody titres by ELISA 
Ninety-six well plates were coated with 2 µg/ml antigen in coating buffer, using 
100 µl per well.  Coating buffer alone was added to one well; this was used as the blank 
for absorbance readings.  Plates were incubated at 4°C overnight.  One well of the first 
row of the plate was used for each of the following controls: no antigen (coating buffer 
only), no blocking, no antisera, no secondary antibody.  All other ELISA steps were 
performed on each of the control wells. 
 
Coating buffer was removed by inverting the plate and tapping several times on 
paper towel.  Wells were washed once with PBS, and were blocked with 200 µl of ELISA 
blocking buffer.  Plates were incubated at 37°C for 1 h, shaking.  Blocking buffer was 
removed by inverting and tapping the plate as before, and wells were washed 3 times in 
PBS Tween.  Vaccine trial antiserum was diluted in ELISA diluent buffer in doubling 
dilutions, with an initial dilution between 1:50 and 1:4,000.  Dilution of primary antisera 
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was performed in a separate 96-well plate, using 120 µl volumes prepared in duplicate.  
Volumes of 100 µl of the serum dilutions were added to the blocked plate and incubated 
at 37°C for 1 h, shaking.  Unbound serum was removed as before and wells were 
washed 3 times in PBS Tween.  Secondary antibody (goat-α-mouse IgG.HRP-conjugate) 
was diluted 1:5,000 in ELISA diluent buffer, 100 µl was added to each well, and plates 
were incubated at 37°C for 1 h, shaking.  Unbound antibody was removed and wells 
were washed 3 times with PBS Tween, followed by one wash in PBS.  A volume of 100 
µl of freshly-prepared TMB substrate was added to each well and the colour 
development was stopped using 50 µl of 2 N H2SO4 once the reaction was saturated 
(usually after ~10 min incubation).  The absorbance readings at 450 nm were plotted 
against the reciprocal serum dilution and a line was drawn between the points.  The 
reciprocal titre was determined to be the point at which the serum dilution line crossed an 
OD of 0.2, which was 4X the background level. 
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2.9 Transfection and Knockout Analysis Materials and 
Methods 
2.9.1 Malarial DNA and protein extraction materials 
2.9.1.1 Ficoll gradient 
5.7% w/v Ficoll in MT-PBS (2.7.1.2). 
 
2.9.1.2 Buffer A 
50 mM NaOAc pH 5.2 
100 mM NaCl 
1 mM EDTA 
 
2.9.1.3 TNE 
10 mM Tris 
0.2 M NaCl 
1 mM EDTA 
pH adjusted to 7.4 
 
2.9.1.4 TNET 
10 mM Tris 
0.15 M NaCl 
5 mM EDTA 
1% v/v Triton-X 100 
pH adjusted to 7.4 
 
2.9.1.5 Pyrimethamine water 
Tap water from the RMIT animal house was pH-adjusted to between 3 and 5 with 
1 M HCl and sterilised by autoclaving or by filtering through a 0.2 µm syringe filter.  A 
freshly-made stock of 7 mg/ml pyrimethamine in DMSO was diluted 1:100 in the pH-
adjusted water. 
 
2.9.2 Malarial transfection and malarial DNA/protein extraction 
methods 
2.9.2.1 Transfection of purified malarial schizonts with target DNA 
All procedures involved in the transfection of malarial schizonts were performed 
by Dr. Tania de Koning Ward at the Walter and Eliza Hall Institute (WEHI), Melbourne, 
Australia, basically as per the method described (Janse et al., 2006b). Briefly, P. berghei 
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ANKA schizonts were purified from an overnight in vitro culture using a Nycodenz 
gradient.  An Amaxa nucleofector™ machine was used for transfection.  Per reaction, 10 
µg of prepared linearised target DNA was used, and the transfected schizonts were 
injected into the lateral tail vein of one BALB/c mouse.  The mouse was treated with 70 
µg/ml pyrimethamine provided in the drinking water (pH adjusted to between 3.5 and 5) 
continuously from 24 - 30 hours post-injection.  The pyrimethamine water was given as 
the sole water source in a light-protected water bottle for the mice to drink ad libitum.  
The pyrimethamine water was generally replaced with freshly made drug-treated water 
every 3 - 5 days until the end of the experiment.  Parasitemia was monitored daily from 3 
dpi.  At a parasitemia of between 2 and 5%, mice were anaesthetised or killed using CO2 
and blood was taken by cardiac puncture.  The blood was used for DNA analysis and 
stabilate creation. 
 
2.9.2.2 Infection of mice with stabilates obtained from transfection 
experiments 
Stabilates created from the transfection experiments performed at WEHI were 
used to infect additional BALB/c mice, for secondary drug-selection and to obtain 
sufficient parasite material for DNA analysis.  Each mouse received an i.p. injection of 
between 50 and 150 µl of stabilate.  Mice were generally treated with pyrimethamine at 
between 24 and 30 hours post-infection.   
 
2.9.2.3 Ficoll gradient separation of erythrocytes from blood 
Blood collected from infected mice was centrifuged at 400 x g for 7 min, and the 
cell pellet was washed once with 10 ml of MT-PBS.  The cell pellet was diluted in four 
volumes of MT-PBS.  Meanwhile, a Ficoll gradient was prepared in a 10 ml centrifuge 
tube using 5.7% w/v Ficoll in MT-PBS, and erythrocytes diluted in MT-PBS were layered 
on top of an equal volume of prepared Ficoll.  Erythrocytes were separated from 
leukocytes by centrifugation of the Ficoll gradient for 20 min at 400 x g with slow 
acceleration and no braking.  After centrifugation, the blood components separated so 
that leukocytes and plasma were retained above the Ficoll gradient and erythrocytes 
pelleted at the bottom of the tube.   The supernatant was removed and the erythrocyte 
pellet was washed twice in 10 ml MT-PBS by centrifugation at 400 x g for 10 min. 
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2.9.2.4 Malarial DNA extraction using SDS and PCI 
The erythrocytes separated by Ficoll gradient centrifugation were resuspended in 
4 volumes of Buffer A and 1 volume of 18% SDS, mixed by inversion and incubated for 2 
min.  An equal volume of PCI was added, and the solution was mixed by repeated 
inversion for 1 min, and centrifuged at 4,500 x g for 10 min.  The upper phase was 
transferred to a new tube, and the PCI extraction was repeated twice.  DNA was 
precipitated from the upper phase by the NaOAc/EtOH purification method (2.3.2.8) with 
a second 70% EtOH wash.  The DNA pellet was resuspended in 250 µl of TE and stored 
at -20°C. 
 
2.9.2.5 DNA extraction with SDS, PCI and Proteinase K 
Leukocytes were removed from blood using a CF11 column:  ~ 1 ml of CF11 
powder (Whatman) was added to a 5 ml column.  The powder was washed with 5 ml of 
PBS, the blood was layered over the CF11 and the column eluate was retained.  The 
column was washed with ~25 ml of PBS until the eluate was clear, the preceding eluate 
was also retained.  The total retained eluate was centrifuged at 4,000 x g for 10 min.  The 
blood cell pellet was resuspended in 1.5 volumes of 0.15% w/v saponin in PBS.  The 
tubes were incubated on ice for 15 min, shaking occasionally.  The tubes were 
centrifuged at 5,000 x g for 10 min and the parasite pellet was washed in 10 ml TNE.  
The pellet was resuspended in 700 µl TNE + 1% w/v SDS and mixed by end-over-end 
tube inversion for 5 min.  A total of 100 µg of RNase A was added and the tubes were 
incubated at 37°C for 30 min.  200 µg/ml Proteinase K was added and the tubes were 
incubated for between 40 min and 1 h at 37°C.  An equal volume of PCI was added, 
tubes were mixed by vigorous shaking for 5 min, and spun at 16,000 x g for 4 min.  The 
top layer was decanted into a new tube, and the PCI extraction was repeated.  An equal 
volume of CI was added.  The tubes were shaken and the top layer isolated as before.  
The DNA was precipitated overnight at -20°C with EtOH/NaOAc.  Each DNA pellet was 
resuspended in 30 µl TE. 
 
2.9.2.6 DNA extraction using Qiagen kits 
Alternately, malarial DNA was extracted following leukocyte removal by Ficoll 
gradient separation using the blood protocol of the DNA mini kit (Qiagen). 
 
2.9.2.7 Malarial protein extraction  
Erythrocytes separated by Ficoll gradient were resuspended in two PCV of 0.15% 
saponin w/v in MT-PBS, and incubated on ice for 15 min.  Free parasites were washed 
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twice in 10 ml of MT-PBS; cells were pelleted by centrifugation at 1,000 x g for 5 min.   
Pellets were resuspended in 0.5 ml of MT-PBS and centrifuged at 16,000 x g for 1 min.  
Parasite pellets were stored at -80°C if not immediately used.  The parasite pellets were 
resuspended in 20 µl of TNET containing a protease inhibitor cocktail (Roche) and 
incubated on ice for 1 h.  Five microlitres of 5X reducing sample buffer (2.6.6.2) was 
added, tubes were incubated at 95°C for 5 min, vortexed, and incubated at 95°C a further 
5 min. 
 
2.9.3 Southern Blot Materials 
2.9.3.1 Denaturation solution 
0.5 M NaOH 
1.5 M NaCl 
 
2.9.3.2 Neutralisation solution 
0.5 M Tris.HCl pH 7.5 
3 M NaCl 
 
2.9.3.3 20X SSC buffer 
3 M NaCl 
0.3 M tri-sodium citrate 
Adjusted pH to 7, sterilised. 
 
2.9.3.4 Maleic acid buffer 
0.1 M Maleic acid 
0.15 M NaCl 
Adjusted pH to 7.5 with solid NaOH, sterilised. 
 
2.9.3.5 10X Southern blocking reagent 
10% w/v Blocking Reagent dissolved in maleic acid buffer, stirred on low heat  
for ~15 min, then sterilised.  Stored at 4°C.  
 
2.9.3.6 Hybridisation buffer 
5X SSC  
0.1% w/v N-laurylsarcosine 
0.02% w/v SDS 
1X Southern blocking reagent 
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2.9.3.7 Low stringency washing buffer 
2X SSC 
0.1% w/v SDS 
 
2.9.3.8 High stringency washing buffer 
0.5X SSC 
0.1% w/v SDS 
 
2.9.3.9 Washing buffer 
0.3% v/v Tween 20 in Maleic acid buffer 
 
2.9.3.10 Blocking solution 
1X Blocking reagent in Maleic acid buffer 
 
2.9.3.11 Antibody solution 
A 1:10,000 dilution of Anti-Digoxigenin-AP antibody (75 mU/ml) was made in  
blocking solution when chemiluminescent substrate was used, a 1:5,000  
dilution of antibody (150 mU/ml) was made in blocking solution when  
chromogenic substrate was used.  
 
2.9.3.12 Detection buffer 
0.1 M Tris.HCl pH 9.5 
0.1 M NaCl  
 
2.9.3.13 Chromogenic substrate solution 
200 µl of NBT/BCIP in 10 ml Detection buffer 
 
2.9.3.14 Chemiluminescent substrate solution 
1:100 dilution of CSPD in detection buffer  
 
2.9.3.15 Probe stripping solution 
0.2 M NaOH 
0.1% w/v SDS  
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2.9.4 Southern blot methods 
2.9.2.1  Probe labelling reaction 
30 µl of PCR product was either cleaned with the Wizard PCR purification kit 
(Promega), or was used following purification with the Qiaquick gel extraction kit.  The 
cleaned PCR product was denatured in a boiling water bath for 10 min and quickly chilled 
on ice for 2 min.  4 µl of hexanucleotide mix, 4 µl of labelled dNTPs and 2 µl of Klenow 
enzyme were added, the tube contents were mixed by vortexing and incubated for 20 h 
at 37°C.  The labelling reaction was stopped with the addition of 4 µl of 0.2 M EDTA pH 
8.    
 
2.9.2.2 Preparation of genomic DNA prior to Southern blot 
Between 3 µg and 15 µg of purified parasite DNA was used in each sample. The 
concentration of genomic DNA was quantified by agarose gel electrophoresis and 
comparison to known quantities of lambda DNA.  Prior to digestion, parasite DNA was 
heated at 55°C for 15 min to destroy nucleases and to aid solubilisation.  Parasite DNA 
was digested for 16 h with 30 to 40 U of NdeI.  When larger volumes were used, DNA 
was precipitated with NaOAc/EtOH following digestion and resuspended in 30 µl of water 
or 10 mM Tris.HCl pH 8.  
 
2.9.2.3 Southern blot of P. berghei ANKA DNA  
The digested genomic DNA was separated on a 1% w/v agarose gel at 50-65 V 
alongside a λ/PstI marker.  The gel was stained and destained and photographed on a 
transilluminator with a ruler next to the marker.  The gel was washed twice in 
denaturation solution for 15 min, shaking gently.  The gel was rinsed in water and 
washed twice in neutralisation solution for 15 min, shaking gently.  Pre-cut Whatman 
paper and Hybond nylon membrane was soaked in 20X SSC.  The blot apparatus was 
set up as follows: 
 
A pyrex dish was filled with 20X SSC.  A glass plate was placed into the dish, 
above the level of the SSC.  A piece of Whatman paper was placed on the glass plate so 
that both ends were in the SSC, forming a wick.  The gel was placed over the Whatman 
paper.  Parafilm was placed around the gel to cover exposed areas of the Whatman 
paper, to prevent short-circuiting.  The Hybond membrane was placed on top of the gel, 
air bubbles were removed by rolling a thin glass tube over the surface, then two pieces of 
Whatman paper were placed on top and bubbles removed as before.  A stack of paper 
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towels (~10 to 15 cm) was placed on top and secured with a glass plate and a medium 
weight (~200 g). 
 
The Southern transfer was left overnight, then the membrane was removed and 
DNA fixed by UV crosslinking for 5 min in a transilluminator.  The membrane was rinsed 
in water, then blocked for 2 h in hybridisation buffer at 65°C in a sealed plastic bag in a 
hybridisation oven.  The labelled probe was denatured in a boiling water bath for 10 min 
then chilled on ice.  The probe was added to 10 ml of pre-heated (65°C) hybridisation 
buffer.  The membrane was incubated with the probe-containing hybridisation buffer at 
63 - 68°C for 16 h in a hybridisation oven. 
 
The probe-containing hybridisation buffer was retained at -20°C at the completion 
of hybridisation, for re-use up to five times.  The membrane was washed two times for 5 
min in low stringency washing buffer at RT, and was then washed two times for 15 min at 
65°C with high stringency washing buffer. 
 
The membrane was transferred to a new container and washed for 2 min at rt, 
shaking at 50 rpm, in 100 ml washing buffer.  The membrane was then blocked in 100 ml 
blocking solution for 30 min at rt, shaking.  The membrane was incubated in 20 ml of 
antibody solution for 30 min, shaking.  The membrane was then washed twice for 15 min 
in 100 ml washing buffer, shaking. 
 
The membrane was incubated for 3 min in 50 ml of detection buffer, and then the 
probe-hybridised DNA bands were detected using either chemiluminescent or 
chromogenic substrates.  The membrane was incubated in the dark in 10 ml of 
chromogenic substrate solution for between 15 min and 16 h, until the desired band 
intensity was obtained.  The reaction was then stopped by washing the membrane for 5 
min in 50 ml of TE buffer.  Alternatively, the membrane was placed between 2 
transparent plastic sheets and 2 ml of chemiluminescent substrate solution was added.  
The membrane was incubated at rt for 5 min, then the sheets were sealed to prevent 
liquid escaping and the membrane was incubated for 10 min at 37°C.  The probe-
hybridised DNA bands were visualised either using X-ray film, with a development time of 
between 10 and 20 min, or were incubated for between 10 and 20 min on a GeneSnap 
imager using GeneSnap software (Syngene).  
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2.9.2.4 Stripping membranes prior to reprobing 
To remove the chromogenic substrate, the membrane was incubated with DMF in 
a glass dish at 50°C for 1 h, the DMF was changed and the membrane was incubated at 
50°C for several hours until all of the colour substrate was removed.  The procedure to 
remove chemiluminescent substrates commenced at this point.  The membrane was 
washed in two changes of water.  The probe was stripped by two 20 min washes in 
probe stripping solution at 37°C, shaking.  The membrane was rinsed and stored in 2X 
SSC at 4°C prior to reprobing.   
 
2.9.2.5 Reprobing membranes 
The stripped membrane was blocked for at least 2 h in hybridisation solution at 
65°C then the Southern procedure was continued as previously described. 
 
2.9.2.6 Re-use of probes 
Probes were stored at -20°C after use.  Prior to re-use, probes were heat-
denatured in a boiling water bath for 10 min, cooled to 65°C and added to blocked 
membranes.  The Southern procedure was continued as previously described.
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CHAPTER 3: Evaluation of P. yoelii and P. 
falciparum TCTP as potential malaria vaccines 
 
3.1 Introduction 
TCTP was first trialled as a potential anti-malarial vaccine by our group in 
2002.  In the initial experiment, P. falciparum and human TCTP were expressed as 
histidine-tagged recombinant proteins in S. cerevisiae yeast.  Groups of eight mice 
were immunised three times, with a four-week interval.  Immunisations consisted of 
25 µg Pf or human TCTP in Freunds adjuvant.  Mice immunised with human TCTP 
did not produce antibodies against the recombinant protein.  This was not 
unexpected, as the mouse and human TCTPs are highly conserved, sharing 95% 
amino acid identity.  Mice immunised with PfTCTP had an average pre-challenge 
antibody titre of 1200, with individual titres ranging from 100 to 10,000 (Taylor, 2002). 
 
Mice immunised with PfTCTP, and the PBS-immunised controls, were 
challenged three weeks after the final immunisation with 1 x 105 P. yoelii YM-infected 
erythrocytes.  Mice immunised with PfTCTP had significantly lower (P<0.01) 
parasitemia than the PBS controls at the early and middle stages of infection, until 
six days post-infection (dpi).  Mice immunised with PfTCTP also had increased 
survival times compared with PBS-immunised controls.  In these experiments, mice 
were euthanised when they reached a symptom score of eight, as required by the 
RMIT Animal Ethics Committee (AEC) (scoring system described in Appendix 2).  A 
symptom score of eight in a P. yoelii YM infection usually corresponded to a 
parasitemia of between 60 and 80%.  At six dpi there was a 100% survival rate for 
the PfTCTP-immunised mice compared with a 25% survival rate for the PBS 
controls.  All control and PfTCTP-immunised mice had reached the experimental 
end-point by the end of seven dpi (Taylor, 2002). 
 
These results indicated some promise for TCTP as a malarial vaccine.  
Although most research into TCTP has focused on the intracellular actions of the 
protein (reviewed in Bommer and Thiele, 2004), (described in section 1.3), some 
evidence exists of a second, extracellular role for TCTP (as described in section 1.5).  
Human TCTP induces histamine release from a subset of allergic human basophils, 
which have been termed IgE+, in an IgE-dependent manner (MacDonald et al., 
1995).  Human TCTP also induces IL-8 release from a subset of human allergic 
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donor eosinophils (Bheekha-Escura et al., 2000).  There is evidence that P. 
falciparum TCTP is secreted during infection and can induce histamine and IL-8 
release in vitro in human basophils and eosinophils, respectively (MacDonald et al., 
2001).  The TCTP from the parasites S. mansoni and B. malayi can also induce 
histamine release in vitro and can induce eosinophil recruitment in mice in vivo 
(Gnanasekar et al., 2002; Rao et al., 2002). 
 
PfTCTP was evaluated as a potential malarial vaccine by our group due to its 
proposed role in inducing histamine release, and the evidence that it could be 
secreted from the parasite into the bloodstream of the host.  Our hypothesis for the 
modest protection conferred by PfTCTP immunisation was that anti-TCTP antibodies 
participated in neutralising the extracellular actions of malarial TCTP.  Histamine 
released by the host is thought to assist the malarial parasite, by causing 
vasodilation and increasing expression of endothelial adhesion factors that allow the 
parasites to sequester in organs such as the brain (as described in section 1.2.4).  
Complications during a malarial infection in humans are thought to be due, to some 
extent, to inappropriate inflammatory or immune responses by the host, and it has 
been shown in rodent models that inflammatory molecules (particularly TNF-α and 
IFN-γ) play a major role in malaria pathogenesis (Li et al., 2001a).   
 
This results chapter describes a vaccine trial that was performed using P. 
yoelii and P. falciparum TCTP as antigens.  P. yoelii TCTP was included in this trial 
as it was thought that a homologous vaccine might confer better protection to P. 
yoelii challenge.  P. falciparum TCTP was included to confirm the results of the first 
vaccine trial.  The two His-tagged recombinant proteins were expressed in the 
w303.1a mutant strain of S. cerevisiae using the pYEULCBX vector.  This vector has 
both a yeast and bacterial origin of replication, two yeast selectable marker genes 
(URA3, encoding the production of uracil, and LEU2d, encoding the production of 
leucine), and an Ampr gene for selection of E. coli transformants.  The pYEULCBX 
vector also encodes a six-histidine tag, followed by a thrombin cleavage site, 
upstream of the multiple cloning site (MCS).  Cloning of exogenous genes into the 
MCS allows for in-frame expression of recombinant protein with an N-terminal His 
tag.  Recombinant protein expression is induced by the addition of copper, which 
activates the metallothionein CUP1 promoter.  The N-terminal His tag was not 
cleaved from either of the proteins used in this vaccine trial, as the first vaccine trial 
Chapter 3: Evaluation of P. yoelii and P. falciparum TCTP as malaria vaccines 
 95 
also used His-tagged PfTCTP.  A map of the pYEULCBX vector and the amino acid 
sequence upstream of the MCS are shown in Figure 3.1 (a) and (b). 
 
This chapter describes the cloning of P. yoelii TCTP into the pYEULCBX 
vector, the expression and purification of PyTCTP and PfTCTP in yeast, and the 
vaccine trial of the two protein antigens using both a P. yoelii YM and XNL challenge 
model.  The P. yoelii XNL strain, which produces a non-lethal infection in BALB/c 
mice (Kim et al., 1980; Li et al., 2001a; Ma et al., 2007; Taylor et al., 1986), was 
included as a challenge using a less virulent malarial strain, with a slower 
multiplication rate, may be a more appropriate model of human infection kinetics.  
Whilst the P. yoelii YM strain is often used in vaccine trials in mice, it produces much 
more rapidly ascending parasitemia than is seen in human infections and is uniformly 
lethal.  In contrast, malarial infection in humans is generally non-lethal.  The mortality 
rate from P. falciparum malaria, which is responsible for ~80% of human malarial 
deaths, is >1%, although this rises to 10-50% in severe infections (Dondorp and Day, 
2007).  
 
The methodology of the TCTP vaccine trials was based on vaccine trials of 
the P. yoelii merozoite surface protein 4/5 (MSP4/5), performed by Coppel’s group 
(Goschnick et al., 2004; Kedzierski et al., 2000; Kedzierski et al., 2002a; Kedzierski 
et al., 2001).  In their trials, MSP4/5 was expressed in E. coli and purified using 
Talon™ metal affinity resin.  Groups of female BALB/c mice were immunised i.p. with 
25 µg MSP4/5 in Freunds adjuvant, with two boosters of 25 µg at monthly intervals.  
Mice were challenged 12-14 days after immunisation with 1 x 105 P. yoelii YM irbc.  
In the 33 immunised mice, 28 survived the P. yoelii infection (Kedzierski et al., 2000). 
 
The most effective malaria vaccine components tested so far have been 
proteins on exposed locations of the parasite and on the surface of infected 
erythrocytes.  There is no evidence to suggest that malarial TCTP is expressed on 
the surface of exoerythrocytic parasites or on the surface of infected erythrocytes, 
however there is evidence that the protein is secreted (MacDonald et al., 2001).  The 
aim of TCTP immunisation was to induce antibodies that are designed to inhibit the 
extracellular actions of a secreted malarial protein, rather than direct recognition and 
inhibition of the malaria parasite. 
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The aims of the experiments outlined in this chapter were: 
 
1: To clone the PyTCTP coding sequence into the pYEULCBX vector. 
 
2: To express PyTCTP and PfTCTP as recombinant His-tagged proteins in 
the w303.1a S. cerevisiae strain. 
 
3: To assess the protective effect of TCTP immunisation in BALB/c mice by 
challenge with a lethal (YM) or non-lethal (17XNL) strain of P. yoelii. 
 
5: To assess the ability of TCTP antisera to recognise TCTP present in 
malarial lysates. 
 
6: To assess the histamine release induced by TCTP injection in ovalbumin-
sensitised C57BL/6 mice.  
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M    R    G    S    H    H    H    H    H    H    G    S    L    V    P    R    G    S    G    G    R    S    G    S    
                                    
                             Hexa-His tag                 thrombin cleavage site                           BamHI 
 
 
Figure 3.1: Map of the pYEULCBX vector 
(a) Plasmid map of the 7.2 kb pYEULCBX vector;  
(b) Sequence of the N-terminal six-histidine tag and thrombin cleavage site of 
the pYEULCBX vector.  The BamHI cloning site is indicated. 
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3.2 Materials and Methods 
For more detailed information on the materials and methods used in this 
chapter, please refer to Chapter 2. 
 
3.3 Results 
3.3.1 Amplification and cloning of P. yoelii TCTP 
The strategy for cloning PyTCTP into the pYEULCBX yeast expression vector 
is depicted in Figure 3.2 (a).  Briefly, the cloning strategy involved amplification of 
PyTCTP by PCR from P. yoelii YM cDNA and cloning into the pCR2.1 vector, 
followed by digestion of the PyTCTP coding sequence from the pCR2.1 vector and 
ligation into the pYEULCBX yeast expression vector.         
 
3.3.1.1 Primers used for amplification of P. yoelii TCTP 
The primers used to amplify P. yoelii TCTP were designed based on the 
published sequence (GenBank accession number XM_720179).  The 5’PyTCTP 
primer was designed to incorporate a BamHI restriction site (CGCG GGA TCC ATG 
AAA GTA TAT AAA GAC ATT TTT ACA), and the 3’PyTCTP primer was designed to 
incorporate a PstI restriction site (GCGC GAC GTC TTA GTA TTT TTC TTC AAA 
TAA ACC ATC).  This allowed for directional cloning into the pYEULCBX yeast 
expression vector.  
 
3.3.1.2 Transformation and purification of pYEULCBX vector 
Purified pYEULCBX plasmid DNA was obtained from Prof. Ian Macreadie, 
CSIRO Health Sciences and Nutrition, Parkville, Victoria, Australia. Plasmid DNA 
was transformed into electrocompetent E. coli DH5α cells and minipreparations were 
performed to obtain sufficient plasmid for cloning (methods described in 2.4.3.2.2 
and 2.3.2.1.1).  
 
3.3.1.3 Amplification of PyTCTP from cDNA 
Purified P. yoelii mRNA was obtained from the laboratory of Prof. Ross 
Coppel, Department of Microbiology, Monash University, Melbourne, Australia.  The 
Omniscript RT kit was used to produce cDNA as per manufacturer’s instructions.  
PyTCTP was amplified from P. yoelii cDNA using Taq polymerase as per the method 
described (2.3.2.2.3) with the following modifications and conditions: Each 50 µl 
reaction contained 0.5 µM of the 5’ and 3’ PyTCTP primers, 1.25 U Taq, and 0.5 µg 
of P. yoelii cDNA.  The DNA was amplified by PCR with the following parameters:  
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Initial denaturation 95°C for 2 min, then 30 cycles of 95°C for 30 s, 50-55°C gradient 
for 30 s, and 72°C for 1 min followed by a final extension at 72°C for 7 min.  The 
amplified products were separated by 1% agarose gel electrophoresis at 100 V 
(method described in 2.3.2.5).  A single band of 516 bp was obtained from PCR at 
each of the annealing temperatures, as shown in Figure 3.2 (b).  The PCR product 
obtained from the 55°C annealing temperature was cloned into the pCR2.1 vector.     
 
3.3.1.4 TA cloning of PyTCTP into the pCR2.1 vector and ligation of 
PyTCTP into the pYEULCBX vector  
Fresh PyTCTP product was ligated into the pCR 2.1 vector as per 
manufacturer’s instructions (method described in 2.3.2.7.1).  Plasmid DNA was 
isolated from resulting white colonies.  The presence of the PyTCTP insert was 
confirmed by restriction enzyme digestion with 20 U each of BamHI and PstI, 0.5 µg 
of pYEULCBX vector was also digested (method described in 2.3.2.4).   An insert 
band at 516 bp was obtained from each of the pCR2.1 vector digests, as shown in 
Figure 3.2 (c) lanes 2-5.  The restriction enzyme digestion also produced two other 
bands of plasmid backbone.  A single band at 7.2 kb was obtained from digested 
pYEULCBX (Figure 3.2 (c) lane 7).  Sequence analysis (2.3.2.2.6) of the 516 bp 
inserts using the 5’PyTCTP and 3’PyTCTP primers produced a sequence identical to 
the published sequence for P. yoelii TCTP (data not shown).  Plasmids with the 
correct insert were designated pCR.PyTCTP. 
 
Bands corresponding to the digested pYEULCBX vector and the PyTCTP 
insert were excised from the gel and DNA was purified using the Qiaquick Gel 
Extraction kit.  Ligations were performed using a 3:1 insert to vector ratio (method 
described in 2.3.2.7.2).  Completed reactions were cleaned using the dextran 
purification method (2.3.2.7.3), and were used to transform electro-competent E. coli 
DH5α.  Plasmid DNA from resulting colonies was purified by minipreparation.  The 
presence of TCTP insert was confirmed by digestion using PstI and BamHI (Figure 
3.2 (d)).  Sequence analysis of the insert confirmed that PyTCTP was in-frame with 
the N-terminal hexa-histidine tag.  Plasmids were named pYEULCBX.PyTCTP.  The 
sequence of the N-terminal portion of the expressed protein, including the His-tag, is 
depicted in Figure 3.3 (a).  A sequence alignment of PfTCTP and PyTCTP, starting 
from the first methionine after the His-tag, is shown in Figure 3.3 (b).  The two 
proteins share 88% identity, with 97% positives. 
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(a) 
 
Step 1: Amplification of PyTCTP from P. yoelii cDNA, using primers engineered to 
contain BamHI and PstI restriction sites: 
BamHI                                                      PstI 
 
P. yoelii cDNA 
 
 
Step 2:  Cloning of PyTCTP into the pCR2.1® TA vector: 
             A                  A                                       T                                         T  
Fresh PyTCTP PCR product                           pCR2.1 vector with TA overhangs 
 
 
Step 3:  Digestion of the pYEULCBX and pCR.PyTCTP vectors with BamHI and PstI 
 
pYEULCBX vector digestion       pCR® Vector digestion 
(pCR vector diagram modified from https://catalog.invitrogen.com/productImages/2000/1995.gif ) 
 
 
Step 4:  Ligation of PyTCTP into the pYEULCBX vector 
 
pYEULCBX.PyTCTP 
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                                  (d) 
                                                      1       2               3 
 
 
Figure 3.2:  Cloning of PyTCTP into the pYEULCBX yeast expression vector: 
(a) Diagram of the PyTCTP cloning strategy  
(b): Amplification of P. yoelii TCTP from cDNA by Taq PCR:  Lane 1:100 bp 
marker (full size range described in Appendix 1); Lanes 2-7: PCR products from 
annealing temperatures 50-55°C  
(c): pCR2.1.PyTCTP and pYEULCBX vectors digested with BamHI and PstI: 
Lane 1: 1 µg λ/PstI marker (full size range described in Appendix 1); Lanes 2-5: 
pCR2.1.PyTCTP plasmid digests; Lane 6: pYEULCBX plasmid digest  
(d): Confirmation digest of pYEULCBX.PyTCTP using BamHI and PstI:  Lane 1: 
1 µg λ/PstI marker; Lanes 2 & 3: pYEULCBX.PyTCTP plasmid digests 
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(a) 
 
M  R  G  S  H  H  H  H  H  H  G  S  L  V  P  R  G  S  G  G  R  S  G  S  M  K  V  Y D  I 
                       Hexa-His tag      thrombin cleavage site              BamHI  PyTCTP   
 
 
  
(b) 
P.y. TCTP   MKVYKDIFTNDEVCSDSYIQEDPFGNPEFREIAFEVKSNKRIKGNDDYGIADNSEDAVDG 
P.f. TCTP   ---F--V-----------V-Q---EV-------------------E------------E- 
 
P.y. TCTP   MGADVEHVIDIVDSFQLTSTSLSKKEYSAYVKNFMQRILKHLEEKKPDRVDIFKTKAQPL 
P.f. TCTP   --------------------AF--------I--Y--KVA-Y---------E--------F 
 
P.y. TCTP   IKHILTNFDDFEFYMGESLDMEAGLIYSYYKGEEITPRFVYISDGLFEEKY 
P.f. TCTP   ------------------------I-------------------------- 
 
 
  
Figure 3.3:  Sequence analysis of the His-tag region of the pYEULCBX.PyTCTP 
vector, and sequence alignment of PyTCTP and PfTCTP 
(a) Sequence of the His-tag and the N-terminal portion of PyTCTP encoded by 
the pYEULCBX.PyTCTP vector  
(b) Amino acid sequence alignment of PyTCTP and PfTCTP 
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3.3.2 Expression of PyTCTP and PfTCTP in S. cerevisiae 
3.3.2.1 Growth of pYEULCBX.PyTCTP and pYEULCBX.PfTCTP 
transformants of S. cerevisiae 
The pYEULCBX.PyTCTP plasmid was transformed into the w303.1a strain of 
S. cerevisiae (method described in section 2.5.2.1).  Transformation with pYEULCBX 
eliminates the growth requirement of the mutant yeast for uracil and leucine.  The 
transformation mix was plated on Complete-Ura agar and incubated at 30°C for 2-3 
days.  A culture of S. cerevisiae w303.1a mutant yeast that had been transformed 
with the pYEULCBX.PfTCTP plasmid was obtained from Prof. Ian Macreadie, 
CSIRO, Parkville Australia, and grown on Complete-Ura agar for 2-3 days at 30°C. 
 
3.3.2.3 Western blot to test for protein expression 
Expression of Pf- and Py-TCTP in several colonies of transformed yeast was 
verified by Western blot (2.6.2.1).  Ten millilitre cultures were induced with CuSO4 for 
16 hours.  Both culture supernatants and cell pellets were analysed.  SDS-PAGE 
was performed (2.6.7) followed by Western blot (2.6.8) with the following 
modifications and conditions: Casein (1% w/v in PBS) was used as a blocking 
solution and as an antibody diluent.  To detect recombinant PfTCTP, the primary 
antibody used was an α-PfTCTP IgG antibody raised in rabbit, at a 1:4,000 dilution 
(obtained from Prof. Steven Meshnick, Department of Epidemiology, University of 
Michigan, USA).  An α-rabbit IgG.HRP conjugate used at a 1:1,000 dilution as a 
secondary antibody.  PfTCTP was detected in all the transformed colonies analysed, 
although expression levels varied.  A major band at around 26 kDa was observed, as 
well as several smaller bands ranging from ~23 kDa to ~16 kDa (Figure 3.4 (a)).  
These smaller protein bands are most likely to be breakdown products of PfTCTP 
due to proteolysis.  No bands were detected in untransformed yeast cultures probed 
with α-TCTP antibodies (results not shown).  The TCTP from the induced yeast 
cultures had been subjected to SDS-PAGE prior to protein purification, indicating that 
some proteolysis of TCTP was occurring during yeast growth. 
 
At the time of these experiments, it was unknown if PfTCTP antibodies would 
recognise PyTCTP, although cross-reactivity was likely given the high sequence 
similarity.  Due to this, expression of PyTCTP in transformed yeast was verified using 
a Penta-His antibody raised in rabbit, at a 1:1,000 dilution.  The α-rabbit secondary 
antibody was used as before.  A major band was detected at around 28 kDa in all of 
the transformants analysed, as well as two to three smaller bands at around 24 and 
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22 kDa (Figure 3.4 (b)).  The His-tag is present on the N-terminus of PyTCTP, so the 
smaller protein bands observed are most likely C-terminal truncates of PyTCTP. 
 
A greater number of lower molecular-weight protein bands were detected 
using the α-PfTCTP antibody compared with the α-Penta-His antibody.  This could 
be due to the presence of N-terminal truncates of TCTP, which would not be 
detected by the α-Penta-His antibody, or this result could indicate that more 
proteolysis occurred in the PfTCTP cultures compared with the PyTCTP cultures.     
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Figure 3.4: Confirmation of PfTCTP and PyTCTP expression in yeast 
(a): PfTCTP transformants reacted with PfTCTP antibody: Lane 1: BenchMark 
pre-stained marker (full size range described in Appendix 1).; Lanes 2-5: PfTCTP 
culture cell pellets  
(b): PyTCTP transformants reacted with Poly-His antibody: Lanes 1, 2, 4: 
PyTCTP culture cell pellets; Lane 3: BenchMark pre-stained marker; Lane 5: His-
tagged positive control protein. 
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3.3.2.5 Large-scale expression and purification of PyTCTP and PfTCTP 
Yeast transformed with either pYEULCBX.PfTCTP or pYEULCBX.PfTCTP 
was used to inoculate 0.5-1L of supplemented YNB+Glucose, and expression was 
induced with 0.5 mM CuSO4 for 40 hours (method described in 2.6.2.2). Yeast cells 
were lysed using a Braun cell homogeniser (2.6.2.4.1) in the presence of protease 
inhibitors (1 mM Pefabloc, 5 mM Benzamidine, 1 µg/ml E-64, 1 µg/ml Pepstatin, and 
1 µg/ml leupeptin).  The lysates were centrifuged at 21,000 x g for 25 min and 
protease inhibitors were added prior to incubation of the supernatants with prepared 
Talon™ resin at 4°C for 16 h.  Metal affinity chromatography was performed using a 
wash step in phosphate buffer containing 5 mM imidazole, followed by elution of His-
tagged proteins using 0.2 M imidazole (method described in 2.6.2.5).  Samples of the 
eluates were subjected to SDS-PAGE.  Figure 3.5 (a) shows the result of Talon 
affinity chromatography performed on PfTCTP yeast lysates.  The 5 mM imidazole 
eluates (lanes 2 and 3) contain a small amount of low molecular weight proteins 
(<15 kDa).  In the 0.2 M imidazole eluate (lane 4), a major protein band is present at 
around 26 kDa, as well as several lower and higher molecular weight proteins.  Talon 
affinity chromatography of PyTCTP lysates yielded similar results, as shown in 
Figure 3.5 (b).  Very low amounts of protein were detected in the 5 mM imidazole 
eluate (results not shown). A major band at around 28 kDa was present in the 0.2 M 
imidazole eluates, as well as several other higher and lower molecular weight 
proteins. 
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Figure 3.5:  Purification of PfTCTP and PyTCTP by IMAC using Talon™ resin 
(a) Purification of PfTCTP: Lane 1: BenchMark pre-stained marker; Lanes 2 and 3: 
5 mM imidazole eluates; Lane 4: 0.2 M imidazole eluate  
(b) Purification of PyTCTP: Lane 1: BenchMark pre-stained marker; Lanes 2 & 3: 
0.2 M imidazole eluate fractions 
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3.3.2.6 Further purification of PyTCTP and PfTCTP 
After IMAC, PfTCTP and PyTCTP were further purified using a Mono-Q 
anion-exchange column (method described in 2.6.2.7).  A broad eluate peak was 
seen start of the NaCl gradient for both PyTCTP and PfTCTP, and a small shoulder 
peak was seen before the major narrow elution peak, as shown in Figure 3.6 (a) and 
(b).  Fractions corresponding to each UV peak above 0.02 were collected and 
subjected to SDS-PAGE (results not shown).  TCTP was present in the major, 
narrow UV peak that eluted at ~48 min, when the buffer B concentration was ~60% 
(~0.3 M NaCl).  Fractions containing TCTP were combined and dialysed against PBS 
(method described in 2.6.2.6).  Preparations of PfTCTP and PyTCTP following 
Mono-Q chromatography and PBS dialysis are shown in Figure 3.7 (a) and (b).  The 
higher molecular weight bands seen in both Py and PfTCTP samples after Talon™ 
column purification (Figure 3.5) were absent following Mono-Q chromatography.  
These larger bands could have been contaminant proteins that were separated by 
the Mono-Q column, or could have been TCTP multimers that were not completely 
reduced on SDS-PAGE, but were reduced by the dithiothreitol (DTT) used during 
Mono-Q chromatography.  Several smaller proteins, most likely TCTP breakdown 
products, were also present following Mono-Q purification.    
 
3.3.2.7 Analysis of protein storage methods 
Following Mono-Q anion exchange chromatography and PBS dialysis, 
centricon columns were used to concentrate proteins to at least 0.5 mg/ml, which 
was the concentration required for use in the vaccine trial.  As previous experiments 
had indicated that TCTP was susceptible to degradation during prolonged storage, 
several methods of protein storage were assessed.  A portion of PfTCTP was 
lyophilised (2.6.2.8), to assess the potential for the protein to be sent to overseas 
collaborators.  Lyophilization of PfTCTP resulted in minimal loss of yield and minimal 
degradation, as seen in Figure 3.7 (a) by comparing lanes 2 and 5 (PfTCTP prior to 
lyophilization) with lanes 3 and 4 (PfTCTP post-lyophilization and reconstitution).  As 
PyTCTP was purified shortly before the commencement of the vaccine trial and 
overseas transportation was not required, it was not lyophilised.   
 
The other methods of protein storage evaluated were storage at -70°C, in 
PBS and in PBS+50% glycerol.  These proteins were analysed by SDS-PAGE to 
assess the yield and proportion of full-length TCTP present after several months of 
storage, just prior to vaccine preparation.  As seen in Figure 3.8 (a) and (b), storage 
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in 50% glycerol resulted in increased protein breakdown compared to proteins stored 
in PBS alone, as a greater proportion of lower molecular weight bands were seen.  
Bradford assays of the glycerol-stored proteins after PBS dialysis indicated that over 
50% of total protein had been lost during storage.  As the SDS-PAGE results showed 
essentially the same amount of protein immediately before and after PBS dialysis 
and concentration, it was determined that the loss of protein yield has occurred 
during the time the proteins were stored in 50% glycerol.   
 
TCTP stored in 50% glycerol was not used in the subsequent vaccine trial 
due to the substantial breakdown, instead TCTP stored at -70°C in PBS was used.  
Whilst some protein breakdown was observed over several months using this 
storage method, SDS-PAGE indicated that a substantial amount of full-length TCTP 
remained. 
 
Additionally, PfTCTP was observed to separate at a slightly lower molecular 
weight than PyTCTP when the two proteins were loaded alongside each other on the 
one gel.  As the two proteins are both 171 amino acids in length, sharing 88% amino 
acid identity, the reason for the observed size difference is unknown.  Pf and 
PyTCTP do not contain potential N-linked glycosylation sites.   
 
3.3.2.8 Sequence analysis of TCTP following Mono-Q chromatography 
N-terminal sequencing (as described in 2.6.2.7) of PyTCTP eluates from 
Mono-Q anion exchange chromatography revealed two major protein sequences.  
One corresponded to the N-terminal sequence of the His-tagged PyTCTP, with the 
sequence Ser-His-His-His-His-His-His.  The other major sequence obtained was Glu-
Asp-Ala-Val-Asp-Gly-Met-Gly-Ala.  This sequence is identical to residues 55-63 of 
PyTCTP, as compared with the sequence of PyTCTP given in Figure 3.3 (b).  Three 
residues were present prior to the Glu in the breakdown product, but the sequencing 
profiles were difficult to interpret.  This result indicates that the lower molecular 
weight protein seen on SDS-PAGE of PyTCTP following Mono-Q chromatography is 
a breakdown product of PyTCTP as the result of cleavage between the Ala51 and 
Asp52 residues.  Lower molecular weight proteins had previously been observed in 
PfTCTP samples following Mono-Q chromatography.  N-terminal sequencing of 
these samples had shown that the major protein present other than full-length 
PfTCTP was a breakdown product due to cleavage between Met61 and Gly62.  The 
minor peak eluting from Mono-Q chromatography prior to the major TCTP peak had 
previously been shown to contain proteins approximately corresponding in size to 
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TCTP breakdown products (unpublished result).  However, the major peak eluting 
from the Mono-Q column also contained proteins corresponding to TCTP breakdown 
products, as well as full-length TCTP.    
  
 
                  (a) 
  
 
                  (b) 
    
 
Figure 3.6: Elution profile of TCTP during Mono-Q purification 
(a) PfTCTP elution profile from Mono-Q purification 
(b) PyTCTP elution profile from Mono-Q purification 
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Figure 3.7: TCTP following Mono-Q purification and PBS dialysis 
(a) PfTCTP after Mono-Q purification: Lane 1: BenchMark Pre-stained marker; 
Lane 2: 2 µg PfTCTP following Mono-Q purification and PBS dialysis; Lane 3: 2 µg 
reconstituted PfTCTP post-lyophilization; Lane 4: 4 µg reconstituted PfTCTP post-
lyophilization; Lane 5: 2 µg PfTCTP dialysed in ammonium bicarbonate, prior to 
lyophilisation  
(b) PyTCTP after Mono-Q purification and PBS dialysis: Lane 1: BenchMark Pre-
stained marker; Lanes 2 & 3: Aliquots of 2 µg of PyTCTP following Mono-Q 
purification and PBS dialysis. 
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Figure 3.8: Comparison of protein yield and quality following storage in PBS or 
in 50% glycerol 
(a) PyTCTP and PfTCTP stored in PBS:  Lane 1: SeeBluePlus2 marker (full size 
range described in Appendix 1); Lane 2: 1 µg PyTCTP; Lane 3: 2 µg PyTCTP; Lane 
4: 0.5 µg PfTCTP; Lane 5: 1.5 µg PfTCTP  
(b) PyTCTP and PfTCTP stored in 50% glycerol: Lane 1: SeeBluePlus2 marker; 
lane 2: 2 µg PyTCTP in 50% glycerol; Lane 3: 2 µg PfTCTP in 50% glycerol 
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3.3.2.9 Analysis of PfTCTP obtained by an alternate expression method 
An alternate method of protein expression with a one-hour induction time 
(method described in 2.6.2.3) was evaluated following the vaccine trial, to assess if 
the modifications would reduce proteolysis.  The method was adapted from 
http://www.clontech.com/images/pt/dis_manuals/PT3081-1.pdf and was designed to 
minimise yeast protease activity by replacement of the culture medium prior to 
induction.  The induction time was also decreased to 1 h.  In this method, yeast cells 
were lysed using glass beads (2.6.2.4.2).  This alternate method of protein 
expression improved protein yield; 25 mg/L of PfTCTP was obtained compared with 
2-3 mg/L from cultures induced for 40 hours.  Figure 3.9 depicts Talon™-purified 
PfTCTP obtained using this alternate expression method.  Less total protein is 
present compared with Figure 3.5 (a), making comparisons of proteolysis difficult, 
however there appears to be equal or less proteolysis in the alternate expression 
method sample.  This protein was used as an ELISA antigen, and was not further 
purified by Mono-Q chromatography.  
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Figure 3.9: Purification of PfTCTP following alternate expression method 
Lane 1: BenchMark marker (full size range described in Appendix 1); Lanes 2 & 3: 
0.2 M imidazole eluate fractions 
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3.3.3 Analysis of TCTP samples under reducing and non-reducing 
conditions 
Smaller MW bands were always observed together with full-length TCTP on 
SDS-PAGE after IMAC and anion-exchange chromatography.  At least some of 
these were TCTP breakdown products, as determined by western blot and N-
terminal sequencing.  It was thought that these breakdown products might be self-
associating with full-length TCTP and co-eluting from the columns, as the self-
interaction of TCTP had previously been reported (Yoon et al., 2000).  An alternative 
explanation is that purified TCTP was subject to continual proteolysis and the 
breakdown products were newly formed after chromatography, prior to SDS-PAGE 
analysis. 
 
To evaluate the self-interaction of malarial TCTP, PyTCTP and PfTCTP 
samples following Mono-Q purification were subjected to SDS-PAGE under reducing 
and non-reducing conditions.  Samples containing 2 µg of either Py or PfTCTP were 
combined with reducing sample buffer or non-reducing sample buffer.  The samples 
resuspended in non-reducing buffer were not boiled prior to loading.  The reduced 
and unreduced samples were run on adjacent wells of a 15-4% SDS-PAGE gel as 
per the standard method (Figure 3.10).  As in Figure 3.8, PfTCTP was observed to 
run at a slightly smaller size than PyTCTP.     
 
Under reducing conditions, both PyTCTP and PfTCTP were present as a 
major band of ~28 kDa as well as several smaller molecular-weight bands.  Under 
non-reducing conditions, higher molecular-weight bands of ~35 and 53 kDa were 
present together with a 28 kDa band in both PyTCTP and PfTCTP samples.  
Additionally, lower molecular-weight bands (~16 and 12 kDa) were present.  The 
presence of a 35 kDa band suggests that some of the breakdown products could 
associate with full-length TCTP under non-reducing conditions.  The presence of a 
53 kDa band suggests that full-length TCTP could form dimers under non-reducing 
conditions.  Anion exchange chromatography was performed under reducing 
conditions (in the presence of 1 mM DTT), and so self-interaction through cysteine 
bonds would not be expected.  Also, a single cysteine is present in Py and PfTCTP 
at residue 14, and self-interaction was reported to involve residues 126-172.   It is 
probable that this self-interaction occurred through another mechanism. 
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Figure 3.10: PyTCTP and PfTCTP separated by SDS-PAGE under reducing and 
non-reducing conditions 
Lane 1: Mark12 marker (full size range described in Appendix 1); Lane 2: PyTCTP 
under reducing conditions; Lane 3: PyTCTP under non-reducing conditions; Lane 4: 
PfTCTP under reducing conditions; Lane 5: PfTCTP under non-reducing conditions 
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3.3.4 Evaluation of PfTCTP and PyTCTP as potential malarial 
vaccines 
3.3.4.1 Mouse immunisation groups and schedule 
Six groups of six BALB/c mice were used in the vaccine trial.  All mice were 
female and were aged six to eight weeks at the commencement of the trial.  Two 
groups of six mice received immunisations of the PBS control, two groups of six mice 
received immunisations of PyTCTP and two groups of six mice received 
immunisations of PfTCTP.  The methodology of the TCTP vaccine trial was based on 
vaccine trials of the P. yoelii merozoite surface protein 4/5 (MSP4/5) (Goschnick et 
al., 2004; Kedzierski et al., 2000; Kedzierski et al., 2002a; Kedzierski et al., 2001).  In 
the MSP4/5 trials, mice were immunised with 25 µg of protein in Freunds adjuvant at 
monthly intervals.   
 
Mice in each group were immunised three times, with PBS or 25 µg PyTCTP 
or PfTCTP in Freunds adjuvant.  The methods of vaccine preparation and mouse 
immunisation are described in sections 2.8.2.1 and 2.8.2.2.  The first immunisation 
utilised Freunds complete adjuvant, the second and third immunisations were 
prepared using Freunds incomplete adjuvant.  Mice were immunised using an i.p. 
injection of 100 µl of emulsion.  There was a three-week interval between 
immunisations.  To assess antibody titres, serum was collected from mice prior to the 
first immunisation and just prior to parasite challenge (2.8.2.3).  A summary of mouse 
vaccine groups is shown in Table 3.1. 
 
Table 3.1:  Mouse immunisation groups 
Group Immunisation Challenge No. of mice 
1 
2 
PBS in adjuvant 
“ 
P. yoelii YM 
P. yoelii 17XNL 
6 
6 
3 
4 
PyTCTP in adjuvant 
“ 
P. yoelii YM 
P. yoelii 17XNL 
6 
6 
5 
6 
PfTCTP in adjuvant 
“ 
P. yoelii YM 
P. yoelii 17XNL 
6 
6 
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3.3.4.2 Health of mice during immunisation period 
One mouse in the PBS control group died three days after the third 
immunisation.  An autopsy was performed but no abnormalities were seen, and the 
cause of death was unknown.  All mice showed slight clinical symptoms (lack of 
grooming, clinical score of 1, as described in Appendix 2) the first day following 
immunisations, but were otherwise healthy throughout the immunisation period.  
 
3.3.4.3 Survival rates of groups challenged with P. yoelii XNL and YM malaria 
Mice were challenged with a dose of 1 x 105 infected erythrocytes of P. yoelii 
17XNL (non-lethal) or P. yoelii YM (lethal) parasites three weeks after the final 
immunisation.  The P. yoelii 17XNL strain was obtained from the Austin Research 
Institute, Heidelberg, Australia.  The P. yoelii YM strain was obtained from the 
Department of Microbiology, Monash University, Melbourne, Australia.  Stabilates of 
these strains were used to infect passage mice (method described in 2.7.2.3); blood 
from these mice was then used to infect immunised mice with the precise parasite 
dose (2.7.2.4).  
 
After infection, immunised mice were closely monitored for the development 
of malarial symptoms.  Blood was taken daily for parasitemia quantification (2.7.2.5).   
After 3 dpi, mice were monitored at intervals of between four and seven hours for 
malarial symptom development (2.8.2.4).  Mouse symptoms were scored following 
the table provided by the RMIT AEC (Appendix 2).  Mice were euthanised when they 
reached a score of 8.  This corresponded to severe morbidity, with respiratory 
distress as a major symptom, as well as weight loss, lack of grooming, and 
decreased body temperature.  These symptoms usually occurred at a parasitemia of 
60 - 80%.   
 
An unexpected result occurred after malarial challenge.  P. yoelii 17XNL, 
which is known to be non-lethal in BALB/c mice, was found to be uniformly lethal in 
both PBS-immunised controls and in Pf- and PyTCTP-immunised mice (Figure 3.11 
(a)).  All mice had rapidly ascending parasitemia and symptoms typical of a lethal P. 
yoelii infection, all reached a symptom score of 8 and were sacrificed.  It was thus 
assumed that the strain had become lethal due to increased virulence by repeated 
passage.  The survival rates for PfTCTP-immunised mice and PBS-immunised 
controls were identical, whilst some mice immunised with PyTCTP survived longer 
than controls.  At 7 dpi, 50% of PyTCTP-immunised mice were surviving, compared 
with 17% of PBS-immunised controls.  At 8 dpi, all control mice had reached a 
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symptom score of 8, whereas one PyTCTP-immunised mouse survived until 10 dpi.  
The average survival time of the TCTP-immunised groups was compared to the PBS 
controls.  The differences were non-significant (Table 3.2).   
 
TCTP immunisation did not increase survival time in mice challenged with P. 
yoelii YM.  As shown in Figure 3.11 (b), at 7 dpi 80% of PBS-immunised controls 
were surviving compared with 50% of PyTCTP-immunised mice and 17% of PfTCTP-
immunised mice.  All mice had reached a symptom score of 8 at 8 dpi.  The average 
survival time of the TCTP-immunised groups was compared to the PBS controls.  
The difference in the PyTCTP-immunised group average survival time was not 
significantly different to the PBS controls, however the PfTCTP-immunised mice 
survived for significantly less time than the PBS group (Table 3.3).   
 
Table 3.2: Average survival of mouse groups challenged with P. yoelii XNL 
Mouse group Avg survival time p-value* 
PBS 6.17 - 
PyTCTP 7.17 0.129 
PfTCTP 6.17 1 
*Survival time compared with PBS control group 
 
Table 3.3: Average survival of mouse groups challenged with P. yoelii XL 
Mouse group Avg survival time p-value* 
PBS 6.8 - 
PyTCTP 6.5 0.343 
PfTCTP 6.0 0.037 
*Survival time compared with PBS control group 
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Figure 3.11:  Survival of TCTP-immunised mice and controls following malaria 
challenge 
(a) Survival of TCTP-immunised mice and PBS-immunised controls following 
challenge with P. yoelii XNL  
(b) Survival of TCTP-immunised mice and PBS-immunised controls following 
challenge with P. yoelii YM  
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3.3.4.4 Comparison of parasitemia 
No significant difference in parasitemia was observed between PBS controls 
and TCTP-immunised mice following either P. yoelii XNL or YM challenge.  As 
shown in Figure 3.12 (a) and (b), large standard variations from the mean were 
generally observed for all groups.   
 
A potentially interesting result was seen as the longest surviving mouse in the 
P. yoelii XNL trial (mouse 5 in PyTCTP #2) had a very low detectable parasitemia 
(<5%) until 7 dpi, when parasite levels rose to 25%.  Parasite levels then continued 
to rise until 9 dpi, when the mouse reached a symptom score of 8 and was sacrificed.  
This mouse had the second-highest reciprocal antibody titre to PyTCTP of all 
individual mice (Figure 3.13 (b)).  The two other longest surviving mice in the 
PyTCTP group #2, mouse 1 and 6, also had some of the highest reciprocal antibody 
titres to PyTCTP.  However, mouse 4 in PyTCTP #2, which was the first mouse to 
succumb to P. yoelii XNL infection, also had high reciprocal titres to PyTCTP.  A 
scatter plot of survival time vs. reciprocal titre for P. yoelii XNL-challenged control 
and PyTCTP-immunised mice was created, no significant correlation was observed 
(data not shown).  There was also no significant correlation between reciprocal 
antibody titre and survival time in mice immunised with PfTCTP and challenged with 
P. yoelii XNL, or in mice immunised with PyTCTP or PfTCTP and challenged with P. 
yoelii YM. 
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Figure 3.12: Parasitemia in TCTP-immunised and control mice  
(a) Parasitemia following challenge with P. yoelii XNL  
(b) Parasitemia following challenge with P. yoelii YM  
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3.3.4.5 Analysis of antibody titres by ELISA 
Pre-challenge TCTP reciprocal antibody titres were quantified by ELISA 
(method described in 2.8.2.7) with the following modifications and conditions:  96-
well plates were coated with 2 µg/ml of PfTCTP or PbTCTP.  Sera obtained from 
immunised mice were used as the primary antibody, with an initial dilution of 1:100 to 
1:400.  A goat-α-mouse IgG.HRP conjugate was used as a secondary antibody at a 
1:5,000 dilution.  The absorbance readings at 450 nm were plotted against the 
reciprocal serum dilution for pooled sera from the six vaccine groups, and for 
individual mice from the Py- and PfTCTP-immunised groups. 
 
Sera from all TCTP-immunised mice, including those immunised with PfTCTP, 
bound more strongly to PyTCTP than PfTCTP (Figure 3.13 (a)).  The average reciprocal 
titres for the pooled sera from PfTCTP groups #1 and #2 were 23,000 and 10,800 when 
tested for binding to PfTCTP, and 215,000 and 85,000 when tested for binding to 
PyTCTP.  This could have been due to the fact that a different preparation of PfTCTP 
was used as an ELISA antigen than was used for immunisation.  The PfTCTP used for 
ELISA was prepared using the alternative protein expression method described in 
section 3.3.2.9.  This method produced less contaminant bands after IMAC, and so 
Mono-Q column purification was not performed. The two preparations gave similar 
banding patterns on SDS-PAGE.  However, it is possible that some of the antibodies 
present in the polyclonal PfTCTP antisera were specific to epitopes only present the 
initial Pf and PyTCTP preparations.   
 
The average reciprocal titres for the pooled sera from PyTCTP groups #1 and #2 
were 175,000 and 225,000 when tested for binding to PyTCTP and 9,100 and 5,800 
when tested for binding to PfTCTP.  Again, reciprocal titres were significantly higher to 
PyTCTP than to PfTCTP.  Sera from PBS-immunised mice did not bind to PfTCTP or 
PyTCTP above background levels.  The pooled sera from the PfTCTP-immunised mice 
from the 2002 vaccine trial (Taylor, 2002) was also included in these ELISAs, the 
average reciprocal  titre was 14,800 against PyTCTP and 12,000 against PfTCTP.   
 
As shown in Figure 3.13 (b), individual mouse reciprocal titres from PyTCTP 
groups #1 and #2 against PyTCTP ranged from 4,500 (mouse 3 PyTCTP #1) to 
1,000,000 (mouse 6 PyTCTP #2).  Individual mouse reciprocal titres from PfTCTP 
groups #1 and #2 against PfTCTP ranged from 5,000 (mouse 2 PfTCTP #1) to 127,500 
(mouse 1 PfTCTP #1).  The titration curves used to calculate each individual mouse 
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reciprocal titre are included in Appendix 3.
Chapter 3: Evaluation of P. yoelii and P. falciparum TCTP as malaria vaccines 
 126 
(a) 
1
10
100
1000
10000
100000
1000000
PBS 1 PBS 2 PyT 1 PyT 2 PfT 1 PfT 2 2002
trial
PfT
PBS 1 PBS 2 PyT 1 PyT 2 PfT 1 PfT 2 2002
trial
PfT
PyTCTP Ag PfTCTP Ag
Ag and group
 
(b) 
1
10
100
1000
10000
100000
1000000
m
o
u
se
 
1
m
o
u
se
 
2
m
o
u
se
 
3
m
o
u
se
 
4
m
o
u
se
 
5
m
o
u
se
 
6
m
o
u
se
 
1
m
o
u
se
 
2
m
o
u
se
 
3
m
o
u
se
 
4
m
o
u
se
 
5
m
o
u
se
 
6
m
o
u
se
 
1
m
o
u
se
 
2
m
o
u
se
 
3
m
o
u
se
 
4
m
o
u
se
 
5
m
o
u
se
 
6
m
o
u
se
 
1
m
o
u
se
 
2
m
o
u
se
 
3
m
o
u
se
 
4
m
o
u
se
 
5
m
o
u
se
 
6
PfTCTP #1 PfTCTP #2 PyTCTP #1 PyTCTP #2
Mouse number and group
 
 
Figure 3.13: Reciprocal titres of vaccine trial mice 
(a) Reciprocal titres of pooled sera from immunised groups 
(b) Reciprocal titres of individual mouse sera against homologous antigen 
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3.3.5 Recognition of P. yoelii TCTP by anti-TCTP antibodies present in 
immunised mouse sera 
Western blot experiments were performed to assess the ability of the PyTCTP 
antisera to recognise TCTP present in P. yoelii lysates.  Parasitised blood taken from 
BALB/c mice was used to create P. yoelii YM lysates (method described in 2.9.2.4).  
Approximately 25 ng of recombinant PyTCTP was also included as a positive control.  
The total parasites obtained from the blood of one mouse with a parasitemia of 10% 
were lysed in a final volume of 50 µl; 20 µl and 10 µl of this lysate were separated by 
SDS-PAGE.  The protein concentration of the parasite lysate could not be accurately 
quantified, due to the final lysis step being boiling for 10 min in reducing sample buffer.  A 
western blot was performed with the following conditions:  Antiserum from mouse 6 in the 
PyTCTP #2 vaccine group was used as a primary antibody at a 1:1,000 dilution.  A goat-
anti-mouse IgG.HRP conjugate was used as a secondary antibody at a 1:3,000 dilution.   
 
Serum from mice immunised with PyTCTP could recognise TCTP present in P. 
yoelii YM parasite lysates, as shown in Figure 3.14.  The recombinant PyTCTP 
separated at a higher molecular weight (~28 kDa) than the endogenous P. yoelii YM 
TCTP(~23 kDa), this is likely to be due to the presence of the hexa-histidine tag.  A 
single band was detected in the malaria lysates, whereas TCTP breakdown products of 
around 12 kDa were detected in the recombinant PyTCTP preparation along with full-
length protein. 
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Figure 3.14 Recognition of TCTP in P. yoelii YM lysates by PyTCTP anti-serum 
Lane 1: ~ 25 ng recombinant PyTCTP; Lane 2: SeeBluePlus2 marker; Lanes 3 and 4: 20 
µl P. yoelii YM lysate; Lane 5: 10 µl P. yoelii YM lysate 
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3.4 Discussion 
Both Pf and PyTCTP were successfully expressed and purified from yeast.  When 
loaded together on SDS-PAGE, PfTCTP was observed to migrate at a lower molecular 
weight than PyTCTP.  The two proteins share a high degree of sequence similarity, are 
the same length, and were both cloned into the pYEULCBX vector in an identical 
manner, so the lower observed size of PfTCTP was unexpected.  TCTP is generally 
acknowledged to migrate more slowly on SDS-PAGE than expected, as the theoretical 
mass of the protein is 19.5 kDa and several reports have observed TCTP migrating 
above 25 kDa (e.g. Bhisutthibhan et al., 1998; Gnanasekar et al., 2002; Rao et al., 2002).  
This is thought to be due to the known calcium-binding capacity of TCTP, as calcium-
binding proteins are known to run abnormally on SDS-PAGE, and the addition of 1 mM 
Ca2+ caused faster migration of human TCTP (Sanchez et al., 1997).  It is possible that 
Py and PfTCTP differ in their calcium-binding capacity, resulting in the size differences 
observed on SDS-PAGE.   
 
Both Pf and PyTCTP were subject to substantial proteolysis during the 
purification procedure, as was previously observed during PfTCTP purification prior to 
the 2002 vaccine trial (Taylor, 2002).  As demonstrated by SDS-PAGE, lower molecular-
weight bands were present at all stages of TCTP purification.  Some of these smaller 
bands were detected by western blot using anti-TCTP and anti-penta-His antibodies, and 
N-terminal sequencing demonstrated that full-length PyTCTP and an N-terminal truncate 
(52-171) were the major products present after anion-exchange chromatography.  
Therefore, at least some of the smaller bands present at all stages of purification were 
due to TCTP proteolysis.  
 
Proteolysis of both PyTCTP and PfTCTP was also observed prior to purification.  
TCTP expression was induced in yeast cultures for 16 hours, and yeast cell pellets were 
boiled in sample buffer prior to SDS-PAGE.  Western blots using both anti-His and anti-
TCTP antibodies detected bands corresponding to full-length TCTP (26 kDa), as well as 
smaller molecular weight bands.   
 
To assess if TCTP proteolysis was caused, in part, by the lengthy expression 
induction period (between 16 and 40 hours), an alternate method of protein expression 
was assessed.  In this method, endogenous yeast protease activity was minimised by the 
replacement of culture medium, prior to induction of recombinant protein expression for 
one hour.  Reduced protein breakdown and improved protein yield were observed in this 
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alternate expression method.  The alternate method also used vortexing with glass 
beads for cell lysis in place of homogenisation, however it is unlikely that this alteration 
improved protein yield, as cell lysis was deemed to be less efficient by microscopic 
analysis.  As the alternate expression method was not assessed until the completion of 
the vaccine trial, mice were immunised with TCTP preparations containing a substantial 
amount of breakdown products.  PfTCTP with a substantial amount of degradation was 
also used in the 2002 vaccine trial.  These protein preparations were able to induce a 
strong humoral response, as demonstrated by ELISA analysis.  
    
It was assumed that the breakdown products were newly formed during each 
purification stage, as they were expected to elute separately from anion-exchange 
chromatography due to charge differences.  However, self-interaction has previously 
been reported for rat TCTP, involving the amino acid residues 126-172 (Yoon et al., 
2000).  As sequence analysis of the major breakdown product of PyTCTP after Mono-Q 
purification determined that it was an N-terminal 52-171 truncate, it is possible that this 
product could interact with full-length PyTCTP.  To assess interaction, PyTCTP and 
PfTCTP samples were subjected to SDS-PAGE under reducing and non-reducing 
conditions.  Some self-interaction of TCTP was observed, as bands of ~35 kDa and ~53 
kDa were present under non-reducing conditions.  Additionally, similar amounts of 
smaller proteins (16 and 12 kDa) were present in both reduced and non-reduced 
samples.  This observed self-interaction suggests that under non-reducing conditions, 
e.g. during IMAC, proteolytic products could have co-eluted with full-length TCTP.  
However, it is not known if TCTP self-interaction would occur under the reducing 
conditions used for Mono-Q chromatography.  The presence of similar amounts of 
breakdown products in reduced and non-reduced samples indicated that TCTP was also 
subject to continual proteolysis, despite the presence of protease inhibitors.   
 
The further breakdown of TCTP during storage meant that a new preparation of 
PfTCTP was required to complete the ELISA experiments.  An alternative method of 
expression and purification was used to prepare the PfTCTP.  By ELISA analysis, a 
much greater antibody response was induced to PyTCTP than to PfTCTP.  Additionally, 
sera from mice immunised with PfTCTP reacted more strongly to the PyTCTP than to 
homologous antigen.  It is possible that some of the antibodies present in the polyclonal 
PfTCTP antisera were specific to epitopes only present the initial Pf and PyTCTP 
preparations, which could explain the higher titre generated to PyTCTP antigen.  This 
hypothesis is supported by the relatively low titre of PyTCTP-immunised group sera 
when reacted with the alternate PfTCTP preparation.  Western blot experiments using P. 
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yoelii YM lysates demonstrated that PyTCTP antisera could recognise malarial TCTP, 
and so the protective effect of TCTP immunisation could be assessed with some 
confidence.   
 
Although a significant humoral response was generated to TCTP, no protection 
against P. yoelii infection was observed following TCTP immunisation.  No significant 
differences were observed in parasitemia or survival time.  Unlike in the previous TCTP 
vaccine trial (Taylor, 2002), there was no delay in the establishment of infection.  The 
reasons for this are unknown.  The lack of protective effect is unlikely to be due to 
insufficient anti-TCTP antibody production.  Comparisons between ELISA experiments 
are difficult, due to variations in antigen preparation and in the reagents used.  For this 
reason, the pooled serum from the 2002 trial PfTCTP vaccine group was included as a 
sample in the ELISAs, a reciprocal titre of 12,000 was obtained.  The reciprocal titres of 
the pooled sera in mouse groups immunised with PfTCTP in the trial described in this 
chapter were similar or higher than the 2002 group sera (11,000 and 23,000), reciprocal 
titres of pooled sera in mouse groups immunised with PyTCTP were higher again 
(215,000 and 85,000).   
 
As compared with the previous trial, the lack of protective effect following TCTP 
immunisation was unlikely to be due to the malarial strains used for challenge.  The P. 
yoelii YM strain used was identical to that used in the 2002 trial, except that it had 
undergone one extra round of passage in mice.  This may have increased the virulence 
of the parasite; however control mice survived at least as long as in the previous 
experiment.  Whilst the second malaria strain used for challenge produced unexpected 
results, in that the strain was uniformly lethal, this did not render that challenge invalid as 
the protective effect of TCTP immunisation could still be assessed.  It is possible that the 
strain obtained was actually a lethal strain of P. yoelii, such as XL or YM, or that a 
previously non-lethal strain of P. yoelii 17XNL had become lethal due to repeated 
passage in mice.  In a typical P. yoelii 17XNL infection in BALB/c mice, parasitemia rises 
to a peak of around 20% at about ten dpi, and then mice rapidly clear the parasite load 
(eg Li et al., 2001a; Ma et al., 2007; Taylor et al., 1986).  The strain used in this vaccine 
trial produced parasitemia that rapidly rose to between 55 and 75% at six dpi, with 
symptoms typical of a lethal infection.  Additionally, it has previously been reported that 
non-lethal strains of P. yoelii preferentially invade reticulocytes, whereas lethal strains 
invade all erythrocytes (Mota et al., 2001).  In the challenge experiment described, the 
strain was observed to invade both immature and mature erythrocytes.   
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TCTP was expressed in S. cerevisiae due to the previous protective effect 
observed using yeast-derived PfTCTP for immunisation.  Additionally, it was thought that 
expressing TCTP in a eukaryotic system rather than in E. coli may result a protein with a 
conformation more similar to the native malarial TCTP.  Although no protective effect was 
observed, the ability of antibodies generated to yeast-derived PyTCTP to recognise 
TCTP in P. yoelii YM lysates was demonstrated.     
 
Yeast-derived PfTCTP has been reported to induce histamine release in vitro in a 
subset of allergic donor basophils (MacDonald et al., 2001). Additionally, filarial TCTP 
was observed to induce eosinophil infiltration in vivo in C57BL/6 mice sensitised by OVA 
injection (Gnanasekar et al., 2002; Rao et al., 2002).  An experiment performed by our 
group assessed the induction of histamine release by TCTP injection in vivo in BALB/c 
mice, no elevations in histamine levels were observed (Taylor, 2002).  It is possible that 
TCTP induces a localised increase in histamine that does not significantly raise systemic 
serum levels.  During the establishment of a malarial infection, a localised release of 
histamine in response to TCTP may assist the parasite by increasing vasodilation, and/or 
by increasing the expression of host endothelial adhesion factors, as discussed in 
section 1.6.1.  It is also possible that the labile histamine was degraded during serum 
collection and lyophilization.   
 
It was thought that the expression of TCTP in a bacterial system might result in 
greater yields and more stable protein, due to a reduced amount of protease activity.  
However, it was not known if E. coli-derived TCTP would induce a protective immune 
response.  TCTP from different host species has been expressed in E. coli, yeast, and 
insect cells.  Although the overall function of TCTP has not been ascertained, protein 
with demonstrated histamine-releasing ability has been obtained from each of these 
expression systems.  It is possible that TCTP expressed in E. coli may give better 
protection against malarial challenge than when expressed in yeast, it is also possible 
that the two expression systems would result in functionally equivalent proteins or that 
yeast-derived TCTP may be immunologically superior.   
 
The protective effect of other malarial vaccine candidates expressed in yeast or 
E. coli systems has been compared, with varying results depending on the antigen 
tested.  Less protection and significantly lower antibody titres were obtained using yeast-
derived MSP4/5 as compared to that expressed in E. coli.  The authors discounted the 
presence of endotoxin as the reason for the increased titres to E. coli-derived MSP4/5, 
as they performed another trial performed using endotoxin-resistant C3H/HeJ mice and 
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found identical results (Kedzierski et al., 2002a).  Mice immunised with E. coli-derived 
MSP4/5 produced specific antibodies that were mainly IgG2a and IgG2b isotypes, 
whereas mice immunised with yeast-derived protein produced mainly IgG1 antibodies 
(Kedzierski et al., 2001).  The proportion of antibody isotypes in the anti-TCTP antisera 
has not been studied.  In other trials, immunisation with MSP119 expressed in yeast gave 
greater protection than when produced in E. coli (Hirunpetcharat et al., 1997), whereas 
expression of recombinant AMA1 in yeast or E. coli resulted in immunologically and 
functionally equivalent proteins (Giersing et al., 2005).  
 
In conclusion, the reasons for the lack of protective effect observed following 
TCTP immunisation in this trial, as compared to our previous trial, are unknown.  Higher 
levels of specific antibodies were generated by TCTP immunisation compared with 
previously, and the recognition of malarial TCTP by these antibodies was demonstrated.  
Although the protein preparations used for immunisation contained a significant amount 
of breakdown products, this was also the case in the initial vaccine trial.  The P. yoelii YM 
strain used produced similar infections in the control mice in both challenge experiments.  
The protective effect observed in the initial vaccine trial was mild, with significant 
differences observed only in the early stages of infection.  Due to this, it may be that 
minor variations between the two trials, e.g. in methodology or in the source of the 
experimental animals, would be sufficient to explain the lack of protection seen in the 
second trial.  If this is the case, it does not augur well for the potential of TCTP as a 
malarial vaccine, as the human parasite is known to rapidly mutate to avoid host 
defences. 
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Chapter 4: Evaluation of P. yoelii and P. berghei TCTP as 
potential malaria vaccines using three malarial species 
 
4.1 Introduction 
Prior to the experiments outlined in this chapter, two vaccine trials using malarial 
TCTP had been performed.  Although a significant protective effect following P. 
falciparum (Pf) TCTP immunisation was observed in the first trial (Taylor, 2002), (poster 
presentation at the Molecular Approaches to Malaria Conference, Lorne, Australia 2004) 
no protection was conferred by P. yoelii (Py) or Pf TCTP in the second vaccine trial 
(described in Chapter 3).  This chapter describes a third vaccine trial of TCTP, using both 
Py and P. berghei (Pb) TCTP as antigens.  P. yoelii is commonly used in mouse 
immunisation and challenge models, whereas P. berghei is commonly used as a model 
of human cerebral malaria (CM), a severe complication of P. falciparum infection (Li et 
al., 2001a).  The susceptibility of mice to CM is strain-specific.  Around 80% of C57BL/6 
mice develop CM following P. berghei ANKA infection, whereas strains such as BALB/c 
do not develop cerebral symptoms.  Non-CM-susceptible strains of mice succumb to 
infection 3-4 weeks after infection due to hyperparasitemia and anaemia (Lou et al., 
2001).   
 
As discussed in section 1.2.5, inflammatory molecules, especially TNF-α and 
IFN-γ, play a large role in the pathology of the mouse model of CM induced by P. berghei 
infection.  Evidence exists that PfTCTP induces histamine release from human immune 
cells in vitro, and is secreted from parasites during infection (MacDonald et al., 2001).  
Therefore, it is possible that this molecule may contribute to host inflammatory responses 
during malarial infection.  As the malarial TCTPs are highly conserved (Figure 4.1), it is 
likely that Py and PbTCTP have similar extracellular activities.  Anti-TCTP antibodies 
could potentially neutralise the extracellular inflammatory actions of TCTP, and might 
confer significant protection against CM.  For this reason, PbTCTP was used as an 
antigen in this vaccine trial, along with PyTCTP.  
 
Following immunisation with either Py or PbTCTP, mice were challenged with P. 
yoelii YM, P. berghei ANKA, or P. chabaudi chabaudi AS.  P.c. chabaudi AS was 
included as a challenge strain to provide a non-lethal malaria model.  P. chabaudi (Pc) 
TCTP was not cloned and expressed for use in this vaccine trial, as the sequence shares 
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98% amino acid identity with PyTCTP.  Instead, mice challenged with P.c. chabaudi were 
immunised with PyTCTP.  PbTCTP also shares 98% identity with PyTCTP, but was 
cloned and expressed for use in the vaccine trial.  This decision was made due to the 
presence of a non-conservative substitution at residue 27 in PbTCTP from proline to 
alanine.  A proline is present at this position in the TCTP of P. falciparum, P. yoelii, and 
P. chabaudi, while an alanine is present at this residue in the TCTP of P. vivax and the 
non-human primate malaria P. knowlesi.  It is generally accepted that proline residues 
may introduce conformational changes in polypeptide chains (eg Cordes et al., 2002), 
due to possessing inflexible phi-psi bond angles.  The lack of a proline residue at position 
25 may alter the structure of PbTCTP as compared with the structure of PyTCTP.  
 
Initially, mice in this vaccine trial were to be immunised with TCTP expressed in 
S. cerevisiae.  Both proteins were cloned into the pYEULCBX vector and were expressed 
using the alternate expression method described in section 3.3.2.6.  This experiment was 
performed numerous times with various optimisation methods, including variations in 
induction time, column purification, and increased additions of protease inhibitors.  The 
major problems encountered were low protein yield and substantial proteolysis.  Due to 
the problems encountered using the S. cerevisiae expression system, it was decided to 
express Py and PbTCTP in E. coli using the pRSETA vector (Figure 4.2).  TCTPs from 
numerous organisms have been expressed in bacterial systems, and filarial and 
schistosome TCTP with histamine-inducing activity has been expressed using pRSETA 
(Gnanasekar et al., 2002; Rao et al., 2002), indicating that a eukaryotic expression 
system is not required to obtain functional protein.    
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The aims of the experiments outlined in this chapter were: 
 
1: To clone the PyTCTP and PbTCTP coding sequences into pRSETA vectors, 
and to express the His-tagged recombinant proteins in E. coli BL21. 
 
2:  To use the recombinant proteins as vaccines in BALB/c and C57BL/6 mouse 
strains, to assess the protective effect of TCTP immunisation following challenge 
with P. yoelii YM, P.c. chabaudi AS, or P. berghei ANKA. 
 
3: To determine if TCTP antisera generated to E. coli-derived protein could 
recognise TCTP present in malarial lysates. 
 
4: To assess histamine release in response to PyTCTP and PbTCTP in vitro in 
the rat basophilic leukaemia cell line RBL-2H3. 
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Yoelii          MKVYKDIFTNDEVCSDSYIQEDPFGNPEFREIAFEVKSNKRIKGNDDYGIADNSEDAVDG 
Berghei         --------------------------A--------------------------------- 
Chabaudi        ------------------A-------P-------------------------------E- 
Falciparum      ---F—V------------V-Q---EVP------------------E------------E- 
                 
Yoelii          MGADVEHVIDIVDSFQLTSTSLSKKEYSAYVKNFMQRILKHLEEKKPDRVDIFKTKAQPL 
Berghei         --------------------------------------------------N--------- 
Chabaudi        --------------------------------------------------E--------- 
Falciparum      --------------------AF--------I--Y--KVA-Y---------E--------F 
                 
Yoelii          IKHILTNFDDFEFYMGESLDMEAGLIYSYYKGEEITPRFVYISDGLFEEKY 
Berghei         --------------------------------------------------- 
Chabaudi        --------------------------------------------------- 
Falciparum      ------------------------I-------------------------- 
                 
Figure 4.1: Alignment of P. yoelii, P. berghei, P. chabaudi and P. falciparum TCTP 
amino acid sequences  
 
 
 
Figure 4.2: pRSET vector diagram 
Reference: 
(https://catalog.invitrogen.com/index.cfm?fuseaction=viewCatalog.viewProductDetails&pr
oductDescription=615)     
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4.2 Materials and methods 
For detailed information about the materials and methods utilised in this chapter, 
please refer to Chapter 2. 
 
4.3 Results 
4.3.1 Analysis of the modelled structure of PyTCTP and PbTCTP 
Models of P. yoelii TCTP and P. berghei TCTP were constructed using the Swiss-
Model program, with the solved crystal structure of TCTP from P. knowlesi used as the 
template in both cases.  Despite the proline-alanine substitution at residue 27, the two 
TCTP models had the same topology, with no perturbation of the predicted 3D structure.  
However, as any true structural differences between P. yoelii and P. berghei TCTP could 
only be determined experimentally, using X-ray crystallography or nuclear magnetic 
resonance, both proteins were cloned and expressed for use in the vaccine trial.     
 
4.3.2 Cloning of PyTCTP and PbTCTP into pRSETA vectors 
4.3.2.1 Amplification of PbTCTP by PCR 
The P. yoelii 5’ and 3’ primers (as described in section 3.3.1.1) were used to 
amplify P. berghei TCTP, as the DNA sequence of the two genes is identical in the 
regions where the two primers bind (P. berghei TCTP accession number XM_674443).  
The P. berghei TCTP gene contains no introns, and so the PCR product was amplified 
from P. berghei ANKA genomic DNA, obtained from Dr. Tania de Koning-Ward, The 
Walter and Eliza Hall Institute (WEHI), Melbourne, Australia. The P. berghei TCTP gene 
was amplified using Taq PCR (method described in 2.3.2.2.3) with 0.5 µg of genomic 
DNA per reaction. An annealing temperature of 55°C was used.  The PCR products were 
subjected to 1.5% agarose gel electrophoresis (2.3.2.5), a single band of 516 bp was 
obtained (Figure 4.3 (a)).   
 
4.3.2.2 Ligation of PyTCTP and PbTCTP into pCR2.1 and pRSETA vectors 
Fresh PbTCTP PCR product obtained was ligated into the pCR2.1 vector as per 
manufacturer’s instructions (2.3.2.7.1).  Plasmid DNA from several resulting white 
colonies was isolated by minipreparation (2.3.2.1.1) and digested using BamHI and PstI 
(2.3.2.4) to confirm the presence of TCTP insert.  Sequence analysis (2.3.2.2.6) was 
performed on clones with inserts of the predicted size using the 5’ and 3’ PyTCTP 
primers, plasmids with the correct insert were designated pCR.PbTCTP. 
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PyTCTP had previously been cloned into the pCR2.1 vector, as described in 
section 3.3.1.4.  Approximately 2 µg of both pCR.PyTCTP and pCR.PbTCTP were 
digested using 10 U of BamHI and PstI.  Approximately 4 µg of purified pRSETA vector 
was linearised using the same method.  The completed digest reactions were separated 
by 1.5% w/v agarose gel electrophoresis at 100 V (Figure 4.3 (b)).  Bands corresponding 
to the digested pRSETA vector and TCTP inserts were excised from the gel with a 
scalpel and DNA was purified using the Qiaquick Gel Extraction kit.  Ligation reactions 
were prepared using 100 ng of digested pRSETA vector and the appropriate amount of 
insert for a 3:1 insert:vector ratio (as per method in 2.3.2.7.2). 
 
4.3.2.3 Transformation and analysis of pRSETA.PyTCTP and 
pRSETA.PbTCTP 
Completed ligation reactions were cleaned using the dextran purification method 
(2.3.2.7.3) and transformed into electrocompetent E. coli DH5α (2.4.3.2).  Plasmid DNA 
from resulting colonies was purified by minipreparation.  To confirm the presence of the 
TCTP insert, plasmid DNA was digested using PstI and BamHI (Figure 4.3 (c) and (d)).  
Sequence analysis was performed on plasmid minipreparations with the correct-sized 
insert.  Plasmids with the correct insert were named pRSETA.PyTCTP and 
pRSETA.PbTCTP. 
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Figure 4.3 Cloning of PyTCTP and PbTCTP into pRSETA vectors 
(a) Amplification of PbTCTP by PCR from P. berghei ANKA genomic DNA:  
Lane 1: λ/PstI marker; Lane 2: negative control; Lanes 3-5: TCTP amplified using P. 
berghei ANKA genomic DNA as template. 
(b) Digestion of TCTPs and pRSETA with BamHI and PstI prior to cloning:  
Lane 1: λ/PstI marker; Lanes 2 and 3: digestion of pCR.PbTCTP; Lane 4: digestion of 
pRSETA; Lanes 5 and 6: digestion of pCR.PbTCTP.   
(c) and (d) Confirmation digests of pRSETA.PyTCTP and pRSETA.PbTCTP using 
BamHI and PstI:  
(c): Lane 1: λ/PstI; Lane 2: pRSETA.PyTCTP. 
(d): Lane 1: λ/PstI; Lane 2: pRSETA.PbTCTP.   
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4.3.3 Py and PbTCTP expression in E. coli BL21 
4.3.3.1 Expression and purification of Py and PbTCTP from E. coli BL21 
Purified pRESTA.PyTCTP or pRSETA.PbTCTP vector DNA was transformed into 
the BL21 (DE3) strain of E. coli by electroporation.  A single colony of transformed E. coli 
BL21 was used in an o/n culture of 10 ml of LB+Amp.  Larger volumes of LB+Amp 
(typically 0.5 L) were inoculated with a 1/100 volume of the o/n culture, expression of 
TCTP was induced for 3 h by the addition of 1 mM IPTG once the OD600nm was ~0.5 
(method described in 2.6.3.1).  The cell pellets were resuspended in a 1/25 volume of 
lysis buffer, incubated at 4°C for 20 min, shaking, and then underwent four cycles of 
freeze/thaw.  Ten units of DNase per 100 ml of original culture volume were added after 
the second freeze/thaw cycle, and cell pellets were incubated at 37°C for 15 min, shaking 
(2.6.3.2).  Supernatants from lysed pellets were filtered (0.2 µM) prior to incubation with 
prepared Profinity resin (2.6.3.3.1).   
 
Column purification was performed with a wash step using 20 column volumes 
(CV) of 5 mM imidazole wash buffer, followed by elution of His-tagged proteins with 5 CV 
of 0.25 M imidazole elution buffer (2.6.3.3.2).  The eluates were collected as 1.5 ml 
fractions, 20 µl samples were analysed for the presence of TCTP by SDS-PAGE (2.6.7).  
As shown in Figure 4.4 (a) and (b), a predominant band at around 13 kDa was observed 
in both the Pb and PyTCTP 5 mM imidazole eluate fractions but not in the 0.25 M 
imidazole eluate fractions. Additionally, a higher amount of protein was observed in the 
PbTCTP 5 mM imidazole eluate compared with the PyTCTP 5 mM imidazole eluate, this 
is likely due to the samples being taken at different wash stages.  Py and PbTCTP of 
high purity were obtained in the 0.25 M imidazole eluates, as a single band at around 29 
kDa was observed in both samples. 
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Figure 4.4: Purification on PyTCTP and PbTCTP from E. coli BL21 lysates using 
Profinity™ resin 
(a) Purification of PbTCTP from BL21 E. coli using Profinity™ resin:  
Lane 1: Mark12 marker; Lane 2: 5 mM imidazole eluate sample; lanes 3-6: fractions from 
the 0.25 M imidazole eluate.  
(b) Purification of PyTCTP from BL21 E. coli using Profinity™ resin:   
Lane 1: Mark12 marker; Lane 2: 5 mM imidazole eluate sample; Lanes 3-7: fractions 
from 0.25 M imidazole eluate. 
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4.3.3.2 Concentration and buffer exchange of Py and PbTCTP 
Following SDS-PAGE analysis, fractions containing Py or PbTCTP were pooled, 
and the 0.25 M imidazole was replaced with PBS by buffer exchange (2.6.5.2).  The final 
concentration of imidazole remaining after buffer exchange was between 10 µM and 30 
µM.  Two micrograms of PyTCTP and PbTCTP were analysed by SDS-PAGE to assess 
purity.  As expected, a predominant band at ~29 kDa was observed for both proteins, as 
well as very faint lower molecular weight bands, most likely TCTP breakdown products 
(Figure 4.5 (a)).  E. coli-derived TCTP was stored at -70°C in aliquots.  No degradation 
was observed over time when aliquots were thawed for use in the vaccine trial.  
 
4.3.3.3 Western blots of Py and PbTCTP 
The recognition of E. coli-derived TCTP (EcTCTP) by sera from mice immunised 
with yeast-derived PyTCTP (ScPyTCTP) was assessed.  Approximately 1 µg of Py and 
PbTCTP in PBS was separated by SDS-PAGE and transferred to a nitrocellulose 
membrane for Western blotting (2.6.8).  The primary antibody used was the high 
reciprocal titre (1,000,000) PyTCTP antisera obtained from a single mouse in the 
Chapter 3 vaccine trial (described in section 3.3.4.5).  The primary antibody was used at 
a 1:1,000 dilution; the secondary antibody used was a 1:3,000 dilution of a goat-anti-
mouse IgG.HRP.  The antisera raised against ScPyTCTP could detect a strong band at 
~29 kDa in EcPyTCTP and EcPbTCTP, small amounts of lower molecular-weight 
breakdown products were also detected for both Py and PbTCTP (Figure 4.5 (b)). 
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Figure 4.5: Western blot of Py and PbTCTP 
Western blot was probed with antisera obtained from mice immunised with yeast-derived 
PyTCTP.  
(a) Coomassie-stained gel of Py and PbTCTP after buffer exchange to PBS: Lane 1: 
SeeBluePlus2 Marker; Lane 2: 1 µg PyTCTP; Lane 3: 1 µg PbTCTP 
(b) Western blot of Py and PbTCTP using anti-ScPyTCTP antiserum: Lane 1: 
SeeBluePlus2 Marker; Lane 2: 1 µg PyTCTP; Lane 3: 1 µg PbTCTP  
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4.3.4 Immunisation of mice with Py or PbTCTP 
4.3.4.1 Preparation of vaccines, mouse immunisation groups and schedule 
Mice were immunised either with PBS (negative control) or with 25 µg of PyTCTP 
or PbTCTP in PBS.  The initial immunisation was emulsified in Freund’s complete 
adjuvant; subsequent immunisations were emulsified in Freund’s incomplete adjuvant.  
Equal volumes of PBS or TCTP in PBS at 0.5 mg/ml concentrations were combined with 
Freund’s adjuvant, emulsions were made using two glass syringes connected with a 
stopcock (method described in 2.8.2.1).   
 
Eight groups of six mice were used in the vaccine trial, two groups of C57BL/6 
mice and six groups of BALB/c mice.  All mice were female and were aged six to eight 
weeks at the commencement of the trial.  One C57BL/6 group and three BALB/c groups 
received immunisations of the PBS control, two groups of BALB/c mice received 
immunisations of 25 µg PyTCTP, and one BALB/c and one C57BL/6 group received 
immunisations of 25 µg PbTCTP.  Three i.p. immunisations were given, with a three-
week interval between immunisations (2.8.2.2).  Mice were challenged with 1 X 105 P. 
yoelii YM, P. berghei ANKA, or P.c chabaudi AS parasites within three weeks of the final 
immunisation (2.7.2.4).  A summary of mouse vaccine and challenge groups is shown in 
Table 4.1.  Some BALB/c mice in TCTP and PBS groups had slightly rough coats and 
were mildly inactive on the day following immunisations (symptom score of 1, as 
measured using the method described in 2.8.2.4).  The C57BL/6 mice had no noticeable 
symptoms.     
Table 4.1:  Mouse immunisation groups 
Group Mouse strain Immunisation Challenge No. of mice 
1 
2 
3 
4 
BALB/c 
BALB/c 
BALB/c 
C57BL/6 
PBS in adjuvant 
“ 
“ 
“ 
P.c. chabaudi AS 
P. yoelii YM 
P. berghei ANKA 
P. berghei ANKA 
6 
“ 
“ 
“ 
5 
6 
BALB/c 
BALB/c 
PyTCTP in adjuvant 
“ 
P.c. chabaudi AS 
P. yoelii YM 
6 
“ 
7 
8 
BALB/c 
C57BL/6 
PbTCTP in adjuvant 
“ 
P. berghei ANKA 
P. berghei ANKA 
6 
“ 
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4.3.4.2 Analysis of antibody titres  
To assess pre-challenge antibody titres, serum was collected from mice prior to 
the first immunisation and one day prior to parasite challenge (2.8.2.3).  Levels of anti-
PyTCTP or anti-PbTCTP antibodies were quantified by ELISA (2.8.2.7) with the following 
modifications and conditions:  96-well plates were coated with 2 µg/ml of PyTCTP or 
PbTCTP.  Sera obtained from immunised mice were used as primary antibody, with an 
initial dilution of 1:100 to 1:4,000.  Goat-α-mouse IgG.HRP conjugate was used as a 
secondary antibody at a 1:5,000 dilution.  Pooled sera from mice in each of the eight 
vaccine groups were tested for binding against PyTCTP and PbTCTP antigens.  
Additionally, serum from individual mice in the PyTCTP- and PbTCTP-immunised groups 
(groups 5-8) was tested for binding against homologous antigen.  The absorbance 
readings at 450 nm were plotted against the reciprocal serum dilution.  
 
All PBS-immunised controls had titres at background levels, and pre-
immunisation sera did not react with TCTP over background levels (data not shown).  
Reciprocal titre results were similar for the pre-challenge sera from immunised mice 
(groups 5-8) when binding against PyTCTP and PbTCTP antigen was tested, indicating 
that the two proteins are immunologically cross-reactive, as expected.  The reciprocal 
titres obtained from the TCTP-immunised groups against homologous and heterologous 
TCTP antigen are displayed in Table 4.2.  C57Bl/6 mice produced far lower reciprocal 
anti-TCTP titres than the BALB/c mice.  This is in contrast to other published reports, in 
which similar IgG antibody responses have been observed in C57BL/6 and BALB/C mice 
immunised with recombinant malarial protein in Freunds adjuvant.  For example, a trial of 
a GST-MSP1 fusion protein in which mice were immunised by i.p. injection three times 
over six weeks, high levels of IgG antibodies were generated in both mouse strains 
(Ahlborg et al., 2002).  In a vaccine trial of MSP-2, similar reciprocal antibody titres were 
obtained in both C57BL/6 and BALB/C mice (Lougovskoi et al., 1999).  The reasons for 
the much lower antibody responses observed following TCTP immunisation in C57BL/6 
mice in this trial are unknown.      
 
Pooled antiserum from a mouse group immunised with yeast-derived PyTCTP 
(PyT #2, as described in 3.3.4.5) was also analysed in this ELISA experiment.  The 
reciprocal titre of the pooled antiserum from this group was 83,000 against EcPyTCTP, 
compared with 85,000 against ScPyTCTP, indicating that the proteins were 
immunologically similar (results not shown).  The titration curves used to calculate 
reciprocal titre are included in Appendix 3. 
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Table 4.2 Reciprocal titres of pooled TCTP sera to homologous and heterologous 
antigen 
Group Mouse strain Immunisation Reciprocal titre 
against PyTCTP 
Reciprocal titre 
against PbTCTP 
5 BALB/c PyTCTP 63,000 81,000 
6 BALB/c PyTCTP 233,000 295,000 
7 BALB/c PbTCTP 138,000 240,000 
8 C57BL/6 PbTCTP 365 1,650 
 
4.3.5 Challenge and monitoring of immunised mice 
4.3.5.1 Assessment of parasite strains in pre-challenge trial 
Due to the unexpected behaviour of the P. yoelii XNL strain used in the trial 
described in Chapter 3, the P. berghei ANKA and P.c. chabaudi parasite strains were 
trialled in mice before commencement of the vaccine trial.  Stabilates of both of these 
strains were obtained from the laboratory of Prof. Alan Cowman, WEHI, Parkville, 
Australia.  Two BALB/c and two C57Bl/6 mice were infected with 100 µl of P. berghei 
ANKA stabilate by i.p. injection.  Another two BALB/c mice were infected with 100 µl of 
P.c. chabaudi AS stabilate by i.p. injection.  Parasitemia was monitored from 2 d.p.i., and 
malarial symptoms were closely monitored for the duration of the infections.   
 
The general pattern of infection and disease progression was as expected for 
each of the parasite strains assessed.  However, in BALB/c mice infected with P. berghei 
ANKA, disease symptoms were observed at 6 dpi, when mice had low parasitemia (6 to 
8%).  At this time, mice developed symptoms of mild respiratory distress, had slightly 
rough coats, and were mildly inactive.  The symptom score reached was 4-5.  The mice 
recovered from these symptoms by 8 dpi, and parasite levels continued to increase 
without obvious malarial symptoms being displayed until 14 dpi, at a parasitemia of 42%.  
 
In the mice given P.c. chabaudi AS, the infection progression was basically as 
expected, however the peak parasitemia (~50%) was higher than generally reported (e.g. 
Hensmann et al., 2004; Li et al., 2001a).  One mouse had a peak parasitemia of 46% on 
two consecutive days.  The day after this extended peak, the parasitemia had decreased 
to 18%, however the mouse reached a symptom score of 8 and was culled.  The high 
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symptom score was most likely due to severe anaemia caused by the extended peak 
parasitemia, compared to the rapid parasite clearance observed in the other P.c. 
chabaudi-infected mouse. 
 
4.3.5.2 Malaria challenge of immunised mice 
Two passage mice were used for preparation of each of the parasite strains prior 
to challenge.  BALB/c mice were used for passage of P. yoelii YM (obtained from the 
laboratory of Prof. Ross Coppel, Department of Microbiology, Monash University, 
Clayton, Australia), P. berghei ANKA and P.c. chabaudi AS.  C57Bl/6 mice were also 
used for passage of P. berghei ANKA.  All mice received an i.p. injection of 100 µl of 
thawed stabilate and parasitemia was monitored daily starting at two dpi (2.7.2.3).  
 
Malaria-infected blood of known parasitemia taken from passage mice was used 
to challenge TCTP-immunised mice and controls (2.7.2.4).  Thin blood smears were 
prepared and Giemsa-stained (2.7.2.5) for quantification of parasite numbers in the 
morning (prior to 10 am) daily, starting at two d.p.i (one d.p.i. for mice challenged with P. 
yoelii YM).  Mice were monitored for the development of malaria symptoms as per the 
method described in 2.8.2.4.  
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4.3.6 Trial results in PyTCTP-immunised mice challenged with P.c. 
chabaudi AS 
4.3.6.1 Parasitemia and infection progression in control and immunised 
mice 
A delay in infection progression was observed in PyTCTP-immunised mice, as a 
significant reduction (p<0.05) in mean parasitemia compared with PBS-immunised 
controls was observed at each observation point from 4 dpi until 9 dpi, when parasite 
levels peaked (Table 4.3).  The delay observed was similar to that seen in the vaccine 
trial of PfTCTP using a P. yoelii YM challenge model (Taylor, 2002).  A reduced mean 
peak parasitemia was also observed for PyTCTP-immunised mice (32.9 at 9 dpi) 
compared with PBS controls (43.6 at 8 dpi).  The mean parasitemia for control and 
TCTP-immunised mice at each dpi is depicted in Figure 4.6 (a).   
 
Variation was observed in the peak parasitemia between individual mice in the 
control and TCTP-immunised groups.  The peak parasitemia ranged from 31.2% (mouse 
#6) to 61.6% (mouse #3) in the PBS controls and from 22.6% (mouse #30) to 63.2% 
(mouse #25) in the PyTCTP-immunised mice.  A small recrudescence was only observed 
in two control mice (#2 and #3) and one PyTCTP-immunised mouse (#26).  The peak 
parasitemia in these recrudescences was between 0.6 and 2%.  The graphs of individual 
parasitemia for PBS control and PyTCTP-immunised mice is depicted in Figure 4.6 (b) 
and (c). 
  
Table 4.3: Mean parasitemia for PyTCTP-immunised mice and PBS controls 
challenged with P.c. chabaudi AS 
D.P.I. PBS 
parasitemia 
Standard 
deviation 
PyTCTP 
parasitemia 
Standard 
deviation 
Statistical 
difference (p-value) 
2 0.13 0.24 0.07 0.16 p>0.05 
3 0.3 0.28 0.2 0.34 p>0.05 
4 0.83 0.29 0.2 0.18 p<0.002 
5 2.07 0.97 1.03 0.39 p<0.05 
6 9.9 2.66 3.13 1.85 p<0.001 
7 21.9 8.53 9 6.19 p<0.02 
8 43.57 12.30 18.43 11.36 p<0.005 
9 33.02 7.48 32.9 19.34 p>0.05 
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Figure 4.6: Malarial progression in BALB/c mice challenged with P.c. chabaudi AS.  
(a) Average parasitemia at each day post-infection (D.P.I.) for PyTCTP-immunised 
mice and PBS controls.  
(b) Individual parasitemia at each D.P.I. for the PBS control group #1.  
(c) Individual parasitemia at each D.P.I. for the PyTCTP-immunised group #5. 
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4.3.5.2 Survival of mice following P.c. chabaudi AS challenge 
Although P.c. chabaudi AS is documented as a non-lethal malaria strain in 
BALB/c mice (e.g. Hensmann et al., 2004; Lamb et al., 2007), in this trial several P.c. 
chabaudi-infected mice reached symptom scores of eight and were euthanased.  These 
high symptom scores were due to severe anaemia induced by a prolonged peak 
parasitemia. One PBS-control mouse (#4) required euthanasia at 9 dpi, it had reached a 
peak parasitemia of 56% at 8 dpi and was 40% at 9 dpi.  Two PyTCTP-immunised mice 
were also euthanased; mouse #25 at 10 dpi, (peak parasitemia of 63% at 9 dpi, was 39% 
at 10 dpi) and mouse #27 at 11 dpi (peak parasitemia of 45% at 9 dpi, the parasitemia 
was 43% at 10 dpi and 21% at 11 dpi).  In all of these mice the parasitemia had peaked 
before the highest symptom score was reached, but the parasite load was not cleared 
quickly, leading to severe malarial symptoms.  The comparative survival rate of the PBS 
controls and the PyTCTP-immunised mice is depicted in Figure 4.7.  
 
4.3.5.3 Individual reciprocal antibody titres in mice immunised with PyTCTP 
and challenged with P.c. chabaudi AS 
Variations in reciprocal antibody titre were observed between individual mice in 
the PyTCTP-immunised group #5.  As shown in Figure 4.8, mouse #25 and #27 had the 
highest pre-challenge reciprocal antibody titres against PyTCTP (98,000).  Mouse #26 
had the lowest reciprocal antibody titre to PyTCTP (18,000).  No correlation was found 
between reciprocal antibody titre and peak parasitemia (data not shown).  The titration 
curves used to calculate reciprocal titre are included in Appendix 3. 
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Figure 4.7: Cumulative survival of mice challenged with P.c. chabaudi AS. 
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Figure 4.8: Individual reciprocal antibody titres for PyTCTP-immunised mice prior 
to challenge with P.c. chabaudi AS. 
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4.3.7 Trial results in PyTCTP-immunised mice challenged with P. 
yoelii YM 
4.3.7.1 Parasitemia and infection progression in control and immunised 
mice 
The P. yoelii YM challenge infections progressed as expected in the majority of 
the mice, with mean parasitemia increasing rapidly (Figure 4.9 (a)) and mice developing 
severe malaria symptoms by seven dpi.  A delay in infection progression was observed, 
as PyTCTP-immunised mice had significantly lower (p<0.05) mean parasitemia 
compared with PBS-immunised controls at 3 and 4 dpi (Table 4.4). 
  
In three mice (#7, a PBS control, and #34 and #35, two PyTCTP-immunised 
mice) the P. yoelii YM challenge did not progress as expected.  These mice were 
eventually able to clear the parasites and survive the lethal challenge.  The parasite 
levels in these mice presented as two waves of parasitemia, with the second increase in 
infection being almost completely limited to reticulocytes. There were differences seen in 
the progression of infection in the three mice able to clear the parasite load. In the PBS-
immunised mouse, parasite levels were lower compared with other P. yoelii YM-
challenged mice at all stages of infection.  This mouse had an initial peak parasitemia of 
21% at 6 dpi, followed by a second peak parasitemia of 28% at 10 dpi.  In the two 
PyTCTP-immunised mice, parasitemia initially rose to a peak of 28.8% (#34) and 38.1% 
(#35) at 7 dpi, before a second peak parasitemia of 45.6% at 11 dpi (#34) and 36.2% and 
13 dpi (#35).  Parasitemia had decreased to undetectable levels in mouse #7 at 16 dpi, in 
mouse #34 at 18 dpi, and in mouse #35 at 19 dpi.  Graphs of infection progression for 
each individual mouse challenged with P. yoelii YM are depicted in Figure 4.9 (b) and 
(c).   
Table 4.4: Mean parasitemia for PyTCTP-immunised mice and PBS controls 
challenged with P. yoelii YM  
D.P.I. PBS Standard 
deviation 
PyTCTP Standard 
deviation 
Statistical difference 
(p-value) 
2 0.2 0.17 0.05 0.06 P>0.05 
3 1.383 0.64 0.517 0.35 P<0.05 
4 9.968 4.07 4.812 2.37 P<0.05 
5 29.11 13.20 22.53 8.31 P>0.05 
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Figure 4.9: Malarial progression in PBS controls and PyTCTP-immunised mice 
challenged with P. yoelii YM.  
(a) Average parasitemia at each day post-infection for PyTCTP-immunised mice 
and PBS controls.  
(b) Individual parasitemia at each dpi for the PBS control group #2.  
(c) Individual parasitemia at each dpi for the PyTCTP-immunised group #6. 
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4.3.7.2 Survival of mice challenged with P .yoelii YM 
The expected mortality following P. yoelii YM infection is 100%, according to the 
literature (e.g. de Souza and Playfair, 1995; De Souza et al., 1997; Wykes et al., 2005).  
Using a different stabilate from the same source (Laboratory of Prof. Coppel, Department 
of Medicine, Monash University, Australia), we observed a 100% mortality rate in both 
controls and in PfTCTP- and PyTCTP-immunised mice in both of the previous vaccine 
trials.  Researchers in the group from which the P. yoelii YM was sourced have also 
previously observed survival of a control mouse following P. yoelii YM infection, in that 
instance the parasitemia reached 40% on day 6 before parasite clearance (Kedzierski et 
al., 2000).   
 
Due to the survival of one PBS control and two PyTCTP-immunised mice, the 
mortality rate following P. yoelii YM infection was 83.33% for PBS controls and 66.67% 
for PyTCTP-immunised mice. In the mice that succumbed to the infection, the average 
time taken to reach a symptom score of 8 was 6.9 days for PBS controls and 7.1 days for 
PyTCTP-immunised mice, which was not significantly different (p=0.124).  The three 
mice that survived the infection were eventually sacrificed at 35 dpi, having been 
parasite-free for more than 14 days.  A graph of comparative mortality for the controls 
and PyTCTP-immunised mice is depicted in Figure 4.10.        
 
4.3.7.3 Individual reciprocal antibody titres of mice immunised with PyTCTP 
and challenged with P. yoelii YM 
In the PyTCTP-immunised mice of group 6, a large variation in reciprocal 
antibody titre was observed, from 41,000 for mouse #33 to 680,000 for mouse #31.  The 
individual reciprocal antibody titres for the six mice in this group are given in Figure 4.11. 
The titration curves used to calculate reciprocal titre are included in Appendix 3.  No 
correlation was observed between reciprocal antibody titre and disease severity.  The 
serum from the control mouse (#7) that survived infection was tested to ensure there was 
no reactivity to PyTCTP.  None was observed (result not shown).  
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Figure 4.10: Cumulative survival of PyTCTP-immunised and PBS control mice. 
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Figure 4.11: Individual reciprocal antibody titres for PyTCTP-immunised mice prior 
to challenge with P. yoelii YM. 
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4.3.8 Trial results in BALB/c mice immunised with PbTCTP and 
challenged with P. berghei ANKA  
4.3.8.1 Infection progression in control and immunised mice 
No delay in parasitemia progression or malarial symptom development was 
observed for BALB/c mice infected with P. berghei ANKA, compared with PBS controls.  
Instead, all BALB/c mice infected with P. berghei ANKA developed severe malaria 
symptoms at relatively low parasitemia.  Mice developed symptoms usually associated 
with severe malaria, including respiratory distress, inactivity and rough coats, during the 
early stages of infection.  Some P. berghei-infected BALB/c mice first showed mild 
disease symptoms at five dpi, with rough coats.  At this time, the parasitemia was 
between nine and 17% for controls and six and 19% for PbTCTP-immunised mice.  At six 
dpi, some P. berghei-infected mice exhibited mild respiratory distress, with all PBS and 
PbTCTP-immunised mice exhibiting respiratory distress at seven dpi.  Typically, 
respiratory distress is observed in malarial infections at high parasitemia (>50%), most 
likely as a result of severe anaemia.  In the BALB/c mice infected with P. berghei ANKA, 
other symptoms of anaemia, including haemolytic urine, were not observed.   
 
At seven dpi, parasitemia was between 12.5% and 25% for controls and between 
11.5% and 15% for immunised mice.  One PbTCTP-immunised mouse (#37) was found 
dead at eight dpi.  The parasitemia for this mouse had been 15% on day seven.  All 
remaining P. berghei ANKA-challenged mice reached a symptom score of eight at 
between eight and ten days post-infection and required euthanasia.  The average time to 
reach a symptom score of eight was 8.8 dpi for PBS control mice and 8.6 dpi for 
PbTCTP-immunised mice, which was not significant (p=0.710).  Graphs of averaged and 
individual parasitemia for PBS controls and PbTCTP-immunised mice are given in 
Figure 4.12 (a)-(c).  The cumulative survival of PBS controls and PbTCTP-immunised 
mice is shown in Figure 4.13.   
 
4.3.8.2 Individual reciprocal titres of BALB/c mice immunised with PbTCTP 
As in the other immunised mouse groups, variation in reciprocal antibody titre was 
observed in the PbTCTP group seven.  Reciprocal titres ranged from 110,000 for mouse 
#41 to 470,000 for mouse #37.  The reciprocal titres for the individual mice in PbTCTP 
group #7 are given in Figure 4.14.  The titration curves used to calculate reciprocal titre 
are included in Appendix 3. 
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Figure 4.12:  Malarial progression in BALB/c mice challenged with P. berghei 
ANKA.  
(a) Average parasitemia at each day post-infection for PbTCTP-immunised mice 
and PBS controls.  
(b) Individual parasitemia at each dpi for the PBS control group #3.  
(c) Individual parasitemia at each dpi for the PbTCTP-immunised group #7. 
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Figure 4.13: Cumulative survival of BALB/c mice challenged with P. berghei ANKA 
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Figure 4.14: Individual reciprocal antibody titres for mice in PbTCTP group #7 
Chapter 4: Evaluation of P. yoelii and P. berghei TCTP as malaria vaccines 
 164 
4.3.9 Trial results in C57BL/6 mice immunised with PbTCTP and 
challenged with P. berghei ANKA 
4.3.9.1 Infection progression and cerebral symptom development in control 
and immunised mice 
The P. berghei ANKA infection progressed as expected in C57BL/6 mice, with all 
mice except one PBS control (mouse #20) developing cerebral malaria symptoms at 
relatively low parasitemia.  No significant delay in malarial symptom progression and no 
significant difference in parasitemia were observed between PbTCTP-immunised mice 
and PBS controls.  The average time of cerebral symptom onset was 6.6 dpi for PBS 
controls and 6.74 dpi for PbTCTP-immunised mice.  There was no significant difference 
between the two groups (p=0.799).  The parasitemia to the point of onset of cerebral 
symptoms is depicted in Figure 4.15.  The cumulative survival of PbTCTP-immunised 
and PBS control mice is depicted in Figure 4.16. 
 
The PBS control mouse that did not develop cerebral malaria reached a peak 
parasitemia of 52% at 17 days post-infection, and was culled at 19 dpi with symptoms of 
anaemia.  It has previously been reported that CM occurs in less than 100% of C57BL/6 
mice infected with P. berghei ANKA (eg Amani et al., 1998; Bagot et al., 2002; Pierrot et 
al., 2003; Renia et al., 2006b).  
 
4.3.9.2 Individual reciprocal antibody titres in C57BL/6 mice immunised with 
PbTCTP 
Variation in reciprocal antibody titre was observed in C57BL/6 mice immunised 
with PbTCTP.  All reciprocal antibody titres were much lower than reciprocal titres 
observed in PbTCTP-immunised BALB/c mice, and two immunised mice (#44 and #46) 
did not produce detectable levels of PbTCTP antibodies.  The highest reciprocal titre 
observed was 38,000 for mouse #48.  The individual reciprocal titres for the mice in 
group #8 are given in Figure 4.17.  The titration curves used to calculate reciprocal titre 
are included in Appendix 3. 
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Figure 4.15:  Malarial progression in C57BL/6 mice challenged with P. berghei 
ANKA 
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Figure 4.16: Survival of C57BL/6 mice challenged with P. berghei ANKA 
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Figure 4.17: Individual reciprocal antibody titres for mice in PbTCTP group #8 
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4.3.10 Recognition of P. yoelii and P. berghei TCTP in parasite lysates 
by anti-TCTP antibodies  
The excess blood taken from mice used for passage of P. yoelii YM, P.c. 
chabaudi and P. berghei ANKA was used as a source of malarial protein.  The total blood 
obtained from two passage mice was pooled and used a single sample for the P. berghei 
and P. yoelii lysates, the total blood from one mouse was used to create the P. chabaudi 
lysate.  The detection of S. cerevisiae-derived (Sc) PfTCTP and PyTCTP by antisera 
raised to E. coli-derived (Ec) PyTCTP was also assessed.  Proteins were separated by 
SDS-PAGE and Western blots were performed with the following modifications: the 
primary antibody used was a 1:500 dilution of antisera from either mouse #31 for 
PyTCTP detection or mouse #37 for PbTCTP detection.  A Zymax Goat-anti-mouse IgG 
(H+L) alkaline phosphatase conjugate was used as a secondary antibody at a 1:2,000 
dilution.  A BCIP/NBT substrate was used in a 1:1 dilution in detection buffer.  
 
The antiserum from mouse #31 was the highest reciprocal titre antiserum 
(680,000) of the PyTCTP-immunised mice.  This antiserum could detect recombinant 
yeast-derived (Sc) PfTCTP and PyTCTP, as well as 10 and 100 ng of E. coli-derived (Ec) 
PyTCTP (Figure 4.18 Lanes 1, 2, 4, 5).  Using the alkaline phosphatase detection 
system, multiple bands of both higher and lower molecular weights were detected in the 
two ScTCTP samples and in the 100 ng sample of EcPyTCTP.  Additionally, the major 
band detected in the ScPfTCTP sample (Lane 1) was of a lower molecular weight than 
the other recombinant TCTPs.  The reduced size of rPfTCTP on SDS-PAGE had 
previously been observed, as described in Chapter 3.     
 
The αPyTCTP antiserum from mouse #31 could also detect very faint bands 
approximately corresponding in size to malarial TCTP (Figure 4.18 Lanes 6, 7, 8).  
Recombinant PyTCTP has previously been observed to resolve at a higher molecular 
weight than the TCTP present in P. yoelii lysate (see Figure 3.16), due to the presence of 
the N-terminal extension in the recombinant protein.  A faint band corresponding in size 
to malarial TCTP was detected in the P. chabaudi lysate (Lane 8). Very faint, non-distinct 
bands were detected in the P. yoelii lysates (Lanes 6 and 7).  Greater detection of 
malarial TCTP in P. yoelii lysates had previously been observed using antiserum raised 
against ScPyTCTP in a less sensitive detection system (Figure 3.16).  This was most 
likely due to the higher titre of antisera previously used, or to variations in sample 
processing.  
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The antiserum from mouse #37 was used to detect PbTCTP in malaria lysates 
made from BALB/c and C57BL/6 mice infected with P. berghei ANKA.  This was the 
highest reciprocal titre antiserum (470,000) obtained from mice immunised with PbTCTP.  
In the blot depicted in Figure 4.19, higher and lower molecular weight bands were 
detected in the sample containing 100 ng of PbTCTP (Lane 1), and distinct bands 
corresponding to malarial TCTP were detected in P. berghei ANKA lysates as well as 
faint higher molecular-weight bands, possibly corresponding to TCTP multimers (Lanes 4 
& 5).  Much stronger bands were detected in P. berghei ANKA lysates compared with 
those from P. yoelii and P. chabaudi samples.   
 
The reason for the variation in TCTP detection between malarial lysates is 
unknown.  The blood used to create the P. berghei ANKA lysates did not contain a higher 
number of parasites.  The method used for malarial protein extraction had a final 
purification stage of boiling the isolated, partially lysed parasites in reducing sample 
buffer, making total protein determination difficult.  Alternate methods of malarial protein 
extraction were assessed but did not produce detectable levels of malarial TCTP as 
analysed by western blot.   
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Figure 4.18: Recognition of PyTCTP in malarial lysates, and cross-reactivity of Sc- 
and Ec-TCTP 
Western blot was probed with PyTCTP antisera from mouse #31. 
Lane 1: 100 ng ScPyTCTP; Lane 2: 100 ng ScPfTCTP; Lane 3: SeeBluePlus2 marker; 
Lane 4: 10 ng EcPyTCTP; Lane 5: 100 ng EcPyTCTP; Lanes 6 and 7: P. yoelii lysates; 
Lane 8: P. chabaudi lysate 
 
 
                                                   1        2        3         4         5     
 
Figure 4.19: Recognition of PbTCTP in P. berghei lysates 
Western blot was probed with PbTCTP antisera from mouse #37. 
Lane 1: 100 ng EcPbTCTP; Lane 2: SeeBluePlus2 marker; Lane 4: P. berghei ANKA 
lysate from BALB/c mice; Lane 5: P. berghei ANKA lysate from C57BL/6 mice. 
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4.3.11 RBL-2H3 degranulation assays using malarial TCTP 
The E. coli-derived PyTCTP and PbTCTP were used in degranulation assays 
using the rat basophilic leukaemia cell line RBL-2H3.  The rationale for performing these 
degranulation assays was based on previous studies of the histamine-release inducing 
properties of TCTP from schistosome and filarial parasites (Gnanasekar et al., 2002; Rao 
et al., 2002).  In these studies, TCTPs from the filarial parasites B. malayi and W. 
bancrofti, and the flat worm S. mansoni, were expressed as His-tagged recombinant 
proteins in E. coli, residual endotoxin was removed.  Histamine release from RBL-2Hs 
cells induced by the recombinant parasite TCTPs was assessed using a commercial 
ELISA kit (Beckman-Coulter).  The calcium ionophore 48/80 (Sigma, USA) was used as 
a positive control; an unrelated recombinant parasite protein was used as a negative 
control.  Significant amounts of histamine (600 to 800 nM) were released after incubation 
with TCTP in a dose-dependent manner up to 20 µg/ml, however higher doses inhibited 
histamine release.  The ionophore 48/80 also induced histamine release of around 800 
nM, and spontaneous histamine release was 100 - 200 nM.   
 
Histamine is labile and is difficult to measure directly, requiring the use of 
relatively expensive methods (e.g. ELISA kits).  In contrast, assays that measure 
degranulation via the release of the much more stable β-hexosaminidase are relatively 
cheap to perform, and are commonly used (e.g. Chan et al., 2007; Hoffmann et al., 1999; 
Morikawa et al., 2002; Pittertschatscher et al., 2002; Tanaka et al., 2006; Yamada et al., 
2007).  β-hexosaminidase is stored in the secretory granules of mast cells and basophils 
along with histamine, and both substances are released upon degranulation.  Therefore, 
it is generally accepted that β-hexosaminidase is a degranulation marker that can be 
used to indirectly assess histamine release (Morikawa et al., 2002; Yamada et al., 2007).  
 
Prior to use in the degranulation assays, residual endotoxin was removed from 
Py- and PbTCTP protein preparations (4.3.3.2) using Detoxi-gel resin (method described 
in 2.6.3.4). Fractions were analysed for protein concentration and purity by Bradford 
assay and SDS-PAGE.  The protein yield decreased around 50% following endotoxin 
removal, and protein purity was essentially unchanged for both PyTCTP and PbTCTP 
(results not shown). 
 
Aya Taki (RMIT) expressed and purified PfTCTP using the E. coli pRSET 
expression system.  SmpB (cloned from Brachyspira hyodysenteriae) was expressed 
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and purified by Amber Mitton (RMIT).  This was used in the degranulation assays as a 
negative control, as it had been expressed and purified in an identical manner to the 
TCTPs.  Residual endotoxin was removed from PfTCTP and SmpB.  The degranulation 
assays were performed by Aya Taki, in collaboration with Dr. Graham Mackay, at the 
Department of Pathology, Melbourne University, Parkville, Australia (Taki, 2007).  The 
method is described briefly in section 2.6.9. 
  
β-hexosaminidase release assays using RBL-2H3 cells generally include an 
incubation with IgE as the initial step.  As a positive control, the antigen specific for this 
IgE is added, prompting degranulation.  In the assays performed using TCTP, IgE 
specific to trinitrophenol (TNP) was used.  Confluent cultures of RBL-2H3 cells were 
incubated with α-TNP IgE for 16 h, then stimulated with either ionomycin, PfTCTP, 
PbTCTP, PyTCTP or SmpB (negative control) at several protein concentrations ranging 
from 10 to 0.3 µg/ml.  Two positive controls were used (TNP or ionomycin), and cells 
lysed with 0.1% Triton-X 100 were used to measure maximum degranulation.  
 
No significant (p>0.05) degranulation was observed at any concentration of TCTP 
or SmpB.  In a separate experiment, degranulation by TCTP following antigen 
enhancement was measured, as it was thought that TCTP may act as an incomplete 
secretagogue.  RBL-2H3 cells were grown to confluency and were incubated with anti-
TNP IgE.  BSA-conjugated TNP at a concentration of 0.3 ng/ml was added to all wells, 
along with TCTP, ionomycin or SmpB at the same concentration range as previously 
tested.  This concentration of TNP induced a low level of degranulation, meaning that 
any increased degranulation induced by TCTP could be measured.  Cells stimulated with 
low levels of TNP had around 22% degranulation.  The addition of malarial TCTP did not 
significantly increase degranulation above this baseline.   
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4.4 Discussion  
The E. coli pRSET expression system gave higher TCTP yield and less 
proteolysis compared with the S. cerevisiae system previously used.  Only a very small 
proportion of the TCTP produced in E. coli was present as lower molecular weight bands 
when analysed by SDS-PAGE, whereas a high proportion of lower molecular weight 
bands were consistently observed in TCTP samples expressed in yeast.  The addition of 
protease inhibitors was not required for purification of TCTP from E. coli, whereas the 
addition of a protease inhibitor cocktail at each stage of TCTP purification from S. 
cerevisiae was required to obtain a sufficient proportion of full-length protein. 
 
Antisera raised against yeast–derived (Sc) and E. coli-derived (Ec) PyTCTP were 
cross-reactive, as expected.  EcPyTCTP and EcPbTCTP could be detected using 
antiserum from a mouse immunised with ScPyTCTP, and antiserum raised to EcPyTCTP 
could detect ScPfTCTP and ScPyTCTP.  Using ELISA analysis, the reciprocal titre of the 
pooled antiserum from mice immunised with ScPyTCTP was 85,000 against homologous 
antigen, and was 83,000 against EcPyTCTP, indicating that the TCTPs expressed in 
yeast and bacterial systems were immunologically similar. 
 
Antiserum raised against EcPyTCTP and EcPbTCTP could recognise TCTP 
present in malarial lysates of P. yoelii YM, P.c. chabaudi AS and P. berghei ANKA.  The 
recognition of malarial TCTP by this antiserum was not as strong as when antiserum 
raised to ScPyTCTP was used (as shown in Figure 3.16, chapter 3).  This is most likely 
due to the lower reciprocal titre of EcTCTP antiserum (680,000 compared with 
1,000,000) and to variations in sample processing.  As the protein extraction method 
used does not allow accurate quantification of malarial protein, due to a final step of 
boiling samples in SDS-PAGE sample buffer, variation between samples is inevitable.  
The variations in TCTP detection between the different malarial samples could also 
possibly indicate that the expression of TCTP varies in different parasite life stages or 
between different rodent malaria species. However, this result is very preliminary and 
further experiments would need to be performed to confirm differential expression of 
TCTP in different rodent malarial species and/or in different life stages.  It has been 
previously reported that more TCTP is present in trophozoite stages of P. falciparum, 
compared with rings (Bhisutthibhan et al., 1998).  As P. yoelii and P. berghei infections 
are relatively asynchronous, it would be difficult to assess the relative proportions of 
TCTP in different life stages.  Quantification of TCTP in P.c. chabaudi AS life stages 
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would be achievable, but would require a different method of malarial protein extraction 
such that total protein concentration could be reliably estimated.  
 
TCTP immunisation resulted in a significant delay in infection progression in mice 
challenged with P. chabaudi and P. yoelii.  The longest delay was seen in mice 
challenged with P.c. chabaudi AS, in that TCTP-immunised mice had reduced mean 
parasitemia from 4 dpi to 9 dpi.  This reduced parasitemia led to a delay in peak 
parasitemia of one day compared with the control group.  Additionally, the peak 
parasitemia was reduced (33%) in TCTP-immunised mice compared with control mice 
(44%), however this reduction in peak parasitemia was not significant (p>0.05).  In mice 
challenged with P. yoelii YM, a statistically significant reduction in parasitemia was 
observed in PyTCTP-immunised mice only at the early stages of infection, at 3 and 4 dpi.  
Although parasite numbers were not significantly different, the peak parasitemia again 
occurred one day later in TCTP-immunised mice (day 7 compared with day 6) (Figure 
4.12 (a)).  Although an increased number of TCTP-immunised mice challenged with P. 
yoelii YM had not reached the infection endpoint at 7 dpi, by 8 dpi most control and 
immunised mice had been killed due to reaching a symptom score of 8.  The reduction 
and delayed increase in parasitemia seen in the EcPyTCTP-immunised mice was not as 
strong as in the initial P. yoelii YM challenge trial, in which mice were immunised with 
ScPfTCTP (Taylor, 2002).  In that trial, the parasitemia was significantly reduced in 
immunised mice on days 3-5 post-infection, peak parasitemia was delayed by one day, 
and immunised mice survived a full day longer than PBS controls.  However, in both 
trials some delay in disease progression was observed.  
 
Unlike in either of the previous TCTP vaccine trials using P. yoelii, in this trial two 
TCTP-immunised mice and one control mouse survived the usually lethal infection, with 
a peak symptom score of 6 or below. In the mice that survived, two parasitemia peaks 
were observed.  Survival of a proportion of control mice following P. yoelii YM challenge 
has been reported (Goschnick et al., 2004; Kedzierski et al., 2000). A second peak 
parasitemia has previously been reported in P. yoelii YM infections (Goschnick et al., 
2004; Kedzierski et al., 2001; Kedzierski et al., 2002b), and in infections using the closely 
related strain P. yoelii 17XL (Mello et al., 2004; Rotman et al., 1999).  In most of these 
reports, a second peak parasitemia was only observed in immunised mice, however an 
observation of two parasitemia peaks in controls following challenge with P. yoelii YM 
and P. yoelii 17XL has also been reported (Goschnick et al., 2004; Mello et al., 2004).  
The survival of two PyTCTP-immunised mice cannot be confidently stated to be due to 
the effects of the TCTP vaccine, as one control mouse also survived, with a lower peak 
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parasitemia. Further immunisation and P. yoelii YM challenge experiments would be 
required to observe if mice immunised with EcPyTCTP consistently had higher survival 
rates than controls. 
 
TCTP immunisation did not result in any significant differences in disease 
progression in C57BL/6 or BALB/c mice challenged with P. berghei ANKA.  Malarial 
TCTP may contribute to inflammation during malarial infection by inducing histamine 
release from the host (MacDonald et al., 2001).  As cerebral malaria (CM) development 
is associated with inflammatory cytokines, particularly TNFα and IFNγ (e.g. de Kossodo 
and Grau, 1993; Jennings et al., 1997; Lou et al., 2001), it was thought that TCTP 
immunisation might confer protection against CM in susceptible C57BL/6 mice.  
However, no significant differences in parasitemia or cerebral symptom development 
were observed in PbTCTP-immunised C57BL/6 mice compared with PBS controls.  All 
mice except one PBS control developed cerebral symptoms and were sacrificed at 
between five and eight days post-infection, with a mean time to cerebral symptom onset 
of six days for both control and immunised mice.  The mouse that did not develop CM 
was eventually sacrificed three weeks post-infection with fulminating parasitemia.  It has 
previously been reported that CM occurs in less than 100% of C57BL/6 mice infected 
with P. berghei ANKA (e.g. Amani et al., 1998; Bagot et al., 2002; Pierrot et al., 2003; 
Renia et al., 2006b).   
 
In BALB/c mice challenged with P. berghei ANKA, both PbTCTP-immunised and 
PBS control mice reached the disease endpoint (a symptom score of 8) at low 
parasitemia, relatively early in the infection.  It is generally reported that BALB/c mice 
infected with P. berghei ANKA succumb to disease at around three weeks post-infection 
(eg Lou et al., 2001).  A literature search of P. berghei ANKA infections revealed that a 
few studies have previously reported deaths of a small proportion of BALB/c mice at 
relatively low parasitemia, with a 10-20% mortality rate observed prior to 10 dpi (Hansen 
et al., 2005; Hansen et al., 2003; Pierrot et al., 2003).  However, reports of severe 
morbidity and/or deaths of all P. berghei ANKA-challenged mice at low parasitemia have 
not been published.   
 
It is known that variability occurs in malaria challenge experiments, due to 
virulence differences between isolates.  Increased virulence was observed in mice 
challenged with P.c. chabaudi AS and with P. berghei ANKA.  The average peak 
parasitemia for the P. chabaudi AS-infected control mice was higher (44%) than is 
generally reported (~20-30%) (e.g. Helmby et al., 2000; Lamb et al., 2007; Stephens et 
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al., 2005).  Also, some P. chabaudi-infected mice reached a symptom score of eight and 
were sacrificed, with a peak parasitemia exceeding 45%.  BALB/c mice infected with P.c. 
chabaudi AS are generally reported to have a 0% mortality rate (e.g. Hensmann et al., 
2004; Lamb et al., 2007).  It is likely that the increase in virulence of the parasite strains 
was due to serial passage in mice. It has been reported that serial passage of malaria 
rapidly increases virulence, as defined by damage to the host (Mackinnon and Read, 
2004).  In contrast, the survival of several mice following P. yoelii YM challenge suggests 
that this strain may have had lower virulence than strains previously tested.  
 
In all TCTP vaccine trials that have produced significant differences between 
immunised and control groups, the greatest observed difference is a reduced parasitemia 
in the early stages of infection, a delayed peak parasitemia, and increased survival time.  
Taken together, these results suggest that malarial TCTP may have a role in the early 
stages of infection progression, and is able to be recognised by the host immune system.  
If malarial TCTP were only found in the cytoplasm of malarial parasites, specific 
antibodies would be unable to recognise and interact with the protein.  TCTP has no 
recognised secretory signal sequence or transmembrane domains, as determined using 
the MalSig and SecretomeP programs (http://bioserve.latrobe.edu.au/cgi-bin/pfsigseq.py, 
http://www.cbs.dtu.dk/services/SecretomeP/).  However, evidence of TCTP secretion 
exists, as reviewed in section 1.4.  Extracellular functions of malarial TCTP have also 
been identified, including the induction of histamine release from basophils and IL-8 
release from eosinophils in vitro (MacDonald et al., 2001).  The protective effect 
observed following TCTP immunisation is most likely due to an induced immune 
response that inhibits the extracellular actions of the protein.  Further determination of 
the specific functions of malarial TCTP is required to better understand the mechanisms 
of the modest protection conferred by TCTP immunisation.  
 
Although histamine-releasing activities of malarial TCTP have been reported, no 
degranulation was induced by malarial or human TCTP in the RBL-2H3 cell line.  Reports 
have demonstrated histamine release from RBL-2H3 cells in response to filarial, 
flatworm, and tick TCTP (Gnanasekar et al., 2002; Mulenga et al., 2003; Rao et al., 
2002).  These studies all used a commercial kit to detect histamine release; the β-
hexosaminidase assay is less sensitive than the commercial kit.  To determine if the lack 
of induction of basophil degranulation by malarial TCTP was due to experimental 
differences between laboratories, the TCTPs previously shown to induce RBL-2H3 
degranulation would need to be assessed together with malarial TCTP under identical 
assay conditions.  
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TCTP immunisation generated only a very moderate protective effect against 
some of the rodent malaria strains tested, and is therefore a much less promising 
malarial vaccine candidate than other proteins already assessed. For example, in a trial 
in which BALB/c mice were immunised with native MSP119 and challenged with P.c. 
chabaudi AS, four of five mice did not develop detectable parasitemia (Hensmann et al., 
2004).  This vaccine candidate is now in clinical trials (Shi et al., 2007).  Other promising 
malarial vaccine candidates able to completely prevent the establishment of malaria 
infection in mice include AMA-1 (Anders et al., 1998), also in clinical trials (Ballou et al., 
2004), and MSP4/5 (Kedzierski et al., 2000).  For this reason, it is unlikely that TCTP 
could be viewed as a potential human malaria vaccine candidate. 
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Chapter 5: Development of TCTP-knockout strains 
of P. berghei ANKA 
 
5.1 Introduction 
The precise function of malarial TCTP is unknown.  It is known to be a target of 
the antimalarial drug artemisinin (Bhisutthibhan and Meshnick, 2001), and there is 
evidence that it is secreted from parasites during infection and can induce histamine 
release in cultured human basophils (MacDonald et al., 2001).  TCTPs from other 
eukaryotes are known to be involved in a variety of functions, including cell growth.        
 
This chapter describes the development of a P. berghei ANKA strain with the 
TCTP gene disrupted.  A TCTP ‘knockout’ malaria strain may be useful in elucidating the 
precise functions of TCTP in the parasite.  As discussed in section 1.8, TCTP knockouts 
have been created in mice and Drosophila flies.  In Drosophila, disruption of the TCTP 
gene led to 100% lethality at the larval stage (Hsu et al., 2007).  Mouse embryos 
heterozygous for the TCTP deleted allele developed normally, however homozygous 
mutant embryos died at around 6.5 days.  Mouse fibroblast cells with the TCTP gene 
disrupted by conditional mutagenesis developed normally, indicating that TCTP is 
essential only in some stages of mouse development, or in some cell types (Chen et al., 
2007).    
 
The methods for the creation of gene knockouts in P. berghei ANKA are well 
established, as discussed in section 1.9.  Targeted gene disruption in involves 
homologous recombination of a linearised target DNA sequence into the genome.  Both 
single and double crossover events can occur, depending on the target DNA design.  
Early transfection experiments used electroporation to introduce exogenous DNA into 
purified schizonts (e.g. Menard and Janse, 1997).  Transfection technology using the 
Amaxa nucleofector™ machine (http://www.amaxa.com/products/technology/) has since 
been developed, and has increased transfection efficiencies from ~10-8 to ~10-3 (Janse et 
al., 2006a). 
 
The selectable marker used in P. berghei transfections is the dihydrofolate 
reductase-thymidylate synthase (DHFR/TS) gene from P. berghei, Toxoplasma gondii, or 
humans.  This gene confers resistance to either the antimalarial drug pyrimethamine (P. 
berghei and T. gondii DHFR) or to both pyrimethamine and the antifolate drug WR99210 
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(human DHFR).  Using these transfection techniques, several malarial genes have been 
disrupted, including those encoding the circumsporozoite (CS) protein (Menard et al., 
1997), the thrombospondin-related anonymous protein (TRAP) (Sultan et al., 1997), and 
the macrophage migration inhibitory factor (MIF) (Augustijn et al., 2007). 
 
As a protective effect following TCTP immunisation was not observed in PbTCTP-
immunised mice, it might have been more relevant to disrupt the TCTP gene in P. yoelii.  
Transfection of P. yoelii has been accomplished using electroporation techniques, and 
the TRAP gene has been disrupted (Mota et al., 2001).  These experiments were 
performed using insertion plasmids rather than replacement plasmids, and gene 
disruption occurred by single-crossover.  Gene analysis of TRAP-disrupted P. yoelii 
parasites indicated that gene reversion had occurred and wild-type TRAP was present, 
most likely from the excision of the linearised TRAP plasmid from the genome.  At the 
time the TCTP disruption experiments were performed, transfection of P. yoelii using the 
nucleofector™ machine had been reported, however gene disruption experiments had 
not been attempted (Jongco et al., 2006).  One such experiment was recently published 
(Mikolajczak et al., 2008).  TCTP knockout experiments were performed in P. berghei 
ANKA due to the more developed transfection methods, and the ability to perform these 
experiments together with collaborators at the Walter and Elisa Hall Institute (WEHI).  
 
The experiments described in this chapter utilised the b3D vector (Figure 5.1) 
encoding the T. gondii DHFR/TS gene with a two multiple cloning sites (MCS) present 
adjacent to the 5’ and 3’ UTRs.  A section of either the 5’ or 3’ TCTP flanking region was 
cloned into each MCS.  In successful transfection experiments, the two TCTP flanking 
regions would undergo homologous recombination with the TCTP gene on the genome, 
resulting in the interruption of chromosomal TCTP with the DHFR gene.  The target DNA 
was also designed so that either 140 bp or 507 bp of the 516 bp TCTP coding region 
would be excised during homologous recombination, to prevent wild-type protein 
expression if the DHFR gene was excised from the chromosome at a later stage.  
Knockout parasites could be selected for by treatment of infected mice with 
pyrimethamine.  Confirmed TCTP-knockout parasites could then be tested for phenotypic 
differences to wild-type, including altered growth morphology and altered resistance to 
artemisinin. 
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The aims of the experiments outlined in this chapter were: 
 
1: To assess the feasibility of the TCTP knockout experiments, by:  
 
a) Investigating whether multiple copies of the TCTP gene are present in P. 
berghei ANKA 
 
b) analysing the TCTP flanking regions on the chromosome to assess if any 
nearby genes might be disrupted during the creation of TCTP knockouts  
 
2: To create vectors suitable for the disruption of TCTP in the P. berghei ANKA 
genome 
 
3: To perform transfection experiments using these vectors, in order to obtain 
TCTP knockout mutant parasites 
 
4: To verify the disruption of TCTP in the P. berghei genome by PCR and 
Southern blot analysis 
 
5: To analyse the phenotype of TCTP-knockout mutant parasites 
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Figure 5.1: The b3D vector 
 (http://www.lumc.nl/1040/research/malaria/plas01.html)  
MCS1 
MCS2 
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5.2 Materials and Methods 
For the materials and methods used in this study, please refer to chapter 2. 
 
5.3 Results  
5.3.1 Feasibility assessment of the TCTP knockout experiments by 
analysis of the P. berghei ANKA genome  
The P. berghei genome sequence has not been fully assembled, and is available 
as a series of contigs.  Using the plasmoDB database 
(http://www.plasmodb.org/plasmo/), the nucleotide sequence of P. berghei TCTP was 
entered into a BLAST search against the P. berghei genome to assess if multiple copies 
of TCTP were present, in which case the transfection experiment would be unlikely to 
result in parasites with no TCTP expression.  No other sequences with high similarity to 
the TCTP coding sequence were found.  
 
The sequence of the P. berghei contig containing TCTP was entered into to an 
open reading frame (ORF) finder program (NCBI) to analyse if other nearby genes might 
be disrupted in the knockout experiment.  The results obtained showed that two very 
small ORFs (35 and 44 amino acids) are present at around 1 kb either side of the TCTP 
coding region.  The closest genes to TCTP with an identified function are a steroyl-CoA 
desaturase protein (accession number XP_679533) 2.8 kb upstream and a WD-repeat 
protein (accession number XP_679536) 3.3 kb downstream of TCTP.   
 
The short and long integration fragment sequences to be cloned into the b3D 
vector were subjected to a BLAST search using NCBI to ensure that they were unlikely to 
recombine in other areas of the P. berghei genome.  Using the Amaxa nucleofector™, 
the minimum length sequence required for homologous recombination in malaria 
transfection is ~300 bp (Janse et al., 2006a).  No other similar sequences approaching 
this size were found in the search.  
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5.3.2 Cloning of the short integration construct 
5.3.2.1 Rationale for the creation of the short target b3Dint1int2 construct 
The standard protocol in P. berghei transfection is to design replacement 
constructs so that the target gene is truncated or deleted after homologous 
recombination, so that the wild-type gene cannot be restored if the exogenous target 
DNA is excised from the genome.  In designing the first integration construct, it was 
decided to use mostly TCTP coding region, due to the higher GC content.  Thus the 
fragments were designed such that the middle 141 bp portion of the TCTP coding region 
would be removed following homologous recombination.  This meant that a 5’ coding 
region of 199 bp and a 3’ coding region of 175 bp would still present following a 
successful transfection, but would be interrupted with the DHFR gene.  PCR analysis 
would be able to detect if the target DNA were excised from the genome at a later stage, 
as the TCTP gene in revertants would be truncated.   
 
The lower limit in size of the homologous DNA used for each integration fragment 
is 300 bp.  As P. berghei TCTP is a small gene (516 bp) containing no introns, the 
integration fragments were designed to incorporate part of the 5’ and 3’ UTRs of TCTP.  
The first integration fragment (int1) was 336 bp in length, from -121 bp upstream of the 
TCTP start codon to position 199 in the TCTP gene.  The second integration fragment 
(int2) was 344 bp in length, from position 340 on the TCTP gene to +152 bp downstream 
of the stop codon.    
 
A schematic diagram for the steps involved in creating the short integration 
construct (b3D.int1.int2) is given in Figure 5.2 (a).  A diagram of the disruption of the 
TCTP region of the P. berghei ANKA chromosome by homologous recombination of the 
int1.int2 target DNA is given in Figure 5.2 (b).  A schematic representation of the P. 
berghei ANKA TCTP region following disruption with the int1.int2 target is given in Figure 
5.2 (c). 
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DHFR/TS 
(a) 
 
PCR amplification of int1 and int2 fragments: 
 
Int1           Int2 
                                               -121      199   340      +152 
 
 
                   P. berghei genome               TCTP 
 
                               Cloning of int1 and int2 into pCR2.1 vectors: 
                                                
                           pCR.int1                                                 pCR.int2 
 
Cloning of int1 and int2 sequentially into the b3D vector: 
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(b) 
 
 
 
(c) 
 
 
 
 
Figure 5.2 Creation of the b3D.int1.int2 vector, and disruption of the TCTP gene 
with the int1.int2 target 
(a) Creation of the b3D.int1.int2 vector by PCR amplification of int1 and int2 from P. 
berghei ANKA genomic DNA, followed by cloning of the int1 and int2 products into 
pCR2.1 vectors, then sequential digestion and ligation of int1 and int2 into the 
MCS1 and MCS2 of the b3D vector 
(b) Schematic diagram of recombination via double cross-over between int1 and 
int2 on the linearised int1.int2 target DNA and the homologous regions on the P. 
berghei ANKA chromosome following transfection, the box represents the TCTP 
coding sequence 
(c) Schematic diagram of the TCTP region of the P. berghei chromosome following 
homologous recombination in a successful transfection experiment with the 
int1.int2 target DNA, the boxes represent TCTP coding sequence remaining 
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5.3.2.2 PCR amplification of the short integration fragments and cloning into 
pCR2.1 vectors 
 The sequence of the primers used to amplify the short integration fragments 
were designed based on the sequence of the P. berghei contig containing the TCTP 
gene (PlasmoDB contig accession number PB_RP1763).  The first fragment primers 
were designed to incorporate ClaI and HindIII restriction enzyme sites (as underlined) to 
allow for directional cloning into the first MCS of the b3D vector.  The second fragment 
primers were designed to incorporate BamHI and XbaI restriction enzyme sites (as 
underlined) to allow for directional cloning into the second MCS of b3D.  The sequence of 
the four primers was: 
 
First for: GCATCGATGAAGCCTTTTAATTATATAGTA 
First rev: GCAAGCTTGTTCAACATCAGCTCCCATTCC 
Second for: GCGGATCCAAACAAAGGCACAACCCTTAAT 
Second rev: GCTCTAGACATTGGACCATTTTAAGAGACA 
 
The first (int1) and second (int2) fragments were amplified by Taq PCR (as per 
the method described in 2.3.2.2.3) from P. berghei ANKA genomic DNA (obtained from 
Dr. Tania de Koning-Ward, WEHI, Australia).  Each reaction contained 0.5 µM 
concentrations of the first for and first rev or the second for and second rev primers and 
25 ng of P. berghei ANKA genomic DNA.  An annealing temperature gradient of 50 to 
65°C was used.  The PCR products were separated by electrophoresis at 100 V 
(2.3.2.5).  A strong band was amplified at ~320 bp for the int1 and int2 products (Figure 
5.3 (a)).   
 
The int1 and int2 PCR products from the 65°C annealing temperature reactions 
were cloned into separate pCR 2.1 vectors as per manufacturer’s instructions (2.3.2.7.1).  
Plasmid DNA from resulting white colonies was purified by minipreparation (2.3.2.1.1).  
Restriction enzyme digests (2.3.2.4) using either ClaI and HindIII (int1) or BamHI and 
XbaI (int2) confirmed that the int1 and int2 products had been successfully cloned into 
pCR2.1 vectors (Figure 5.3 (b)).  Sequence analysis was performed (as per the method 
described in 2.3.2.2.6); pCR2.1 vectors containing inserts with the correct DNA sequence 
were named pCR.int1 and pCR.int2. 
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Figure 5.3: Amplification and pCR2.1 cloning of the int1 and int2 fragments 
(a) PCR amplification of the int1 and int2 products: Lane 1: 100 bp marker; Lane 2: 
int1 PCR neg control; Lanes 3-8: int1 PCRs with annealing temp 50-65°C; Lane 9: int2 
PCR neg control; Lanes 10-15: int2 PCRs with annealing temp 50-65°C.  
(b) Confirmation of int1 and int2 in pCR2.1 cloning vectors: Lane 1: λ/PstI marker; 
Lanes 2-5: pCR.intI digested with ClaI and HindIII; Lanes 6-9: pCR.int2 digested with 
XbaI and BamHI. 
size 
(bp) 
 
 
 
 
500 
300 
size 
(bp) 
 
4507 
 
 
 
 
 
339 
 
int1 and int2 
products 
pCR2.1 vector 
int1 and int2 
products 
Chapter 5: Development of TCTP-knockout strains of P. berghei 
 186 
5.3.2.3 Cloning of the int1 and int2 products into the b3D vector 
Overnight cultures of single colonies of E. coli DH5α transformed with the b3D 
plasmid (obtained from Dr. Tania de Koning-Ward) were grown in LB+Amp broth, and 
plasmid was extracted by minipreparation.  The int1 and int2 fragments were cloned into 
the two multiple cloning sites of the b3D vector sequentially.  First, 1 µg each of the 
pCR.int1 and the b3D vectors were digested with 10 U each of ClaI and HindIII.  The 
completed digestion reactions underwent electrophoresis at 50 V on a 1% agarose gel 
(Figure 5.4 (a)).  Bands of the correct size were excised with a scalpel, and DNA was 
purified from the agarose using the Qiaquick Gel Extraction kit following manufacturer’s 
instructions. 
 
The ligation reaction was prepared as standard (2.3.2.7.2) with the modification 
that 50 ng of b3D vector was used, with the appropriate amount of insert for a 3:1 insert: 
vector ratio.  The completed ligation reaction was used to transform electrocompetent E. 
coli (2.4.3.2); plasmid DNA from resulting colonies was purified by minipreparation.  
Plasmid preparations were screened for the presence of the int1 insert by digestion with 
ClaI and HindIII.  The completed digestion reactions were separated by 1.5% agarose 
gel electrophoresis at 100 V (Figure 5.4 (b)).  
 
One microgram of the pCR.int2 and b3D.int1 vectors were digested with 10 U 
each of BamHI and XbaI.  Completed digestion reactions were separated by 1.5% 
agarose gel electrophoresis at 60 V (Figure 5.4 (c)).  Desired bands were excised with a 
scalpel and DNA was purified using the Qiaquick Gel Extraction kit.  Ligation reactions of 
the int2 insert and the b3D.int1 vector were prepared using 100 ng vector and the 
appropriate amount of insert DNA for a 3:1 ratio.  The completed ligation reaction was 
used to transform electrocompetent E. coli.  Plasmids from resulting colonies were 
purified by minipreparation and screened for confirmation of the presence of both the int1 
and the int2 insert by digestion with 10 U each of either ClaI and HindIII or BamHI and 
XbaI (Figure 5.4 (d)).  Plasmid preparations containing both the int1 and int2 inserts 
were named b3D.int1.int2.   
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Figure 5.4: Creation of the b3D.int1.int2 construct 
(a) Digestion of pCR.int1 and b3D vectors with ClaI and HindIII: Lane 1: 100 bp 
marker; Lanes 4 & 7: pCR.int1; Lanes 10 & 13: b3D.  
(b) Confirmation digest of b3D.int1 using ClaI and HindIII enzymes: Lane 1: 100 bp 
marker; Lane 3: b3D.int1; Lane 7: pCR.int1.  
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Figure 5.4: Creation of the b3D.int1.int2 construct 
(c) Digestion of b3D.int1 and pCR.int2 with XbaI and BamHI: Lane 1: λ/HindIII 
marker; Lane 4: b3D.int1; Lanes 6 & 8: pCR.int2.  
(d) Confirmation digests of b3D.int1.int2: Lane 1: λ/HindIII marker; Lanes 3 and 5: 
b3D.int1.int2 digested with ClaI and HindIII for confirmation of int1 cloning; Lane 4 and 6: 
b3D.int1.int2 digested with XbaI and BamHI for confirmation of int2 cloning; Lane 8: 100 
bp marker. 
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5.3.3 First transfection of P. berghei ANKA parasites using the short 
target b3D.int1.int2 vector 
5.3.3.1 Preparation of target DNA prior to transfection 
Transfection of P. berghei ANKA requires linearised target DNA.  Residual intact 
plasmid can transform P. berghei parasites, resulting in episomes, which can be 
transferred to daughter parasites during schizont formation.  This can result in drug-
resistant parasites without the target gene disrupted.  Therefore, target DNA must be 
completely digested prior to transfection.  
 
The short target DNA used in the first transfection experiment was prepared from 
the b3D.int1.int2 construct.  The target DNA was prepared by excising the region 
spanning the int1 fragment and int2 fragments out of the b3D plasmid backbone, using 
ClaI and XbaI.  To further ensure that no intact plasmid remained, the b3Dint1int2 
construct was digested with a third restriction enzyme that cut within the plasmid 
backbone (BglI).   
 
A final concentration of 10 µg of target DNA was required per transformation 
experiment.  A total of 120 µg of the b3D.int1.int2 plasmid was digested with 200 U each 
of ClaI, XbaI and BglI in Buffer C for 15 h.  Aliquots of 20 µl of the digest reaction were 
separated by 1% agarose gel electrophoresis at 60 V (Figure 5.5 (a)).  The target DNA 
bands (5270 bp) were excised from the gel using a scalpel and DNA was purified using 
the Qiaquick Gel Extraction kit.  All preparations of gel-purified short target DNA were 
combined and DNA was precipitated with EtOH/NaOAc (2.3.2.8).  The target DNA was 
resuspended in 10.5 µl of TE.  A small amount of prepared short target DNA was 
quantified before transfection by comparison with known quantities of PstI-digested-λ 
DNA (Figure 5.5 (b)).  
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Figure 5.5:  Preparation of short integration target DNA prior to first transfection 
(a) Representative sample of b3D.int1.int2 digestions with ClaI, BamHI and BglI:  
Lane 1: λ/HindIII marker (full size range described in Appendix 1); Lanes 4,6,8,10,12,14: 
b3D.int1.int2 digests 
(b): Quantification and purity assessment of purified target DNA preparations prior 
to transfection: (b) Lane 1: λ/PstI marker; Lanes 3-6: dilutions of target DNA.   
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5.3.3.2 Growth of parasites and secondary infection of mice following 
first transfection 
The initial transfection, drug treatment and parasitemia monitoring experiments 
were performed at WEHI by Dr. Tania de Koning-Ward.  Briefly, P. berghei ANKA 
schizonts were purified from an overnight in vitro culture using Nycodenz columns.  An 
Amaxa nucleofector™ machine was used for transfection.  Per reaction, 10 µg of purified 
short integration target DNA was used, and the transfected schizonts were injected into 
the lateral tail vein of one BALB/c mouse.  The mouse was treated with 70 µg/ml 
pyrimethamine provided in the drinking water (pH adjusted to between 3.5 and 5) 
continuously from 24-30 hours post-injection.  Parasitemia was monitored at regular 
intervals.  Detectable parasitemia was only observed in the mouse at 18 days post-
injection, at this time the mouse was sacrificed and blood was used for stabilate creation.  
Successful transfection experiments usually yield a parasitemia of 0.1-5% at 4-7 dpi, and 
it has previously been noted that parasites are often detected between 13 and 15 dpi in 
unsuccessful transfection experiments.  These parasites are typically non-drug resistant 
parasites that have survived pyrimethamine treatment 
(http://www.lumc.nl/1040/research/malaria/model.html). 
 
 Therefore, it was unknown whether the finding of detectable parasitemia at 18 
dpi was due to an unsuccessful transfection experiment, with the parasites present being 
wild-type, or if the result obtained was due to a slow-growth phenotype in parasites with 
the TCTP gene successfully disrupted.  For this reason, the parasite stabilate from the 
first transfection experiment was used to inject two mice at RMIT, to obtain sufficient 
DNA for genotype analysis by Southern blot and PCR.  These mice were designated as 
1.1 and 1.2.  Each mouse received 100-150 µl of stabilate by i.p. injection (method 
described in 2.7.2.3).  As it was thought that the parasites obtained were most likely wild-
type, mice received no pyrimethamine treatment.  At the same time, four mice received 
an i.p. injection of 75 µl of P. berghei ANKA stabilate, to obtain sufficient wild-type (wt) 
parasite DNA.  
 
In all mice, a parasitemia of between 2 and 4% was reached at between 3 dpi 
and 6 dpi. Mice were anaesthetised and blood was taken by cardiac puncture (2.7.3.2).  
Blood was used to create stabilates (2.7.2.2) and for malarial DNA extraction using SDS 
and PCI (2.9.2.4).  
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5.3.3.3 Analysis of the genotype of the transfected parasites by PCR 
Primers were designed to assess disruption of the TCTP gene by integration of 
the target DNA in the P. berghei ANKA genome.  Two primer sets were used that should 
only amplify products in parasite DNA with the TCTP gene disrupted.  These were the 
5’PyTCTP (CGCGGGATCCATGAAAGTATATAAAGACATTTTTACA) and Pf1rev 
(AAAATAAAAGGGAAATCAATG) combination and the Pf2for 
(TCTTCAATGATTCATAAATAG) and 3’PyTCTP 
(GCGCGACGTCTTAGTATTTTTCTTCAAATAAACCATC) combination.  In successfully 
transfected parasites, the 5’PyTCTP and Pf1rev primer combination would amplify a 
region from the remaining 5’ section of the PbTCTP to just inside the 5’UTR of the DHFR 
gene used for disruption, producing a product of 309 bp designated as TCTP1.  Likewise, 
the Pf2for and 3’PyTCTP primer combination would amplify a region from the end of the 
DHFR 3’UTR to the end of the remaining 3’ portion of the PbTCTP, resulting in a 348 bp 
product designated as TCTP2.  The 5’ and 3’PyTCTP primer set was also used.  These 
primers would give a PCR product of 5007 bp (long TCTP) in parasite DNA with the 
TCTP gene successfully disrupted, due to the insertion of the DHFR gene within the 
TCTP gene.  A diagram of the primer binding sites in wild-type and TCTP-knockout 
parasites is given in Figure 5.6.  
 
 
 
 
 
                                         Disrupted TCTP on P. berghei chromosome 
 
 
Figure 5.6: Amplification products of primers initially used to confirm disruption of 
TCTP with the DHFR gene 
1: TCTP1 - 5’PyTCTP and Pf1rev 
2: TCTP2 - Pf2for and 3’PyTCTP 
3: long TCTP - 5’PyTCTP and 3’PyTCTP 
 
1 2 
3 
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 The integration of the short target DNA into the genome of transfected parasites was 
assessed by Taq PCR analysis.  In all PCRs, a one-minute extension time was used.  
Wild-type P. berghei ANKA DNA was used as a control. 
 
In transfected parasite DNA obtained from mouse 1.1, a 516 bp wild-type TCTP 
band was not amplified, but was present in wt P. berghei ANKA DNA.  Using the 
5’PyTCTP and Pf1rev primer combination, a TCTP1 product of ~300 bp was obtained 
from the mouse 1.1 parasite DNA but not from wt DNA, indicating that the TCTP gene 
may have been successfully disrupted.  However, no TCTP2 product was obtained using 
the Pf2for and 3’PyTCTP primer combination, so it was unclear whether the transfection 
experiment had been successful (Figure 5.7 (a)).  The annealing temperature was 
reduced to 45°C in an attempt to amplify the TCTP2 product using the Pf2for and 
3’PyTCTP primers.  Again, no product was amplified (results not shown).   
 
In transfected parasite DNA obtained from mouse 1.2, a faint wt TCTP band was 
obtained, as well as a strong 300 bp TCTP1 band (Figure 5.7 (b)).  Again, no TCTP2 
product was amplified.  This indicated that a mix of parasite genotypes might be present 
in the blood taken from this mouse.  
 
To confirm the presence of the TgDHFR/TS gene in the transfected parasite 
DNA, the TgDHFRf (GGCATCGGCATCAACAACGG) and TgDHFRr 
(GCTAGACAGCCATCTCCATC) primers were used.  These primers were designed to 
amplify a 1,790 bp product corresponding to the majority of the coding region.  PCRs 
were performed using Pfu polymerase with a 10 min extension time.  A strong 1,800 bp 
DHFR product was amplified in transfected DNA from both mouse 1.1 and 1.2.  Very 
faint non-specific bands were also observed.  No distinct products were observed in P. 
berghei ANKA wt DNA  (Figure 5.7 (c)).  The presence of a strong band in the 
transfected parasite DNA suggested that the T. gondii DHFR gene was present.  
 
Under appropriate PCR conditions, the 5’PyTCTP and 3’PyTCTP primer set 
should have theoretically amplified a 5,007 bp band in successfully transfected parasites.  
The 5’PyTCTP and 3’PyTCTP primer set was used in PCRs using Pfu or Expand long 
template polymerase and a 10 min extension time, no products were amplified in either 
sample of transfected parasite DNA (results not shown).
Chapter 5: Development of TCTP-knockout strains of P. berghei 
 194 
         (a) 
                            1      2      3     4     5     6     7     8     9  
                                    
 
  
                                   
                                   (b) 
                            1         3   4    5   6   7   8   9  10 11 12  
                          
size 
(bp) 
 
 
 
 
 
514 
339 
264 
 
 
 
wt TCTP 
TCTP1 integration 
fragment 
size 
(bp) 
 
 
 
 
 
 
514 
339 
264 
 
 
wt TCTP 
TCTP1 integration 
fragment 
Chapter 5: Development of TCTP-knockout strains of P. berghei 
 195 
                                   (c)          
                                     1          3    4    5          7    
                                               
 
Figure 5.7: PCR analysis of parasite DNA obtained from the first transfection 
experiment 
(a) PCR analysis of transfected parasites from mouse 1.1:  Lane 1: λ/PstI marker; 
Lanes 2-5: TCTP PCR – (2) neg control; (3-4) dilutions of mouse 1.1 parasite DNA; (5) 
wt DNA; Lanes 6-9: TCTP1 PCR – (6) neg control; (7-8) dilutions of mouse 1.1 parasite 
DNA; (9) wt DNA  
(b) PCR analysis of transfected parasites from mouse 1.2: Lane 1: λ/PstI marker; 
Lanes 3-7: TCTP PCR - (3) neg control; (4-5) dilutions of wt DNA; (6-7) dilutions of 
mouse 1.2 parasite DNA; Lanes 8-12: TCTP1 PCR – (8) neg control; (9-10) dilutions of 
wt DNA; (11-12) dilutions of mouse 1.2 parasite DNA  
(c) PCR amplification of TgDHFR/TS from transfected parasite DNA from mouse 1.1 
and 1.2: Lane 1: λ/PstI marker; Lanes 3-8: TgDHFR/TS PCR – (3) neg control; (4) 
parasite DNA from mouse 1.1; (5) parasite DNA from mouse 1.2; (7) DNA from P. 
berghei wt. 
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5.3.3.4 Genetic analysis of parasite DNA from the first transfection 
experiment by Southern blot  
The PCR results obtained indicated that the target DNA was present in the 
transfected parasite DNA obtained from mouse 1.1 and 1.2, as the TCTP1 and 
TgDHFR/TS products were amplified.  However, integration of the target DNA in the 
correct genomic location could not be confirmed from these results, as the TCTP2 
product was not amplified.  To clarify the location of the integrated target DNA, a 
Southern blot was performed, using both TCTP and TgDHFR/TS probes.  The TCTP 
probe would hybridise with both wt and transfected DNA, as only the middle 141 bp of 
the TCTP coding region would have been removed in a successful integration 
experiment, leaving 375 bp remaining, interrupted by the ~5 kb TgDHFR/TS gene.   The 
TgDHFR/TS probe should only hybridise with transfected parasite DNA.   
    
5.3.3.4.1 PCR amplification of the TCTP probe 
PbTCTP was amplified from P. berghei ANKA genomic DNA by PCR using 
AmpliTaq polymerase with a final concentration of 0.3 µM 5’ and 3’PyTCTP primers and 
50 ng DNA per reaction.  An annealing temperature of 55°C was used.  The PCR 
products were analysed by agarose gel electrophoresis (Figure 5.9 (a)) prior to 
hexanucleotide labelling (as per the method described in 2.9.4.1).   
 
5.3.3.4.2: PCR amplification of the TgDHFR/TS probe 
The TgDHFR/TS probe was amplified by PCR using ~ 2 ng of b3D vector as the 
template.  An annealing temperature gradient of 55 - 65°C was tested.  As shown in 
Figure 5.9 (b), faint non-specific bands were also amplified at all annealing 
temperatures.  For this reason, the band corresponding to the TgDHFR/TS product was 
excised from the gel and purified prior to hexanucleotide labelling. 
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Figure 5.8: Preparation of probes for Southern blot of parasite DNA from the first 
transfection experiment  
(a) Amplification of TCTP probe: Lane 1: λ/PstI marker; Lane 2: TCTP PCR neg 
control; Lanes 3 & 4: TCTP PCR products 
(b) Amplification of DHFR probe: Lane 1: λ/PstI marker; Lane 2: DHFR PCR neg 
control; Lanes 3-7: DHFR PCR using an annealing temperature from 55-65°C. 
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5.3.3.4.3:  Southern blot of transfected parasite and wt berghei DNA 
A DNA concentration of ~10 µg per sample is recommended by the manufacturer 
for Southern blotting using the DIG system with a chromogenic substrate 
(http://www.roche-applied-science.com/).  The transfected parasite DNA obtained from 
mouse 1 and 2 was pooled to obtain a total of 10 µg.  The DNA from two mice infected 
with wt P. berghei ANKA was also pooled.  The genomic DNA was digested with 30 U of 
NdeI for 16 h (as per the method described in 2.9.4.2).  This digest would result in a 3.5 
kb band containing wt TCTP in non-transfected parasites and a band of 8 kb in parasite 
DNA with the TCTP gene successfully disrupted.  The digested genomic DNA was 
separated on a 1% w/v agarose gel at 60 V alongside a λ/PstI marker.  The DNA gels 
and Southern membranes were photographed next to rulers, so that the band sizes could 
be compared.  Figure 5.10 (a) depicts the digested wt and transfected parasite DNA 
separated by agarose gel electrophoresis.   
 
The DNA was transferred to a nylon membrane and probed with DIG-labelled 
TCTP at a 65°C hybridisation temperature, as per the method described in 2.9.4.3.  
When hybridised DNA was detected using anti-DIG antibody and a chromogenic 
substrate, undigested parasite DNA was detected in the well positions, at 2 cm from the 
top of the membrane.  This allowed the distance migrated from the wells to be measured 
for other bands.  A band approximately 3.8 cm from the wells, corresponding to a size of 
~3.5 kb, was observed in the wt P. berghei ANKA DNA.  A band approximately 2.5 cm 
from the wells, corresponding to a size of ~8 kb, was observed in the transfected parasite 
DNA (Figure 5.10 (b)).  This indicated that the TCTP gene had been disrupted.    
 
To confirm this result, the blot was then stripped and re-probed (2.9.4.4) with the 
TgDHFR/TS probe at a 65°C hybridisation temperature.  No bands were detected in the 
wt P. berghei ANKA DNA, as expected.  A single band at ~2.5 cm from the wells was 
again observed in the transfected parasite DNA (Figure 5.10 (c)).  From these results, it 
was determined that the TCTP gene had been successfully disrupted by the integration 
of the TgDHFR/TS gene in at least the majority of transfected parasites.  
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Figure 5.9: Southern blot of transfected and wild-type (wt) parasite DNA using TCTP and DHFR probes  
(a) Separation of NdeI-digested genomic DNA by agarose gel electrophoresis: Lane 1: wt P. berghei ANKA DNA; Lane 2: transfected 
parasite DNA; Lane 3: λ/PstI marker.   
(b) Southern blot using TCTP probe: Lane 1: wt P. berghei ANKA DNA; Lane 2: transfected parasite DNA.   
(c) Southern blot using DHFR probe:  Lane 1: wt P. berghei ANKA DNA; Lane 2: transfected parasite DNA. 
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5.3.3.5 Secondary drug-selection of parasites obtained from the first 
transfection experiment 
5.3.3.5.1 Growth of parasites during drug selection 
Due to the successful transfection result as indicated by Southern blot, the 
parasites obtained from the first transfection experiment were passaged into new mice 
for further drug selection using pyrimethamine.  Three mice received an i.p. injection of 
100 µl of parasites, these mice were designated 2.1, 2.2 and 2.3.  Only ~125 µl of the 
initial transfected parasite stabilate (obtained from WEHI) remained, 100 µl of this was 
used to infect mouse 2.1.  Mouse 2.2 and 2.3 received the stabilate made from the 
second passage of the original stabilate, obtained from non-drug treated mice (mouse 
1.1, and 1.3, as described in 5.3.2.2).  The mice were treated with pyrimethamine 
continuously, starting at 28 h post-infection (as per the method described in 2.9.2.2).  A 
tree diagram of the parasite sources and recipients is shown in Figure 5.10.   
 
1:  Parasites following transfection 
  
2:  Used to infect one mouse at WEHI, drug treated, parasite stabilate created 
 
3: Stabilate used to infect mouse  
     1.1 and 1.2, not drug treated 
                                                                  4: Stabilate used to infect mouse 2.1,                   
                                                                     drug treated 
 
5: Stabilates used to infect mouse 2.2  
and 2.3, drug treated 
 
 
Figure 5.10: Tree diagram of parasite recipients from the first transfection 
experiment 
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Mouse 2.1, which received the original transfected parasite stabilate, reached a 
parasitemia of 5% at 9 dpi.  At this point, the mouse was sacrificed and blood was taken 
for stabilate creation and malarial DNA extraction.  Mouse 2.2, which received the non-
drug treated stabilate made from the original stabilate passage, reached a parasitemia of 
8% at 7 dpi.  At this time the mouse was sacrificed and blood was taken for stabilate 
creation and malarial DNA extraction.  Mouse 2.3, which also received the non-drug 
treated stabilate, developed low but detectable parasitemia  (<0.1%) at 6 dpi.  The 
parasite numbers remained at ~0.1% until 11 dpi, then dropped below the detection limit.  
Mouse 2.3 was eventually sacrificed at 28 dpi, having had no detectable parasitemia 
since 11 dpi. 
 
5.3.3.5.2 Analysis of the transfected parasite DNA from the secondary drug-
selection by PCR 
PCR was performed to confirm the integration of the short target DNA in the 
parasites that had undergone secondary drug selection, using the 5’PyTCTP+Pf1rev and 
Pf2for+3’PyTCTP primer combinations; PCRs were also performed to assess the 
presence of wt TCTP in transfected parasites using the 5’ and 3’PyTCTP primers. 
 
A band corresponding to wt TCTP (516 bp) was amplified in both the wt DNA 
control and in the drug-selected parasites from both mouse 2.1 and 2.2.  A TCTP1 
integration product was only obtained in the DNA from mouse 2.2 (Figure 5.11).  No 
TCTP2 integration products were amplified in any of the DNA samples (results not 
shown).     
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Figure 5.11:  PCR analysis of parasite DNA from secondary drug selection   
Lane 1: λ/PstI marker; Lanes 3-6: TCTP PCR: (3) neg control; (4) wt DNA; (5) parasite 
DNA from mouse 2.1 (received original transfected parasite stabilate); (6) parasite DNA 
from mouse 2.2 (received passaged, non-drug treated parasite stabilate); Lanes 7-10: 
TCTP1 PCR: (7) neg control; (8) wt DNA; (9) parasite DNA from mouse 2.1; (10) parasite 
DNA from mouse 2.2. 
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5.3.3.5.3 Analysis of the transfected parasite DNA from the secondary drug-
selection by Southern blot 
A Southern blot was performed on the transfected parasite DNA following 
secondary drug selection. Ten micrograms of genomic DNA was digested with 30 U of 
NdeI for 16 h.  The DNA was separated by 1% agarose gel electrophoresis (Figure 5.12 
(a)).  The migration distance of the DNA bands in the λ/PstI marker was calculated by 
placing a ruler with the 1 cm mark at the position of the wells, and measuring the 
distance to the bands relative to the wells.  
 
In this experiment, sufficient DNA was obtained from mouse 2.1 and 2.2 to allow 
them to be analysed as separate samples.  Unfortunately, no wt P. berghei DNA was 
available for use as a control in this experiment.  The TCTP and TgDHFR/TS probes 
were re-used from the first Southern blot experiment (as per the method described in 
2.9.4.5).  Hybridisation was performed at 68°C.  As previously observed (Figure 5.9), 
bands corresponding to the well position on the original agarose gel were present on the 
membrane when reacted with the substrate, due to the presence of undigested parasite 
DNA.  The presence of these bands allowed the distance from the wells of other bands to 
be calculated.  
   
As shown in Figure 5.12 (b), a single band at about 3.7 cm from the wells, 
corresponding to a size of ~3.5 kb, was detected in the DNA from both mice using the 
TCTP probe.  In comparison, a single band at ~1.8 cm from the wells was detected using 
the TgDHFR/TS probe in both samples (Figure 5.12 (c)).  By comparison with Figure 
5.12 (a), the largest band (11.5 kb) in the λ/PstI marker migrated to just over 2 cm from 
the wells.  This combination of results indicated that two events had occurred: 1 - TCTP 
was present as a non-disrupted wt gene in the majority of parasites present after the 
second round of drug selection, and 2 - the TgDHFR/TS gene was present in the drug-
selected parasites, but in an incorrect location that was not digested to less than 11.5 kb 
using NdeI.   
 
The TgDHFR/TS probe should react with an identical band as the TCTP probe in 
parasites with the target DNA correctly integrated.  The result obtained indicated that 
secondary drug treatment had selected for parasites containing non-disrupted wild-type 
TCTP together with the TgDHFR/TS gene in an incorrect genomic location. 
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Figure 5.12: Genetic analysis by Southern blot of transfected parasites following secondary drug selection 
(a) Transfected parasite DNA digested with NdeI from mouse 2.1 (infected with original transfected parasite stabilate) and mouse 
2.2 (infected with passaged non-drug treated stabilate).  Lane 1: Mouse 2.2 DNA; Lane 2: Mouse 2.1 DNA; Lane 3: λ/PstI marker 
(b) Southern blot using TCTP probe: Lane 1: mouse 2.1 DNA; Lane 2: mouse 2.2 DNA. 
(c) Southern blot using TgDHFR/TS probe: Lane 1: mouse 2.1 DNA; Lane 2: mouse 2.2 DNA. 
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5.3.3.5.4 Southern blot using HindIII-digested DNA 
To further analyse the genotype of the transfected parasites, DNA from parasites 
prior to and following secondary drug selection was digested with HindIII.  When reacted 
with the TCTP probe, this should result in the detection of a 5 kb band in TCTP-knockout 
parasites, and a 1 kb band in wild-type parasites.  A faint 5 kb band was detected in the 
parasites prior to secondary drug selection, whereas no distinct bands were observed in 
the parasite DNA following secondary drug selection when probed with either TCTP or 
TgDHFR/TS (results not shown). 
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5.3.3.6 Repeat of secondary drug selection of parasites from the first 
transfection experiment 
The secondary drug selection was repeated on the original parasites obtained 
from the first transfection experiment, to assess if parasites with the desired, TCTP-
disrupted genotype would again be selected against.  
 
5.3.3.6.1 Growth of parasites during drug selection 
Three mice were infected with various transfected parasite stabilates, in an 
identical regimen as was shown in the tree diagram in Figure 5.10.  Mouse 3.1 received 
an i.p. injection of the last of the original transfection stabilate (from WEHI).  Mouse 3.2 
and 3.3 received stabilates from the passage of the original stabilate (from mouse 1.1 
and 1.2), in which mice were not drug-treated and the majority of parasites contained the 
desired integration event.  The mice received 100 µl of stabilate by i.p. injection and were 
treated continuously with pyrimethamine, starting at 28 hours post-injection.  The 
pyrimethamine water was replaced at five, seven and 15 dpi.  Mouse 3.2 and 3.3 
reached a parasitemia of 3-4% at 9 dpi.  Mouse 3.1 reached a parasitemia of 4% at 16 
dpi; this was most likely due to the lower dose of stabilate received.  Mice were sacrificed 
and blood was taken for stabilate creation and malarial DNA extraction.   
 
5.3.3.6.2 Genetic analysis of drug-selected parasites by Southern blot 
A total of 10 µg of DNA from each of the three mice was digested with NdeI as 
previously described.  Again, no wt P. berghei ANKA control DNA was available.  The 
DNA was separated on a 1% agarose gel (Figure 5.14 (a)).  In this experiment, the 
membrane was placed on the gel such that the top of the membrane corresponded to the 
well position on the agarose gel.  The DNA was transferred to a membrane and reacted 
with the TCTP probe; then the membrane was stripped and reacted with the TgDHFR/TS 
probe.  When probed with TCTP, a single band, corresponding to wt TCTP, was detected 
at approximately 3.7 cm (~3.5 kb) in all of the DNA samples.  When probed with 
TgDHFR/TS, a single band was detected at ~1.8 cm from the wells, corresponding to a 
size of >11.5 kb.  The results are shown in Figure 5.14 (b) and (c).  This is an identical 
result to that obtained in the parasites from the initial secondary drug-selection (section 
5.3.3.5.3), and gave further indication that parasites containing non-disrupted wild-type 
TCTP together with the TgDHFR/TS gene integrated in an incorrect location were 
selected for during the secondary drug treatment.  
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Figure 5.14: Southern blot on repeated secondary drug-selection of transfected parasites 
(a) Separation of NdeI-digested DNA by agarose gel electrophoresis: Lane 1: λ/PstI marker; Lane 2: Mouse 3.3 parasite DNA (passage 
of non-drug treated parasites from mouse 1.2); Lane 3: Mouse 3.2 parasite DNA (passage of non-drug treated parasites from mouse 1.1); 
Lane 4: Mouse 3.1 parasite DNA (infected with original transfection stabilate) 
(b) Southern blot using TCTP probe, and (c): Southern blot using TgDHFR/TS probe: Lane 1: mouse 3.1 parasite DNA; Lane 2: 
mouse 3.2 parasite DNA; Lane 3: Mouse 3.3 parasite DNA. 
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5.3.4 Second transfection experiment 
5.3.4.1 Design of the long target b3D.Lf1.Lf2 construct 
The overall result obtained from the first transfection experiment was that initially, 
the TCTP gene was disrupted with the TgDHFR/TS gene in the majority of parasites, 
however further drug selection resulted in the majority of parasites containing wt TCTP 
together with the TgDHFR/TS gene integrated in another location.  Due to this, another 
targeting construct was designed, with longer stretches of DNA for homologous 
recombination, in the hope that this longer target might result in more stable integration. 
 
The first integration construct (referred to as the short integration construct or 
b3D.int1.int2) used homologous sequences of ~340 bp, which is at the lower limit of 
fragments that have resulted in successful integration. It has been observed that longer 
stretches of homology result in higher transformation efficiencies, however an upper size 
limit of ~1 kb has been recommended for integration fragments, due to the known 
instability of vectors containing large stretches of A/T rich Plasmodium DNA (Menard and 
Janse, 1997). 
 
The second integration construct was referred to as the long integration construct, 
or b3D.Lf1.Lf2.  The first integration fragment (Lf1) was 906 bp in size, and corresponded 
to a region from -878 bp upstream to position 9 of the TCTP coding sequence.  The 
second integration fragment (Lf2) was 759 bp in size, and corresponded to a region from 
+19 to +761 downstream of the TCTP stop codon.  This long target DNA was designed 
such that almost the entire TCTP coding sequence, except for the first nine bases, would 
be replaced by the DHFR/TS gene in successfully transfected parasites.  The steps 
involved in creating the b3D.Lf1.Lf2 were essentially identical to the steps involved in 
creating the b3D.int1.int2 vector, as represented in Figure 5.2.  A schematic 
representation of the disruption of the TCTP region of the P. berghei ANKA chromosome 
by homologous recombination of the Lf1.Lf2 target DNA is given in Figure 5.15 (a).  A 
schematic representation of the P. berghei ANKA TCTP region following disruption with 
the Lf1.Lf2 target is given in Figure 5.15 (b). 
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(a) 
 
 
 
 
(b) 
 
 
 
 
 
 
Figure 5.15: Disruption of TCTP on the P. berghei ANKA genome with the Lf1.Lf2 
target DNA 
(a) Schematic diagram of recombination via double cross-over between Lf1 and 
Lf2 on the linearised Lf1.Lf2 target DNA and the homologous regions on the P. 
berghei ANKA chromosome following transfection, the box represents TCTP 
coding sequence 
(b) Schematic diagram of the TCTP region of the P. berghei chromosome following 
homologous recombination in a successful transfection experiment with the 
Lf1.Lf2 target DNA 
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5.3.4.1.1 PCR amplification of the long integration fragments and cloning 
into pCR2.1 vectors  
The sequences of the primers used to amplify the long integration fragments were 
designed based on the sequence of the P. berghei contig containing the TCTP gene.  
The first long fragment primers (Lf1for and Lf1rev) were designed to incorporate ApaI 
and KpnI restriction enzyme sites (as underlined), to allow for directional cloning into the 
first MCS of the b3D vector.  The second long fragment primers (Lf2for and Lf2rev) were 
designed to incorporate BamHI and XbaI restriction enzyme sites (as underlined), to 
allow for directional cloning into the second MCS of b3D.  The sequence of the four 
primers was: 
Lf1for: GCGGTACCTATACTTTGAAGTGTCCAAGAT 
Lf1rev: GCGGGCCCATACTTTCATTTTGGCTTATGC 
Lf2for: GCGGATCCTATACGATGGACGTGTTATTAC 
Lf2rev: GCTCTAGACGACAATGTTTTGGTCAAGTTT 
 
The Lf1 and Lf2 fragments were amplified using Taq polymerase, under standard 
conditions using ~25 ng of P. berghei ANKA genomic DNA.  Thirty amplification cycles 
were performed.  Lf1 was amplified using a 50°C annealing temperature; Lf2 was 
amplified at a 55°C annealing temperature.  A single product was amplified for each PCR 
at these annealing temperatures (Figure 5.16 (a)).  
 
The Lf1 and Lf2 integration fragments obtained by PCR amplification were cloned 
into pCR2.1 vectors.  Plasmid DNA from resulting white colonies was isolated using the 
Qiaprep Spin Miniprep kit, and restriction digests were performed to confirm insert size.  
Multiple bands, most likely due to star activity of the restriction enzymes, were observed 
when pCR.Lf1 plasmids were digested with both ApaI and KpnI (results not shown).  To 
avoid this, the plasmid preps were digested sequentially with 20 U of ApaI and then KpnI 
in the appropriate buffer, with the reactions cleaned using the Qiaprep Spin Miniprep kit 
in between the first and second digest.  Potential pCR.Lf2 plasmid preps were digested 
with BamHI and XbaI.  Analysis of digest reactions by electrophoresis indicated that the 
inserts had been successfully cloned into the pCR vectors (results not shown).  
Sequence analysis was performed on both inserts, and confirmed that the correct 
sequences had been ligated into the pCR2.1 vectors. 
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5.3.4.1.2 Cloning of the Lf1 and Lf2 products into the b3D vector 
 The pCR.Lf2 and b3D vectors were digested with 20 U each of BamHI and XbaI.  
DNA was separated by 1% agarose gel electrophoresis, correct-sized bands were 
excised with a scalpel and DNA was purified using the Qiaquick Gel Extraction kit as per 
manufacturer’s directions.  Standard ligations of prepared DNA were performed using 50 
ng vector and the appropriate amount of insert as calculated.  The completed ligation 
reaction was used to transform electro-competent E. coli.  Plasmid DNA from resulting 
colonies was isolated by minipreparation and was screened for the presence of the Lf2 
insert by digestion of 10 µl of DNA with 10 U each of BamHI and XbaI (Figure 5.16 (b)).  
Plasmid preparations with the correct-sized insert were named b3D.Lf2. 
 
To avoid star activity, pCR.Lf1 and b3D.Lf2 plasmids were digested with ApaI 
then KpnI sequentially, using 20 U of enzyme per reaction.  The DNA was cleaned 
between digest reactions using the Qiaprep Spin Miniprep kit.  The digested DNA was 
separated on a 1% w/v agarose gel, the bands were excised from the gel and DNA 
purified using the Qiaquick Gel Extraction kit.  Ligation reactions of digested pCR.Lf1 and 
b3D.Lf2 plasmid DNA were performed using 50 ng vector and the appropriate amount of 
insert.  Dextran-cleaned ligation product was used to transform electro-competent E. coli.  
Plasmid DNA from resulting colonies was isolated by minipreparation.  Plasmids were 
analysed for the presence of the Lf1 insert by sequential ApaI and KpnI enzyme 
digestion (Figure 5.16 (c)).  Plasmid preps with the correct-sized insert were named 
b3D.Lf1.Lf2. 
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Figure 5.16: Creation of the b3D.Lf1.Lf2 construct 
(a) PCR amplification of the Lf1 and LF2 integration fragments: Lane 1: λ/PstI 
marker; Lanes 2 & 3: Lf1; Lanes 4 & 5: Lf2 
(b) Confirmation of insertion of Lf2 fragment into the b3D vector by digestion with 
XbaI and BamHI: Lane 1: λ/PstI marker; Lanes 2-5:  b3D.Lf2 
(c) Confirmation of insertion of Lf1 into the b3D.Lf2 vector by digestion with ApaI 
and KpnI: Lane 1: λ/PstI marker; Lanes 2-4: b3D.Lf1.Lf2 
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5.3.4.2 Rationale for the second transfection experiment 
In the second transfection experiment, both the short integration target and the 
long integration target were used in separate transfections. The short integration target 
was included to see if unstable integration would again be observed.  
 
5.3.4.2.1 Preparation of short and long target DNA prior to transfection 
A final concentration of 10 µg of target DNA was required per transformation 
experiment.  The short target DNA was prepared by digestion of the b3D.int1.int2 vector 
as previously described in section 5.3.3.1.  Several preparations of the digested short 
target DNA prior to gel excision and purification are shown in Figure 5.17 (a); the purified 
short target DNA prior to transfection is shown in Figure 5.17 (c).  
 
The long target DNA was prepared by digestion of the b3D.Lf1.Lf2 plasmid with 
XbaI and BglI, followed by digestion with KpnI to avoid star activity.  As with preparation 
of the short integration target, BglI was used to cut within the plasmid backbone, to 
minimise the likelihood of parasite transfection with residual intact plasmid.   
 
Multiple aliquots containing 15 µg of the b3D.Lf1.Lf2 plasmid were digested with 
25 U each of XbaI and BglI for 16 h.  The completed digest reactions were each cleaned 
using the Qiaprep Spin Miniprep kit and digested for 5 h with 20 U of KpnI.  The digested 
DNA was separated on a 1% w/v agarose gel (Figure 5.17 (b)).  The resulting target 
DNA of 6,280 bp was excised from agarose gels and DNA was purified using the 
Qiaquick Gel Extraction kit.  The purified DNA preps were combined, precipitated using 
EtOH/NaOAc, and resuspended in a total volume of 10.5 µl in TE.  A small aliquot of 
several preparations of prepared long target DNA was quantified before transfections by 
gel electrophoresis of 0.5 µl of target DNA using known quantities of PstI-digested λ DNA 
for comparison.  Samples of the purified long target DNA prior to transfection are 
depicted in Figure 5.17 (c).  
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                                   (a)                            
                                    1       3      5      7      9      11    13    15  
                                   
 (b)                                                                
   1      3      5      7      9      11    13  14         
                                
                                   (c) 
                                    1     2    3    4     5    6     7     
                                    
Figure 5.17: Preparation of short and long integration target DNA prior to second 
transfection  
(a) Preparation of short target: Lane 1: λ/PstI marker; Lanes 3-15: Digestion of 
b3D.int1.int2 with ClaI, BamHI and BglI.  
(b) Preparation of long target: Lane 1: λ/PstI marker; Lanes 3-14: Digestion of 
b3D.Lf1.Lf2 with XbaI, KpnI and BglI.  
(c) Quantification of target DNA prior to transfection: Lane 1: 1 µg λ/PstI marker; 
Lanes 2-4: long target; Lanes 5-7: short target. 
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5.3.4.2.2 Parasite transfection using the short and long target DNA 
The prepared long target DNA was used in one transfection experiment, the 
prepared short target DNA was used in another transfection experiment.  The 
transfection experiments were performed at WEHI by Dr. Tania de Koning-Ward.  Each 
completed transfection mix was injected into the tail vein of one mouse.  Both mice were 
treated with pyrimethamine water, commencing at between 24 and 30 hours post-
infection, and parasitemia was monitored at regular intervals.  At 10 dpi, parasitemia was 
1% in the mouse that had received parasites from a short target transfection (designated 
mouse 4.1) and in the mouse that had received parasites from a long target transfection 
(designated mouse 4.2).  These mice reached a parasitemia of ~5% at 11 dpi, and were 
sacrificed for blood collection.  The blood was used for stabilate creation and for malarial 
DNA extraction.  
 
5.3.4.3 Analysis of parasites obtained from second transfection 
experiments 
5.3.4.3.1 Initial PCR analysis of transfected parasites  
A PCR using Taq polymerase was performed to analyse the presence of the 
DHFR gene in the parasites from the short and long target transfection experiments.  A 
product corresponding to the size of the DHFR gene was amplified in both the short and 
long target-transfected parasite DNA.  Faint bands were also amplified in wt P. berghei 
ANKA DNA, however none of these bands was at the correct size.  This result is shown 
in Figure 5.18 (a).       
 
The parasite DNA obtained from transfections using the short (int1.int2) target 
was analysed using the same primer sets used to assess integration in the first 
transfection experiment (5’PyTCTP+Pf1rev and Pf2for+3’PyTCTP).  Bands were 
observed for both the TCTP1 and TCTP2 integration PCRs in the transfected parasite 
DNA, but not in wt P. berghei.  However, a strong wt TCTP band was also amplified in 
the transfected parasite DNA and in the wt DNA (Figure 5.18 (b)).  This indicated that a 
mix of wild-type and TCTP-disrupted parasites might be present.  
 
A strong wild-type TCTP band was detected in parasites from mouse 4.1, which 
had received parasites transfected with long target DNA (results not shown).  This primer 
combination should not amplify a band in parasite DNA successfully transfected with the 
long target, as the primer binding sites should have been removed. 
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Figure 5.18: Initial genetic analysis of parasites from second transfection 
experiment by PCR 
(a) Presence of TgDHFR/TS gene in transfected parasites: Lane 1: λ/PstI marker; 
Lanes 2-4: TgDHFR/TS PCR: 2: wt P. berghei ANKA DNA; 3: parasite DNA from short 
target transfection (mouse 4.2); 4: parasite DNA from long target transfection (mouse 
4.1). 
(b) Presence of TCTP1 and TCTP2 products, as well as wt TCTP, in parasites from 
short transfection experiment: Lane 1: λ/PstI marker; Lanes 3-5: TCTP1 PCR: 3: neg 
control; 4: parasite DNA from short transfection; 5: wt DNA; Lanes 6-8: TCTP2 PCR: 6: 
neg control; 7: parasite DNA from short transfection; 8: wt DNA; Lanes 9-11: TCTP PCR: 
9: neg control; 10: parasite DNA from short transfection; 11: wt DNA. 
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5.3.4.3.2 Further PCR analysis of the short and long target-transfected 
parasites 
The primer sets used to assess integration in parasites transfected with the short 
target could not be used to assess integration in parasites transfected with the long 
target, as the binding sites for the 5’ and 3’PyTCTP primers would have been removed.   
 
Furthermore, it was realised that the primer sets previously used to assess 
integration in short target (5’PyTCTP+PF1rev and Pf2for+3’PyTCTP) could not 
distinguish between integration of the target at the right genome location or in other 
areas of the genome, as the 5’ and 3’PyTCTP primers did not bind outside the integration 
target region.  Also, if short target DNA was present as extrachromosomal episomes in 
the transfected parasites, these primer sets would give false positive results as all 
primers had binding sites present on the b3D.int1.int2 plasmid.   
 
To resolve this problem, new primer sets were designed.  Initially, the primer pair 
of Lf1for and Pf1rev was used to check for integration of the first fragment, and the 
primer pair of Pf2for and Lf2rev was used to check for integration of the second 
fragment.  These primer sets could be used to confirm correct integration in the parasites 
transfected with the short target, as the Lf1for and Lf2rev primers would bind outside the 
target sequence, but couldn’t be used to confirm integration in parasites transfected with 
the long target.  These primer sets should have produced bands of ~1.1 kb in parasites 
from successful transfection experiments using the short target DNA. The PCRs were 
repeated several times at different annealing temperatures, no products were amplified.  
It is unknown whether this result was due to unsuccessful transfections, or was a PCR 
artefact due to the formation of primer dimers, etc.  At a later stage, another set of 
primers was designed to detect integration; these PCRs are described in section 5.3.5.5.   
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5.3.4.4 Secondary drug-selection of parasites obtained from second 
transfection experiment 
The initial PCR analysis results gave some indication that the transfections had 
been successful, due to the presence of the TgDHFR/TS gene product in parasites 
transfected with both the short and the long target.  However, the presence of this gene 
in the correct location on the genome could not be determined by PCR, and further 
genetic analysis of parasites transfected with the short target indicated that wild-type 
TCTP was present.  For this reason, parasites underwent secondary drug selection.  The 
parasite stabilates from mouse 4.1 (infected with parasites from short target transfection) 
and mouse 4.2 (infected with parasites from long target transfection) were each used to 
infect three mice for secondary drug selection (mouse 5.1-5.6).  After drug selection, the 
parasite DNA obtained from the three mice was pooled, such that there was one sample 
of secondary drug-treated parasites from the initial short target (mouse 5.1-5.3) and long 
target (mouse 5.4-5.6) transfection experiments.  Mice received an i.p. injection of 75 µl 
of stabilate, and were treated with pyrimethamine provided in the drinking water from 26 
hours post-infection.  Parasitemia was around 2.5% in mice at 5 dpi, after this time 
parasite levels slightly decreased.  Mice were sacrificed and blood was taken at 7 dpi, 
with parasitemia between 1 and 2%.  Blood was used for stabilate creation and malarial 
DNA extraction. 
  
5.3.4.5 Genetic analysis of initial and secondary drug-selected 
parasites from the second transfection experiment by Southern blot 
5.3.4.5.1 Preparation of the long TCTP probe 
Various primer combinations that would amplify a ‘long TCTP’ probe, containing 
the flanking regions of TCTP, were evaluated.  This probe should bind to the TCTP 
flanking regions present in both wild-type parasites and in parasites transfected with the 
short or long target.  Of the primer sets evaluated, the combination of First for (described 
in 5.3.2.2) and Lf2rev (described in 5.3.4.1.1) produced a strong band at the expected 
size of ~1,300 bp from wt P. berghei ANKA DNA, as well as several other faint non-
specific bands.  Entire PCR reactions were split in two and separated on adjacent lanes 
of a 1% agarose gel, to obtain sufficient DNA (Figure 5.19).  The PCR products were 
excised from the gel and purified prior to hexanucleotide labelling.   
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                     1                  5  6       8   9       11 12      14 15 
                    
Figure 5.19: Separation of whole PCR reactions used to amplify long TCTP probe   
Lane 1: λ/PstI marker; Lanes 5, 6, 8, 9, 11, 12, 14,15: PCR products used to create the 
long TCTP probe. 
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5.3.4.5.2 Southern blot 
A Southern blot was performed using DNA both from the initial parasites obtained 
from the second transfection experiments (from mouse 4.1 and 4.2), and from the 
combined DNA of parasites following secondary drug selection (from mouse 5.1-5.3 and 
5.4-5.6).  Preparations of 10 µg of genomic DNA were digested with NdeI.  The digested 
DNA was separated by 1% agarose gel electrophoresis (Figure 5.20 (a)).  The DNA was 
transferred to a nylon membrane and probed with the long TCTP probe.  In NdeI-
digested DNA from successfully transfected parasites, the long TCTP and DHFR probes 
should detect a band of 7,988 bp in parasites transfected with short target, a band of 
7,643 bp in parasites transfected with the long target, and a 3.5 kb band in parasites 
containing wild-type TCTP.  The size of the bands detected in the Southern blot was 
calculated by placing a ruler next to the wells on the stained agarose gel and next to the 
well mark on the Southern blot.  The wells were visible on the Southern blot due to the 
presence of undigested parasite DNA.  
 
A strong background was observed in blots probed with the long TCTP probe 
(Figure 5.20 (b)).  A band at ~3.6 cm from the wells, corresponding to a size of ~3.5 kb, 
was detected in the wt P. berghei ANKA sample (Lane 1).  This band was detected 
faintly in parasites from both transfection experiments following secondary drug selection 
(from mouse 5.1-5.3 and 5.4-5.6) (Lanes 3 and 5).  The parasite DNA obtained from the 
initial short and long target transfection experiments (mouse 4.1 and 4.2) gave a slightly 
different binding pattern to either wild-type or secondary drug selected-parasites.  A 
strong band at ~3.7 cm from the wells, corresponding to a size of ~ 3.2 kb, was detected 
(Lanes 2 & 4).  It is probable that these bands also correspond to wild-type TCTP, and 
the size difference is due to the different migration of the digested genomic DNA.  The 
DNA corresponding to lanes 2 and 4 on the Southern blot appears to have migrated 
more rapidly on the agarose gel (Figure 5.20 (a), lanes 3 and 5).  
 
The membrane was stripped and reprobed with the DHFR probe (Figure 5.20 
(c)).  Only two DNA samples produced distinct bands.  One of these samples was from 
the initial parasites transfected with the long target, prior to secondary drug selection 
(from mouse 4.2).  In this sample, a band was detected at ~3.3 cm from the wells, with a 
size of 4.7 kb.  Indistinct bands above 11.5 kb were also detected (Lane 4).  An indistinct 
band at >11.5 kb was also detected in parasites transfected with the short target prior to 
secondary drug selection (from mouse 4.1) (Lane 2).  
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Figure 5.20: Southern blot of parasite DNA from second transfection experiment   
(a) Separation of NdeI-digested parasite DNA: Lane 1: λ/PstI marker; Lane 3: wt P. berghei DNA; Lane 4: initial parasite DNA from short 
target transfection (mouse 4.1); Lane 5: parasite DNA from short target transfection following secondary drug selection (mouse 5.1-5.3); 
Lane 7: initial parasite DNA from long target transfection (mouse 4.2); Lane 8: parasite DNA from long target transfection following 
secondary drug selection (mouse 5.4-5.6). 
(b) Southern blot using long TCTP probe, and (c) Southern blot using TgDHFR/TS probe: Lane 1: wt P. berghei DNA; Lane 2: initial 
parasite DNA from short target transfection; Lane 3: parasite DNA from short target transfection following secondary drug selection; Lane 4: 
initial parasite DNA from long target transfection; Lane 5: parasite DNA from long target transfection following secondary drug selection. 
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5.3.5 Third transfection experiment 
5.3.5.1 Rationale for final transfection experiment 
A final transfection experiment was performed, using long target DNA (from 
b3D.Lf1.Lf2).  As well as the initial drug selection following transfection, the secondary 
drug selection was also performed at WEHI, as it was thought that the unexpected 
results obtained following secondary drug selection in the previous transfection 
experiments may have been due to differences in the drug selection procedure or in the 
mice used between WEHI and RMIT.  
 
5.3.5.2 Preparation of long target DNA prior to transfection 
The long target DNA was prepared by digestion of the b3D.Lf1.Lf2 plasmid by 
XbaI and BglI, followed by purification of the DNA and subsequent digestion with KpnI.  
Representative samples of the digested target DNA prior to purification are shown in 
Figure 5.21 (a), samples of long target DNA after purification are shown in Figure 5.21 
(b).  Two final samples of 10 µg long target DNA were prepared. 
 
5.3.5.3 Transfection of parasites with long target DNA 
The purified long target DNA was used in two separate transfection experiments.  
Transfection experiments were performed at WEHI by Dr. Tania de Koning-Ward as 
previously described, and each transfection experiment was used to infect one mouse 
(mouse 6.1 and 6.2).  At a parasitemia of ~5%, mice were sacrificed and blood was taken 
for malarial DNA extraction.  An alternate DNA extraction method was evaluated.  In this 
method leukocytes were removed by passing blood over a CF11 column, erythrocytes 
were lysed with saponin and the parasites were lysed with SDS (as per the method 
described in 2.9.2.4.2).  Two malarial DNA preparations were performed on the blood of 
each of the two mice.  
 
5.3.5.4 Initial genetic analysis of parasite DNA 
PCRs were performed using the 5’ and 3’PyTCTP primers.  A wild-type TCTP 
band was amplified in all transfected parasite DNA preparations, as well as in wild-type 
P. berghei ANKA DNA.  This result is shown in Figure 5.22. 
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(a)                                                            (b)   
  1        3       5   6       8   9                                                     1     2     3     4            6     7   
                                              
Figure 5.21: Preparation of long target DNA prior to third transfection experiment 
(a): Digestion of b3D.Lf1.Lf2 with XbaI, KpnI and BglI: Lanes 1, 3, 5, 6, 8, 9: 
b3D.Lf1.Lf2 digests  
(b) Samples of purified long target DNA prior to third transfection: Lane 1: 1 µg 
λ/PstI marker; Lane 2-4: long target samples from three separate preparations; Lane 6 & 
7: 0.5 µg λ DNA. 
 
                                                 1    2    3    4   5    6    7 
                                               
Figure 5.22: TCTP PCR analysis of parasite DNA from 3rd transfection experiment 
Lane 1: neg control; Lanes 2 & 3: DNA obtained from mouse 6.1; Lanes 4 & 5: obtained 
from mouse 6.2; Lane 6: wt P. berghei ANKA DNA; Lane 7: λ/PstI marker. 
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5.3.5.5 Further genetic analysis of parasite DNA obtained from the 1st, 2nd 
and 3rd transfection experiments 
As previously discussed (section 5.3.4.3.2), the PCRs previously used to assess 
integration in short target transfections could not distinguish between correct integration 
and integration of the target DNA elsewhere on the genome, or the presence of the 
target DNA as episomes.  Also, previous attempts to analyse integration in parasites 
transfected with the long target did not result in PCR products, but it was not known 
whether this was due to a PCR artefact.  Due to this, another set of primers was 
designed to assess correct integration of the short and long target DNA.  The Intf1f 
primer (CGTGGGCGTAGCATATATTTTG) was designed to bind upstream of the Lf1 
integration fragment in the P. berghei genome, so it could be used together with the 
Pf1rev primer to assess for correct integration of the first homologous region in both the 
short and long target DNA.  The Intf2r primer (TTTTTACCCTTAATACAATAGT) was 
designed to bind downstream of the Lf2 integration fragment in the P. berghei genome, 
so it could be used together with the Pf2for primer to assess for correct integration of the 
second homologous region in both the short and long target DNA.  The Pf1rev and Pf2for 
primers bind within the TgDHFR/TS UTRs, and therefore should not bind to wild-type 
parasite DNA.  PCRs were performed on DNA obtained from each of the three knockout 
experiments. 
 
The Intf1f+Pf1rev primer combination should have resulted in 1.6 kb and 1.4 kb 
products in parasites successfully transfected with the short and long target DNA, 
respectively.  These potential products were designated longTCTP1.  The Pf2for+Intf2r 
primer combination should result in 1.15 kb and 0.97 kb products in parasites 
successfully transfected with the short and long target DNA, respectively.  These 
potential products were designated longTCTP2.  The smaller size of products in 
parasites transfected with the long target DNA is due to the deletion of more of the TCTP 
coding sequence.  
 
The Intf1f and Intf2r primers were used to assess correct integration in parasite 
DNA from the first, second and third transfection experiments.  PCR experiments were 
performed using Taq polymerase, and the Int1f+Pf1rev or Pf2for+Int2r primer sets.  The 
longTCTP2 PCR product was amplified from parasite DNA obtained from the first 
transfection experiment, both in the initial non drug-treated parasites (from mouse 1.1 
and 1.2) and in the parasites subjected to secondary drug selection (from mouse 2.1 and 
2.2) (Figure 5.23, lanes 2-5).  The longTCTP2 product was also amplified from both 
parasite preparations obtained in the third transfection experiment (from mouse 6.1 and 
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6.2) (Figure 5.23, lanes 6-9). No products were obtained from the wt P. berghei DNA or 
from parasites obtained in the second transfection experiment (results not shown).    
 
Several attempts were made to amplify the longTCTP1 products, using annealing 
temperatures as low as 45°C.  No products were obtained.  This was somewhat 
unexpected, as in the earlier genetic analyses the TCTP1 product was amplified from 
parasites extracted from mouse 1.1, 1.2 and 2.2, whereas the TCTP2 product was not.  
As the longTCTP2 fragment was amplified in these parasites, the TCTP2 product should 
also have been amplified in the earlier PCRs.  This combination of results suggests that 
a negative PCR result could not be taken as confirmation of an unsuccessful transfection 
reaction.  The longTCTP2 products obtained indicated that, in the first and third 
transfection experiments, the target DNA had integrated in the correct location by at least 
a single crossover event.  Due to this somewhat positive result, parasites obtained from 
the third transfection experiment were used to infect mice at WEHI for secondary drug 
selection.  
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Figure 5.23: Analysis of target DNA integration in parasites from the 1st and 3rd 
transfection experiments 
Lane 1: λ/PstI marker; Lanes 2, 4, 6, 8: Long TCTP1 PCR; Lanes 3, 5, 7, 9: 
LongTCTP2 PCR: (2 & 3) non-drug selected parasites from 1st transfection experiment 
(combined DNA from mouse 1.1 and 1.2); (4 & 5) parasites from 1st transfection after 
secondary drug selection (combined DNA from mouse 2.1 and 2.2); (6 & 7) parasites 
from 3rd transfection experiment extracted from mouse 6.1; (8 & 9) parasites from 3rd 
transfection experiment extracted from mouse 6.2.  
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5.3.5.6 Secondary drug selection of parasites from 3rd transfection 
experiment 
5.3.5.6.1 Secondary drug selection of parasites from mouse 6.1 and 6.2 
The two parasite stabilates obtained from the third transfection experiment (two 
separate transfections, both using the long target) were each injected into two mice for 
secondary drug selection (designated mouse 7.1 - 7.4).  The second round of drug 
selection was performed at WEHI.  At a parasitemia of ~5%, mice were sacrificed and 
blood was collected for stabilate creation and parasite DNA extraction. 
 
5.3.5.6.2 Genetic analysis of parasites from 3rd transfection experiment after 
secondary drug selection 
PCRs were performed on the malarial DNA obtained from each of the four mice 
following secondary drug selection.  The Intf1f + Pf1rev and Pf2for + Intf2r primer 
combinations were used to assess for correct integration of the Lf1 and Lf2 fragments in 
the P. berghei genome.  An annealing temperature of 50°C was used.  As observed in 
the parasites from the first round of drug selection, only longTCTP2 products (0.97 kb) in 
were obtained in all of the transfected parasite samples.  No integration products were 
amplified in wt P. berghei ANKA DNA.  These results are shown in Figure 5.24 (a).  A 
strong wt TCTP band of 516 bp was also amplified in all of the transfected parasite 
samples, as well as in wt P. berghei DNA.  This result is shown in Figure 5.24 (b). 
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Figure 5.24: Genetic analysis of parasites from 3rd transfection experiment 
following secondary drug selection 
(a) Analysis of long target integration by PCR: Lane 1: λ/PstI marker; Lanes 2, 4, 6, 
8, 10, 12: longTCTP1 PCR using Intf1f and Pf1rev primers; Lanes 3, 5, 7, 9, 11, 13: 
longTCTP2 PCR using Pf2for and Intf2r primers: (2 & 3): neg control; (4 & 5): wt P. 
berghei DNA; (6 & 7): secondary drug-selected parasites from mouse 7.1; (8 & 9): 
secondary drug-selected parasites from mouse 7.2; (10 & 11): secondary drug-selected 
parasites from mouse 7.3; (12 & 13): secondary drug-selected parasites from mouse 7.4. 
(b) Analysis of presence of wild-type TCTP by PCR: Lane 1: λ/PstI marker; Lane 2: 
neg control; Lane 3: wt P. berghei DNA; Lanes 4-7: parasite DNA from mouse 7.1, 7.2, 
7.3 and 7.4, respectively.  
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5.3.5.7 Genetic analysis of parasites from 3rd transfection experiment 
by Southern blot 
The PCR results were identical for the initial and secondary drug-selected 
parasites obtained from the third transfection experiment.  In all of these parasite 
preparations, a strong wt TCTP product was amplified, as well as a longTCTP2 product.  
This indicated that a mix of parasite genotypes were present in the preparations.  To gain 
a better understanding of the relative proportion of wild-type and TCTP-disrupted 
parasites present, a Southern blot was performed.  
 
5.3.5.7.1 Preparation of Lf2 and TgDHFR/TS probes 
The Lf2 and TgDHFR/TS probes were prepared by digestion of the b3D.Lf1.Lf2 
plasmid, rather than by PCR.  The Lf2 probe was prepared by digestion of b3D with 
BamHI and XbaI, and the TgDHFR/TS probe by digestion with ApaI and BamHI.  The 
completed digest reactions are shown in Figure 5.25 (a).  The bands of the correct size 
for the probes were excised from the gel and purified.  A sample of the purified probes 
was separated by agarose gel electrophoresis for DNA quantitation prior to 
hexanucleotide labelling.  The purified probes are shown in Figure 5.25 (b).  
 
5.3.5.7.2 Preparation of λ/NdeI marker 
A λ/NdeI marker was prepared, to allow for better determination of bands 
detected by Southern blot.  A total of 10 µg of λ DNA was digested with 10 U NdeI for 16 
h, 2 µg was loaded per gel lane.  Theoretically, the fragment sizes obtained would be: 
27,633, 8,371, 3,801, 2,433, 2,253, 1,689, 1,174, and 556 bp.  This marker would allow 
for differentiation between target DNA integration in the genome (a band of 7.6 kb) and 
the presence of intact b3D.Lf1.Lf2 plasmid as episomes.  The intact b3D.Lf1.Lf2 plasmid 
would be 9.16 kb in size, and contains a single NdeI site. 
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Figure 5.25: Preparation of Lf2 and DHFR probes 
(a) Digestion of b3D.Lf1.Lf2 plasmids for Lf2 probe and TgDHFR/TS probe.  Lane 1: 
λ/PstI marker; Lanes 3 & 4, 6 & 7: b3D.Lf1.Lf2 digested with BamHI and XbaI for Lf2 
probe; Lanes 9 & 10, 12 & 13: b3D.Lf1.Lf2 digested with ApaI and BamHI for 
TgDHFR/TS probe. 
(b) Purified Lf2 and TgDHFR/TS probes. Lane 1: λ/PstI marker; Lane 2: Lf2 probe; 
Lane 3: TgDHFR/TS probe. 
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5.3.5.7.3 Southern blot of parasite DNA from 3rd transfection experiment 
Seven DNA samples were analysed: wt P. berghei ANKA, each of the initial 
transfected parasite preparations (obtained from mouse 6.1 and 6.2) and the parasites 
following secondary drug selection (obtained from mouse 7.1, 7.2, 7.3 and 7.4).  
Approximately 10 µg of genomic DNA from each of the samples was digested with 30 U 
of NdeI, and separated on a 1% agarose gel at 70 V (Figure 5.26 (a)).  
 
The DNA was transferred to a nylon membrane, and hybridised with the Lf2 
probe, which should detect a 3.5 kb band in wt DNA, and a 7.6 kb band in parasites 
successfully transfected with the long target.  The probe binding reaction was detected 
using the chemiluminescent CSPD substrate, for enhanced sensitivity.  Hybridisation was 
performed at a hybridisation temperature of 63°C. The reaction was detected by 
autoradiography using X-ray film, as depicted in Figure 5.26 (b), and also by 
chemiluminescent detection using the GeneSnap machine, as shown in Figure 5.26 (c).  
The membrane was placed such that the top edge was flush with the wells on the gel, so 
a ruler starting from the top of the membrane could be used to compare band distances 
with those of the markers on the agarose gel. 
 
Several incubation times of X-ray film were tested, from 10 to 20 minutes.  The 
banding pattern was similar for all incubation times.  To clarify the sizes of the bands 
obtained, the blot was visualised using a GeneSnap™ imaging machine capable of 
chemiluminescent detection (Figure 5.26 (c)).  A ruler could not be used in this detection 
method.  The same banding pattern was observed for each of the samples as on the X-
ray film. 
 
Two bands were detected in the wt DNA sample (Figure 5.26 (b) and (c), Lane 
1).  A major band was observed at ~3.5 cm from the wells, corresponding to a size of 
~3.8 kb.  Another band was detected at approximately 1.9 cm from the wells, 
corresponding to a size of greater than 11.5 kb, which was most likely due to the 
presence of residual undigested parasite DNA.  
 
In all transfected parasite samples, multiple bands were present (Figure 5.26 (b) 
and (c), lanes 2-7).  A band was present at 3.5 to 3.7 cm from the wells, at around ~3.8 
kb.  This corresponded to wild-type TCTP.  The minor differences in size of this low band 
were most likely due to differences in migration of the digested genomic DNA through the 
agarose gel, as previously observed.   
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Several higher molecular-weight bands were detected in each of the transfected 
parasite samples.  In successful transfection experiments, a single band of 7.6 kb, 
corresponding to a distance of ~ 2.5 cm from the wells was expected.  Instead, a major 
band at ~2.8 cm from the wells, corresponding to a size of ~ 6kb, was present in all 
samples, as well as several other bands above this size.  In the parasites obtained 
initially from the transfection experiment (from mouse 6.1 and 6.2), and in the secondary 
drug-selected parasites from mouse 7.3 and 7.4, the 6 kb band was the most prominent 
band present (Figure 5.26 (b) and (c), Lanes 2, 3, 6, 7).  
 
In the parasite DNA obtained from mouse 7.2, the major band present was at 
~2.5 cm from the wells, corresponding to a size of ~ 8 kb.  This was also the major band 
detected in the parasites from mouse 7.1 (Figure 5.26 (b) and (c), Lanes 4 & 5).  It is 
possible that this major band represents successfully transformed parasites.  A band at 
around this size was also present, at a much lower proportion, in the other transfected 
parasite preparations.  As this band was detected at a far greater proportion in the 
secondary drug-selected parasites from mouse 7.2 than in the parental parasites from 
the initial transfection (from mouse 6.1, Lane 2) it is possible that in this case, the 
secondary drug treatment was selecting for the correctly transformed parasites.  
However, it is clear that a number of other parasite genotypes were still present, 
including a proportion of parasites that contained wild-type, non-disrupted TCTP.  
 
It is possible, but unlikely, that the lower hybridisation temperature used with the Lf2 
probe (63°C) compared with the TCTP and TgDHFR/TS probes used previously (65 - 
68°C) contributed to the detection of multiple bands.  However, hybridisation of this probe 
to the wild-type P. berghei ANKA sample produced the expected banding pattern. 
 
In the transfected parasite samples a bright band was observed on the stained 
agarose gel, corresponding to a size of ~2.4 kb.  It was thought that this might be a 
plasmid, but no DNA of that size should have been produced with any of the restriction 
enzymes used.  This band was not detected with the Lf2 probe.  It is assumed that if this 
band is a contaminating plasmid, it is too small to confer drug resistance, as the 
TgDHFR/TS gene with the 5’UTR is around 4 kb.  It is possible that this band 
corresponds to a ribosomal RNA gene, transcripts of P. berghei rRNA genes at around 
2.7 kb have been identified (Waters et al., 1997b).  
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Figure 5.26: Southern blot of parasite DNA obtained from 3rd transfection experiment 
(a) Separation of NdeI-digested parasite DNA: Lane 1: λ/PstI marker; Lane 2: P. berghei ANKA DNA; Lane 3: initial parasite DNA from 
3rd transfection (from mouse 6.1); Lane 4: initial parasite DNA from 3rd transfection (from mouse 6.2); Lanes 5-8: parasite DNA after 
secondary drug selection (from mouse 7.1 to 7.4, respectively). Lane 9: λ/NdeI marker.  
(b) Detection of Lf2-hybridised DNA bands using X-ray radiography: Lane 1: P. berghei ANKA DNA; Lane 2: initial parasite DNA from 
3rd transfection (from mouse 6.1); Lane 3: initial parasite DNA from 3rd transfection (from mouse 6.2); Lanes 4-7: parasite DNA after 
secondary drug selection (from mouse 7.1 to 7.4, respectively) 
(c) Detection of Lf2-hybridised bands using chemiluminescence reader: Lane 1: P. berghei ANKA DNA; Lane 2: initial parasite DNA 
from 3rd transfection (from mouse 6.1); Lane 3: initial parasite DNA from 3rd transfection (from mouse 6.2); Lanes 4-7: parasite DNA after 
secondary drug selection (from mouse 7.1 to 7.4, respectively) 
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In an attempt to further characterise the genotype of the parasites obtained from 
the third transfection experiment, the membrane was stripped and re-probed using the 
TgDHFR/TS probe.  Unexpectedly, the initial Lf2 probe could not be stripped from the 
membrane. This was determined due to the fact that identical bands were obtained using 
the TgDHFR/TS probe as for the Lf2 probe, including in the wild-type P. berghei ANKA 
sample (results not shown).  It is possible that the nylon membrane dried sufficiently for 
the DIG-labelled Lf2 probe to become permanently attached.  Therefore, the possible 
correct integration of the target DNA in some of the parasite samples could not be 
confirmed, as the location of the TgDHFR/TS gene could not be identified. 
 
There was insufficient DNA remaining from the original parasite samples to 
perform another blot.  The parasite stabilates could have been used to infect new mice, 
however from previous observations this would have most likely resulted in further 
genomic rearrangements.   
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5.4 Discussion 
 Prior to the start of the transfection experiments, the genomic sequence of P. 
berghei ANKA was analysed to assess the feasibility of developing a TCTP knockout 
malaria strain.  The genome sequence of P. berghei ANKA is not yet assembled, 
however a contig sequence of ~11.5 kb containing the TCTP gene was available on the 
PlasmoDB database (www.plasmodb.org/plasmo).  A BLAST search using the TCTP 
coding sequence indicated that only a single gene copy was present in the genome.  The 
Southern blot results using wild-type P. berghei ANKA DNA also indicated that only a 
single copy of the TCTP gene was present.  By analysis of the TCTP flanking regions of 
the contig, the nearest identified genes were around 3 kb from the TCTP coding 
sequence.  Therefore it was feasible that TCTP could be knocked out without disruption 
of adjacent genes. 
 
The first transfection construct (b3D.int1.int2) was designed to include mainly 
TCTP coding sequence, due to the higher GC content.  The entire TCTP sequence could 
not be contained within the insertion fragments, as this could result in transfected 
parasites with wild-type TCTP if the TgDHFR/TS gene was excised from the genome.  
As TCTP is a small gene (516 bp), and the minimum fragment size that has previously 
resulted in successful integration in Amaxa transfections is ~300 bp (Janse et al., 2006b; 
Jongco et al., 2006), around 150 bp of the 5’ and 3’ TCTP UTRs were also included in 
the integration fragments.  In successful transfection experiments, this should lead to the 
permanent excision of the middle 141 bp of TCTP.  It was thought that this would be 
sufficient to result in non-active protein in the event of TgDHFR/TS gene excision from 
the genome following transfection.       
 
In the initial transfection experiment, parasites grew very slowly, with the recipient 
mouse only developing detectable parasitemia at 18 dpi.  It has been stated that wild-
type parasites can survive and slowly develop drug resistance during pyrimethamine 
treatment, and are typically observed at day 13-15 following unsuccessful transfection 
experiments (Dr Tania de Koning-Ward, pers. comm., 
http://www.lumc.nl/rep/cod/redirect/1040/research/malaria/malaria.html).  Due to this 
previous finding, it was assumed that the parasites obtained at 18 dpi were wild-type.  In 
order to obtain sufficient DNA for Southern blot analysis, two mice were injected with 
stabilate, drug treatment was not performed as this would have killed wild-type parasites.   
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However, genetic analysis indicated that the initial knockout experiment had been 
successful.  By PCR analysis, no wild-type TCTP was amplified, and the Southern blot 
results indicated that the majority of parasites present contained the TCTP gene 
disrupted with TgDHFR/TS. PCRs using primers that should only give products in 
transfected parasites gave mixed results.  The TCTP1 integration fragment was 
amplified, this involved primers that would bind to the start of the TCTP coding sequence 
and the 5’UTR of the TgDHFR/TS.  However, the TCTP2 fragment was never amplified, 
this involved primers that bound in the 3’UTR of the TgDHFR/TS and the end of the 
TCTP coding sequence.  It was thought that the target DNA might have integrated 
incorrectly in the second crossover region.   
 
It was later apparent that the primer combinations used to amplify TCTP1 and 
TCTP2 would not differentiate between correct integration and the presence of the target 
DNA in other areas of the genome, including as episomes.  To properly assess 
integration of the int1.int2 target in the parasite DNA from the first transfection, the Int1f 
and Int2r primers, which bound outside of homologous recombination regions, were used 
along with primers that bound in the TgDHFR/TS UTRs.  Only the longTCTP2 product 
was amplified, indicating that the target DNA had integrated correctly in this region.  The 
inability to amplify the longTCTP1 fragment could have been due to suboptimal PCR 
conditions, or could possibly have been due to incorrect integration such that the int1f 
primer binding site was not present in the correct location.   
 
Primers were designed using the CloneManager program (SECentral), which 
analyses potential primer stability and the possibility of primer dimer formation.  Despite 
this, it is possible that the inconclusive PCR results were due solely to PCR failure, or 
they could indicate that a more complex integration reaction had occurred, rather than 
straightforward homologous recombination.  Southern blot results were relied on for a 
more accurate determination of the parasite genotype following transfection. 
 
Due to the positive result obtained on the initial Southern blot, the parasites from 
the first transfection were used to infect three mice for further drug selection.  In two of 
the mice, the parasitemia increased to between 5-8% at 7-9 dpi.  In the third mouse, 
detectable parasitemia (~0.1%) was observed at 6 dpi, but the parasites then decreased 
and were not detectable from 11 dpi onwards.  Initial PCR analysis indicated that a 
mixture of parasite genotypes were present, in that products indicative of integration 
(TCTP1 and longTCTP2) were amplified, as well as wild-type TCTP.  This suggested that 
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TCTP-knockout parasites might be at a selective disadvantage, despite the 
pyrimethamine drug pressure.   
 
To further analyse the mixture of parasite genotypes present, Southern blots were 
performed.  The parasite DNA from each drug-treated mouse was analysed individually.  
The Southern result was identical for each mouse, and indicated that the majority of the 
parasites present following drug selection consisted of wild-type, uninterrupted TCTP, 
with the TgDHFR/TS gene present in another, incorrect genomic location.   
 
The secondary drug selection was repeated with three more mice.  The same 
Southern result was obtained, indicating that secondary drug treatment was selecting for 
parasites containing the TgDHFR/TS gene integrated in an incorrect location, with the 
wild-type TCTP gene also present.  The presence of the wild-type TCTP gene was most 
likely not due to reversion correctly transfected parasites leading to excision of the target 
DNA, as this should have resulted in a TCTP PCR product 141 base pairs shorter (375) 
than the wild-type TCTP gene (516 bp).  Instead, it is hypothesised that the secondary 
drug treatment strongly selected against parasites with the TCTP gene disrupted.  The 
genotype that was obtained following secondary drug treatment could have been the 
result of strong selection of a very small initial population of parasites containing 
incorrectly-integrated TgDHFR/TS, which were not detected by the initial TCTP PCRs.   
 
It was thought that transfection with a second construct containing longer 
integration fragments might result in higher transfection efficiencies and more stable 
integration, therefore the b3D.Lf1.Lf2 construct was created.  The two fragments 
designed for homologous recombination were between 750 and 900 bp in size, 
compared with the 340 bp fragments used in the first integration construct.  This 
construct was also designed such that almost the entire TCTP coding sequence 
(excluding the first 9 bp) would be removed from the genome in a successful transfection 
experiment.   
  
In the second transfection experiment, target DNA prepared from both the short 
(b3D.int1.int2) and long (b3D.Lf1.Lf2) constructs was used in two mice each.  In both 
transfections, parasites appeared more rapidly than in the first transfection experiment 
(~10 dpi compared with 18 dpi), but were still somewhat slow to appear compared to 
other published reports using the Amaxa nucleofector (3-7 days), (Janse et al., 2006b).   
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In the parasites transfected with the short target in the second knockout 
experiment, the TCTP1 and TCTP2 integration products, the TgDHFR/TS product, and a 
strong wild-type TCTP band were amplified.  These results indicated that either a mixture 
of parasite genotypes were present, or that the entire short target DNA had integrated in 
the wrong area of the genome.  The longTCTP1 and longTCTP2 products were not 
amplified, supporting the assumption that the short target DNA was either present as 
episomes or had integrated in an undesired area of the genome.  In parasites transfected 
with the long target, a wild-type TCTP band was amplified, as well as a TgDHFR/TS 
product.  The longTCTP1 and longTCTP2 products were not amplified.  
 
Secondary drug selection was performed on parasites from both the short and 
long target transfections.  The genotype of these parasites was analysed by Southern 
blot, as well as the genotypes of the parasites prior to secondary drug selection.  A band 
corresponding to wild-type TCTP was detected in all parasite preparations.  The 
TgDHFR/TS gene was only detected by Southern blot in the parasite preparations 
initially transfected with both the short and long target, and was in an incorrect genomic 
location.  In the parasites transfected using the short target DNA, the TgDHFR/TS probe 
detected a band at >11.5 kb.  In the parasites transfected using the long target DNA, the 
TgDHFR/TS probe detected a band at 4.7 kb.  Unexpectedly, the TgDHFR/TS probe did 
not detect a band in either the short- or long-target transfected parasites following 
secondary drug selection.  These parasites were pyrimethamine-resistant, as 
parasitemia had rapidly increased to ~3% at five days post-infection.  The reason for the 
lack of detection of a TgDHFR/TS gene in the secondary drug-selected parasites is 
unknown.  If pyrimethamine resistance was conferred by the presence of episomal 
b3D.int1.int2 or b3DLf1.Lf2, detection of a band corresponding to the size of the 
linearised construct would be expected, as both plasmids contain one NdeI site.   
 
A third transfection experiment was performed using long target DNA, in which 
both the initial and secondary drug selection was performed at WEHI.  In both the initial 
parasites obtained following transfection and in the parasites following secondary drug 
selection, wild-type TCTP and longTCTP2 products were amplified by PCR.  LongTCTP1 
products were never amplified.  This indicated that in a proportion of parasites, at least 
the second homologous fragment of the long target DNA had integrated in the correct 
location on the genome.  It was unknown whether the inability to amplify the LongTCTP1 
product might be due to a PCR artefact, and so Southern blots were relied on for more 
accurate genotying of the transfected parasites.   
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Southern blot analysis was performed, using a more sensitive method of 
detection (chemiluminescence) together with a new probe (Lf2) prepared by digestion of 
the b3DLf1.Lf2 plasmid rather than PCR.  Both X-ray film and a chemiluminescent 
imager were used to detect DNA bands reacted with the Lf2 probe. Multiple bands were 
detected in all parasite samples.  Two bands were detected in the wild-type P. berghei 
sample; one corresponding to wild-type TCTP, the other band was most likely undigested 
parasite DNA.  A band corresponding in size to wild-type TCTP was present in of the 
transfected parasite samples.  Additionally, multiple bands ranging in size from ~6 kb to 
over 11.5 kb were detected.  It is unlikely that these multiple bands were due to 
incomplete digestion of the parasite DNA, as bright smears had been present on the 
agarose gel for all samples, and the wild-type P. berghei sample had given the expected 
banding pattern.  Also, only faint bands corresponding to undigested parasite DNA were 
present.  As the Lf2 probe gave the expected banding pattern in wild-type parasites, it 
was clear that in all of the transfected parasites, a mixture of genotypes was present, and 
a proportion of parasites possessed a non-disrupted TCTP gene.  
 
A band possibly indicative of correct long target DNA integration was present at 
~7.6 kb in several of the transfected parasite samples.  This 7.6 kb band appeared to be 
selected for by repeated pyrimethamine treatment, as it was present in a higher 
proportion of secondary-drug selected parasites than in the parental parasites.  The Lf2 
probe could not be stripped from the membrane, so the presence of the TgDHFR/TS 
gene at this same location could not be assessed.  Insufficient parasite DNA remained to 
repeat the Southern blot using the TgDHFR/TS probe.  Obtaining more parasite DNA 
would have required further drug selection in mice, which would be likely to further alter 
the proportions of parasite genotypes present, based on the results of earlier 
experiments.  Multiple rounds of drug selection to obtain a single transfected genotype 
are not generally required, according to published reports. These transfection 
experiments were performed at a time when the Amaxa transfection protocols were still 
being developed for P. berghei ANKA, it has been since reported that no secondary drug 
selection is necessary for Amaxa transfections of malaria parasites, due to the high 
transfection efficiencies obtained (Janse et al., 2006b).   
 
In the majority of parasites obtained from the transfection experiments, the 
Southern blot results indicated that the target DNA used for transfection had integrated 
incorrectly in the genome.  Bioinformatics analysis had indicated that only a single copy 
of the TCTP gene was present in P. berghei ANKA, and that no additional highly similar 
sequences to any of the integration fragments were present.  However, as the P. berghei 
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genome has not been fully assembled, it is possible that other sequences highly similar 
to TCTP may exist, allowing for homologous recombination in undesired areas of the 
genome.  As the wild-type P. berghei DNA used in the Southern blots produced a single 
band when reacted with TCTP probes, this is not the most likely explanation for the 
results observed.   
 
Pyrimethamine-resistant non-targeted parasite clones may arise by replacement 
of the endogenous DHFR/TS with the mutant TgDHFR/TS, as the 5’ and 3’UTRs on the 
b3D plasmid are obtained from P. berghei DHFR/TS and may act as target sequences 
for homologous recombination (Menard and Janse, 1997).  Analysis of the contig 
containing P. berghei DHFR/TS indicated that digestion with NdeI would result in a band 
of over 5.5 kb, the exact size could not be determined as a second NdeI site was not 
present on the contig downstream of the DHFR/TS gene.  It is possible that the >11.5 kb 
bands sometimes observed on Southern blots probed with TgDHFR/TS could have been 
due to homologous recombination between the exogenous and endogenous DHFR/TS 
genes.  However, in a published report a drug-resistant mutant version of the P. berghei 
DHFR/TS gene together with UTRs was used as a selectable marker, and integration in 
the endogenous P. berghei DHFR/TS region did not occur (Menard and Janse, 1997). 
 
The confirmed correct integration of target DNA was observed to occur in the 
majority of parasites in the first transfection experiment, however these parasites were 
selected against during further passage and drug treatment.  One possible explanation is 
that TCTP contributes in some way to growth in the presence of pyrimethamine, such 
that parasites with the gene disrupted are selected against by repeated drug treatment.  
The facts supporting this hypothesis are that the occasion in which the majority of 
transfected parasites contained a disrupted TCTP gene was when secondary selection 
was performed in the absence of drug pressure.  When the identical parasite stabilate 
was subjected to secondary pyrimethamine treatment, parasites with the TgDHFR/TS 
gene integrated elsewhere in the genome were strongly selected for.  However, parasites 
with the TCTP gene disrupted were able to survive the initial round of pyrimethamine 
treatment following the transfection experiment.  The proportion of these parasites in the 
initial stabilate obtained is unknown, as direct genetic analysis was not performed.  
Although TCTP is known to interact with the antimalarial drug artemisinin (Bhisutthibhan 
and Meshnick, 2001; Meshnick, 2002), there is no published literature to support the 
involvement of TCTP in antifolate drug resistance, which has a separate mode of action.  
An alternate hypothesis is that parasites with the TCTP gene grew much more slowly 
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and were out-competed by other parasites containing the TgDHFR/TS gene, which were 
more strongly selected for when drug pressure was applied.    
 
Other methods to inhibit the expression of TCTP in malaria parasites, such as 
through the use of RNAi, could be attempted.  Such methods would abolish the need for 
long periods of drug selection, which appeared to lead to the selection of parasites with 
undesired integration events in the majority of these experiments. The PCR results from 
the first and third transfection experiments, together with the first Southern blot result, 
suggested that a proportion of the parasites contained the desired integration event. 
Therefore it cannot be concluded that TCTP is an essential gene in P. berghei malaria 
asexual life stages.  It is concluded that a stable TCTP knockout parasite could not be 
generated by the transfection methods described.  
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TCTP from several malarial species was successfully expressed in both S. 
cerevisiae yeast and in E. coli.  Initially, TCTP was expressed in yeast due to the 
protective effect observed when yeast-derived TCTP was used as a vaccine against P. 
yoelii YM (Taylor, 2002).  Also, in published reports yeast-derived TCTP had induced 
histamine release in vitro in purified allergic donor basophils (MacDonald et al., 2001).  
However, purification of TCTP from yeast was hampered by substantial amounts of 
protein breakdown and relatively low yields.  Alternative methods of expression and 
purification were trialled.  A yeast expression system in which protease activity was 
minimised, by the replacement of culture media prior to expression induction and by 
substantial reduction of the induction time, resulted in greater protein yields.  However, 
expression of TCTP in E. coli gave the best protein yields with minimal breakdown.  
Purification of TCTP from E. coli was also achieved more rapidly than from yeast, and 
protease inhibitors were not required. 
 
Yeast-derived and E. coli-derived TCTP were cross-reactive, as determined by 
western blot and ELISA.  A similar protective effect to malaria challenge was observed 
using E. coli-derived TCTP as in the first trial when yeast-derived TCTP was used 
(Taylor, 2002), indicating the proteins were immunologically similar.  Antibodies 
generated against both yeast-derived and E. coli-derived PyTCTP could react with 
malarial TCTP by western blot.  Antibodies generated against E. coli-derived TCTP 
reacted less strongly to the malarial protein, this could have been due to several factors 
including lower antibody titre or variations in malaria lysate preparation.  
 
Malarial and recombinant TCTP migrated more slowly on SDS-PAGE than 
expected from their theoretical mass.  This has previously been observed in TCTPs from 
other species, and is thought to be due to the calcium-binding activity of the protein (e.g. 
Arcuri et al., 2004; Bhisutthibhan et al., 1999; Sanchez et al., 1997).  In P. yoelii YM 
lysates, TCTP migrated at around 23 kDa, the theoretical mass of the protein is 19.8 kDa 
(http://ca.expasy.org/tools/pi_tool.html).  Recombinant TCTP migrated more slowly 
again, at around 28 kDa, due to the presence of the N-terminal hexa-his tag.   
 
In the yeast protein purification experiments, PfTCTP migrated faster than 
PyTCTP, and was present on SDS-PAGE at around 26 kDa.  The reasons for this are 
unknown, but could indicate differences in calcium-binding activities between the two 
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proteins, as they were cloned into the same vector and expressed using identical 
methods.  One possible area of future research would be to determine the calcium-
binding activities of TCTPs from different species.       
 
Self-interaction of rat TCTP has been reported (Yoon et al., 2000), and multimers 
of yeast-derived Pf and Py TCTP were observed when proteins were separated by SDS-
PAGE under non-reducing conditions, however the predominant band present was the 
monomeric form.  A possible future experiment would be to perform western blots on 
malarial lysates separated under reducing and non-reducing conditions, to establish the 
dominant form of TCTP present in the parasite.   
 
A mild protective effect against malaria challenge was generated by TCTP 
immunisation in two of the three trials.  The reasons for the lack of protection in the 
second vaccine trial (described in Chapter 3) are unknown.  Although the proteins used 
for immunisation contained a substantial amount of breakdown products, this is unlikely 
to be the reason for the lack of protection observed, as the proteins used in the first 
vaccine trial contained similar amounts of breakdown products.  Also, the proteins used 
in the Chapter 3 vaccine trial generated high titre antibodies capable of malarial TCTP 
recognition.  The difference in protective effect between the first and second vaccine trial 
is unlikely to be due to increased virulence of the malarial strains used for challenge, as 
the control mice challenged with P. yoelii YM survived for similar amounts of time in both 
vaccine trials.  The lack of protection observed in the second vaccine trial, along with the 
difficulties encountered in purification of yeast-derived TCTP, prompted the decision to 
evaluate the vaccine potential of TCTP expressed in a bacterial system in the third trial. 
 
Immunisation with E. coli-derived TCTP conferred a mild protective effect in P. 
yoelii YM and P.c. chabaudi AS-challenged mice, but not in mice challenged with P. 
berghei ANKA.  In PyTCTP-immunised mice challenged with P. chabaudi, mean 
parasitemia was significantly reduced from 4 to 9 dpi as compared with PBS-immunised 
controls.  In P. yoelii YM-challenged mice, PyTCTP immunisation resulted in a 
significantly reduced mean parasitemia at 3 and 4 dpi.  In both groups peak parasitemia 
was delayed by one day.  In mice challenged with P. yoelii YM, two PyTCTP-immunised 
mice and one control mouse survived the usually lethal infection.  However, the mean 
survival times of immunised and control mice were not significantly different.   
 
In the initial vaccine trial using yeast-derived TCTP (Taylor, 2002), immunised 
mice survived a day longer than controls following P. yoelii YM challenge, and the 
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reduction in parasitemia in the early stages of infection was more pronounced than was 
observed in the vaccine trial using E. coli-derived TCTP.  This could indicate that 
immunisation with yeast-derived TCTP has the potential to generate stronger protective 
immune responses, or the differences could be due to minor variations in methodology or 
in parasite virulence between trials. 
 
Treatments that specifically inhibit histamine release by the host have been 
shown to have a protective effect against malarial infection in mice.  Tricyclic 
antihistamine treatment could prevent patent infection in mice challenged with P. yoelii 
nigeriensis (Singh and Puri, 1998).  Additionally, C57BL/6 mice deficient in histamine 
responses via several methods (through disruption of the histidine decarboxylase gene 
or the H1 histamine receptor, or by drug treatment to inhibit of the H1 receptor) were 
resistant to cerebral malaria development, instead succumbing to hyperparasitemia at 
around 20 dpi.  In these mice, integrity of the BBB was preserved, sequestration of 
infected erythrocytes in brain blood vessels did not occur, and the expression of vascular 
adhesion molecules was reduced (Beghdadi et al., 2008).        
 
It was thought that TCTP immunisation might result in significant protection 
against cerebral malaria development in C57BL/6 mice challenged with P. berghei 
ANKA.  However, no differences in cerebral malaria development were observed 
between control and TCTP-immunised C57BL/6 mice.  Although unexpected morbidity 
and mortality was observed at low parasitemia in all BALB/c mice challenged with P. 
berghei ANKA, it could be determined that PbTCTP immunisation did not reduce 
parasitemia or increase survival time.  
 
In summary, the results so far have indicated that TCTP is not a good malarial 
vaccine candidate compared to others previously reported, such as AMA-1, MSP-1 or 
MSP4/5 (e.g. Anders et al., 1998; Crewther et al., 1996; Daly and Long, 1996; 
Hirunpetcharat et al., 1997; Kedzierski et al., 2000).  TCTP immunisation generated only 
a very modest protective response, and sterile immunity or significant reduction in 
disease symptoms was not observed.  Additionally, the protective result obtained was not 
consistent in all of the vaccine trials or in all of the challenge models used. This is a 
further argument against the further assessment of TCTP as a malarial vaccine 
candidate, as a human malaria vaccine would be required to generate a strong protective 
effect with broad specificity.  
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The major effects generated by TCTP immunisation have been a reduced 
parasitemia early in infection and a delayed peak parasitemia.  Taken together, these 
results indicate that malarial TCTP may have a role in the early stages of infection 
progression.  The protective effect seen also indicates, but does not confirm, that 
malarial TCTP can be recognised and inhibited by the specific host antibodies during 
malarial infection.  This supports the hypothesis that malarial TCTP is secreted into the 
bloodstream of the host during infection, as previously reported (MacDonald et al., 2001).  
Secretion of TCTP from other species, including other human parasites, has been 
reported (Amzallag et al., 2004; Gnanasekar et al., 2002; MacDonald et al., 1995; 
Oikawa et al., 2002).  TCTP has no extracellular signal sequence or transmembrane 
domains, however cell culture experiments have indicated that around half of the total P. 
falciparum TCTP is released during schizogony (MacDonald et al., 2001).  It has not 
been proven that this is due to an active secretion process, and future experiments could 
evaluate the secretion of malarial TCTP.  For example, culture supernatants of P. 
falciparum could be analysed for the present of TCTP by western blot, using antibodies 
specific to intracellular malarial proteins as a negative control.  The presence of malarial 
TCTP in the sera of infected rodents could also be analysed by western blot.  However, a 
high-titre antibody would be required, as only faint bands of malarial TCTP were detected 
in purified P. yoelii and P. berghei lysates using the antibodies generated as described in 
chapters 3 and 4. 
 
It is unknown if the expression of TCTP in yeast and E. coli generated proteins 
with functional differences.  No active protein, as measured by the induction of histamine 
release, was generated using either expression system.  Yeast-derived TCTP did not 
induce an in vivo response in mice; it was first thought that this could have been due to 
TCTP possessing local rather than systemic effects (Taylor, 2002).  However, in vitro 
experiments using rat basophilic leukaemia (RBL-2H3) cells also showed no 
degranulation induced by E. coli-derived TCTP. Hexosaminidase assays were used in 
place of direct measurement of histamine release as it was thought that the earlier 
negative results could also have been due to the labile nature of histamine.   
 
A previous report stated that human TCTP did not stimulate histamine release 
from RBL-2H3 cells, and that they are considered to be a mast cell lineage rather than a 
basophil model (Wantke et al., 1999).  However, other researchers have demonstrated 
the capacity of filarial, schistosome and tick TCTP to induce histamine release from RBL-
2H3 cells (Gnanasekar et al., 2002; Mulenga et al., 2003; Rao et al., 2002).  Based on 
these results, malarial TCTP should have induced histamine release from RBL-2H3 cells, 
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as the methods for protein purification and basophil degranulation were highly similar to 
those previously reported for filarial TCTP (Gnanasekar et al., 2002).  To determine if the 
lack of induction of basophil degranulation by malarial TCTP was due to true differences 
in histamine-releasing activities of the proteins, or are due to experimental differences 
between laboratories, the TCTP from several different species would need to be 
assessed together in both in vivo and in vitro assays.  
 
In all malarial TCTP immunisation and activity experiments, the N-terminal His-
tag was not removed from the recombinant proteins.  It is possible that the inclusion of 
the His-tag could have affected the secondary structure of the recombinant proteins and 
their activity.  Many vaccine trials use recombinant proteins with His-tags attached, as 
they appear to have little or no effect on immunogenicity.  Further TCTP vaccine 
evaluations could include recombinant protein with the His-tag removed.  However, 
recognition of TCTP present in malarial lysates by antibodies raised to recombinant His-
tagged malarial TCTP was detected by western blot.  In all published reports of the 
histamine-releasing activity of TCTP, recombinant protein has been used with the 
purification tag left intact.  For example, His-tagged PfTCTP and GST-tagged human 
TCTP were used in the histamine assays of human basophils (Macdonald et al., 2001).  
Histamine release from RBL-2H3 cells was induced by filarial worm TCTP with the His-
tag present (Gnanasekar et al., 2002; Rao et al., 2002).  Tick TCTP with an intact 
thioredoxin tag induced histamine release from RBL-2H3 cells (Mulenga et al., 2003).  
Therefore, the negative results obtained in the activity assays described in this thesis are 
unlikely to be due to the inclusion of the His tag in the recombinant malarial TCTPs. 
 
Experiments aimed at generating a TCTP-knockout malaria strain were 
performed in an attempt to more fully characterise the function of the protein.  These 
experiments involved the transfection of purified P. berghei ANKA schizonts with 
linearised DNA designed to disrupt TCTP with the TgDHFR/TS gene, removing part of 
the TCTP coding sequence in the process.  Successfully transfected parasites could then 
be selected for by treatment of infected mice with the antifolate drug pyrimethamine.  
Genetic analysis of the parasites obtained was performed using PCR and Southern blot.   
 
In the parasites initially obtained from the first knockout experiment, determination 
of the transfected parasite genotype by both PCR and Southern blot indicated that the 
TCTP gene had been successfully disrupted with the TgDHFR/TS gene.  However, prior 
to any genotype analysis these parasites had undergone a second passage in mice, to 
obtain sufficient DNA for Southern blot analysis.  These mice were not drug-treated, as 
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the extended time (18 days) required for detectable parasitemia immediately following 
transfection had indicated that the parasites obtained were most likely wild-type.    
 
When the initial parasite stabilate was used to infect six mice which were then 
drug treated, in all mice the majority of parasites obtained had a genotype in which the 
TCTP gene was non-disrupted, together with the TgDHFR/TS gene integrated in an 
incorrect location that was not digested to less than 11.5 kb using NdeI.  The presence of 
the wild-type TCTP gene was most likely not due to excision of the target DNA from the 
correctly transfected parasites, as this should have resulted in a shorter TCTP PCR 
product.  This result suggested that parasites containing a disrupted TCTP gene were 
out-competed by parasites containing the TgDHFR/TS gene integrated in another 
location during secondary drug selection.  It is unknown if this was due to a previously 
unreported function of TCTP in resistance to pyrimethamine, such that TCTP-knockout 
parasites were at a selective disadvantage during drug treatment.  However, the negative 
selection of TCTP-disrupted parasites during drug treatment may have been due to a 
more general selective disadvantage, in that TCTP-knockout parasites grew much more 
slowly and were out-competed by other parasites containing the TgDHFR/TS gene, 
which were more strongly selected for when drug pressure was applied.    
 
Due to the overall unsuccessful results of the first knockout experiment, further 
transfections were performed.  In some of these experiments target DNA with longer 
integration fragments were used, in an attempt to generate higher transfection 
efficiencies and more stable integration.  Southern blot and PCR analysis revealed that in 
all of these experiments wild-type TCTP was present in the transfected parasites 
following both the initial and secondary rounds of drug selection.   In the final transfection 
experiment, multiple bands of unknown identity were also detected using the TCTP 
probe, ranging in size from 6 kb to >11.5 kb.  The TgDHFR/TS probe could only be used 
in genotype analysis of some of the transfected parasite samples.  When used, the 
TgDHFR/TS probe detected bands at several locations that did not correspond with 
TCTP disruption.  
 
Although none of the transfection experiments were completely successful, 
genotype analysis by Southern blot and PCR indicated that a proportion of the parasites 
contained the desired integration event.  From these results, it cannot be stated that 
malarial TCTP is an essential gene.  One potential future experiment would be to use 
RNA interference technology to inhibit TCTP expression in specific malaria life stages.  
Whereas the creation of homozygous TCTP mutants by targeted gene disruption was 
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100% lethal in the Drosophila larval stage, inhibition of TCTP expression by RNAi 
allowed for the mutant phenotype to be studied in several adult tissues.  Reduced size, 
caused by a decreased cell size and number, was observed in several tissues, including 
eye and wing (Hsu et al., 2007).  This supports the hypothesis that disruption of malarial 
TCTP expression leads to slower cell growth. 
 
The strong selection pressure against parasites with the TCTP gene disrupted, 
together with the ability of TCTP immunisation to generate mild protective responses 
against several rodent malaria species, indicates that TCTP has an important role in 
malaria.  As the most significant effect was observed early in infection, it is hypothesised 
that the protein has a role in the parasite establishment within the host.  It remains to be 
proven whether this is due to the induction of histamine release, or through other 
extracellular functions of TCTP. 
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Appendix 1: Markers used 
 
Full sizes of DNA ladders: 
 
                                   λ/PstI:                     λ/HindIII: 
         
http://www.fermentas.com/catalog/electrophoresis/convlambdamarkers.htm 
 
100 bp ladder: 
 
http://www.neb.com/nebecomm/products/productN3231.asp  
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Full sizes of protein markers: 
 
         SeeBlue®Plus2                                      Mark12™ 
 
     (4-12% Bis-Tris gel)                                (4-12% Bis-Tris gel) 
 
         pre-stained BenchMark™                                unstained BenchMark™ 
          
     (4-20% Tris-Glycine gel)                 (12.5% SDS-polyacrylamide gel) 
 
http://products.invitrogen.com:80/ivgn/en/US/adirect/invitrogen?cmd=IVGNcatDisplayCat
egory&catKey=94101  
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Appendix 2: Quantifying Pain/Distress/Suffering   
Variable Predicted 
Score 
A. Body Weight Changes 
0    Normal 
1    <10% weight loss 
2    10-15% weight loss 
3     >20% weight loss 
 
 
1 
B.  Physical Appearance 
0     Normal 
1     Lack of grooming 
2     Rough coat, nasal/ocular discharge 
3     Very rough coat, abnormal posture, enlarged pupils 
 
 
1 
 
C.  Measurable Clinical Signs 
0     Normal 
1     Small changes of potential significance 
2     Temp change 1-2°C, cardiac and respiratory rates increased up 
to 30% 
3     Temp change >2°C, cardiac & respiratory rates increased up to 
50%, or markedly reduced 
 
 
 
2 
D.  Unprovoked Behaviour 
0     Normal 
1     Minor changes 
2     Abnormal/reduced mobility, decreased alertness, inactive 
3     Unsolicited vocalisations, self-mutilations either very restless or 
immobile 
 
 
 
2 
E.  Behavioural Responses to External Stimuli 
0     Normal 
1     Minor depression / exaggeration of response 
2     Moderately abnormal responses 
3     Violent reactions, or comatose 
 
 
 
2 
Total predicted score: 8 
Adapted from Morton & Griffiths 1985 Vet Rec 116:431-436. 
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Appendix 3: Titration curves used to calculate 
reciprocal titres: 
 
Titration curves for chapter 3: 
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Pooled group sera against PfT (1st)
0
0.5
1
1.5
2
2.5
100 1000 10000 100000 1000000
Reciprocal titre
Ab
s 
(45
0 
n
m
) p. PBS 1
p. PBS 2
p. PyT 1
p. PyT 2
p. PfT 1
p. PfT 2
old p. PfT
 
Pooled groups against PfT (2nd)
0
0.5
1
1.5
2
2.5
100 1000 10000 100000 1000000
Reciprocal titre
Ab
s 
(45
0 
n
m
)
p. PBS 1
p. PBS 2
p. PyT 1
p. PyT 2
p. PfT 1
p. PfT 2
old p. PfT
Appendix 3 
 266 
Individual mice from PyT1 (1st)
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Individual mice from PyT2 (1st)
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Individual mice from PfT1 (1st)
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Individual PfT2 mice (1st) 
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Titration curves for chapter 4: 
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Reciprocal titres pooled group sera against PyTCTP 2nd
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Reciprocal titres pooled group sera against PbTCTP 1st dup
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Reciprocal titres pooled group sera against PbTCTP 2
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Mouse 25-30 against PyTCTP - avg of two replicates
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mouse 37-42 against PbTCTP -  avg of two replicates
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